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Abstract 
Extracellular signal-regulated kinase 5 (ERK5) is a member of the mitogen activated 
protein kinase (MAPK) family responsible for activating a number of transcription 
factors in the cell nucleus. Downstream effects of ERK5 activation have been linked to 
cell survival, proliferation and differentiation. Overexpression of ERK5 has been 
observed in a number of tumour cell lines and has been linked with poor prognosis in 
cancer patients. ERK5 gene knockout studies have proved it plays a role in 
angiogenesis. Inhibition of ERK5 with XMD8-92 (12) showed correlation with tumour 
growth. All ERK5 validation experiments to date have lacked a compound with good 
ERK5 potency, selectivity, cell permeability and metabolic stability. The aim of this 
project is to prove the role of ERK5 in cancer with a drug-like tool compound through 
in vivo validation experiments. 
Small molecule ERK5 inhibitors have been discovered through a high-throughput 
screen revealing indazole-sulphonamide hit compounds with moderate potency, such 
as N-(1H-indazol-6-yl)benzenesulfonamide 30 (enzymatic ERK5 IC50 = 4.7 ± 0.04 µM). 
Hit expansion via library synthesis identified a set of sulphonamide aromatic groups 
associated with good ERK5 inhibitory activity. 
 
Structural optimisation around the sulphonamide linker elucidated a key binding 
interaction between Lys39 in the ERK5 active site and an S=O group. Removal of the 
hydrogen bond donor capacity of the sulphonamide yielded compounds with potency 
in the nM range. Alkylation or removal of heteroatoms in the indazole indicated that 
compounds form two hydrogen bonds with the hinge region of the kinase active site. 
Molecular modelling using GOLD predicted the 3- and 4-positions were suitable for 
substitution. Subsequent synthesis of key bromo intermediate 3 was conducted in a 68% 
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yield over five steps allowing for library synthesis of 4-alkyl indazoles, including current 
lead compound 199 (enzymatic ERK5 IC50 = 12 ± 7 nM). 
 
Compound 199 shows favourable drug-like properties (MW = 318, CLogP = 4.7, LE = 
0.51, Caco-2 efflux ratio = 0.52) and good ERK5 potency in transfected HEK 293 cells 
(cellular ERK5 IC50 = 24 nM). However, the compound is rapidly metabolised in mouse 
liver microsomes (MLM Clint = 378 µl/min/mg) and has a poor oral bioavailability in 
mice (24%). Compound 199 was also screened for activity against a panel of 456 
kinases but unfortunately showed poor selectivity. 
 
 
Metabolite identification conducted with 199 revealed oxidation of the indazole and 
cyclopropyl group as the major routes of metabolism by CYP enzymes. Unsubstituted 
3-, 5-, and 7- positions around the indazole were systematically blocked from 
metabolism by chlorination, with data indicating the 3-position is most susceptible to 
oxidation. Improving the LogP of the series was explored by re-optimisation of the 
sulphonamide aryl group and substitution of the 3-position. It was found that 3-amino 
Figure 1. A) Key interactions made between compound 199 (cyan) in the ERK5 active site (green); (B) 
Structure of Compound 199. 
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compound 269 had excellent microsomal stability (MLM Clint = 8.3 µl/min/mg) but 
potency was inferior to 199 (enzymatic ERK5 IC50 = 790 ± 80 nM). 
 
The work presented in this thesis describes the synthesis and SARs of over 130 novel, 
indazole compounds for the inhibition of ERK5. Through SAR development a binding 
mode has been proposed and a lead compound (199) obtained with excellent ERK5 
potency. Major routes of compound metabolism have been identified and methods to 
impeded metabolism have been demonstrated. The indazole series is in the lead 
optimisation phase with an aim to provide a tool compound able to critically assess the 
anti-cancer effect of ERK5 inhibition in vivo. 
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Chapter 1: Introduction 
1.1 Drug Discovery 
1.1.1 The Inception of Drug Discovery 
The human race has been using medicines for centuries, however, the use of chemistry 
in the discovery of new drugs is much more recent. The field of chemistry reached a 
level of sophistication in the late 19th century which allowed its application in a 
pharmacological setting. Before agreement on Mendeleev’s periodic table, Avogadro’s 
atomic hypothesis, and the ability to determine the structure of organic molecules, the 
rational development of active drug compounds was not possible. Advances in the 
biological sciences such as the elucidation of the structure of DNA, protein synthesis 
and the amino acid structures facilitated the formation of a crossover discipline which 
could be described as medicinal chemistry.1 When chemical dyes were studied by Paul 
Ehrlich in the 1870’s an affinity between chemicals and living tissues was first 
described. His discoveries lead to the development of Gram staining, used to 
categorise bacteria. He also proposed the chemical exploitation of differences in cells 
to a therapeutic end. 
Arsphenamine (1) was the first synthetic drug and was prepared in Ehrlich’s laboratory 
in 1907 for the treatment of Syphillis.2 The arsenic based structure was associated with 
a host of side effects but was the treatment of choice until eventually superseded by 
Penicillin. Arsphenamine was the first example of lead optimisation, as Ehrlich’s group 
synthesised, tested and modified structures to find the optimum anti-bacterial 
compound for a specific strain.  
 
Figure 1. A possible structure of arsphenamine (1) and the structure of sulbactam (2). 
A great number of medicinal products were isolated from natural sources, with opiates 
and penicillin among the most commercially successful. Penicillin was first isolated 
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from Penicillium mould, and subsequently, many other derivatives were also defined 
with varying properties. Chemical modification of natural products like Penicillin gave 
rise to the first semi-synthetic compounds such as sulbactam (2).3 The subtle 
differences in these compounds improved the understanding of their biological 
receptors and gave rise to some of the first structure-activity relationships (SAR). 
An improved understanding of enzyme and receptor function, along with advances in 
X-ray crystallography, permitted the rational design and optimisation of drug 
molecules.4 The publication of the human genome project in 2003 supplied a great 
number of previously unknown possible drug targets to be investigated.5 
 
Figure 2. Timeline showing significant advances to aid, and leading to modern medicinal chemistry. 
Advances in organic synthesis in the late 20th century gave rise to combinatorial 
chemistry that allows the synthesis of libraries of millions of compounds.4 The first 
clinical trials were conducted well before the inception of the Food and Drugs 
Administration (FDA), as early as 1747 with James Lind’s documentation of his 
potential scurvy remedies.6 Over time the methods used have developed to include 
placebos, control groups, double blind controls, and randomised screening.  
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The FDA began in 1906 with the passing of the Pure Food and Drugs Act which 
regulated the quality of commercial medicines and foods in the USA.7 This body as well 
as European and regional equivalents have controlled the licencing of medicines to 
ensure the safety of the relevant populations and make the purveyors accountable for 
their products. Sanctions such as mandatory animal testing and the clinical trial tier 
system ensures that compounds are well vetted before general release. In modern 
practice a large amount of preclinical data must be obtained to prove compounds are 
of limited risk to the patients in phase 1 clinical trials.  
The basic outline of clinical trials is shown in Table 1. Usually, clinical evaluation takes 
between 10 and 15 years. In comparison James Lind’s trial lasted 6 days before the use 
of citrus fruit for the treatment of scurvy was declared curative, although this is only a 
dietary treatment.6 
Table 1. Progression of clinical trials. 
Phase Size of 
study 
Purpose Typical 
Duration 
Pre-clinical - In vitro and in animal assessment of 
biological effect and safety 3-4 years 
Phase I 20-100 
patients 
Determine safe dosage regimen, 
pharmacokinetics and 
pharmacodynamics properties 
8-10 years 
Phase II 100’s Identify effect and any side effects 
Phase III 300-3000 Decide if new treatment is superior to 
those already in place 
Post 
Clinical 
trials 
- Continued monitoring of patients to 
conclude any long term side effects 1.5 years 
 
1.1.2 Modern Medicinal Chemistry 
The modern drug discovery cascade begins with a therapeutic need and target 
identification. Once the role of the target is determined and a therapeutic effect from 
its modulation has been demonstrated, an assay is required. If the target is a member 
of a well-studied protein family it is likely that an assay format can be 
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transferred/adapted, for example assays exist in some format for almost the entire 
kinome. However, consistent expression of protein and optimisation of the exact assay 
conditions can be time consuming. The primary assay is typically a high-throughput 
biochemical measure of a compound’s affinity to the target as either an agonist or 
antagonist. For simplicity and speed, assays are often cell-free which gives the fewest 
variables, although this is not always possible and depends on the nature of the target.  
 
Figure 3. Progression of the modern drug discovery process. 
 
1.1.3 Hit Identification 
For well-established biological targets, active compounds or licenced drugs may have 
been disclosed. Literature data also exists on a wide range of natural products which 
regularly exhibit biological activities. Many drugs have come to market as unmodified 
natural products, such as epibatidine (3) and morphine (4) (Figure 4). Active 
compounds have been sourced from a wide diversity of life including plants, bacteria, 
fungi, marine life and animals. Natural products are often large macromolecules with a 
high degree of chirality. Synthesis of such molecules has become a sub-division of 
organic chemistry and has a reputation for pioneering novel synthetic methods.8 
However, total syntheses are commonly low yielding and lengthy and not viable for 
scale up. Where possible natural products or precursors are isolated from an organism, 
for example paclitaxcel (9) can be synthesised from a precursor isolated from 
European yew tree needles.9 It could be argued that a large portion of natural products 
are not suitable leads for a drug discovery campaigns due to their inherent complexity 
and large size.  The lipase inhibitor orlistat (5) was derived from lipstatin (6), by a 
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medicinal chemistry campaign to optimise the SAR, and is one of many drugs 
discovered in this way (Figure 4).10 
 
Figure 4. Structures of Epibatidine (3), Morphine (4), Orlistat (6) and Lipstatin (7). 
Alternatively and increasingly popularly, hits are found in a library of synthetic 
scaffolds. Combinatorial chemistry along with microwave-assisted synthesis have 
simplified the production of drug-like compound libraries which can be screened for 
activity.11 Library sizes range from a few thousand to millions of compounds. 
Organisations like the European Lead Factory allow the compounds in their possession 
(approximately 300,000) to be used by applicants, but most large pharmaceutical 
companies restrict access to their proprietary libraries.12 Focussed libraries contain 
compounds that are most likely to have affinity to a particular class of target which 
saves time and resources. The pharmaceutical industry has driven a ‘fail fast, fail cheap’ 
philosophy to minimise losses on dead-end research which is inherent in the design of 
these large compound banks.  
A well curated compound library should only contain compounds which make good 
lead compounds. High molecular weights (MW) and highly halogenated systems can 
lead to cul-de-sacs during development or are singletons in the first screen. Efforts 
have been made to remove toxicophores such as nitro groups, unstable ring systems 
and electrophilic species but maintain a representative library.13  Frequent hitting are 
structures which are routinely flagged up as potent against many targets and target 
types. Privileged structures appear in drug compounds, so starting a project from one 
can limit the novelty of the project and may present problems with intellectual 
property (Table 2).14 The heterocycles in Table 2 appear repeatedly in hit compounds 
due to their drug like structures, which is unsurprising given their abundance in nature.  
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Table 2. Selected privileged scaffolds and their appearance in biologically active compounds. Adapted 
from Welsh et al.
14
 
Privileged scaffold Drug examples 
Natural product 
Examples 
 
Indole 
Medmain 
Oxypertine 
Psilocybin 
Okaramine 
Nostodione A 
Vinblastine 
 
Purine 
Abacavir 
Pentoxifyilline 
Cafaminol 
Caffeine 
1,3 Dimthylisoguanine 
3,7 Dimethylisoguanine 
 
3,3-Dimethylbenzopyran 
Nabilone 
Levcromaklim 
Centchroman 
Metachromin T 
Phaseolin 
Acronycine 
 
Benzoxazole 
Zoxazolamine 
Flumoxaprofen 
Benzoxaprofen 
Pseudopteroxazole 
Antibiotic A 16886A 
Antibiotic A23187 
 
Chromone 
Efloxate 
Favoxate 
Cromolyn 
Tricin 
Homothamnione 
Cissampelflavone 
 
It has been estimated that 1060 drug like structures are possible and that so far only an 
infinitesimal proportion of that space has been explored (estimated at 2.7 x 107 
compounds).15, 16 With that in mind taking a privileged scaffold as an initial hit is 
unnecessary but, because of the way most high throughput screen (HTS) compound 
libraries are maintained, it is recurrent. A modern alternative to HTS of large 
compound libraries is fragment library screening. Fragment libraries are collections of 
low MW (<300 Da) structures. Complexity ranges from unsubstituted heterocycles to 
moderately functionalised heterocycles. By generating a hit from such a small 
compound there is greater freedom of development with regard to increasing LogP, 
MW and other such parameters defining drug likeness (Chapter 1.1.5). Hits from a 
fragment screen have lower affinity for the target than hits from a HTS but should have 
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a similar or improved ligand efficiency (LE). LE is a measure of a compound’s affinity to 
the target in proportion to compound size (See Chapter 1.1.6 for full definition). 
Structure-based fragment discovery gives rise to hits with their interactions defined 
from the outset. In contrast, larger HTS hits may require preliminary SAR studies to 
identify their pharmacophore. It is possible for fragments to bind in one or more 
locations of the protein active site. In this case fragments can be linked or one grown 
to incorporate the interactions of others with isosteres. When crystallography is 
employed in the identification of fragments merging ligands is made simpler through 
visualisation data. 
1.1.4 Methods of Drug Administration 
The parameters defining drug likeness change depending on the method of 
administration. Topical treatments are applied directly to the target and need only to 
permeate the area whereas an oral drug is required to pass through the stomach and 
permeate the intestine to reach the blood before passing through the liver and 
eventually the cell membrane to reach the target (Table 3). Intravenous drugs only 
need to permeate the cell membrane but are less popular and are not commonly self-
administered, therefore, most drug discovery projects aim to provide an orally 
available compound. 
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Table 3. Routes of drug administration. 
Route of 
administration 
Organs passed before 
 reaching the blood 
Advantages Disadvantages 
Oral Stomach, Gut 
Can be self- 
administered 
Highest exposure to 
metabolic enzymes 
Intravenous/ 
Subcutaneous 
- 
Rapid onset, 
lowest exposure to 
metabolic 
enzymes 
Not favoured with 
patients 
Topical N/A Non-invasive 
Slow absorption, 
limited to skin 
disease 
Inhaled Lungs 
Excellent for lung 
related illness 
Dose received is 
highly variable 
Suppository Gut 
Avoids stomach 
and hepatic portal 
vein (first pass 
metabolism) 
Not favoured by 
patients 
 
1.1.5 Metrics of Drug-Likeness 
Lipinski et al was the first to define guidelines for the design of orally bioavailable drug 
compounds, known as Lipinski’s rule of 5 (Table 4).17 The rules were deduced by 
analysing 2245 small molecule drug structures entering phase II clinical trials (not 
including peptides, polymers natural products or phosphates).17 It was found that a 
correlation exists between oral bioavailability and all the physiochemical properties 
give in Table 4.  
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Table 4. Lipinski’s rule of five. 
Parameter Definition Rule 
MW Mass of the compound <500 Da 
LogP 
A measure of a compound’s solubility in 
water by partition with octanol.  
LogP = Log([H2O]/[octanol]) 
<5 
HBA Hydrogen bond acceptors <10 
HBD Hydrogen bond donors <5 
 
A compound must be small enough to pass through the gut wall to reach systemic 
blood flow which generally requires a molecular weight below 500 Da. The compound 
must be soluble in H2O/blood but also lipophilic enough to pass through the cell 
membrane which is of course made up of lipids. As ionised drugs cannot pass 
membranes the desirable range for LogP is between 0 and 5 but a better measure of 
this is LogD which takes into account the pKa of the drug compound. HBA are better 
tolerated than HBD and both are relevant to the solvation of the compound in the 
body. 
Since these guidelines were published in 1997 they have been widely adopted by the 
medicinal chemistry community but some flaws have been identified and refinements 
made. Expansions on Lipinski’s metrics have been made to include; topological polar 
surface area (tPSA), number of aromatic rings, number of rotatable bonds and number 
of toxicophores to give a quantitative estimate of drug likeness (QED) (Table 5).18 
Parameters were chosen based on known effects on drug-likeness, for instance the 
number of toxicophores, but also values easily measurable in a library of compounds 
where distinct trends exist.  
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Table 5. Factors that influence a compound’s QED (quantitative drug-likeness) score plus Lipinksi’s Rules 
(Table 4) 
Parameter Desirable range 
Topological polar surface area (tPSA) defined as 
Vander Waals radius of all HBDs and HBAs. 
<140 Å 
Number of aromatic rings <3 
Number of rotatable bonds <10 
Number of toxicophores <2 
 
There are many drugs which do not satisfy all of Lipinski’s rules but are orally available, 
therefore a trigger for the definition of a new metric, QED, was to obtain a score 
function (0-1, where 1 is most drug-like) as apposed to a binary yes/no system.  
Compounds approved by the FDA are frequently at the upper limits of Lipinski’s rules 
(median patented compound has a cLogP of 4.1 and MW of 450 Da) meaning that the 
majority of research is on compounds with poor drug QED scores (represented in 
Figure 5).1916 The pharmaceutical industry has a very poor attrition rate resulting in 
failure of 93-96% of candidate compounds in the clinic.20 This may be attributed to the 
poor drug-likeness of compounds submitted. 
 
Figure 5. Graph showing distribution of QED scores and proportion of drugs that passed/failed Lipinksi's 
rules of 771 FDA approved drugs.(taken from Hopkins et al) 
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1.1.6 Ligand Efficiency Metrics 
The ligand efficiency (LE) is a method of quantifying each atoms contribution to 
potency given by; LE = ΔG/N where ΔG is Gibbs free energy and N is the number of 
heavy atoms i.e. not hydrogen. The equation can be transformed by substituting ΔG 
out to give: 
LE =
−1.37Log(IC50)
N
 
The formula above is representative of ligand binding energy per heavy atom and gives 
a high score for high efficiency (desirable values are over 0.3). This metric is 
particularly useful when identifying hit compounds and scrutinising functionalities. LE 
is commonly defined in simpler terms as LE = pIC50/N which is referred to as the ligand 
efficiency index (LEI). 
Ligand efficiency can be modified to include other compound properties such as 
lipophilicity (lipophilic ligand efficiency, LLE or LipE). LLE is given by LLE = pIC50 – CLogP 
with high scoring compounds having higher efficiency with regard to the lipophilicity 
and potency. LLE is useful when optimising the solubility of a compound as a drop in 
potency may actually be beneficial to a compound’s overall profile if the LogP is 
affected enough. 
Comparison of LE values can be done to determine differences between functionalities 
and also a group efficiency (GE) metric can be calculated by:  
GE =
[−1.37Log(IC50
𝐴
 
)] − [−1.37Log(IC50
𝐵 )]
N𝐴 − N𝐵
 
GE can be used to compare different substituents and also predict potential benefits. 
When choosing functionalities to include the theoretical change in heavy atoms is 
known, as is the LE of original molecule.  Therefore, the potency increase to maintain 
the LE can be calculated. For example an addition of 3 atoms (e.g. primary amide) on a 
molecule of 500 Da and an IC50 of 10 nM must improve potency 4.6 fold in order to 
maintain the LE.16, 21 Rough guidelines can be extracted from these type of calculations 
such as the addition of 1 heavy atom needs to improve potency ~2-fold to be 
worthwhile whilst the addition of a 6 membered ring needs to cause a potency 
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improvement over 30-fold to be justified. This same logic can also be applied to LLE for 
various groups, as shown in Figure 6.21 
 
Figure 6. The fold increase in potency needed to maintain an LLE value of 0.3 of various substituents 
(taken from Hopkins et al
21
) 
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1.2 Anti-Cancer Drug Discovery 
1.2.1 Introduction to Cancer 
In 2012 Cancer Research UK estimated there were 8.2 million deaths as a direct result 
of cancer and 14.1 million new cases worldwide.22 A cancer cell can be defined as a cell 
that has escaped the intrinsic control mechanisms of the cell cycle. This change is 
brought about by a modification to the genetic makeup of the cell, caused by mutation. 
The total number of cells in the average human body is in the region of tens of trillions 
and therefore many mutation events occur as DNA is read and replicated in each cell. 
Due to the length of DNA, each cell is thought to produce over 10,000 replication 
errors each day.23 The likelihood of mutation is further increased by overexposure to 
UV or radiation of any kind or the consumption of mutagens such as those found in 
cigarettes. Mutations ultimately affect the DNA code which leads to errors in the 
amino acid sequence of synthesised proteins. Commonly DNA mutations are identified 
by repair mechanisms in the cell, however, in some cases the cell cycle progresses 
resulting in a modified cell.  
Some mutations, known as passenger mutations convey no benefit to the cell and can 
be described as biologically inert. These do not affect a cell’s tendency to become 
cancerous.24 If the mutation conveys a benefit over cells in the surrounding tissue it 
will prosper in a Darwinian ‘survival of the fittest’ manner. Mutations of this nature are 
called driver mutations as they are responsible for the cancerous properties of a 
malignant tumour when accumulated.24 The development of cancer is thought to 
require a number of characteristic mutations in order to overcome certain processes 
which normally facilitate the prevention of tumour formation. Cancer cells are capable 
of invading tissues and therefore metastasising, resulting in multiple sites of tumour 
growth. Cancer fatality occurs when the function of vital organs is lost due to the 
overwhelming presence of cancer cells. 
1.2.2 The Hallmarks of Cancer  
The hallmarks of cancer (Figure 7) have been reported as a combination of properties 
which allow the cell to grow without regulation but with sufficient access to necessary 
resources.25, 26 
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Figure 7. The Hallmarks of cancer (taken from Hanahan & Weinberg
25
) 
Almost all cancer driver mutations that occur in a cell can be attributed to one of the 
hallmarks of cancer. The order in which these mutations and properties occur is not 
consistent but typically all six are necessary for a malignant cancer. Driver mutations 
result in either the loss of function, by which the expression of tumour suppressors is 
suppressed or the expression of a natural cell cycle inhibitor is down regulated or a 
gain in function where a pathway becomes permanently active or expressed in greater 
concentrations. Angiogenesis allows a cancer tumour to propagate its own blood 
vessels ensuring an ample supply of resources necessary to sustain a constantly 
replicating group of cells. If this weren’t the case a tumour would have a maximal size 
or rate of growth dependant on the tumour’s location. Cancer cells are resistant to 
apoptosis which should be caused by recognition of the irregular genetic material, 
elevated levels of signalling and other physical stresses on the cell. Once pathways 
which control DNA replication are bypassed the cell is predisposed to garner more 
genetic variations causing rapid development into a cancer cell.  
1.2.3 Classical Chemotherapy 
The first chemical treatments for cancer were cytotoxic agents discovered as a result 
of research into the side-effects of chemical weapons used in warfare during the early 
20th century. Chemical warfare was subsequently banned by the Geneva protocol in 
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1925 but mustard gasses were modified and repurposed as pharmaceuticals.27 Whilst 
cancer is by no means a new disease, a deep understanding of the key principles was 
not present at this time and therefore treatments were highly toxic to the patient. 
Agents such as cyclophosphamide (7) are still used today and work by linking DNA 
bases together, typically the N-7 position of purine bases. DNA alkylation causes 
apoptosis or programmed cell death as the replication of genetic material is prevented. 
The nitrogen mustards gave birth to not only a class of anti-cancer drugs, DNA 
alkylating agents, but also the founding principles of chemotherapy.28 Platinum based 
agents such as carboplatin (8) (Figure 7) also produce a therapeutic effect by forming 
DNA adducts and, like nitrogen mustards, are associated with toxic side effects. 
Paclitaxel (9) prevents tubulin structures from disassembling causing the cell cycle to 
halt before reaching metaphase, leading to apoptosis. Some early chemotherapy relies 
on the higher rate of proliferation in cancer cells and therefore increased consumption 
of resources to produce a higher concentration of the drug compound in cancer cells. 
As a result most of these drugs cause cell death in normal body cells that are naturally 
dividing leading to hair loss, gastrointestinal disorder and weakening of the immune 
system. 27 It has been shown that normal cells are replaced quicker than cancer cells 
when put under the extreme stress of chemotherapy which may be due to the loss of 
some cellular process in the cancer cells. However, patients treated with cytotoxic 
agents suffer numerous side effects and extreme discomfort due to the narrow 
therapeutic index. Cisplatin, paclitaxel and vinblastine all cause nausea among more 
serious side effects such as loss of sight. It is questionable in some circumstances 
(when treatment is not curative) that the life extension they grant to a late stage 
cancer patient is not worth the pain and hardship that chemotherapy presents.29 
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Cyclophosphamide 
(7) - DNA Alkylator 
Carboplatin 
(8)- DNA 
Alkylator 
Paclitaxel (9) - Anti-Tubulin 5-
Fluorouracil 
(10) - Anti-
Metabolite 
Figure 8. Structures and mode of action of cytotoxic chemotherapy agents. 
Due to the way in which a cell becomes cancerous, a tumour may contain several cell 
lines that have achieved the hallmarks of cancer through different means and 
therefore possess different properties. Clonal evolution means that if one cancer cell 
line is sensitive to an administered agent another insensitive cancer cell line will 
prosper. This means that intrinsic or acquired resistance to therapy is very common as 
certain cell lines react differently to drugs. Genetic instability of the cancer genome 
causes many cell lines to be created from one cancer cell line making targeting a 
tumour even harder. Cytotoxic agents are generally administered as a cocktail of one 
or more active ingredients to limit the effects of toxicity. Resistance to drugs can 
develop in a number of ways such as increased expression of efflux pumps (Chapter 
3.4). 
1.2.4 Targeted Therapies  
The hallmarks of cancer define the key differences between a normal and cancerous 
cell and each hallmark is brought about by a change in expression levels or activity of a 
relevant protein. Targeted therapies aim to regain control of one of the processes 
contributing to carcinogenesis or assisting tumour growth. A number of key driver 
proteins have been identified in particular cancer types that have been exploited with 
effective drug compounds (Figure 9). Tractable targets such as androgen or growth 
factor receptors have been exploited for the treatment of cancer as well as the 
inhibition of signalling pathways. The strategy behind this target selection is to create 
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better selectivity between cancerous and normal cells so a therapeutic effect is 
brought about without the side effects associated with cytotoxic agents.   
 
Figure 9. The Hall marks of cancer and associated therapeutic targets (taken from Hanahan & 
Weinberg
25
) 
One particular targeted therapy success story is the kinase inhibitor, imatinib 
(Gleevec®, 11) which targets the Bcr-Abl kinase. This is a mutant kinase encoded by the 
Philadelphia chromosome, which is formed by a translocation event of chromosomes 9 
and 22, and is expressed exclusively in chronic myeloid leukaemia cells. There are very 
few side effects associated with imatinib as the protein target is only present in cancer 
cells and the compound is sufficiently selectivity to not affect other kinase signalling 
pathways. Although the Bcr-Abl kinase is an isolated case of a mutant protein target, 
numerous other kinase targets have been identified as overexpressed or activated in 
cancerous cells.30-33 
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Figure 10. The structure of Imatinib (Gleevec) 11. 
1.3 Protein Kinases 
The role of a kinase within a cell is to coordinate signalling through phosphorylation of 
proteins. The phosphorylation causes the activation or suppression of protein function 
by incurring a change in the conformation of the protein. The introduction of a 
phosphate group has a profound effect on the shape of a protein, although it is not a 
particularly large group the polarity is high and parts of the protein recoil due to 
unfavourable ionic interactions such as similarly charged dipoles or hydrophobic areas. 
Other functionalities embrace and accommodate the oxygens through hydrogen 
bonding and favourable dipole interactions. This change in shape presents a new 
active site for a specific substrate or de-activates a site so it no longer functions. In 
some cases the phosphorylation allows the protein to be recognised by another 
protein or be transported across an intercellular membrane. 
For a phosphorylation to occur the kinase and substrate must be in the presence of 
adenosine triphosphate (ATP). This is the source of the phosphate group and is 
converted to adenosine diphosphate (ADP) during the process. ATP is abundant in the 
body not only for use in kinase action but also it is the body’s principal source of 
cellular energy.  
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Figure 11. The structure of Adenosine Triphosphate (ATP) 
 The human genome encodes approximately 500 kinases. Within a single cell 
phosphorylation occurs thousands of times a second34, and is the primary method for 
coordinating a cell’s routine and is the mainstay of signal cascades and transduction. 
Kinases are located throughout the cell in the membrane, cytoplasm, and nucleus. 
There are three categories of protein kinases: Ser/Thr kinases that phosphorylate the 
side-chain hydroxyl group of serine or threonine; Tyr kinases that phosphorylate the 
phenolic hydroxyl group of tyrosine; and dual kinases which act at both. Even though 
all kinases have the same cofactor, i.e. ATP, there is enough variation between protein 
structures to give selectivity in a drug, as subtle residue changes in the active site are 
witnessed in all kinases. As expected, there are groups of kinases which display highly 
conserved active site sequence and structure and so designing selective drugs 
becomes more difficult. An attractive feature of kinase inhibition is the type of 
molecule that the active site demands. Compounds are typically entropically 
constrained meaning that there are limited permutations that can be performed on 
the structure. Most inhibitors are highly conjugated, have limited entropy and contain 
aromatic rings, carbonyl and amide groups. Heterocycles feature heavily, as expected 
when mimicking the binding of a purine base.35 These moieties fit nicely within drug-
like compound criteria and generally suit pharmacokinetic demands. 
 
Figure 12. The structures of amino acid phosphorylation sites; serine, threonine and tyrosine. 
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 Although the kinase active site varies between every kinase, the key features of the 
site and binding mode are conserved. The binding of ATP (Figure 13) shows the key 
areas to exploit in inhibitor design, most hydrogen bonding is found in the hinge region 
at the end of a bi-lobed cleft. A pocket accommodates the ribose with the phosphate 
chain projecting into solvent-exposed open space. Any area in this model not used by 
ATP holds potential to give a drug a competitive edge. These areas vary between 
proteins, however, a hydrophobic pocket behind a ‘gatekeeper’ residue is a staple of 
kinase structure. Around 82% of the gatekeepers are defined as small or medium 
residues and the most common is methionine, accounting for 40% of the currently 
mapped kinases.36 The smaller the residue here the more accessible the pocket behind 
it becomes. As such from a drug design point of view, a small residue is favourable due 
to the potential for exploitation. Most active sites also contain a glutamic acid along 
the cleft which is not involved with ATP binding. This highly conserved feature can be 
utilised in the design of non-selective kinase inhibitors which are suggested to yield 
higher efficacy and safer drugs by synergistic effects and targeting multiple kinases.37 
However, selective kinase inhibitors remain the chief target to most research groups 
and as such drug interactions with highly conserved residues are avoided unless 
selectivity can be derived elsewhere. Previous crystal structures of kinase bound-ATP 
show that the association is not very strong, this is yet another attractive feature of 
protein kinases as a drug target. An inhibitor needs to form a stronger interaction than 
the substrate it is displacing to be competitive, if this original substrate complex has a 
weak binding energy the task is smaller to achieve greater energy.10 
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Figure 13. The Binding of ATP in a generic kinase active site. 
A key aspect of the kinase activity is the activation loop which needs to adopt a 
particular conformation for the protein to accept its substrate. Although this is crucial 
in kinase activity it is the source of most variation as it is a moveablestring of amino 
acids. The activation loop contains a conserved sequence of residues DFG (aspartate, 
phenylanaline, glycine) and activated kinases are referred to as ‘DFG-in’ or ‘DFG-out’ if 
inactive. 
In the last 35 years there has been an explosion of research into the therapeutic 
application of these proteins due to the crucial roles many of them play in various 
pathways. It is quite common for kinases to be over-expressed, over activated or 
mutated in a cancer cell.  
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1.3.1 Types of Kinase Inhibitors 
Kinase inhibitors can be classified by the key interactions they make with the kinase 
active site. Four classes exist, which are shown in Table 6.38 
Table 6. Kinase inhibitor classes. 
Class of kinase 
inhibitor 
Description 
I 
Mimics the interactions made by ATP at the hinge and 
adjacent pockets. Bind to the active or DFG-in kinase form 
II 
Compounds bind to the DFG-out or inactive kinase 
conformation and are therefore not ATP-competitive. 
III Compounds bind a site adjacent to the ATP binding location 
IV Allosteric kinase inhibitors 
 
1.3.2 Mitogen-Activated Protein Kinases (MAPKs)  
The Mitogen-activated protein kinase (MAPK) family is one of the largest described 
making up 8% of the kinome.39 The MAPKs are a large family of proline-directed 
serine/threonine kinases that coordinate an important portion of cellular processes 
including cell differentiation, proliferation and apoptosis.40,41 MAPK pathways begin 
with an extracellular stimulus resulting in a kinase signalling cascade terminating at the 
activation of transcription factors or cytoplasmic substrates by the MAPK resulting in 
the expression or activation of a specific protein. 
There are 14 MAPKs defined in mammalian cells which are characterised as typical and 
atypical.42 The typical MAPKs are further divided into four groups namely: Extracellular 
signal-regulated kinase 1/2 (ERK1/2), c-Jun amino N-terminal kinases or stress 
activated protein kinases 1/2/3 (JNK or SAPK1/2/3), p38α/β/γ/δ and ERK5. Atypical 
MAPKs are ERK3/4, ERK7 and Nemo-like kinase (NLK), however, much less is known 
about the function of these pathways.42 
MAPK signalling cascades are activated by mitogens, which are defined as chemical 
substances that trigger mitosis, and therefore largely consist of extracellular growth 
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factors, e.g. epidermal growth factor (EGF), platelet derived growth factor (PDGF) or 
nerve growth factor (NGF), cytokines and stress factors. Before the MAPKs are 
involved these extracellular signals bind to membrane bound receptor proteins such as 
tyrosine kinases or G-protein coupled receptors (GPCR) and downstream pathways are 
activated.43 
The conventional MAPKs are the focus of a three tiered pathway, beginning with the 
MAPK kinase kinase (MAPKKK) which activates the MAPK kinase (MAPKK) which 
subsequently activates the MAPK (Figure 14).44 The MAPKK activates the MAPK by a 
dual phosphorylation event on a Thr-X-Tyr motif on the activation loop.40 These two 
phosphorylation sites are separated by one residue which varies between each  
sub-group of MAPKs. In ERKs the separating residue is a glutamic acid, whereas it is a 
bulkier proline in JNK and a much smaller glycine in p38 isoforms. Once activated the 
MAPK goes on to phosphorylate either a protein upstream of a transcription factor or 
the factor itself which in turn causes the production of specific proteins related to a 
range of processes.  
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Figure 14. Typical MAPK signalling cascade. 
Atypical kinase signalling is not consistently a three membered cascade and although 
all are activated by dual phosphorylation on the activation loop, the motif is not 
conserved, (only one atypical MAPK has the Thr-X-Tyr sequence (ERK7)). Unifying 
characteristics of all typical and atypical MAPKs include dual phosphorylation 
activation, high sequence homology in the kinase domain and downstream activation 
upon serine/threonine residues followed by proline (i.e. proline-directed). 
MAPK pathways are predominantly found as part of a scaffold-bound complex 
containing all three members of the conventional three tier system and a specific 
scaffold protein45. Cross pathway signalling is limited by the formation of these 
complexes despite the similar activation motifs and sequence homology between 
equivalent proteins. All MAPKs bind the upstream MAPKK by an ionic interaction 
between negatively charged residues on the MAPK and positive on the MAPKK but 
each of these protein-protein interactions is unique to the particular pathway.46 
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Table 7. Details of Typical and Atypical MAPK signal cascades. 
MAPK MAPKKK MAPKK 
Activation 
loop 
motif 
Gatekeeper 
residue 
Typical/ conventional MAPKs 
ERK1/2 Raf-1/A/B, c-Mos MEK1, MEK2 
Thr-Glu-
Tyr 
Gln 
p38α/β/γ/δ 
MEKK1-4, DLK, MLK2, Tpl-2, 
ASK1, TAK1, TAO1/2 
MEK3, MEK6 
Thr-Gly-
Tyr 
α = Thr 
JNK1/2/3 
MEKK1-4, DLK, MLK2, Tpl-2, 
ASK1, TAK1, TAO1/2 
MEK4, MEK7 
Thr-Pro-
Tyr 
- 
ERK5 MEKK2/3, Tpl-2 MEK5 
Thr-Glu-
Tyr 
Leu 
Atypical/ non-conventional MAPKs 
ERK3 
Unconfirmed 
Ser-Glu-
Gly 
- 
ERK4 
Ser-Glu-
Gly 
- 
ERK7/8 
Thr-Glu-
Tyr 
- 
NLK TAK1 
HIPK2 
(unconfirmed) 
Thr-Gln-
Glu 
- 
 
The numerous members of the MAPK family are of particular interest in oncology 
because of the links to cell cycle progression and cell differentiation as well as other 
downstream effects related to the hallmarks of cancer. 
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1.4 Extracellular Signal-Regulated Kinase 5 (ERK5) 
1.4.1 The Biological Role of ERK5 
ERK5 was first described in 1995 as around twice the size of most MAPKs (816 amino 
acids) and is ubiquitously expressed in human cells.47, 48 ERK5 is encoded by the MAPK7 
gene and has 10 consensus phosphorylation sites in its 400 residue excess (which 
shows no homology to any other MAPK).49, 40It is implicated in a number of important 
cell functions such as proliferation, survival, and cell cycle progression among other 
processes that relate to the hallmarks of cancer. 
1.4.2 The ERK5 Pathway 
The ERK5 pathway consists of ERK5, which is activated by MEK5, which is in turn 
activated by MEKK2/3. It has been noted that MEKK2, which is activated by growth 
factors including the nerve growth factor (NGF) and oxidative stress, has higher affinity 
for MEK5 than MEKK3.50 The role of Ras in the ERK5 signal cascade is not fully 
understood, but it is thought to be involved under epidermal growth factor (EGF) and 
NGF-stimulated signalling.51 Leukaemia inhibitory factor (LIF) is a cytokine which causes 
activation of the pathway by activation of surface bound tyrosine kinase GP130, which 
in turn activates Grb2-associated binder (GAB1) and protein tyrosine phosphatase 
(SHP2). Whether the GAB1-SHP2 complex activates MEKK2/3 is disputed but this 
trigger has only been witnessed in cardiomyocytes and causes elongation of the cell.52 
Other routes have been described for the activation of the ERK5 signalling cascade and 
are shown schematically in Figure 15.53 
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Figure 15. ERK5 signalling cascade (© 2009 QIAGEN, all rights reserved).
53
. 
Like many other MAPK pathways the ERK5 pathway is supported by scaffold proteins 
when propagating signals.54 The relevant kinases are joined together on a framework, 
which ensures that phosphorylation of the next kinase in the pathway is made quick 
and specific due to the proximity of the target. The activation of MEK5 by MEKK2 is 
aided by the Lck-associated adaptor (Lad) which increases the rate of association and 
therefore phosphorylation.55 MEK5 is activated by dual phosphorylation on Ser 311 
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and Thr 315 by either MEKK2/3 and goes on to doubly phosphorylate ERK5 as 
discussed previously.56, 57 At present MEK5 is thought to be the only activator of ERK5 
but can exist in two isoforms; MEK5α and MEK5β.58 MEKK2/3 binds to MEK5 on the N-
terminal lobe which is also the ERK5 binding site and therefore disassociation of the 
MAPKKK is required before ERK5 can be activated.59  
ERK5 can be differentiated from other typical MAPK family members ERK1/2 by its 
extended C-terminus despite, possessing the same Thr-Glu-Tyr activation motif. ERK5 
has a nuclear localisation domain which allows transport from the cytosol into the cell 
nucleus and an additional transactivation domain (TAD), both of which are absent in all 
other typical MAPKs.42 The TAD regulates autophosphorylation which may be required 
for nuclear localisation and activation of ERK5 itself.60 Once activated ERK5 is able to 
partially unfold allowing it to pass into the nucleus and activate several transcription 
factors such as c-Fos, c-Myc, Myocyte enhancer factor 2 (MEF2) and c-Jun affecting cell 
cycle progression, proliferation, differentiation and cell survival.61 ERK5 is deactivated 
by resuming its folded conformation which causes transportation back to the cystol.62 
1.4.3 The Role of ERK5 in the Cell Cycle 
Cell proliferation is induced by several transcription factors, importantly ERK5 has been 
shown to be essential in epidermal growth factor (EGF) activated cell division. Using an 
inactive mutant of ERK5, proliferation caused by EGF ceases, indicating ERK5’s crucial 
involvement.63 
 Transcription factors MEF2 and c-Jun are both implicated in cell proliferation and are 
substrates of ERK5. MEF2 also activates c-Jun, which drives the expression of cyclin 
D1.64 Cyclin D1 is a cofactor of cyclin dependant kinase 4 and 6 (CDK4/6)(Figure 16). 
These CDKs are vital to the cell cycle check point between the first gap phase (G1) and 
the synthesis phase (S) by inactivation of the retinoblastoma protein (Rb) which is a 
tumour and cell cycle suppressor.65 As expression of the CDKs is constant throughout 
the cycle, the level of specific cyclins is the controlling factor. Expression of c-Jun is 
inversely proportional to expression of the tumour suppressor p53 by binding to the 
p53 promoter causing deregulated cell proliferation.66 In cancer cells with up regulated 
ERK5 the production of cyclin D1 is increased and levels of natural CDK inhibitor p21 
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are reduced.Due to decreased p53 expression the cell can more readily enters the 
synthesis phase of the cell cycle.  
 
Figure 16. The Cell cycle showing the functions of Cyclin dependant kinase proteins (CDKs) and the 
various stages of cell division. (Taken from D. Morgan Controlling the cell cycle slides
67
). 
 
ERK5 has been shown to deactivate, by phosphorylation, the tumour suppressor 
capacity of promyelocytic leukaemia protein (PML).68 PML, when active, upregulates 
the expression of p21, and therefore ERK5 activity contributes to cell proliferation by 
p21 suppression in two ways; activation of c-jun and deactivation of PML.69  
1.4.4 The role of ERK5 in Cell Survival and Differentiation 
MEF2 is found in almost all cell types and is one of the oldest transcription factors in 
encoded in the human genome. MEF2 is known to assist in cell differentiation during 
embryogenesis and beyond during the formation of skeletal muscle, the heart, the 
brain/neurons, and bones.70 These effects are achieved by ERK5 activation and also 
members of the p38 MAPK family.71 ERK5 knockout mice do not live longer than 10 
days due to inhibited brain growth attributed to limited cell differentiation, however, 
this is not caused when ERK5 is only eliminated in neurons.72, 73 
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The transcription factor forkhead box O3A (FoxO3A) and Bcl-2-associated death 
promoter (BAD) both lead to apoptosis when active in the nucleus and mitochondria 
respectively (Figure 15).54 Phosphorylation of BAD and FoxO3A, which is caused by 
ERK5 directly (BAD) or by ERK5 activated serum- and glucocorticoid-inducible kinase 
(SGK)(FoxO3A) traps them in the cytoplasm thus inhibiting apoptosis.74, 75 
1.4.5 The Role of ERK5 in Angiogenesis 
Ablation of ERK5 activity via a conditional mutation could be triggered in adult mice 
but caused death due to internal bleeding within 1 month.76 It was concluded from this 
data that ERK5 plays an essential role in the maintenance of healthy blood vessels. 
However, the concept has not been proven in other tissues and studies require a 
specific inhibitor of the ERK5 pathway to eliminate the involvement of ERK1/2 in 
vascular endothelial growth factor (VEGF) induced angiogenesis.47 
1.4.6 Evidence of ERK5 in Carcinogenesis 
The downstream effects of ERK5 discussed so far all have the potential to augment 
cancer development if unregulated. Remarkably, ERK5 is implicated in four of the six 
original hallmarks of cancer (i.e. resisting cell death, sustaining proliferative signalling, 
evading growth suppressors, and inducing angiogenesis). There is some evidence for 
ERK5 effecting invasion or cell migration by increasing levels of matrix 
metalloproteinase 1/2/9 (MMP1/2/9).77 MMPs normally break down extracellular 
material to facilitate organ growth but are often found in high levels in aggressive 
cancer cells.78 This means that ERK5 is of relevance to five out of six hallmarks. The 
ERK5 signalling pathway is also related to known oncogenes Ras and c-Myc and ERK5 
has been shown to be overexpressed or constitutively active in a number of cancer cell 
lines.49 
The Myc family of transcription factors are one of the most commonly deregulated or 
mutated groups in cancers and trigger the expression of various proteins related to cell 
proliferation.79, 80 ERK5 is not the only activating pathway of c-Myc but when ERK5 is 
overexpressed in cancers, c-Myc is also found to be over active inducing a proliferative 
effect. Anaplastic lymphoma tyrosine kinase receptor (ALK) -induced activation of ERK5 
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causes the transcription of c-MycN, which has a strong correlation to proliferation in 
neuroblastoma cell proliferation.81 
ERK5 over-expression has been witnessed in a number of common cancers such as 
triple negative breast cancer (TNBC) which comprises 15% of breast cancers, and 
prostate cancers which killed over 10,000 people in the UK in 2012.82, 83 MEK5/ERK5 
has been shown to be overexpressed highly in 37% of malignant prostate cancers, 
showing correlation to tissue invasion.84 Further to this high levels of ERK5 in the 
nucleus relate to poor patient prognosis and aggressive disease.85 Similarly to this, 
ERK5 expression in TNBC is linked to an aggressive phenotype and evidence for its role 
in cell proliferation has been shown through gene knockout and pharmacological 
inhibition.83 ERK5 is to be found constitutively active in Hodgkin lymphoma cells lines 
and shown to be responsible for cell proliferation and inhibited apoptosis.86 High 
expression of ERK5 in oral squamous cell carcinoma is linked to tissue invasion.87 ERK5 
has also been shown to be pivotal in the cancerous capacity of leukaemia T cells, 
human mesothelioma cells and various other cell lines.88-90 In inflammation-driven 
cancer occurring in epidermal cells, ERK5 has been found to activate substrates that 
mediate inflammation, making it a potential target for these cancer types.91  
ERK5 requires full validation as an anti-cancer target, despite the wide range of cell 
lines in which it is found in high levels and been shown to play a key role in growth or 
another cancer hallmark.61, 69 s. 
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1.4.7 MAP Kinase p38α 
p38α shares a large amount of active site homology with ERK5: 48% sequence identity 
in the kinase domain and 56% in the ATP binding site, even though its closest family 
member is again ERK2, sharing 51%  and 78% sequence identity respectively to ERK5. A 
key variation here comes from the gatekeeper residue in each active site. In ERK2 it is a 
large glutamine residue, whereas in ERK5 and p38α, it is smaller (leucine and threonine, 
respectively). p38α also known as SAPK2 is one of four isoforms of the p38 MAPK and 
is a stress activated protein kinase (SAPK). The stresses these kinases respond to 
include oxidative, ultraviolet light, osmolarity, cytokines and various others. The p38 
pathway begins with the MAPKKK’s ASK, TAK1, MEKK1-4, MLK3 and possibly others. 
These phosphorylate and activate MKK3/6, which activate the MAPKs p38α/β/γ/δ. Like 
the ERK5 pathway this is the conventional route and the p38 isoforms go on to activate 
transcription factors and other kinase pathways. The main responses derived from the 
p38 pathway are inflammatory and immune responses, due to the nature of their 
activation. There is also evidence for p38 inhibiting the cell cycle by suppressing the 
release of cyclins and producing CDK inhibiting proteins.42 p38 activity may also play a 
role in initiation of apoptosis.  
From evidence gathered to date it appears that p38α only plays a suppressive role in 
the cell cycle, so inhibition of this site in cancer cells would likely induce a negative 
effect. p38 isoforms may be appropriate targets for the production of anti-
inflammatory drugs, but for the purpose of this project,  p38α activity is not desirable. 
92, 93 In order to minimise off-target effects, compounds made in this project are 
counter screened against p38α. 
1.4.8 ERK5 Inhibitors in the Literature  
In 2010 Deng et al reported the discovery of benzo[e]pyrimido-[5,4-b][1,4]diazepin-
6(11H)-ones as ERK5 inhibitors with good drug-like properties.94,95 Selected 2-amino-
pyrido[2,3-d]pyrimidines were screened for potency against a wide range of kinases, 
showing moderate potency against  ERK5. This series was developed into the more 
potent benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one (Figure 17).  
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Figure 17. Structure of benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-ones (XMD8-92, 12) and closely 
realted ERK5 inhibitor 13. 
SAR studies identified the hinge binding region of XMD-8-92 (Figure 18A) showing that 
the core structure is making two hydrogen bonds with the hinge region of the active 
site, while the rest of the molecule binds to the mainly hydrophilic periphery. This 
analysis was confirmed with the publication of a co-crystal structure of ERK5 with a 
closely related inhibitor 13 (Figure 18B/C).96 
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Figure 18. A) SARs developed by Deng et al on the benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one 
core shown on the structure of XMD8-92;
94, 95
 B) 2D representation of the binding of compound 13 
(Cyan) and the ERK5 active site; C) 3D representation of the binding of compound 13 (Cyan) and the 
ERK5 active site (PDB code: 4B99).
96
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XMD8-92 (12, Figure 16) is the most widely used compound in in vitro and in vivo 
studies of ERK5 inhibition. Mice  presenting tumour cells were treated with XMD8-92 
at a dose of 50 mg/Kg twice a day for 1-4 weeks interperitoneally. The results showed 
that ERK5 was inhibited successfully and tumour growth significantly reduced. In this 
study of 24 animals there was limited evidence of side-effects or toxicity.69 XMD8-92 
has an IC50 of 240 nM in an enzymatic assay achieving 76% inhibition of ERK5 at 
0.5µM.94 In vivo data collected in rats shows XMD8-92 (12) to have good bioavailability 
(69%) and a good PK profile overall (Table 8).94 
Table 8. In vivo Pharmacokinetic data collected in Rat for XMD8-92 (12).
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Parameter XMD8-92 (12) 
ERK5 IC50 (nM) 240 
t1/2 (min) 204 
Clearance (ml/min/kg) 37 
Vd (L/kg) 3.4 
Bioavailability (%) 68.6 
 
Indole-based compounds BIX02188 (14) and BIX02189 (15) are potent MEK5/ERK5 dual 
inhibitors (Figure 19).  Cellular IC50s were obtained in HeLa and HEK293 cells. 
Compound 15 is the more potent in a cellfree assay with a range of 260-530 nM versus 
820-1150 nM for compound 14. Despite being non-selective on the ERK5 pathway, 
good selectivity is seen over other MAPK families including MEK1/2, ERK1 and JNK2. 
Good selectivity has also been demonstrated in HeLa cells by Western blotting that 
showed reduced levels of phosphorylated ERK5 substrate MEF2 but no effect on 
MAPKs.98 
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Figure 169. Structures of MEK5 inhibitors BIX02188 (14) and BIX02189 (15). 
TG02 (16) is a non-selective ERK5 inhibitor that has been used in identifying ERK5 as a 
target in triple negative breast cancer.83 TG02 (16) shows good potency against ERK5 
(IC50 = 43 nM) but also CDKs 1, 2, 3, 5 and 9 (IC50 = 3-9 nM) and a wide range of other 
kinases at sub 100 nM levels. The compound has shown evidence of limiting leukaemia 
growth but due to the lack of kinase selectivity this cannot be attributed to the 
inhibition of any defined signalling pathway.99 
 
Figure 20. Structure of TG02 (16). 
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1.5 The Indazole Series of ERK5 inhibitors 
Work in Newcastle began with the identification of the pyrrole carboxamide scaffold 
from a high-throughput screen at Cancer Research Technology Discovery Labs (CRT-DL) 
(Figure 21). After development of this series to good potency, challenges regarding the 
pharmacokinetic profile have delayed progression in the lead optimisation phase and 
so the need for a back-up series was established (see Chapter 3). In 2009, a kinase-
focussed library of compounds were screened for activity against ERK5 by CRT-DL and 
identified a number of potential scaffolds.  The indazole series (Figure 21) was selected 
for further development because of its low molecular weight, moderate potency, and 
chemical accessibility.  
 
Figure 21. Representative structures of the Pyrrole (17) and Indazole (18) Series. 
1.5.1 Medicinal Chemistry Tools and Assays used on the ERK5 Project 
Final compounds synthesised on the project were first subjected to the primary ERK5 
enzymatic assay and the p38α assay to determine selectivity. Potency of the 
compound in the primary assay determined if the compound would then be tested in 
the cellular assay. If the compound met the criteria for potency and selectivity mouse 
microsomal clearance data was obtained along with plasma protein binding and 
solubility. Following this, compounds were further profiled by permeability (measured 
in a Caco-2 assay) and wider kinase selectivity panel. Compounds meeting the criteria 
for progression were then profiled for mouse pharmacokinetics and then in vivo 
xenograft tumour regression experiments (Figure 22). 
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Figure 22. ERK5 drug discovery cascade. 
1.5.2 ERK5 IMAP assay 
ERK5 IC50 values were obtained through a cell free IMAP (immobilised metal affinity 
polarisation) assay that is conducted by staff at CRT.100 ERK5 is expressed and 
incubated with a potential inhibitor before the introduction of a specific peptide with a 
fluorescent tag. The peptide is phosphorylated by ERK5 which enables binding to the 
IMAP agent and a measurable florescence directly proportional to the amount of 
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phosphorylated peptide present and therefore the inhibition of ERK5 (Figure 23). The 
ATP concentration of this assay is 350 µM.  
 
Figure 23. Schematic representation of the IMAP assay.
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1.5.3 p38α LANCE assay 
All compounds submitted for biological testing are screened against both ERK5 and the 
close homologue p38α in a Lance assay. The kinase is incubated in solution with ATP 
(350 µM), the chosen inhibitor and a specific peptide substrate labelled with a Ulight 
tag. This substrate, without the presence of any inhibitor is phosphorylated, the 
location of which is recognised by a Europium tagged antibody. The Europium is 
excited by light at a wavelength of 320 nm. This irradiation excites all the Europium in 
the system regardless of its binding to the peptide, however the fluorescence given off 
by the Ulight tag varies depending on its proximity to the Europium. Fluorescence at 
665 nm denotes the phosphorylated peptide and 630 nm the non-phosphorylated. The 
inhibitory effect on ERK5 can be quantified by the ratio of these two outputs and 
therefore a percent inhibition or IC50 calculated. 
1.5.4 Molecular Modelling 
Protein crystallography was first developed by Dorothy Hodgkin and John Bernal at 
Cambridge in 1932. Since then it has become common place in drug discovery, with 
particular focus on co-crystal structures of proteins and small molecules. Once this 
type of crystal structure becomes available informed simulations can be run in silico to 
predict SAR using docking programmes such as GOLD. Tools like this make it possible 
for  potent, selective structures to be reached more quickly, without the need for 
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synthesis of excessively large compound libraries. Docking programmes consider a 
number of parameters which are condensed into a scoring function and visualisation. 
Ideally the binding conformation of a compound is similar to its most energetically 
favourable conformation and any deviation from this is taken into account by the 
programme as well as clashes or repulsion with functionalities on the protein (See 
Table 33 Chapter 2.8.1 for full scoring breakdown). The ERK5 crystal structure has been 
published with a bound inhibitor and has been used on the project for molecular 
modelling using GOLD software.96 
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1.5.5 Measuring Absorption, Distribution, Metabolism, Excretion and Toxicity 
(ADMET) in vitro 
ADMET data was collected on the project to define lead compounds and quantify the 
quality of leads. Table 9 shows the data types collected and the rationale for each 
assay. 
Table 9. in vitro assays to determine ADMET properties. 
Assay Rationale 
Caco-2 
The Caco-2 assay measures compound permeation through a 
colon carcinoma cell monolayer. The cells include transporter 
proteins and measurements are made in both directions; A2B 
and B2A where A denotes the extracellular matrix and B the 
intracellular matrix. An efflux ratio is generated by dividing 
B2A divided by A2B and is ideally 2 or lower, however, it is 
important that A2B is high no matter the ratio. 
Plasma protein 
binding (PPB) 
Denotes what fraction of compound is bound to plasma 
proteins in the blood. Ideally a compound is less than 99.9% 
bound. 
Mouse liver 
microsome 
Metabolism by Cyp enzymes found in the liver of mice. A 
human assay is also available but was rarely used in the 
project. The results of this assay indicate the metabolism/ 
clearance of a compound. Ideal values are less than 50 
µL/ml/mg 
hERG 
Human ether-a-go-go related gene product is an ion channel 
that when inhibited causes severe cardiac arrhythmias. 
Ideally the  compound has very little effect on this target. 
CYP inhibition 
Accumulation of drug compounds can be caused by Cyp 
inhibition leading to unpredictable side effects. Drug-drug 
interactions are avoided if common Cyp enzymes are not 
inhibited. 
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1.5.6 Indazoles and Sulphonamides in Medicinal Chemistry 
The indazole is an attractive scaffold for drug design, in particular as a protein kinase 
inhibitor. This two ring heterocycle meets some of the key criteria described earlier 
that are typical of kinase inhibitors. In particular, it has groups capable of hydrogen 
bonding and has a rigid structure with scope for conjugation into its ring systems from 
suitable substitutions. The ring system is able to establish π-stacking and hydrophobic 
interactions with appropriate amino acids, completing the structure’s set of attributes. 
It is, therefore, not surprising that this pharmacophore appears in numerous drug 
structures, is a regular feature in HTS libraries, and appears in a large number of 
patents. Two FDA approved drugs, axitinib (19) and granisetron (20), contain an 
indazole group (Figure 24).  
 
Figure 24. Structures of indazole based drugs axitinib (19) and granistron (20). 
Axitinib (19) is an angiogenic inhibitor specifically targeting the tyrosine kinase vascular 
endothelial growth factor receptors 1, 2 and 3.101 It has been approved for use in 
advanced renal cell carcinoma as of January 2012. Granisetron (20) is a much older 
compound first used in the UK in 1991 for the treatment of nausea as a serotonin 
receptor antagonist. There are an abundance of papers that feature an indazole 
moiety in kinase inhibitor compound. Kinases such as JNK3102, Lck103, EphB4104, KDR105, 
Aurora kinases106, B-Raf107, ROCK-II108, Chk1109, Rho110, Tpl2111, B/Akt112, CDKs113, c-ABL114, 
CDC7115, PI3K/mTOR116, I kappa kinase117 and PKC-zeta118 are reportedly inhibited by 
derivatised indazole. The co-crystal structure of indazole 21 has been described for 
inhibition of cell cycle checkpoint kinase Chk1 with an IC50 of 42 nM.
109 Compound 21 is 
a 6-substituted indazole but has a benzimidazole group attached in the 3-position 
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(Figure 25). The most transferable aspect of this crystal structure is the dual binding of 
the indazole, with both nitrogens forming hydrogen bonds with the backbone of the 
hinge region amino acids. The geometry of the phenyl group in the 6-position is not 
very similar to our series as there is no form of linker between the aromatic groups 
however, it can be seen that this rather large di-substituted phenyl group is well 
accommodated. Perhaps an interesting feature is the presence of a hydrogen bond 
donor two bonds away from the 3-position, which is able to form another interaction 
with the hinge region. 
 
Figure 25. Binding mode of indazole-containing compound 14 in the Chk1 active site (PDB: 1IA8). 
Another MAPK under investigation is the c-Jun N-terminal kinase-3 (JNK3) with 
inhibitors proposed to have a neurological effect.102 These compounds also possess 
p38α activity, the MAPK which shows the greatest active site homology to ERK5. 
Inhibitors in development are 3,6 substituted indazoles with a homologous NH at the 
6-position equivalent to the sulphonamide NH in the indazole hits generated for ERK5 
series. The crystal structure of the lead compound (22) shows how it sits in the binding 
site and exploits areas not used by ADP (Figure 26). Both indazole nitrogens are 
involved in hydrogen bonding with the kinase hinge. 
 
44 
 
 
Figure 26. X-ray crystal structure of compound 22 (green) bound in JNK3, overlaid on ADP binding 
(white)(PDB: 2B1P). 
Sulphonamides are especially abundant in drug design featuring in 9% of all candidate 
drugs.119 They present a centre with excellent hydrogen bonding potential and 
therefore solubility. They are often incorporated into drugs to improve solubility and 
also as an isostere to amides. Unless sterically hindered sulphonamides are readily 
metabolised to a number of products undergoing acylation, hydroxylation and 
glucoronidation.120  
The design of an indazole sulphonamide (23) has been described in the literature for 
action as a nucleosidase inhibitor (Figure 27). The lead described is a mono-substituted 
indazole with the sulphonamide unit in the five position with developments being 
made in the three and seven positions. In the X-ray structure the indazole nitrogens 
are seen making two hydrogen-bond interactions with the backbone of leucine 152. 
The sulphonamide also forms two bonds through the sulfonyl oxygens, and the 
attached aromatic forms π-π interactions with surrounding phenylalanine residues.121 
Whilst the structure investigated here (23) is very similar to the hits proposed for ERK5 
inhibition the biological targets are fundamentally different. 
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Figure 27. Schematic representation compound 23 bound in SAH/MTA nucleosidase created using 
homology modelling (not available on the PDB). 
Functionalised indazoles have been investigated previously for the inhibition of CDK2 
as it makes a strong interaction with the hinge region of the kinase domain.122 
An indazole based inhibitor (24, Figure 28) of ERK1/2 has also been described in the 
literature.123 The compound shows strong cellular potency and shows good selectivity 
for the MAPKs ERK1 and ERK2 over related kinases and has been shown to cause 
reduced tumour growth in xenograft studies. It is typical of kinase inhibitors to possess 
2-4 ring systems but 24 exceeds this with 5 aromatic and 2 aliphatic cyclic systems. 
 
Figure 28. Structure of ERK1/2 inhibitor 24. 
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1.5.7 Indazole Metabolism 
Many drug examples including an indazole moiety have been described which is 
testament to the stability of the system towards metabolism and the low inherent 
toxicity despite being a masked aniline. Indazoles are less susceptible to oxidative 
cleavage than other two heteroatom heterocycles such as thiazoles, oxazoles and 
imidazoles, although there is some precedent.124 The 3-position of the indazole can be 
oxidised by CYP enzymes and then exists in equilibrium as either tautomer 25 or 26 
(Figure 29). The indazole one position can also undergo glucuronidation (27) or 
conjugation with ribose (28, Figure 29). 
 
Figure 29. Metabolites of indazoles 
Dealkylation of the indazole 1-position is witnessed in drug molecules benzydamine 
and granisetron (20).124 
1.5.8 Indazole Chemistry 
Indazole has a predicted LogP of 1.32 which is an acceptable solubility for any drug 
compound (logP is a factor of lipophilicity with a value below 5 being desirable for a 
drug compound).10 It has pKa values of 13.86 and 1.25 for the protonated and non-
protonated nitrogen units respectively making it mildly acidic.125 Unsubstituted 
pyrazoles have a pKa of 19.9 and are therefore subtley more basic, essentially however 
the chemistry of both the indazole and pyrazole 1, 2, and 3 positions is analogous. 
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There are three possible tautomeric forms of Indazole possible (Figure 30) but the 1H 
and 2H forms are more commonly found than the 3H. The most stable form is the 1H 
tautomer by 2.3 kcalmol-1 in either ground or excited state and is typically the only 
visible form by NMR in solvent.126 
 
Figure 30. Tautomers of Indazole. 
1.5.8.1 Synthesis of Functionalised Indazoles 
Indazoles can be synthesised in a number of different ways. Table 10 summarises some 
of the described methods. 
Table 10. Common methods of indazole synthesis. 
 
Functionalised 
benzene 
Reagents Product Reference 
1 
 
AcOH, NaNO2, 
H2O   
127 
2 
 
NHNH2, NaOBu
t 
[Pd(cinnamyl)Cl2]  
128 
3 
 
Na2WO4, H2O2 
 
129 
4 
 
CsF, TMSCH2N2  
 
130 
5 
 
NHNH2 
 
131 
6 
 
NHNH2 
 
132 
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7 
 
CuBr, Boc-NHNH2, 
K2CO3 
 
133 
8 
 
NHNH2  
 
126 
9 
 
NaNO2, HCl, H2O 
 
134 
10 
 
RCHN2 
 
135 
11 
 
i) RCHNNHTs, 
Cs2CO3 
ii) NaH  
136 
 
In most of the examples in Table 10 the introduction of the azo group is the key step in 
the synthesis that is most commonly done using hydrazine or a derivative but can also 
be done by diazotisation of an aniline. Once the hydrazine moiety is introduced, either 
through SNAr or another method, it attacks an electrophilic centre such as carbonyl or 
nitrile to close the ring and form the aromaticity of the pyrazole portion of the 
molecule. In reactions 6-11 in Table 10, the indazole is formed with functionalization in 
the 3-position and also with the indazole NH protected by a Boc group in reaction 7. 
The 3-position of the molecule is accessible after ring closing by selective halogenation 
using a hydroxide base which can then be exploited for further functionalization.137 The 
3-position is most readily exploited using palladium or copper coupling reactions upon 
halogenated aromatics.138-141 
The most acidic position on indazole is the protonated nitrogen which can be 
abstracted with a strong base and is also sufficiently acidic to undergo a Mitsunobu 
reaction.142 Protection of this position can be done using a tetrahydropyran (THP), tert-
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butyloxycarbonyl (Boc) or trimethylsilylethyoxymethyl (SEM) groups amongst others.143, 
144, 133 The 5-position is the favoured site for electrophilic aromatic substitution on an 
unprotected indazole due to the conjugated para-azo group. There is no literature 
precedent for substitution at the 4, 6 or 7 position on a protected or unprotected 
indazole. Functionalities can more easily be introduced by a ring closing reaction on a 
functionalised phenyl ring such as the examples shown in Table 10. 
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Chapter 2: The Indazole Series 
2.1 Series Inception & Hit Validation 
In 2009 a kinase-focussed library of compounds were screened for activity against 
ERK5 by Cancer Research Technology Discovery Labs (CRT-DL) revealing a number of 
potential scaffolds for development.  Eight distinct chemotypes were identified of 
which two were considered for further structure activity relationship studies (Figure 
31). The oxindole and indazole functionalities occur in numerous drug molecules and 
many patents already exist for both compound classes and therefore may create 
difficulties when filing a patent of our own with a unique molecule and application.  
Both molecules (18 & 29) have a low molecular weight and good predicted lipophilicity. 
The geometry of oxindole 29 suggests an intramolecular hydrogen bond may form, 
which not only may reduce the measured solubility of the compound but also means 
the molecule is very flat. As both compounds are equipotent, ligand efficiency (LE) 
informs that the oxindole scaffold is superior with regards to the contribution each 
atom has to potency. However, this parameter considers very few factors and the 
profile of the indazole compound is arguably better. The indazole series has three 
conserved rotatable bonds, which is preferable as flexibility generally improves 
solubility, selectivity and reduces the likelihood of CYP inhibition. For these reasons 
and the feasibility of a synthetic campaign, the indazole series was chosen for further 
exploration. 
 
Figure 31. ERK5 hits from a kinase-focussed library 
To determine the selectivity of the selected series a counter screen of 40 kinases 
representing all major families was performed by Millipore using compound 18. No 
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significant inhibition of p38α or any other kinase was observed (Table 11). The indazole 
scaffold is well known in the literature as a kinase inhibitor (Chapter 1.5.6) due to the 
adjacent hydrogen bond donor and acceptor motif which can bind favourably to the 
kinase hinge. It is therefore encouraging to find the selectivity results so favourable for 
such a discreetly functionalised core. 
Table 11. Millipore counter screen results for 18. Values represent the percent inhibition of the Kinases 
in the presence of 10 µM of the compound. 
Kinase 
Percentage 
inhibition at  
10 µM  
Kinase 
Percentage 
inhibition at  
10 µM  
Abl -37  MAPKAP-K2 -1  
Aurora-A -1  MEK1 -6  
CDK2/cyclinA 11  Met 3  
CDK7/cyclinH/MAT1 3  MSK1 -9  
c-RAF 2  MST1 -16  
cSRC 1  mTOR -9  
DAPK1 0  NEK2 -17  
EGFR -2  NLK 3  
GSK3α 29  p70S6K -1  
HIPK1 -6  PAK4 -3  
IKKα -8  PDK1 -3  
IR -11  PKA -2  
IRAK4 1  PKBβ 2  
JAK3 -8  PKCα 0  
JNK1α1 -5  Plk3 3  
KDR -8  ROCK-I -7  
LIMK1 -3  ROCK-II -6  
MAPK1 6  Rsk1 -6  
MAPK2 -4  Rsk2 6  
SGK 3  SAPK2a -3  
 
With the exception of the pyrrole carboxamide series (Chapter 3) hit validation 
previously undertaken on this project has not been fruitful, as potency seen in the HTS 
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was not replicated when compounds were re-synthesised. Confidence in a chemical 
series is gained if a number of examples appear in a HTS with similar potency. To prove 
a chemotype’s potency active molecules were re-synthesised and re-tested as HTS 
samples can become contaminated or degrade in prolonged storage. 
Six indazole compounds were present in the HTS library which showed comparable 
potency to 18, all of which were re-synthesised in house via a facile, one step synthesis 
(Scheme 1)(synthesis conducted by Elina Boubouresi, except 31). These compounds 
were fully characterised and resubmitted to CRT for testing at a high purity (>95%). 
The results (Table 12) show good correlation between potency of HTS and re-
synthesised samples encouraging further exploration of this series. 
Table 12. SAR for ERK5 inhibition: Comparison of HTS samples and resynthesized samples. 
  
  ERK5a IC50 (μM) 
Compound R1  HTS Results 
 
Resynthesised in 
house  
30 
 
4.8 4.7 ± 0.04 
18 
 
5.4 7.4 ± 0.4 
31 
 
9.3 24 ± 5.5 
32 
 
34 26 ± 0.4 
33b 
 
87 - 
34c 
 
- 20 ± 1.4 
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a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b This compound was not 
resynthesized, instead a close analogue was submitted instead; c Close analogue of 33. 
2.2 Proposed Libraries for the Indazole Series 
There are 6 positions around the indazole pharmacophore which are amenable to 
investigated (Figure 32). The most logical starting point, as some variants already exist 
in the original hits, is the 6-position aryl sulphonamide. A large library of analogues are 
accessible by the coupling of various sulphonyl chlorides with 6-aminoindazole to form 
the sulphonamide linker (Chapter 2.3). 
 
Figure 32. Proposed structure activity relationship studies around the indazole core. 
A primary objective was to determine the nature of any hinge binding motif present on 
the hits. It is likely that the indazole core forms a pair of hydrogen bonds with the 
backbone of the amino acid chain in the kinase active site. One way to define this is by 
the sequential removal of the H-bonding character within the molecule i.e. 
methylation of the indazole NH and swapping the indazole for an indole will also reveal 
the role of the second indazole nitrogen (Chapter 2.4.2). 
The role of the sulphonamide linker can be better understood by isosteric replacement 
and removal of the hydrogen bonding capability it carries. Replacement of the group 
with an amide reduces the flexibility of the whole molecule and also diminishes the 
capacity to accept H-bonds. Reversal of the linker will maintain the flexibility but 
significantly disturb any interactions the sulphonamide makes. Replacement of the 
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nitrogen with an sp3 carbon again changes the hydrogen bonding profile. The synthesis 
of the sulphone also facilitates the synthesis of thioether and sulphoxide compounds 
which establish the role of the S=O groups in ERK5 activity. 
The indazole molecule, at this stage, is substituted only in the 6 position leaving the 1, 
3, 4, 5 and 7 positions free for further elaboration. Molecular modelling data was used 
when prioritising positions and selecting functionalities for inclusion. 
2.3 Variation of the 6-Position Aryl-Sulphonamide 
2.3.1 Synthetic Strategy Towards various 6-Position Aryl-Sulphonamide Indazoles 
The initial HTS hits provided an excellent starting point to commence SAR 
development. However, in the absence of an ERK5 co-crystal structure a hit-expansion 
library was designed for synthesis based on commercially available building blocks. The 
‘hit explosion’ technique consists of the synthesis of a large number of diverse 
compounds related to a hit compound. In this case the aryl-sulphonamide was varied. 
Target molecule selection was based on the feasibility of synthesis, the cost of building 
block and length of synthetic scheme. Variation of the aryl-sulphonamide is seen to be 
tolerated in the SAR of the validated hits (Table 12). To ascertain the significance of 
these groups, synthetic targets were selected to represent electron rich and poor 
aromatic systems including a range of substitution patterns, fused ring systems and 
heterocycles (Figure 33). All 41 building blocks chosen, with one exception, are 
aromatic systems and were sourced from major chemical suppliers without excessive 
expense. The overall aim of this target set was to identify a refined set of compounds 
with an ERK5 IC50 below 10 µM to progress into the hit to lead process. The secondary 
aim was to draw conclusions about this area of the molecule and begin to develop a 
robust SAR. 
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Figure 33. Target compound libraries with selected examples. 
Final compounds were synthesised in one step using 6-amino indazole and various 
sulphonyl chloride building blocks in pyridine. Other methods exist for the synthesis of 
sulphonamides, however, this simple procedure was chosen due to its suitability for 
parallel synthesis. A stock solution of 6-aminoindazole in pyridine was used for 
numerous reactions, reducing reaction set up time and allowing for simultaneous 
synthesis. A limited amount of di-substitution was witnessed as both the indazole NH 
and the free amine are sufficiently nucleophilic to attack the electrophilic centre.  
Formation of the by-product ((36), Scheme 1) formed in the synthesis of thiophene 
target 38 could be controlled by reducing the temperature to 0 oC in the first instance 
and also by using a 1:1 solvent mix of THF and pyridine to lower the basicity of the 
system. All the targets were synthesised using this refined procedure which routinely 
gave the desired molecules in high yields. The employment of a Biotage v10 
instrument for the rapid removal of high boiling solvents meant that the use of 
pyridine did not impede the work up time. The reaction mixture was concentrated to a 
residue which was then suspended in a saturated sodium hydrogen carbonate solution 
and extracted with EtOAc before purification by flash chromatography. 
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Scheme 1. Reagents and conditions; a) R
1
-SO2Cl, Pyr:THF (1:1), 3-6 h, 0 
o
C-RT 9-70%.  
In a select number of cases a desired sulphonyl chloride was not available and 
therefore a longer synthesis was required. Literature precedent exists for the synthesis 
of sulphonyl chlorides from thiols in a one pot procedure or from sulphonic acids.145-146 
Conversion of pyridine-3-sulphonic acid into the corresponding sulphonyl chloride was 
attempted using PCl5 giving the product in a very low yield, 16% final product 37, and 
so was deemed an unsuitable procedure for library synthesis. It was found that 
isolation of the sulphonyl chloride further reduced the yield due to exposure to 
aqueous solution in the work up and hydrolysis of the product. For this reason the 
crude material was used directly in the sulphonamide formation reaction. 
 
Scheme 2. Formation of pyridine-3-sulphonylchloride. Reagents and conditions; a) PCl5, POCl3, 120
o
C, 
overnight; b) Pyr:THF (1:1), 3-6 h, 0 
o
C-RT 16% (over two steps). 
The conversion of sulphonic acids to sulphonyl chlorides using cyanuric trichloride has 
been reported. 147 The reaction proceeds in the presence of a base and a low boiling 
solvent at reflux as shown in Scheme 3.147 Conversion of pyridine-3-sulphonic acid was 
conducted showing some product formation. However, the stability of the sulphonyl 
chloride formed was brought in to question when the product was not isolated after a 
low temperature work up. 
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Scheme 3. Formation of sulphonyl chlorides using cyanuric trichloride. 
Sulphonyl fluorides are reportedly more stable than sulphonyl chlorides due to the 
electronegativity of fluorine and therefore an analogous reaction was conducted using 
cyanuric trifluoride. In this instance no product formation was witnessed and therefore 
a method was sought for the conversion of alternate starting materials. 
A one pot conversion of thiols to sulphonyl chlorides has been described using 
hydrogen peroxide and thionyl chloride in high yields and a short timeframe.145 This 
procedure also describes the direct conversion of thiols to sulphonamides via the 
sulphonyl chloride intermediate, making the scheme particularly attractive (Scheme 4).  
 
Scheme 4. Formation of sulphonyl chlorides and in situ amine coupling. Reagents and conditions; a) i) 
H2O2, SOCl2, MeCN, RT. ii) 6-Aminoindazole, pyridine, RT (7% over 2 steps) 
Addition of hydrogen peroxide to the thiol and thionyl chloride was exothermic and 
therefore the poor conversion witnessed was attributed to the escape of volatile 
materials or overheating. The desired final product (31) was isolated only after an 
addition of 6-amino indazole to the crude sulphonyl chloride product (Scheme 4) to 
give the sulphonamide in a 7% yield overall. 
Due to difficulties experienced in formation of sulphonyl chlorides the selection of 
starting materials was limited to sulphonyl chlorides, with the exception of compounds 
37 and 31 detailed above. 
 
58 
 
2.3.2 ERK5 structure activity relationships of indazole sulphonamides 
Final compounds of purity over 95% by HPLC were tested for inhibitory activity against 
ERK5 and p38α in the cell free, enzymatic IMAP and LANCE assays, respectively. This 
library of compounds was completed before any further design decisions were made. 
Compounds have been defined into groups for ease of comparison. Compounds 
showing potency below 10 µM (IC50) were selected as templates for further 
modifications. Synthesis of compounds in this section (2.3.2) not appearing in the 
experimental section of this thesis was conducted, under supervision, by MChem 
project student Amy Roberts. 
2.3.2.1 Aromatic and aliphatic rings 
The results in Table 13 show the different ring systems which differed from the 
substituted phenyl derivatives present in the original hits. The cyclohexane group (39) 
gives a very poor IC50 value because, even though the compound has a predicted LogP 
of 2.47, the compound was not soluble in the assay. Addition of a nitrogen atom to the 
ring (Pyridine, 37) reduces the potency significantly (> 10-fold) when compared to the 
phenyl (30). It may be that in this position the nitrogen lone pair is forming a negative 
interaction in the active site. It is therefore not possible, at this stage, to conclude that 
the 2 and 4 pyridines will also show a drop in activity. Pyrazole (41) and imidazole (40) 
compounds show no or very poor ERK5 activity, although the other 5-membered ring, 
thiophene (38), is 2-fold more potent than phenyl 30. Further thiophene derivatives 
are discussed in the following section (Chapter 2.3.2.2). 
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Table 13. Enzymatic activity data of compounds 30, 37-41 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R1 ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
38 
 
2.2 ± 1.1 >120 
37 
 
59 ± 1.3 >120 
39c 
 
>120 >120 
40 
 
>120 >120 
41 
 
64 ± 9.1 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). c Insoluble in IMAP and Lance assay. 
2.3.2.2 Thiophene derivatives 
Compound 38 (Table 13) shows marginally improved potency compared with the 
parent phenyl compound highlighting the fact that there is potential for an electron 
rich system or even a possible dipole interaction. However, various thiophene 
substitution patterns, also included in this library, do not confer any additional potency 
(Table 14).  
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Table 14. Enzymatic activity data of compounds 38, 42-47 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R1 ERK5a p38αb 
38 
 
2.2 ± 1.1 >120 
42 
 
22 ± 3.5 >120 
43 
 
41 d >120 
44 
 
79 d >120 
45c 
 
>120 >120 
46c 
 
>120 >120 
47c 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). c Insoluble in IMAP and Lance assay. d n=1 therefore 
no calculable error. 
Compounds 45-47 possess poor solubility and therefore an accurate assay result could 
not be obtained. This data suggests that only an unsubstituted thiophene is tolerated. 
However, the dataset is not conclusive as a diverse range of sulphonyl chloride building 
blocks was not available. 
2.3.2.3 Bicyclic rings 
A small number of bicyclic compounds were included in the library, shown in Table 15, 
producing some encouraging results. In the case of compound 48 and 52 the potency 
was maintained showing a large amount of tolerance in both 2,3- and 3,4- substituted 
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bicyclic systems. Comparisons between compounds 52 and 53 suggest that the 
oxindole derivative may form a hydrogen bond interaction either through the carbonyl 
group or the free NH whilst the oxazolone analogue (53) shows that there is no 
favourable interaction to be gained by including the additional oxygen. This may be 
due to a negative interaction by the oxygen or the effect it has on the hydrogen 
bonding strength of the adjacent hetero atoms. It is also possible that because of the 
hydrogen bond donor-acceptor array, the oxindole can replicate the assumed hinge 
binding interaction of the indazole thus giving two binding modes for this compound. 
The discrepancy between compounds 52 and 53 could be explained by hydrogen 
bonding strength. These theories are tested by a reversed sulphonamide series of 
compounds (Chapter 2.5.4). 
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Table 15. Enzymatic activity data of compounds 30, 34, 48-54 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R1 ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
48 
 
3.5 ± 1.7 >120 
49 
 
79d >120 
34 
 
20 ± 1.4 >120 
50 
 
16 ± 0.8 >120 
51 
 
11 ± 1.8 >120 
52 
 
1.5 ± 0.4 >120 
53 
 
9.5 ± 2.4 >120 
54c 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). c Insoluble in IMAP and Lance assay. d n = 1  
Quinoline compound 48 shows good potency, which is interesting considering the 
result of pyridine 37 shown earlier. Pyridine and quinoline are both electron deficient 
aromatics, however, the difference in potency here is over 15-fold in favour of the 
larger group. The potency may be derived from a superior conformation or lipophilic 
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interaction. Unfortunately compound 48 is the only example of a 2,3-bicyclic system in 
the library so an SAR cannot be defined. 
Cyclic-ether compounds 33-34 and 50-51 show a reduction in potency as their 
complexity increases (these gains are not significant enough to extrapolate a sensible 
SAR). These results  do indicate, along with compounds 52 and 53, that there is room 
for 3,4-fused bicycles in the ERK5 active site. 
2.3.2.4 Substituted Phenyls 
A set of compounds was chosen to explore the substitution pattern around the ring 
including electron withdrawing and donating substituents. Table 16 shows the results 
indicating that no apparent trend exists, but significant differences are seen between 
matched pairs.  para-substituted compounds 61 and 63 (CN and CF3) exhibit potency at 
least a factor of two better than the corresponding meta-substituted analogues (60 
and 62). This relationship suggests that the para-position could be a source of potency 
although this is not supported by the whole data set. 
para-Fluoro compound 57 has poor potency (IC50 33 ± 4.7 μM) and whilst both meta 
and ortho substituted analogues (56 and 55) have only moderate potency both results 
are superior. In the case of the electron rich, methoxy compounds, meta (66) and para 
(18) substitution gives reasonable potency (the only examples in the data set below 10 
μM (IC50)). There is no improvement over the unsubstituted phenyl (30) in this set of 
compounds, which suggest, contrary to the bicycle library, that space around the 
sulphonamide aryl is limited. 
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Table 16. Enzymatic activity data of compounds 18, 30-31, 55-67 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R1 ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
55 
 
23 ± 0.8 98 ± 2.7 
56 
 
22 ± 1.5 82 ± 0.03 
57 
 
33 ± 4.7 >120 
58 
 
12 ± 0.3 >120 
59 
 
14 ± 1.3 >120 
60 
 
47 ± 4.7 >120 
61 
 
17 ± 1.0 >120 
62 
 
>120 >120 
63 
 
69 ± 16 
 
>120 
64 
 
70 ± 4.0 >120 
65 
 
73 ± 11 >120 
65 
 
31 
 
24 ± 5.5 
 
>120 
66 
 
7.0 ± 0.4 >120 
18 
 
7.4 ± 0.4 >120 
67 
 
71 ± 12 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
2.3.2.5 Di-substituted Phenyls 
The di-substituted compound set shows a little difference between the various 
substitution patterns. The 2,6-difluoro compound (70) shows good potency, which is 
presumably due to the twist this substitution pattern imposes on the ring. The 
conformation invoked in compound 70 should also be seen with the mono-substituted 
derivative 55 but an almost 3-fold potency difference exists which indicates there may 
be other contributing factors. It is important to note, in both cases where the 3,5 and 
2,4 substitution patterns are repeated with both fluorine and another halogen (Cl and 
Br respectively) that the fluorinated derivative has higher activity. Bromine and 
chlorine atoms are much larger than fluorine and therefore the space around the 
aromatic group could be restricted. 
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Table 17. Enzymatic activity data of compounds 30, 68-74 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R1 ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
68 
 
37 ± 3.4 >120 
69 
 
72 ± 0.4 >120 
70 
 
7.7 ± 0.3 44 ± 8.6 
71 
 
80 ± 4.7 >120 
72 
 
26 ± 0.4 >120 
73 
 
>120 >120 
74 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
Compound 70 is the first example synthesised of interest that also shows activity 
against p38α. Other fluorine containing compounds 55 and 56 also show measurable 
activity against p38α suggesting that an electron deficient ring system confers potency 
or a beneficial interaction with a  fluorine might exist. 
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2.3.2.6 Cellular Potency of Selected Hit Compounds 
The small library synthesis revealed eight compounds with IC50 values lower than 10 
μM which were deemed suitable for future optimisation (Table 18). There is no clear 
unifying property that these compounds share meaning that the SAR remains largely 
unknown. The purpose of this screen was achieved as compounds suitable for further 
exploration have been identified without any prior knowledge of SARs. Future 
derivatives feature the potent aryl sulphonamide groups when possible, to generate 
broad and reliable SARs. 
Cellular potency gathered on select compounds in this set show that in most cases the 
enzymatic potency is representative of cellular activity. Oxindole compound 52 shows 
a discrepancy between the two assay types, however, this was not a major concern at 
this stage of the project. 
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Table 18. Enzymatic and cellular ERK5 activity data of compounds showing ERK5 IC50 below 10 μM. 
 
Compound R1 ERK5 IC50 (μM)
a 
Cellular Reporter 
assay IC50 (μM)  
52 
 
1.5 ± 0.4 13.5  ± 4.1 
38 
 
2.2 ± 1.1 - 
48 
 
3.5 ± 1.7 3.58  ± 0.3 
30 
 
4.7 ± 0.04 5.4  ± 0.8 
66 
 
7.0 ± 0.4 - 
18 
 
7.4 ± 0.4 6b 
70 
 
7.7 ± 0.3 - 
53 
 
9.5 ± 2.4 - 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b n=1 therefore no error 
available. 
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2.4 Modifications Affecting the Indazole H-bonding Profile 
To establish the role of the indazole binding to the ERK5 active site a strategy was 
devised to systematically remove the H-bond capacity of the structure. Two distinct 
targets were devised to answer these questions. Methylation of the Indazole NH 
removes its capacity to donate a Hydrogen bond but is only a small change which 
should not perturb other interactions greatly (Figure 34). Exchange of the indazole for 
an indole eliminates the H-bond acceptor capacity at the 2-position without 
introducing any significant changes to the shape or size of the molecule (Figure 34). 
Both changes were investigated in the context of the best sulphonamide substituents 
identified previously. Synthesis of these compounds was conducted, under supervision 
by MChem project students Amy Roberts (75) and Amy Heptinstall (76-80) 
 
Figure 34. Indazole H-bonding modification targets. 
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2.4.1 Synthesis and SAR of N-(1-methyl-1H-indazol-6-yl)benzenesulfonamide (75) 
The synthesis of 75 was completed in one step from the commercially available 1-
methyl-1H-indazol-6-amine and benzenesulphonyl chloride in the same way as the 
previous library was synthesised (Scheme 5, Synthesis conducted by Amy Roberts). 
 
Scheme 5. Reagents and conditions; a) RSO2Cl, Pyr, 3-6 h, 0 
o
C-RT. 
The activity data (Table 19) shows that potency is completely lost when a 1-methyl 
group is introduced on the indazole and therefore gives strong reason to believe the 
indazole NH plays a crucial role in binding. 
Table 19. Enzymatic activity data of compounds 30 and 75 against ERK5 and p38α. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
75 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
2.4.2 Synthesis and SAR of 6-Sulphonamide Indole Compounds 
Synthesis was carried out in an analogous manner to previous sulphonamide libraries 
(Scheme 6) which again gave good yields despite the instability of 6-aminoindole which 
is known to decompose at room temperature.(Synthesis was carried out by Amy 
Heptinstall) 
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Scheme 6. Reagents and conditions; a) RSO2Cl, Pyr, 3-6 h, 0 
o
C-RT. 
The ERK5 activity results show complete abolition of activity thus proving the hydrogen 
bond acceptor role of the indazole in binding. This conclusion can be made with 
confidence due to the range of sulphonamide-aryl groups included in the data set and 
the range of properties represented. 
Table 20. Enzymatic activity data of compounds 30, 76-80 against ERK5 and p38α. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
76 
 
>120 >120 
80 
 
>120 >120 
78 
 
>120 >120 
79 
 
>120 >120 
77 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
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2.4.3 Molecular Modelling of Indazole Hinge Binding 
Molecular modelling software (GOLD) has been used to propose an ERK5 binding 
interaction with compound 30 (Figure 35). The indazole is suggested to sit an 
appropriate distance from the hinge region to hydrogen bond i.e. 1.5-2.5 Å. 
Simulations have speculated that interactions exist between the indazole NH and 
Asp95 backbone carbonyl and the second indazole nitrogen with the NH of Met93. 
 
Figure 35. Molecular modelling of compound 30 (teal) in the crystallised ERK5 kinase domain (PDB: 4IC8) 
with active site surface shown in blue (H-bond acceptor) to orange (H-bond donor) and the ERK5 protein 
(rainbow). AProposed shape of compound 30 in the ERK5 active site. B) Key interactions with the ERK5 
hinge regionand compound 30 (teal) showing h-bond distances inangstroms (Å). 
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2.5 Linker Modifications 
The role of these target compound sets was to improve potency by defining the role of 
the sulphonamide linker. Systematic removal or attenuation of hydrogen bonding 
capabilities and modification of the linker conformation was conducted. 
2.5.1 Sulphonamide Alkylation 
2.5.1.1 N-Methylation 6-sulphonamide indazoles 
Sulphonamides have a pKa value of around 6-7, depending on adjacent groups, and can 
therefore be deprotonated at physiological pH. The B-Raf inhibitor Vemurafenib (81, 
Figure 36) is an example of a drug compound which is deprotonated to facilitate 
binding. In this case the sulphonamide is adjacent to an electron deficient 
difluorophenylketone which contributes to the low pKa (7.17). Without conducting a 
pH study on our compounds, we can only estimate the ionisation state and therefore it 
is unknown if the sulphonamide retains or loses its capacity as a hydrogen bond 
donator.  
 
Figure 36. Structure of B-Raf inhibitor Vemurafenib. 
To ascertain the role of this moiety in the molecule, a methyl group was introduced to 
the sulphonamide nitrogen atom removing the possibility of deprotonation and the 
ability to interact favourably with δ- groups.  To make the methylated sulphonamide, 
compounds in Table 18 were treated with methyliodide and K2CO3 in DMF (Scheme  7). 
Good selectivity was found between the sulphonamide and indazole NH, due to the 
difference in pKa (~ 6-8 and 13.2 respectively).  
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Scheme 7. Reagents and conditions; a) R
1
SO2Cl, Pyr, 3-6 h, 0 
o
C-RT. b) MeI, K2CO3, DMF, 8h 0 
o
C-RT. 
The products formed were significantly more active against ERK5 than the un-
methylated counterparts with an average 4-fold improvement and no p38α activity. 
Overall the results show that no beneficial interaction is made by the H-bond donor 
unit in question whether protonated or not. 
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Table 21. Enzymatic activity data of compounds 82-89 against ERK5 and p38α. 
 
   IC50 (μM) 
Compound R1 R2 ERK5a p38αb 
30 
 
H 4.7 ± 0.04 >120 
82 Me 1.1 ± 0.6 >120 
52 
 
H 1.5 ± 0.4 >120 
83 Me 0.33 ± 0.17 >120 
38 
 
H 2.2 ± 1.1 >120 
84 Me 0.45 ± 0.09 >120 
48 
 
H 3.5 ± 1.7 >120 
85 Me 1.5 ± 0.4 >120 
66 
 
H 7.0 ± 0.4 >120 
86 Me 3.2 ± 0.4 >120 
18 
 
H 7.4 ± 0.4 >120 
87 Me 0.35 ± 0.04 >120 
70 
 
H 7.7 ± 0.3 44 ± 8.6 
88 Me 2.6 ± 0.4 >120 
53 
89 
 
H 9.5 ± 2.4 >120 
Me 1.7 ± 0.97 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
Three compounds show an IC50 value below 1 μM (83, 84 & 87) but again there is not a 
unifying characteristic between these compounds. A distinction can be made between 
the two methoxy compounds 86 and 87 as the para-positioning gives ten-fold better 
activity than the meta. 
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2.5.1.1.1 Alternate Aryl groups on N-Methyl Sulphonamide Indazoles 
Three further N-methyl sulphonamide compounds were synthesised with variation of 
the aryl R1 group. The use of benzylsulphonyl chloride produced a compound with an 
extended linker by introduction of a benzyl carbon atom. A cyclopropyl group was 
installed as an aliphatic group that was predicted to be soluble in the assay conditions. 
A furan ring was also included in the data set as a close analogue to thiophene 84 
which has shown good potency. 
For ease of synthesis N-methyl-1H-indazol-6-amine (90) was synthesised to truncate 
the scheme to one step from a common intermediate (Scheme 8). Mono-methylation 
of 6-amino indazole was achieved by forming an imine using paraformaldehyde in the 
presence of a base and subsequent reduction using sodium borohydride in a one pot 
procedure. Yields of the sulphonamide formation were generally improved via this 
route due to the increased nucleophilicity of the reactive centre by the alkyl group. 
 
Scheme 8. Reagents and conditions; a) i) paraformaldehyde, NaOMe,  MeOH, 5h RT. ii) NaBH4, 80 
o
C, 2 h, 
(38%)   b) R
1
SO2Cl, Pyr, 3-6 h, 0 
o
C-RT (39-79%). 
As predicted the furan derivative (91) had moderate potency however the close 
analogue (84 thiophene) is significantly more potent. 
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Table 22. Enzymatic activity data of compounds 91-93 against ERK5 and p38α. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
91 
 
3.7 ± 0.5 >120 
92 
 
19.7c >120 
93 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). C no duplicate result available therefore no calculable 
error. 
The cyclopropyl derivative (92) is not aromatic and therefore possesses protons 
directed out of plane with the 3-membered ring (Figure 37). This means that even 
though it doesn’t project as far as the thiophene it occupies different space 
immediately next to the sulphonamide centre, which may affect the orientation or 
create a clash with the protein surface. It is possible that the aromatic groups included 
here are making a π-π or π–dipole interaction. However no correlation has yet been 
seen between electronics of the ring and activity. 
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Figure 37. Simulations created using Torchlite (Cresset) to show the shape of both cyclopropane 
methylsulphone (A) and 2-thiophene methylsulphone (B). 
Homologation of the linker (93) resulted in a complete loss of potency in spite of the 
good potency of considerably larger groups such as bicycles 48 and 52. It is likely that 
the vector required to orientate the phenyl ring in the most favourable position in the 
active site is not achieved by the inclusion of the extra benzylic carbon. 
2.5.1.1.2 Selectivity of N-Methyl sulphonamide Indazoles 
For all compounds tested for ERK5 activity to date, p38α activity has also been 
collected. p38α is a member of the MAP kinase family and a close homologue of ERK5, 
particularly in the kinase domain. No significant activity has been seen for p38α but the 
wider kinome shares a large amount of structural features in the active site and so 
inhibition of other kinases may occur. To determine the selectivity profile of the 
indazole sulphonamide scaffold, phenyl compound 82 was submitted for a wide kinase 
screen. 131 Kinases were screened with results given as a percent inhibition at 1 μM 
concentration of compound 82. The overall profile was good and only moderate 
inhibition of ERK8 (48%) and CDK2/A (52%) was seen (these values are directly 
comparable to potency against ERK5 (IC50 of 1.1 μM i.e. ~50% at 1 μM ).  
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An assay had previously been established in house for CDK2, so a number of close 
analogues to 82 were tested including the corresponding un-methylated 
sulphonamides. 
Table 23. Enzymatic activity data of compounds against ERK5, p38α and CDK2/A. 
 
 
   IC50 (μM) 
Compound R1 R2 ERK5a p38αb CDK2/A 
30 
 
H 4.7 ± 0.04 >120 19.2 
82 Me 1.1 ± 0.6 >120 2.1 
52 
 
H 1.5 ± 0.4 >120 12.9 
83 Me 0.33 ± 0.17 >120 5.8 
38 
 
H 2.2 ± 1.1 >120 18.4 
84 Me 0.45 ± 0.09 >120 1.3 
48 
 
H 3.5 ± 1.7 >120 2.1 
85 Me 1.5 ± 0.4 >120 0.19 
18 
 
H 7.4 ± 0.4 >120 69.7 
87 Me 0.35 ± 0.04 >120 6.7 
70 
 
H 7.7 ± 0.3 44 ± 8.6 46.9 
88 Me 2.6 ± 0.4 >120 0.48 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
Unlike p38α, compounds showed significant activity against CDK2/A. In some cases 
such as 85, 48 and 88 greater affinity is seen for CDK2/A than ERK5. As is the case with 
ERK5 activity, methylation of the sulphonamide improves potency of compounds 
against CDK2/A with an average 10-fold increase. These results show the quinolone 
moiety could be associated with CDK2/A activity making it a less interesting group for 
the design of ERK5 inhibitors. 
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From this point in the project CDK2 activity has been closely monitored whilst further 
structural modifications were made. At this stage of the project it was deemed 
unnecessary to commit to designing out CDK2 activity as a thorough SAR for ERK5 
activity had not yet been built. 
2.5.1.2 Sulphonamide N-Ethyl & N-Isopropyl Derivatives 
It has been shown that methylation of the sulphonamide nitrogen increases ERK5 
inhibition.  To investigate this gain further, progressively larger alkyl groups (ethyl and 
isopropyl) were introduced to the sulphonamide. The potency gain achieved by N-
methyl sulphonamides may have been due to the removal of an unfavourable 
interaction or the creation of a beneficial interaction. If the increase in alkyl 
substituent size improves potency it is likely that a new interaction has been identified. 
However if potency decreases it shows that masking the H-bond potential of the 
sulphonamide was the sole reason for improved potency. 
A strategy was devised to synthesise compounds first by a mono alkylation upon 6-
aminoindazole followed by a sulphonyl chloride coupling. Alkylation of the indazole 
NH2 prior to the formation of the sulphonamide presented a more efficient reaction 
sequence. Mono-alkylation has been achieved previously through reductive amination 
which worked to a satisfactory degree to give N-methyl-1H-indazol-6-amine (90, 
Scheme 8). The reductive animation using  acetaldehyde and AcOH (Reaction 2, Table 
24) gave poor conversion (12%) . However, when TFE (2,2,2-trifluoroethanol) was used 
in place of solvent and acting as the acid a significant improvement is made to 
conversion148. This is presumably due to the acidity of TFE which is sufficient to 
catalyse the reaction without the addition of strong acid such as AcOH, HCl or H2SO4. 
The reductive amination conducted to give N-isopropyl-1H-indazol-6-amine (95) 
progressed with the use of H2SO4 in a comparable yield owing to the increased stability 
of the carbonyl reagent. 
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Table 24. Conditions and yields of N-alkylation reactions. 
 
Reaction Reagent Conditions 
Yield 
/ % 
Comments / reference 
1  CsOH.H2O, DMF, 4Å MS 10 
Major product was 
6-diethylaminoindazole 
2 
 
i) DCM, AcOH 
ii) NaBH4 
12 - 
3 
 
i) TFE 
ii) NaBH4 
38 148 
4 
 
CsOH.H2O, DMF, 4Å MS 38 
Major product was 
1-isopropylaminoindazole 
5 
 
KI, MeCN, 170oC µ-wave, 10 mins 20 - 
6 
 
i) H2SO4 
ii) NaBH4 
39 - 
 
Yields of SN2 alkylations varied from poor to modest due to a number of factors (Table 
24, reactions 1, 4 and 5). There is competition between formation of primary and 
secondary amines at the 1- and 6- positions as well as the possibility for dialkylation of 
the 6-amino group. Reactions 1 and 4 rely on the ‘caesium effect’, which is reported to 
give monoalkylated amines. Cesium coordinates strongly to the lone pair on the amine 
nitrogen and because of the large size of the atom multiple alkylation reactions are 
blocked (Figure 38)149. Reactions of ethyliodide (1) or 2-bromo propane (4) gave low 
yields of the desired product accompanied by a diethyl product and the 1-propyl 
product respectively. The literature describes the use of bromoalkanes for this 
transformation and therefore the use of the more reactive iodoethane may be the 
cause of over-alkylation. The 1-NH-position is less nucleophilic than the free amine and 
therefore would be expected to react second to the aniline portion. However, 
coordination of the caesium may take precedent over the alkylation causing a 
paradoxical result. 
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Figure 38. The proposed 'Caesium effect' resulting in mono N-alkylation
149
. 
Stoichiometric control was used in the microwave assisted reaction 5 (Table 24) which 
gave the desired product in a 20% yield. The potassium iodide in the reaction is 
expected to convert the bromopropane to the iodopropane in situ which is the more 
reactive species and should therefore decrease reaction time150. The limitation of this 
reaction was the inefficient use of the amine species (3:1 equivalence with the bromo 
alkane) and therefore a more elegant procedure was sought. 
Material isolated from alkylation test reactions was used to test the sulphonyl chloride 
coupling, now with a larger degree of steric hindrance. The reaction requires the attack 
of the nucleophilic nitrogen upon the aromatic sulphonyl chloride in close proximity 
and therefore reactivity is limited by large alkyl groups attached to the nucleophile. In 
the case of the isopropyl compound 95 this resulted in sulphonamide formation at the 
indazole NH to give 96 (Scheme 9), and as a result none of the isopropyl desired 
targets were synthesised. 
 
Scheme 9. Reagents and conditions; i) Pyridine, THF, RSO2Cl, RT, 3h. 
Limited success of the sulphonyl chloride coupling reaction and poor conversion to 
monoalkylated species meant that the target compounds were synthesised by other 
means (Scheme 10). In an analogous manner to the N-methylsulphonamide compound 
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synthesis intermediates were subjected to ethylation conditions using ethyl iodide, 
Cs2CO3 in DMF which gave the desired products in satisfactory yields. 
 
Scheme 10. Reagents and conditions; a) Pyridine, THF, RSO2Cl, RT, 3h, (40-70%). b) EtI, K2CO3, DMF, 0
o
C-
RT, 4h, (30-60%). 
The activity results conclusively show that the N-ethyl group is not well tolerated in 
comparison to the N-methyl and consequently N-isopropyl analogues were not 
pursued further. Potency has fallen on average 20-fold between the methyl and ethyl 
analogues despite compounds 98, 99 and 102 achieving potency below 10 µM. 
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Table 25. Enzymatic activity data of compounds 97-104 against ERK5 and p38α. 
 
   IC50 (μM) 
Compound R1 R2 ERK5a p38αb 
97 
 
Et 17 ± 7 >120 
82 Me 1.1 ± 0.6 >120 
98 
 
Et 7.5 ± 2.2 >120 
83 Me 0.33 ± 0.17 >120 
99 
 
Et 8.7 ± 2.5 >120 
84 Me 0.45 ± 0.09 >120 
100 
 
Et 18 ± 1 >120 
85 Me 1.5 ± 0.4 >120 
101 
 
Et 57 ± 3 >120 
86 Me 3.2 ± 0.4 >120 
102 
 
Et 7.0 ± 2.9 >120 
87 Me 0.35 ± 0.04 >120 
103 
 
Et 40 ± 9 44 ± 8.6 
88 Me 2.6 ± 0.4 >120 
104 
 
Et 67 ± 24 >120 
89 
 
Me 1.7 ± 0.97 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
This data suggests that this region of the active site cannot accommodate a group as 
big as an ethyl and that the previous gain in potency between SO2NH and SO2NMe 
derivatives was because of the removal of the ionisable centre or hydrogen bonding 
potential. 
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2.5.2 Synthesis and SAR of 6-Amide Indazole Compounds 
One isostere of a sulphonamide is an amide, both groups have hydrogen bonding 
donor and acceptor moieties at equivalent proximities. The major difference of the 
sulphonamide is the presence of a second oxygen atom and the hybridisation of 
thesulphur atom. To identify if the shape of this linker is important in binding a 
number of amide targets were proposed (Figure 39). Compounds appearing in this 
section were synthesised by MChem student Amy Roberts. 
 
Figure 39. Amide Linker Targets. 
1,1'-Carbonyldiimidazole (CDI) was used with various carboxylic acids in an amide 
coupling reaction which proceeded favourably with 6-aminoindazole (Scheme 11). 
Sulphonamide aryl systems exhibiting moderate potency were selected for synthesis 
when starting materials were commercially available as carboxylic acids (Figure 39). 
 
Scheme 11. Reagents and conditions; i) CDI, R-COOH, THF. 
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Table 26. Enzymatic activity data of compounds 105-110 against ERK5 and p38α. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
106 
 
>120 >120 
110 
 
>120 >120 
108 
 
>120 >120 
109 
 
>120 >120 
107 
 
>120 >120 
105 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
The results (Table 26) show that all compounds made were inactive in the enzymatic 
assay. Although both linkers are capable of making similar interactions, the shape of 
each moiety is very different. The sulphur centre is tetrahedral whereas the carbonyl 
sp2 centre of an amide is planar. The amide is a conjugated system with partial double 
bond character. Further conjugation exists with the adjacent indazole and aryl ring 
systems. Typically, only strong steric effects can force an aromatic ring out of plane 
with an amide, as the conformation is more favourable when electron density is 
spread over a larger area, which is only possible in plane.  
It is proposed that the planarity of the amide linker compounds 104-110 is a potential 
reason for the sharp drop in potency and therefore the bend in the molecule (Figure 
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40) facilitated by the sulphonamide is in part responsible for the potency observed. 
Modelling data has suggested that the linker portion of the molecule is in close 
proximity to a Lys39 which is capable of forming an interaction with a hydrogen bond 
acceptor. It is possible that this interaction is present in the sulphonamide compounds 
but not in the amides due to the shape of the linker. It is therefore possible that 
planarity is tolerated and potency is lost only due to the loss of the H-bond interaction. 
 
Figure 40. Energetically favourable conformation of: amide (106) (A); sulphonamide (30) (B); amide(106, 
yellow) and sulphonamide(30, red) (C); amide (106) resonance (D) 
 
2.5.3 Synthesis and SAR of Cyclised Linker Indazoles 
 To investigate if the amide linker series of compounds lost potency due to lost 
hydrogen bonding interactions or the planarity of the molecule a synthetic target was 
proposed which preserves the planarity of the amide and a tetrahedral linker centre. In 
light of molecular modelling data (Figure 41) it appears that a pocket may exist that 
can accommodate an aryl group that is in plane with the indazole. By exchanging the 
aromatic and linker portion of the molecule, for a benzothiophenedioxide the 
compound will have a tetrahedral sulphonyl centre and an energetically favourable 
planar conformation. 
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Figure 41. Molecular modelling of compounds 112 (cyan), 30 (red) and 106 (yellow) in the ERK5 active 
site (PDB: 4IC8) showing the linearity of 112 and 106 in comparison to the ‘bent’ (more potent) 
conformation of 30. 
The entropy of a compound can be decreased by making it more conjugated, planar or 
by reducing the number of rotatable bonds. Kinase inhibitors are generally entropically 
constrained and highly conjugated151. Cyclisation of the linker in the indazole series 
reduces the number of rotatable bonds from three to one (not including any rotatable 
bonds on various aryl-sulphonamide groups). This design change also creates a 
completely aromatic system with the potential to be entirely planar. By installing a 
benzothiophene in the 6-position of the indazole and oxidising to the di-oxide a subtle 
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change is made to the compound’s physiochemical properties and the placement of 
functionalities, whilst the conformation is changed significantly. 
The compound 111 was synthesised via a Suzuki coupling using 6-bromoindazole and 
2-boronic acid benzothiophene to give the product in a good yield, without having to 
protect the indazole nitrogen (Scheme 12). Compound 111 was oxidised using m-CPBA 
to give the desired sulphone 112 and sulphoxide 113. The aromaticity of the thiophene 
ring detracts from the nucleophilicity of the sulphur as one lone pair is delocalised 
within the ring system. In this case the strong oxidising agent m-CPBA was used, which 
readily oxidises thiophenes to thiophene dioxide.  
 
Scheme 12. Reagents and conditions; a) 6-bromoindazole, Pd(PPh3)4, Na2CO3, Dioxane, H2O, µ-wave 
110
o
C, 30mins, (77%). b) DCM, m-CPBA, 0
o
C-RT. 
Compounds 112 and 113 were screened for activity against ERK5 and p38α with all 
results showing less than 50% inhibition at a concentration of 120 µM (Figure 42). 
Although the conformation of compound 112 matches 30 with regard to hydrogen 
bonding capacity they do not have comparable potency and therefore we can confirm 
that this class of ERK5 inhibitors require the bend in conformation shown by molecular 
modelling (Figure 43). 
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Figure 42. Activity data for the cyclised linker compounds 112 and 113. 
a
 ERK5 IC50 values generated by 
IMAP cell free assay (350 μM ATP); 
b
 p38α IC50 values generated by Lance assay (350 μM ATP).  
 
 
Figure 43. Energy minimised structure of 112 showing the structure to be completely planar (A); overlay 
of compound 112 (blue) and the more potent compound 30 (red) (B). 
 
 
 
91 
 
2.5.4 Synthesis and SAR of Reversed Indazole-6-Sulphonamide 
Having established that linear molecules, such as amides and benzothiophene 
compounds (Chapter 2.5.2 & 2.5.3), are not potent against ERK5, linker moieties which 
retain a bent conformation were investigated. A bend can be achieved with a number 
of groups such as a carbon chain, sulphone, ether as well as a sulphonamide. The 
physiochemical properties of the molecule are maintained when the sulphonamide is 
reversed but potentially interacting groups are moved. The reversal of the linker may 
add additional potency if the binding groups in the linker now find themselves at a 
preferable proximity or angle to complementing groups in the active site. The 
positioning of the sulphonamide NH in original hit compounds is known to be 
unfavourable as methylation improved potency (Table 21, Chapter 2.5.1.1). A small 
group of compounds were selected based on available materials and previously 
identified potent aryl groups (Figure 44). Because of the bend in these compounds any 
interactions made by the indazole and aromatic groups should be retained. 
 
Figure 44. Synthetic targets for reversed sulphonamide series of compounds. 
The synthesis of reversed sulphonamides 114-117 required the synthesis of indazole-6-
sulphonyl chloride 118. The sulphonyl chloride can be synthesised from 6-
aminoindazole via diazotisation followed by variations on the Sandmeyer reaction 
using either a thiol species or by forming the sulphuryl dichloride/sulphonyl chloride 
cuprate in situ (Figure 45). The latter was chosen as the introduction of the thiol would 
require oxidation to the sulphonic acid and subsequent conversion into the sulphonyl 
chloride, which had proved troublesome earlier in the project (Chapter 2.3.1). 
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Figure 45. Retrosynthetic approach to reversed sulphonamide compounds. 
Using a literature method, the conversion of 6-aminoindazole was undertaken via 
diazonium formation followed by chlorosulfonylation and sulphonamide formation 
(Scheme 13)152-155. This series of reactions was conducted without isolation of 
intermediates due to their reactivity. Diazonium formation was conducted in 
concentrated HCl with the minimum amount of water used to dissolve the sodium 
nitrite. The presence of the diazonium ion was confirmed by disappearance of the 
starting material peaks on both TLC and LCMS and with potassium iodide-starch paper 
(liberation of iodine on contact with an oxidising agent causes a dark blue colour when 
it chelates to starch, this is triggered by the presence of diazonium species). Diazonium 
salts pose an explosion risk at temperatures in excess of 10oC as diatomic nitrogen is 
released triggering a dramatic increase in volume. These temperamental materials 
were not allowed to crystalise and were kept chilled unless in the reaction mixture of 
the following step. Isolation of the diazonium is possible as a tetrafluoroborate salt 
which can be stable at room temperature.  
Once all the starting material had been converted into the diazonium-chloride salt, the 
solution was added to a pre-saturated solution of sulphur dioxide in acetic acid with 
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copper(II) chloride and SO2 gas was continuously driven through the reaction mixture. 
Sulphonyl chlorides are unstable in aqueous conditions, forming the sulphonic acid if 
not properly temperature or pH controlled.For this reason the sulphonyl chlorides 
were freshly synthesised for each aniline coupling. 
 
Scheme 13. Reagents and conditions; a) HCl, NaNO2, H2O, 0
o
C, 1h; b) SO2, CuCl2, AcOH, RT, 1h; c) 
Pyridine, RNH2, THF, RT, 3h (5-11% over three steps) 
Formation of 6-chloroindazole (119) was observed as an undesired product. This 
material was formed in roughly a 10% yield using CuCl2. This reaction goes via a 
Sandmeyer reaction mechanism which is typically used for the conversion of anilines 
to halogenated aromatics. 156 Optimisation of the reaction was undertaken by varying 
the copper species. The use of Copper(I) chloride, copper(II) chloride and copper(II) 
chloride dehydrate, however, resulted in no significant difference and copper(II) 
chloride became the reagent of choice only due to slightly improved conversion to the 
product irrespective of side products.  
 
Scheme 14. Sandmeyer side reaction. 
Sulphonyl chloride (118) formation is estimated to have been achieved in yields under 
50% based on crude material isolated.An attempt to purify this material was made by 
chromatography on silica, however, it was found that significant amounts of material 
were lost and purification was not optimised. 
Crude materials were used directly in the sulphonamide formation (Scheme 13) and 
products were formed with the overall yields shown in Table 27. 
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Table 27. Yield and activity data for the reversed linker compounds synthesised. 
   IC50 (μM) 
Compound Structure Overall yield (%) ERK5a p38αb 
30 
 
- 4.7 ± 0.04 120 
114 
 
6 
32 ± 3 
 
>120 
 
115 
 
11 
>120 
 
>120 
 
116 
 
5 
>120 
 
>120 
 
 a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
The ERK5 IC50 results illustrate that the reversed linker provides no benefit and that the 
superior isomer is in fact the more straight forward to synthesise. Measureable 
potency was seen for compound 114, however, this is almost 7-fold less active than 
the isomer 30, which has an IC50 of 4.7 µM against ERK5 and therefore reflects the loss 
of one strong interaction. Modelling predictions show that these compounds are not 
able to form the important interaction with Lys39, even though the general shape of 
the molecule is very similar (Figure 46). The sulphonyl group of compound 114 (Figure 
46, gold) is too far away from the Lys residue, even with flexibility of this residue 
simulated. If this set of reversed linker compounds had given high potency the next 
stages of SAR development would have proceeded through N-methylation and CH2 
replacement as well as the reversed amide isosteric replacement. However, this work 
becomes redundant based on these results.  
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Figure 46. Molecular modelling of compounds in the ERK5 active site; A, Compound 114 (gold); B, 
Compound 114 (gold) and compound 30 (red) (PDB: 4IC8). 
Synthesis of the reversed sulphonamide oxindole compound (117) was not completed 
due to low yielding steps and prioritisation of other series. Based on the results 
obtained (114-116, Table 27) good potency from compound 117 would have meant 
that the oxindole was able to make the key hinge interaction in place of the indazole 
which is also likely to be tolerated in the aryl pocket. However, modelling data has 
shown that this is unlikely (Figure 47). 
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Figure 47. Modelling images of compound 117 (pink) in two suggested poses showing very abstract 
conformations from the assumed potent conformation of 30 (red); A and B.  
Two in silico binding solutions of compound 117 are shown in Figure 47, neither of 
which show similar binding to compound 30 (the solutions shown (Figure 47, pink) are 
representative of the whole dataset). If the two compounds showed similar hinge 
binding then it is possible that compound 52 would have two binding modes. However, 
This theoretical result suggests that the oxindole compound 52 has good potency 
because of binding in the aryl pocket and not a dual binding mode. 
2.5.5 Synthesis and SAR of 6-Sulphone indazoles 
2.5.5.1 Synthetic targets 
Investigation into the sulphonamide linker has shown that the NH is redundant in 
compound binding and that N-Me sulphonamides conveyed better potency than the 
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un-methylated analogue (Chapter 2.5.1.1). Permutations of the linker such as reversal, 
isosteric replacement, cyclisation and alkylation did not yield an improvement to 
potency over the N-methylated sulphonamide. It is clear that an exploitable, lipophilic 
pocket or hydrogen bond acceptor is not present at this location in the active site. 
Exchange of the sulphonamide nitrogen for a carbon in the linker remained to be 
explored. This linker maintains the bent conformation in the molecule proven 
necessary from the planar molecules synthesised (Chapter 2.5.2 and 2.5.3) and the 
positioning of the sulphonyl groups to make the interaction with Lys39. Previously 
identified, potent aryl groups were selected for incorporation into the molecule when 
starting materials were available (Figure 48). 
 
Figure 48. Synthetic targets incorporating sulphone linker. 
2.5.5.2 Synthesis of 6-Sulphone Indazoles 
Target sulphone compounds (Figure 48) were synthesised using a four step synthesis 
(Scheme 15). 1H-Indazole-6-carbaldehyde was reduced to the alcohol (125) using 
sodium borohydride in a high yield and short reaction time. Two different bromination 
procedures were trialled using PBr3 or SOBr2 as the bromine sources with the latter 
found to be preferable. The bromination of hydroxyl groups to alkyl bromides has been 
described in the literature using catalytic DMF and also without DMF for the 
conversion of phenol groups. However, omission of DMF from this reaction 
significantly reduced product formation over the 4 hour reaction time.157,158 The 
increased reaction rate in the presence of DMF was therefore attributed to the 
formation of a Vilsmeier type reagent (Figure 49). This is contrary to the proposed 
98 
 
mechanism of Nagle et al which describe a nucleophilic attack on the thionyl group to 
release the bromo anion.157  
 
Figure 49. The proposed mechanism for bromination using SOBr2 with (green) and without (red) DMF on 
the hydroxy indazole. 
A one step indium/zinc mediated coupling reaction was identified for the formation of 
the sulphone using the benzylic bromide species and sulphonyl chlorides. However the 
procedure was found to be unrepeatable after testing multiple conditions.159, 160 The 
bromo-indazole was also treated with magnesium to perform a Grignard reaction, as a 
literature precedent for reaction on sulphonyl chlorides exists, but unfortunately none 
of the desired product was formed.161 The conversion of sulphonyl chlorides to sodium 
sulfinates was also conducted to then combine with bromo-indazole material. 
However, a model reaction of this was not successful and therefore an alternate 
scheme to form the sulphone via a thioether was chosen (Scheme 15). 162 This new 
scheme beneficially, facilitated the synthesis of a number of secondary targets 
(Chapter 2.5.5.4 & 2.5.5.5). 
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Scheme 15. Reagents and conditions; a) NaBH4, EtOH, RT, 3h, 86%. b) SOBr2, DMF, DCM, 0
o
C-RT, 4h, 92%. 
c) R
1
-SH, NaOH, TBAB, H2O, Toluene, RT, 18h, 36%. d) KHSO5, MeOH, H2O, RT, 18h, 19-72%. 
The SN2, thioether formation conditions shown in Scheme 15 are biphasic utilising the 
phase transfer catalyst tetrabutylammonium bromide (TBAB). Although the desired 
products were formed, solubility was an issue in this reaction when thiol species were 
varied. Further optimisation has taken place when this thioether formation was 
revisited during synthesis of later targets yielding the desired products in a faster 
reaction time and in repeatable yields. Optimisation of this reaction is shown in Table 
28 illustrating where compounds relate to this set of targets. 
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Table 2. Optimisation of SN2 reaction with various aromatic thiols. 
 
 
 R4 Substrate (R1) Conditions 
Yield (Conversion by 
LCMS) 
1 H 
 
NaOH, EtOH 42% 
     
2 H 
 
EtOH 48% 
     
3 H 
 
CsCO3, THF 35% 
     
4 H 
 
Toluene, H2O, TBAB, NaOH 
(2.2 eq) 
36% 
     
5 H 
 
NaOH, H2O 20% 
     
6a Br 
 
Toluene, H2O, TBAB, (5%) 
7a Br DMF 28% 
     
8 Br 
 
1M in THF 
THF 66% 
     
9 Br 
 
CsCO3, DMF 92% 
10 Br K2CO3, DMF 78% 
11 Br Pyridine 92% 
All reactions were conducted at room temperature.a Sodium thiophenolate had degraded and 
was therefore responsible for the low yield.  
The yield increase is explained by the solvation of all reagents in one reaction solvent 
and therefore the more efficient mixing of materials. Yields were low in water and 
ethanol presumably due to a side reaction in which a hydroxyl group is added or the 
ethyl ether is formed, both of which form an unreactive by-product. In the last three 
reactions (9-11) an aprotic base and solvent were used which reduced the risk of side 
reactions completely. A small assessment of base solubility in DMF and acetonitrile 
was done with the former proving superior and therefore used. 
101 
 
For the final oxidation step of the thioether to the sulphone, two sets of conditions 
were considered using potassium permanganate or potassium peroxymonosulfate 
(Oxone®)163. The use of Oxone®prevailed due to the handling requirements and the 
reaction progress which facilitated, in some cases, the isolation of the sulphone and 
sulphoxide species which were desired as a secondary targets. 
2.5.5.3 SAR of 6-Sulphone Indazoles 
The sulphone compounds in Table 29 all have good potency between 2.2 – 0.59 µM 
which is directly comparable to the corresponding N-Me sulphonamides which have a 
similar range (3.2-0.45 µM). all these compounds can be regarded as equipotent and 
therefore prove that the unique properties of the nitrogen, such as the H-bond 
acceptor capacity or the influence it has on the electronics of the rest of the compound, 
play no role in binding to the ERK5 active site. The ERK5 IC50 values show, explicitly, 
that the sulphonamide nitrogen is not required for potency. 
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Table 29. Activity data of sulphone compounds 120-124 compared to sulphonamides 30 and 82. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
30 
 
4.7 ± 0.04 >120 
82 
 
1.1 ± 0.6 >120 
122 
 
0.91 ± 0.15 >120 
124 
 
0.71 ± 0.25 >120 
123 
 
2.2 ± 0.2 >120 
121 
 
0.59 ± 0.07 >120 
120 
 
1.1 ± 0.2 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
These compounds are assumed to mimic the conformation of the sulphonamide 
derivatives giving similar bond angles and therefore occupying the same space in the 
active site. A molecular modelling overlay of compounds 30 and 122 in the binding 
pocket illustrates the similarity in conformation (Figure 50). 
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Figure 50. Overlay of compound 30 (red) and 122 (teal) in the ERK5 active site showing almost identical 
binding conformations. (PDB: 4IC8). 
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2.5.5.4 SAR of 6-Thioether Indazoles 
Thioethers (127-131) from Scheme 15 were also tested for potency showing complete 
inactivity except for one example, 130 (Table 30). These results suggest that a key 
interaction must exist between Lys39 and at least one sulphonyl group. 
Table 30. Activity data of thioether compounds 127-131. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
127 
 
>120 >120 
128 
 
>120 >120 
129 
 
>120 >120 
130 
 
17 ± 1 >120 
131 
 
>120 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
2.5.5.5 Synthesis and SAR of 6-Sulphoxide Indazoles 
Synthesis of sulphoxide linker compounds was possible by slight modification of the 
sulphone synthesis (Scheme 16). Sulphoxide compound 132 and sulphone compound 
122 were isolated from the same reaction by terminating the Oxone® oxidation before 
complete conversion. It was found that conversion of thioethers to sulphoxides was 
quicker than the subsequent oxidation to the sulphone and therefore compounds 132 
and 122 were isolated without any unreacted starting material present in the reaction 
mixture. Compound 133 was synthesised from thioether 128 using sodium periodate 
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which oxidises only to the sulphoxide due to the reduced nucleophilicity of the sulphur 
and reactivity of the oxidising agent.19 
 
Scheme 16. Reagents and conditions; a) KHSO5, MeOH, H2O, RT, 18h, 45% (132). b) NaIO4, MeOH, 0
o
C-RT, 
18 h, 80% (133). 
 
Table 31. Activity data of sulphoxide compounds 132 and 133. 
  IC50 (μM) 
Compound Structure ERK5a p38αb 
132 
 
15 ± 3 >120 
133 
 
14 ± 2 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
The hybridisation of the sulphur atom in the linker gives a tetrahedral shape which as 
the sulphoxide forms a stereocentre. Suphoxides do not readily invert and therefore 
give stable a racemic mixture at room temperature. All results gathered are for 
unresolved mixtures in ca. 1:1 ratio. Activity data shows that at least one isomer is 
capable of making a hydrogen bond through the sulphoxide group to Lys39 whilst the 
other has reduced activity. Molecular modelling suggests that only one interaction is 
made through a salt bridge to Lys39 (Figure 51). The area that would be occupied by 
the second oxygen is an open area with very little activity to be gained. It is possible 
that one enantiomer would have better potency than the equivalent sulphone 
compound.. However, the additional oxygen in the sulphone may align the compounds 
in a more favourable conformation and also affects the electronics on the adjacent 
aromatic. Neither of these postulations has been further investigated by resolving the 
racemic mixture and repeating the assay. 
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Figure 51. Proposed binding of the sulphoxide compound (132) showing an interaction with Lys39 (PDB: 
4IC8). 
The sulphone linker compounds show that the oxidation of the sulphone is critical and 
as a result this scaffold has been used to develop further SARs elsewhere on the 
molecule.  
2.6 Synthesis and SAR of 5-Substituted Indazoles 
The 5-position of an indazole is the most reactive to electrophilic aromatic substitution 
due to the conjugation with the heteroatom lone pairs. This means that synthesis of 
compounds substituted at this position is well described. The targets here proposed 
are isomers of the potent compounds 82-89 with N-methylated sulphonamide linker. 
Both 5 and 6-substituted indazoles project into similar space in the active site and the 
new targets have the potential to make the crucial interaction with Lys39. This set of 
target compounds can be viewed in two ways (Figure 52).  If the linker interaction is 
conserved in compound binding the flipped indazole may find a new interaction with 
the hinge region of the active site which contains numerous, exposed H-bonding sites. 
Without a crystal structure it can only be speculated which binding mode, if either 
(Figure 52), is adopted even with the aid of molecular modelling. 
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Figure 52. Proposed binding modes of 5-substituted indazole 134. 
2.6.1 Synthesis of 5- Substituted Indazoles 
Synthesis of compounds (134-149) was performed in an analogous procedure to the 6-
position sulphonamides (Scheme 17). By allowing longer for the amination and 
subsequent reduction,  N-methyl-1H-indazol-5-amine (150) was obtained in a higher 
yield (62%) compared to N-methyl-1H-indazol-6-amine (90, 38%) made when 
synthesising the 6-position analogues.  
 
Scheme 17. Reagents and conditions; a) paraformaldehyde, NaOMe, MeOH, RT, 18h, b) NaBH4, 60
o
C, 5h 
(62% over two steps), c) Pyridine, THF, R
1
-SO2Cl, RT, 3h (50-80%). 
2.6.2 Activity of 5-Substituted Indazoles 
Methylated and unsubstituted sulphonamide compounds were submitted to the ERK5 
assay to ascertain the role of the sulphonamide NH in this modified series. Table 32 
shows activity data for both linker types with variation at R1. 
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Table 32. Enzymatic activity data of sulphonamides 134-141 and N-methyl sulphonamides 142-149 
against ERK5 and p38α. 
 
   IC50 (μM) 
Compound R1 R2 ERK5a p38αb 
134 
 
H 30 ± 6 >120 
142 Me 4.7 ± 0.46 >120 
135 
 
H 4.1 ± 0.3 >120 
143 Me 3.1 ± 1.5 >120 
136 
 
H 6.4 ± 0.1 >120 
144 Me 4.1 ± 0.1 >120 
137 
 
H 82 ± 14 >120 
145 Me 23 ± 1 >120 
138 
 
H 46 ± 6 >120 
146 Me 31 ± 4 >120 
139 
 
H 51 ± 4 >120 
147 Me 10 ± 1 >120 
140 
 
H 75 ± 7 44 ± 8.6 
148 Me 24 ± 3 >120 
141 
 
H 27 ± 4 >120 
149 Me 8.6 ± 1.0 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). 
Potency of the N-methylated derivatives 142-149 is comparable to the 6-position 
analogues but overall the series has suffered a 10–fold loss in potency and no single 
analogue is more potent in the 5-position series than the 6-position. As seen with N-
methylated 6-sulphonamides the introduction of the small alkyl group improves 
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potency for all 5-sulphonamide matched pairs. This trend suggests that the 
sulphonamide interaction is retained and the indazole hinge binding is modified. If the 
same hinge interaction between the indazole and protein were retained, the alkylation 
of the sulphonamide should have little effect on potency as the group projects towards 
solvent when simulated.  
Molecular modelling in this instance does not entirely agree with the binding mode 
suggested as the R1 aromatic does not occupy the same space in 82 as it does in 
compound 142 (Figure 53). An interaction may exist with Lys39 and the linker as 
flexibility of this residue was included in the docking study but is not visualised in 
Figure 53. Regardless of the mode, this set of compounds has not changed the lead 
compound as both potency and the binding score from GOLD are inferior to the 
matched pairs of the 6-position sulphonamide compounds. 
 
Figure 53. A)Molecular modelling of compounds 142 (green) and 82 (blue) in the ERK5 active site 
showing the hinge binding of 142 is not consistent and with the established binding mode.B) 
conformation of compound 142 (green) alone in the ERK5 active site. (PDB: 4IC8). 
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2.7 4,6- and 3,6- Disubstituted Indazoles 
The SAR of the indazole and linker interactions are now well established (Figure 54), 
revealing the hinge binding between the indazole and ERK5, and the interaction 
between sulphonyl functionalities and Lys39 in the active site. A number of potency 
providing, sulphonamide aryl groups have been identified but no unifying properties 
exist regarding electronics or size. Further potency may be gained by substitution of 
other positions around the indazole. Substitution of the indazole  1-position 
(compound 75) showed complete loss of potency as the hinge interaction was 
disturbed. Investigation of the 5-position showed that there may be room in this area, 
although it is likely that when both the 5- and 6-positions are substituted the sulphonyl 
linker interaction will be reduced in strength, due to steric effects of the adjacent 
substitution. The 7-position, according to molecular modelling, directs towards 
confined space in the active site and is not expected to yield potency through 
substitution. Both the 3- and 4-positions point into open space with part of the ERK5 
active site in close proximity and therefore it was predicted that potency could be 
gained by substitution at either position. 
 
Figure 54. SARs developed in previous chapters. 
Existing indazole based kinase inhibitors are frequently di-substituted and commonly 
the 3-position is occupied, such as in axitinib (19, Figure 24). The proposed binding 
mode of lead indazole compounds is typical of kinase inhibitors. A strong hinge binding 
interaction is present in almost all marketed kinase inhibitors. This area of the enzyme 
active site is rich in functionalities capable of hydrogen bonding, usually through the 
111 
 
amino acid backbone. Molecular modelling of lead compounds suggests that the 3-
position of the indazole directs along the hinge region in good proximity to install polar 
substituents and form an additional hydrogen bond (Figure 55). Incorporation of a 
hydrogen bond donor-acceptor-donor motif is likely to be potent in a large number of 
kinases thus reducing the selectivity of the series. This is largely because the motif is 
replicated in the binding of ATP. 
 
Figure 55. Molecular modelling image of N-methyl-N-(3-(methylamino)-1H-indazol-6-yl)benzenesulfonamide 232 
(orange) in the ERK5 active site (A) and in selected binding residues (B). 
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The 4-position, according to molecular modelling, projects towards the ceiling of the 
active site in the direction of solvent (Figure 55). The space around this position 
suggests that alkyl or hydrophobic groups should be well accommodated but further 
out towards solvent, polar functionalities may be beneficial. The ceiling of the site is 
the glycine rich loop which is known to be highly flexible and therefore predicting 
anything but a broad interaction here is not possible. A valine residue sits over the 
indazole 4-position surrounded by other similar alkyl amino acid residues, therefore, 
the first set of groups to probe this position were a set of progressively larger alkyl 
groups. 
2.8 Substitution on the Indazole 4 & 6-Positions 
2.8.1 Molecular Docking of 4,6-Substituted Indazoles 
Using the described crystal structure of ERK5, potential synthetic targets were docked 
into the active site using ‘GOLD’ docking software.164 The docking study was run to a 
high efficiency with ca. 12 poses simulated for each compound. The active site was 
treated as rigid for the study with the exception of Lys39 which was permitted free 
rotation. Data generated by the programme indicates which compounds make the 
strongest interactions with ERK5, but results are not as accurate as measured activity 
in the biochemical assay. The GOLD fitness score is an amalgamation of all scoring 
functions provided by the program to give a high score designed to reflect compound 
binding enthalpy (scoring breakdown shown in Table 33). All compounds chosen are 
synthetically plausible and include the N-methyl sulphonamide. 
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Table 33. GOLD Molecular docking scoring functions. 
Score function Explanation 
Fitness 
Total fitness value of docked ligand (combination of all other 
scores) 
PLP 
All other piecewise linear potential (PLP) terms plus chemscore 
clash and internal energy term 
PLP-Part H-Bond 
Protein to ligand H-bond score - A hydrogen bond is deemed to 
be present if the distance between the acceptor and the donor 
heavy atoms are within the range 2.85 Å ± 0.45, the acceptor 
angle is within 145o ± 65 and the donor angle is within 115° ± 40. 
PLP-Part Buried 
Buried interaction types i.e. H-bond donor/acceptor of either 
protein or ligand buried in a non-polar region of the 
corresponding structure. 
PLP-Part Non-Polar Non-polar interactions e.g. lipophilic 
PLP-Part Repulsive Repulsion between protein and ligand 
PLP-Ligand clash Penalty of protein and ligand clash 
PLP-Ligand torsion Penalty for unfavourable internal ligand torsion angles 
Chemscore H-Bond Alternate Protein-ligand H-bond score 
Chemscore CH-O Score 
Weak aromatic (CH) to O H-bonding - an interaction is deemed 
to be present if the distance between the acceptor and the 
aromatic carbon is within the range 3.35Å ± 0.65, the acceptor 
angle is within 145Å ± 65, the donor angle is within 115Å ± 40 
and the CH…O bond is not more than 30° out of the aromatic 
plane 
Chemscore Protein Energy Penalty for protein clashes when flexible side chains are used 
Chemscore Internal 
Correction 
Ligand internal energy offset 
Adapted from the GOLD User Guide 
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Table 34. Molecular docking data gathered for compounds 151-158 in the ERK5 active site using GOLD. 
 
   
GOLD Fitness highscore Compound R4 
151 Et 64.4 
152 iPr 67.2 
153 CycPr 70.4 
154 Ph 68.0 
155 Benzyl 79.0 
156 NMe2 65.0 
157 Piperidine 65.7 
158 CONHMe 63.7 
 
The program has a bias towards larger compounds, making comparisons between 
compounds 151 and 155 less meaningful than those of similar molecular weight such 
as 152, 153 and 156. When comparing tertiary amine 156 with propyl groups 152 and 
153, it is clear that the lipophilic groups are better tolerated, and furthermore the 
polar amide 158 has the worst score in the set. It is most likely, from looking at this 
data and the empty crystal structure, that alkyl or lipophilic groups would be best 
tolerated in this area. Compound 155 probes furthest into the space and has the 
highest score value leaving us to assume a large lipophilic space is available for 
exploitation. 
2.8.2 4 & 6-Substituted Indazole Sulphonamide/Sulphone Synthetic Targets  
The initial set of targets probed the space at the 4-position with progressively larger 
alkyl substituents i.e. methyl, ethyl, cyclopropyl. As equivalent potency is seen for 
sulphone and N-methyl sulphonamide matched pairs, the decision of which to include 
was made based on synthetic feasibility. For this series of compounds the number of 
aryl sulphonamide systems examined was reduced from eight to four as the 2-
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thiophene, 4-methoxyphenyl, phenyl and 8-quinoline groups had consistently given 
superior potency. 
 
Figure 56. Synthetic targets exploring the 4-position 
Suitable starting materials could not be sourced that possessed the required 
functionalization without employment of an indazole ring-closing procedure. 
Retrosynthetic analysis to a derivatised 2-amino toluene revealed a commercially 
available starting material (Figure 57).  
 
Figure 57. Retrosynthetic analysis of desired compound set. 
The indazole ring-closure method progresses via diazonium formation upon the aniline 
and subsequent attack by the adjacent methyl group. Model reactions were set up 
using 3-bromo-2-methylaniline with two sets of conditions to test the critical ring-
closure step of the synthesis before commencement of the lengthy scheme (Table 
35).127  
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Table 35. Model reaction conditions for indazole ring closure. 
 
 
 Product Conditions Yield Comments Ref 
1 
 
i) HBF4 (aq), NaNO2, H2O,  
   0 oC –RT, 2 h 
ii) KOAc, 18-crown-6, DCM, 
RT, 2 h 
29% 
Starting material was 
poorly soluble in H2O. 
127 
2 
 
Acetic anhydride, KOAc, 
Toluene, Isoamylnitrite;  
60 oC, 72 h 
67%  internal 
 
Reaction 1 (Table 35) presented solubility issues despite the literature conditions 
described being employed on the same substrate.127 The procedure also required the 
isolation of a stable diazonium salt, however, this can be hazardous and introduces an 
unnecessary opportunity to lose material. At this stage reaction 2 was preferred due to 
an improved yield and minimised handling. Isoamylnitrite used in place of sodium 
nitrite allows the diazonium formation without the use of water to solubilise inorganic 
materials and therefore reagents are more readily dissolved in reaction 2.The product 
is in a protected form which may prove beneficial to the overall synthesis.  
Retrosynthetic analysis of the desired compounds (Figure 57) led to key, dibrominated 
indazole 159 from which steps previously developed in the synthesis of sulphone 
compounds (Scheme 15, Chapter 2.5.5) could be used alongside a Suzuki reaction. It 
was also determined that because of the need for an aniline-like species to undergo 
ring-closing that installing the sulphone linker would simplify the scheme. A halogen at 
the 4-position also means that intermediates generated in this synthesis can be used 
to perform Ullman, carbonylation or lithium-halogen exchange reactions to synthesise 
alternate compound libraries. 
A scheme was proposed to reach the key dibromoindazole (159) intermediate in six 
steps using typical methods and the previously modelled ring closure. The success of 
the ring closing reaction meant that functionalised benzene rings could be investigated 
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as potential starting materials leading to identification of 4-methyl-3-nitrobenzoic acid 
and a high yielding literature procedure for a regioselective bromination using 
dibromoisocyanuric acid (DBI) (Scheme 18)165. The nitro group was reduced to an 
amine to form unnatural amino acid 165 which was highly water soluble and found to 
be unrecoverable from aqueous media. This situation was remedied by the 
esterification of the acid prior to nitro reduction (160). Esterification was conducted in 
a high yield, as was the following zinc/acetic acid reduction of the nitro group giving 
162. Ring closure was attempted using the model reaction conditions. However, slow 
progress of the acetylation step meant that alternate conditions were used. 
Intermediate amine 162 was dissolved in acetic acid and a solution of NaNO2 in H2O 
was added which gave the 4,6-functionalised indazole 163 in a 94% yield. The presence 
of a minimal amount of water to solubilise NaNO2 did not affect the solubility of the 
aniline starting material. 
 
Scheme 18. Reagents and conditions; a) DBI, H2SO4, 60 
o
C, 3h, 98%. b) MeOH, H2SO4, 60 
o
C, 18h, 92%. c) Zn, AcOH, 
MeOH, 50 
o
C, 1h, 98% (yield for compound 162). d) AcOH, NaNO2, H2O, RT, 15 mins, 94%. e) LiAlH4, THF, 0 
o
C-RT, 4h, 
82%. f) SOBr2, DMF, DCM, 0 
o
C-RT, 4h, 58%. 
Conversion of the ester to benzylic bromine 159 was achieved via LiAlH4 reduction of 
163 to the alcohol 164 and the use of SOBr2 to put in place the bromine as discussed in 
Chapter 2.5.5.166 Despite the key intermediate presenting two bromine derived, active 
centres, selectivity is gained through the hybridization of each. The sp3 centre is 
sensitive to an SN2 reaction whereas the SNAr, which can occur at the 4-position under 
the same conditions is, much slower (Scheme 19). The conditions previously optimised 
for SN2 reactions in DMF with Cs2CO3 gave the desired thioethers 166-168 in good 
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yields. Oxidations proceeded well giving substrates for Suzuki reaction optimisation 
and relevant intermediate compounds 169-171 to send for testing. 
 
Scheme 19. Reagents and conditions; a) R
1
-SH, CsCO3, DMF, RT, 6h, 73-91%. b) KHSO5, MeOH, H2O, RT, 18h, 65-95%. 
Suzuki conditions previously optimised for the cyclised linker compounds (Chapter 
2.5.3) were employed but the mild palladium tetrakis catalyst and trimethylboroxine 
did not yield any product formation (Table 36). The reaction was repeated using an 
alternate boron species, methylboronic acid, but no improvement was witnessed. 
Previously developed conditions using (Pd[(P(tBu)2C5H4)2Fe]Cl2  and Cs2CO3) were 
applied,  however, the highly activated catalyst did not aid product formation only 
resulting in the dehalogenation of a small amount of starting material. Cs2CO3 is often 
used in place of sodium or potassium carbonates as it is more soluble in organic 
solvent due to the reduced charge density of the metal ion.167 
Table 36. Optimisation of Suzuki reaction on 4-methyl-6-((phenylsulfonyl)methyl)-1H-indazole (169). 
 
 Boron species Palladium Base 
Solvent 
system 
Heating Conversion 
1 
Trimethylboroxine 
(1 eq) 
Pd(PPh3)4 
(10 mol%) 
Na2CO3 
(2 eq) 
1,4-
Dioxane
and 
H2O 
150 oC, 
30 min, 
MW 
No reaction 
2 
Methylboronic acid 
(3 eq) 
Pd[(P(tBu)2C5H4)2 
Fe]Cl2 (10 mol%) 
Cs2CO3 
(1.5 eq) 
1,4-
Dioxane 
150 oC, 
30 min, 
MW 
13 % de-
halogenated 
(compound 
122) 
aConversion estimated by LCMS. 
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As reaction 2 (Table 36) showed evidence of palladium oxidative addition/ bond 
insertion these conditions were used on a protected version of compound 169. The 
indazole NH was protected with tetrahydropyran (THP). A facile procedure using 
dihydropyran (DHP), p-toluenesulfonic acid (p-TSA) in DCM giving good conversion 
(Scheme 19).144 The Suzuki reaction on 173 using conditions described in Table 37 gave 
the desired methyl product in a high yield. However, a significant amount of de-
halogenated material was generated and, therefore, a milder catalyst (Pd(dppf)cl2) was 
used in later reactions. A persistent, close running, impurity was identified after the 
Suzuki reaction as de-halogenated material which was carried forward through the 
THP deprotection using HCl in MeOH. Standard, amine and reversed phase silica were 
all used but did not remove the impurity; only semi-preparative HPLC afforded the 
pure products, impacting on the overall yield and throughput of the scheme. 
Table 37. Yields of various Suzuki reactions on bromo compounds 173-175. 
 
 R1 Palladium Species 
Yield over  
 steps i) & ii) 
172 
 
Pd[(P(tBu)2C5H4)2Fe]Cl2  
(10 mol%) 
41% 
 
179 
 
Pd[(P(Ph)2C5H4)2Fe]Cl2.DCM 
(10 mol%) 
54% 
 
180 
 
Pd[(P(Ph)2C5H4)2Fe]Cl2.DCM 
(10 mol%) 
 52% 
120 
 
 
Scheme 19. Reagents and conditions; a) DHP, p-TSA, DCM, RT, 6h 58-80%. b) Pd[(P(Ph)2C5H4)2Fe]Cl2.DCM, 
CH3B(OH)2, Cs2CO3,1,4-dioxane, 150 
o
C, MW, 0.5 h. c) MeOH.HCl (1.25 M), 18 h followed by HPLC,  30-54% (over two 
steps). 
2.8.3 Revised Synthetic Scheme for 4 & 6-Substituted Indazole Sulphones 
The remaining synthetic targets were synthesised in a revised order which avoided the 
use of semi-preparative HPLC purification (Scheme 20). By installing the alkyl R4 group 
earlier in the scheme, products were separable by reversed phase MPLC (medium 
pressure liquid chromatography) but the total number of intermediate compounds 
was increased. It was seen previously that compound 159 (dibromo) was able to 
dimerise (Figure 58). By protecting the indazole earlier in the scheme, to perform the 
Suzuki reaction, it was hoped that the homo-dimer formation would cease. In the 
SOBr2 bromination, the THP is partially removed during the reaction by HBr generated 
in situ. Because of this, the reaction was pushed to complete deprotection by the 
addition of HCl and therefore unprotected bromo compounds 186-187 were produced. 
This did not greatly impact the synthesis as dimer formation was found to be 
concentration-dependant and therefore easily avoided. 
 
Figure 58. Spontaneous dimer formation of bromine compound 159 in solution. 
The yield of the Suzuki reaction was improved significantly (from ~50% to 71-87%) 
when performed on the 6-ester, THP protected indazole (181). Final products were 
obtainable from the revised scheme without further optimisation of previously used 
reaction procedures (Scheme 20).  The overall yield of this scheme was comparable 
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with the initial scheme but could be performed more rapidly due to simplified 
purifications. 
Scheme 20. Reagents and conditions; a) DBI, H2SO4, 60 
o
C, 3h, 98%. b) MeOH, H2SO4, 60 
o
C, 18h, 92%. c) Zn, AcOH, 
MeOH, 50 
o
C, 1h, 98%. d) AcOH, NaNO2, H2O, RT, 15 mins, 94%. e) DHP, p-TSA, DCM, RT, 6h  82%. f) 
Pd[(P(Ph)2C5H4)2Fe]Cl2.DCM, R
4
-B(OH)2, Cs2CO3,1,4-dioxane, 150 
o
C, MW, 0.5 h. 71-87%.  g) LiAlH4, THF, 0 
o
C-RT, 4h, 
86-93%. h) SOBr2, DMF, DCM, 0 
o
C-RT, 4h. i) MeOH.HCl (1.25 M), 18 h, 64-91% (over two steps). j) R
1
-SH, CsCO3, 
DMF, RT, 6h,  61-97%. k) KHSO5, MeOH, H2O, RT, 18h, 34-99%. 
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2.8.4 Structure Activity Relationships of 4 & 6 Substituted Indazoles 
Pure final compounds and 4-bromo intermediates were screened for activity against 
ERK5 and p38α. Results are shown in Table 38. 
Table 38. Enzymatic activity data of 4 & 6 substituted indazoles against ERK5 and p38α. 
 
   IC50 (μM) 
Compound R1 R4 ERK5a p38αb 
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H 0.91 ± 0.15 >120 
169 Br 0.87 ± 0.47 >120 
172 Me 0.18 ± 0.04 >120 
196 Et 0.04 ± 0.01 >120 
197 CycPr 0.03 ± 0.01 >120 
120 
 
H 1.1 ± 0.2 >120 
170 Br 0.52 ± 0.31 >120 
179 Me 0.14 ± 0.04 >120 
198 Et 0.08 ± 0.01 >120 
199 CycPr 0.01 ± 0.01 >120 
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H 0.71 ± 0.25 >120 
171 Br 1.7 ± 1.0 >120 
180 Me 0.22 ± 0.03 >120 
200 Et 0.09 ± 0.01 >120 
201 CycPr 0.08 ± 0.01 >120 
121 
 
H 0.59 ± 0.07 >120 
- Br - - 
- Me - - 
202 Et 0.05 ± 0.01 - 
203 CycPr 0.03 ± 0.01 - 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
It is clear from the results that substitution at the 4-position is well tolerated and can 
have a dramatic improvement on potency. With the exception of 4-bromo derivatives 
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(169-170) potency has increased with the size of R4 substituents from methyl to 
cyclopropyl. This trend can be seen in Figure 59, R4 groups increase in size impacting 
overall  lipophilicity (represented by cLogp) as potency improves (represented by pIC50 
(pIC50 = -Log(IC50))). This relationship applies to all three complete compound sets with 
a fixed 6-position substituent (disregarding data for the brominated compounds). It is 
expected that the trend (Figure 59) will adopt a bell shape as the size of the groups 
increases eventually revealing an optimal size and lipophilicity before larger groups are 
less potent. More potency values are needed to prove this hypothesis such as 
cyclobutyl, cyclopentyl and cyclohexyl substituents (Chapter 2.4.1).  
 
Figure 59. Graph of ERK5 potency vs CLogP showing a near linear relationship. 
Comparing the 4-H and 4-cyclopropyl in each compound set the average improvement 
in potency is 42-fold. This is most likely due to the lipophilic space being occupied with 
the small alkyl group pointing along the ceiling of the active site producing a beneficial 
interaction. It is also possible that the introduction of this group changes the most 
energetically favourable conformation of the compound so that it better aligns with 
the ERK5 binding conformation (Figure 60). 
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Figure 60. Compound 196 (red) docked into the ERK5 active site showing the vector of the 4-position pointing along 
the ceiling of the active site, towards solvent. (PDB: 4IC8). 
2.4.1 Large alkyl substituents in the Indazole 4-position 
After the success of introducing alkyl groups in the 4-position and the gain in potency 
observed, the limits of this space were further investigated with progressively larger 
alkyl groups. Three aliphatic rings were chosen for incorporation increasing 
methodically in size (Figure 61). 
 
Figure 61. Synthetic targets exploring the 4-position 
These targets were synthesised using the same procedures developed in Scheme 20, 
however, large amounts of material were lost during the second bromination step due 
to formation of dimers (Figure 58). Sufficient material was not available to facilitate a 
thorough purification and therefore activity data was collected on material of purity 
below 95% by HPLC. Cyclopentyl compound 205 could not be synthesised. It is 
important to note that neither NMR nor HPLC showed a major impurity in either 
compound 204 or 206. 
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Table 39. Enzymatic activity data of compounds 204-205 against ERK5 and p38α. 
 
   IC50 (μM) 
Compound 
Purity by HPLC 
(acid/basic) 
R4 ERK5a p38αb 
120 >95%/>95% H 1.1 ± 0.2 >120 
179 >95%/>95% Me 0.14 ± 0.04 >120 
198 >95%/>95% Et 0.08 ± 0.01 >120 
199 >95%/>95% CycPr 0.01 ± 0.47 >120 
204 87%/85% Cyclobutyl 0.33 ± 0.01 - 
205 - Cyclopentyl - - 
206 82%/82% Cyclohexyl 1.6 ± 0.1 - 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
This data is less accurate than activity values shown previously, however, the results 
gathered show a drop in potency and presumably the potency limit for alkyl 
substituents in the 4-position. According to Figure 62 the optimally sized alkyl 
substituent at the 4-position is, the most potent, cyclopropyl (199). The graph displays 
the clear drop in potency as units increase in size beyond the C3H5 unit. These probes 
only elucidate the lipophilic space available at this position and therefore future 
targets were devised to introduce polarity in space beyond the reach of a cyclopropyl 
group.  
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Figure 62. Graph of ERK5 pIC50 vs molecular weight for 2-thiophene compounds 120, 179, 198, 199, 204, 206 (Table 
39). 
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2.8.5 Cellular potency of 4 & 6-position substituted indazole 
The most potent compounds from this series were tested for ERK5 activity in two cell 
lines, in different assays; a reporter assay in HEK293 cells and a Western blotting assay 
in HeLa cells.  
Table 40. Enzymatic and cellular ERK5 potency for 4,6-substituted indazole compounds. 
 
   ERK5 
Enzymatic IC50 
(μM) 
 Cellular IC50 (μM) 
Compound R1 R4 Helaa HEK293b 
172 
 
Me 0.18 ± 0.04 - 1.07 
196 Et 0.04 ± 0.01 1.3 ± 0.8 0.16 
197 CycPr 0.03 ± 0.01 0.08 ± 0.01 0.03 
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Me 0.14 ± 0.04 - 0.20 
198 Et 0.08 ± 0.01 0.02c 0.08 
199 CycPr 0.01 ± 0.01 0.04 ± 0.04 0.024 
180 
 
Me 0.22 ± 0.03 - 0.75 
200 Et 0.09 ± 0.01 0.66 ± 0.06 0.15 
201 CycPr 0.08 ± 0.01 0.27 ± 0.04 - 
a Western blot assay; b MEF2D, luciferase reporter assay; c n=1 therefore no errors. 
Both cellular assays show good correlation to enzymatic data and encouraging cellular 
potency is seen for all tested ligands. 4-Cyclopropyl compounds 197 and 199 show 50% 
inhibition at sub 100 nM concentrations. However, the thiophene compound 199 
performs best in all assay types and was therefore nominated as the lead compound in 
the series and selected for further investigation. 
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2.9 Full Profile of 4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (199) 
2.9.1 Physiochemical properties, in vitro pharmacology and in vitro DMPK profile of 
199 
The physiochemical properties of 199 are favourable as it satisfies all of Lipinski’s rules 
whilst having 4 rotatable bonds and 3 aromatic rings, which is within the typical range 
described by licenced kinase inhibitors. 168 The molecular weight is low (318 Da) 
meaning that the ligand efficiency of this molecule is exceptionally high (0.51), 
reflecting the fact that all parts of the molecule contribute to activity. There is good 
selectivity between ERK5 and p38α, however, a wider kinase screen has been carried 
out on this molecule and is discussed in Chapter 2.9.2. 
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Table 41. Medicinal chemistry profile of 4-cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (199). Good 
results are highlighted in green, undesirable in amber and poor in red. Solubility and metabolism data supplied by 
Cyprotex. 
Criteria 
Desired value 
for lead 
 
 
ERK5 IC50 (cell free) < 0.1 µM 0.012 ± 0.007 (n=6)  
ERK5 cellular potency (Hela) <1 µM 0.04 ± 0.04 (n=2)  
ERK5 cellular potency 
(HEK293) 
<1 µM 0.24 (n=1) 
 
Selectivity >10-fold 
p38α IC50 >120 µM 
+ kinase screen (Chapter 2.9.2) 
 
ERK5 Ligand Efficiency >0.3 0.51  
xLogP <5 4.8  
TPSA 75-100 63  
MW <500 318  
Plasma Protein binding <99% 92  
Caco-2 A2B/B2A 
Efflux Ratio 
>1 x10-6 cm/s 
<2 
39/20 
0.52 
 
Solubility (Lower/Upper) >50 µM 100/100  
Mouse microsomal 
clearance 
<48 µl/min/mg 378 
 
hERG inhibition IC50 >25 µM 27% at 25 µM  
CYP1A inhibition IC50 >10 µM 25  
CYP2C19 inhibition IC50 >10 µM 11  
CYP2C9 inhibition IC50 >10 µM 25  
CYP2D6 inhibition IC50 >10 µM 15  
CYP3A inhibition IC50 >10 µM 6  
 
No concern is raised by values for plasma protein binding, solubility or efflux ratio, all 
of which are within the desired range. Inhibition of hERG and selected CYP metabolic 
enzymes was found to be adequate therefore there is not a strong reason to expect 
toxicity from the compound in mice.  
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Metabolism data collected in mouse liver microsomes shows that 199 is cleared very 
quickly; this is discussed in much greater depth in Chapter 2.9.6. 
2.9.2 Selectivity profile of 4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-
indazole 199 
4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole 199 was screened for 
activity against 139 kinases, this data shows some degree of off target kinase inhibition. 
Results are gathered as percentage remaining activity at 1 µM drug concentration. 
Table 42 shows all kinases with remaining activity lower the 50% and therefore a 
theoretical IC50 below 1 µM. 
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Table 42. Selectivity data gathered for 4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole 199. Only 
inhibited kinases are shown. 
Kinase Remaining activity at 1 µM /% Notes 
IRAK1 1  
CDK9-Cyclin T1 2 CDK family 
ERK8/7 3 MAPK family 
CDK2-Cyclin A 7 CDK family 
PRK2 8  
CLK2 9  
TrkA 13  
DYRK1A 16  
DYRK2 16  
CAMKKb 17  
AMPK (hum) 19  
IRAK4 23  
HIPK2 27  
BRSK2 27  
STK33 31  
BRSK1 31  
JAK2 33  
DYRK3 34  
MAP4K3 39 MAPK family 
TAO1 40  
ERK5 42 MAPK family – Target  
ULK1 43  
ULK2 43  
TSSK1 48  
Aurora A 49  
ERK1 52 MAPK family 
ERK2 58 MAPK family 
Despite 199 showing poor activity against ERK5 in this selectivity panel, we are 
confident that our assay gives a more dependable result due to the repeatability and 
high ATP concentration. 
Collectively this data shows 23 kinase targets where 199 shows a theoretical IC50 below 
1 µM. A number of MAPK family targets (ERK1/2) are susceptible to inhibition by this 
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compound, which was not entirely unexpected given the shared sequence homology 
with ERK5. As this data showed a wide spread of inhibition, it was decided that a wider 
profile of kinases needed to be screened, therefore 199 was submitted to DiscoverX 
for a kinomescan™ which measures activity against 456 kinase targets. 
Activity is given as %ctrl given by (test signal - +ve ctrl signal)/(-ve ctrl signal - +ve ctrl 
signal) x 100). Low values indicate strongly inhibited proteins. In this assay ERK5 is 
identified as a strongly inhibited target (0.05 %ctrl) and MEK5, the upstream ERK5 
activating kinase, shows limited inhibition (82% ctrl). It may be desirable to inhibit both 
enzymes as it is currently believed the sole role of MEK5 is the activation of ERK5 
making it an equally valuable target. 
Overall the results of this assay showed that 199 possess relatively ambiguous binding 
properties. 29 Targets have a % ctrl value of 1 or less, representing a number of 
important kinase families. Data has been mapped onto the kinome (Figure 63) showing 
a number of cases of subfamily associated activity. Notably, the subfamilies are a 
mixture of serine/threonine, tyrosine and dual specificity kinases. 
 
Figure 63. Kinase Activity map for 199 on the known kinome. Red spots show <2 %ctrl, orange <10 %ctrl, green = 
ERK5.
169
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The selectivity of this compound is undesirable as some key kinase families are 
inhibited as well as ERK5 by 199 (Table 43). Ideally a lead compound should show at 
least ten-fold better potency for the target over closely related targets and one 
hundred fold for a drug candidate. In this case there are a range of kinase targets for 
which compound 199 is more active than ERK5 and therefore any effect of this 
compound in vivo cannot be directly attributed to ERK5 inhibition. 
Table 43. Selectivity data gathered for 4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole 199. Only 
inhibited kinases are shown. 
Kinase subfamily 
Inhibitory range 
(%Ctrl) 
Inhibited Members/ 
Subfamily Members 
Name 
CAMK 3.3-5.6 4/9 
Calcium/calmodulin-
dependent protein 
kinase 
CAMKK 1.2-1.7 2/2 
Calcium/calmodulin-
dependent protein 
kinase kinase 
ULK 4.2-4.6 2/4 Unc-51-Like Kinases 
CLK 1.4-3.5 4/4 
Dual specificity kinase 
acting on both 
serine/threonine and 
tyrosine-containing 
substrates 
HIPK 0.25-2 3/4 
Homeodomain-
interacting protein 
kinase 
DYRK 0.25-16 3/5 
Dual specificity Tyrosine 
Regulated Kinase 
CDK 0-5.4 4/11 
Cyclin-dependent 
kinases 
ROCK 0.3-3.2 2/2 
Rho-associated protein 
kinase 
IRAK 0-0.7 2/4 
Interleukin-1 receptor-
associated kinase 
JAK 0-0.6 2/4 Janus kinase 
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2.9.2.1 CDK2-(4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole) 199 crystal 
structure 
CDK2 inhibition by an indazole compound has been noted previously (Chapter 
2.5.1.1.2) and again with 4-cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole 
199. As CDK2 activity has been maintained it was further investigated by the 
crystallisation of 199 in the CDK2 active site (Figure 64) with the aim of designing out 
the unwanted activity. 
 
Figure 64. A-C, Crystal structure of 199 (purple) in the CDK2 active site visualised from three angles to show 
orientation of the sulphonamide aromatic and conserved hinge binding; D, molecular modeling of 199 in the ERK5 
active site. 
The CDK2 binding mode is very similar to the suggested binding of 199 in the ERK5 
active site. Subtle differences include the orientation of the thiophene ring which in 
the CDK2 structure is proposed to form a π-π stacking interaction with the indazole 
and so the rings lie in parallel planes. The geometry of the sulphonyl groups is fixed by 
this intramolecular interaction but they do not make an interaction in the site as seen 
with the ERK5 modelling. The 8-quinoline compound 85 (CDK2 IC 50 = 0.19 μM) showed 
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high CDK2 activity, presumably due to the increased overlap of the quinoline and 
indazole π-clouds therefore fixing the structure in the binding conformation. In the 
ERK5 structure the sulphonamide aryl plane is almost perpendicular to the indazole 
and therefore the aromatic group possesses a very different vector array. By adding 
groups to the sulphonamide aryl to disrupt the π-π stacking seen in the CDK structure 
selectivity may be improved.  
2.9.3 Pharmacokinetic profile of 4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-
indazole 199 
Pharmacokinetic data for 199 was collected in mice after dosing at 10 mg/Kg (Table 44). 
Three dosing methods were used; intravenous (IV), intraperitoneal (IP) and oral (PO). 
IV and IP produce very similar data however IP was conducted in this case as 
administration is preferable. The total volume tolerated through IP is higher than IV 
allowing for an easier formulation. For IP dosing the drug compound was taken in 10% 
N-methyl-2-pyrrolidone (NMP), 30% polyethylene glycol (PEG) and 60% encapsin; a 
solution which could not be used for IV. From a practical point of view IP 
administration is much easier to conduct than IV due to the size of veins in a mouse. 
All in vivo pharmacokinetic studies were performed by Dr Huw Thomas in the NICR, 
Newcastle-upon-Tyne. 
Table 44. Pharmacokinetic data for 199. 
Parameter Intravenous Dose (IV) Oral Dose (PO) 
Intraperitoneal Dose 
(IP) 
Dose (mg/kg) 10 10 10 
AUC (µg/ml.min) 74 17 79 
Cmax (µg/ml) 5.4 0.25 3.2 
tmax (min) 5 30 5 
t1/2 (min) 49 81 55 
Clearance (ml/min/kg) 136 - 126 
Vdss (L/kg) 2.2 - 3.8 
Bioavailability (%) - 24 - 
AUC = Area under curve; Vdss = volume of distribution at steady state. 
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The compound is cleared at approximately the same rate as the mouse liver blood flow 
(90 -110 ml/min/kg) which was to be expected given the high value for mouse 
microsomal clearance (378 µl/min/mg, Table 41).170 The compound had unremarkable 
plasma-protein binding figure of 92% which means that the blood clearance of the 
unbound fraction (CLu = CL/fu) is extremely high ~1600 ml/min/kg. The volume of 
distribution values are typical of a neutral compound and reflect the absorption of the 
compound. The bioavailability (24%) is therefore low due to the rapid clearance as we 
know from Caco-2 assay data (Table 41) that the compound has good cell permeability. 
 
Figure 65. A) Plasma drug concentrations following administration of 10 mg/kg 199 by three different routes (PO, IV, 
IP); B) plasma and tumour drug levels following IP administration of 10 mg/kg 199. 
 
Graphical data (Figure 65A) shows that drug plasma concentrations fall evenly in all 
dosing methods. A pharmacokinetic experiment was also conducted using mice with a 
tumour xenograft to ascertain the drug concentration in the tumour (Figure 65B). This 
analysis showed the plasma and tumour concentrations are equivalent over the 
measured time period. This data shows that cellular uptake of the compound is good 
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and with a better clearance profile this compound would be an appropriate tool for an 
in vivo ERK5 target validation experiment. 
2.9.4 Target validation using 4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-
indazole 199 
199 Has been used in a number of biological experiments in a bid to validate ERK5 as a 
target and this compound series as useful inhibitors. Results have been generated 
regarding the effect of ERK5 in angiogenesis by a matrigel plug assay and cell invasion 
by scratch assays. However, given the selectivity of compound 199 the positive results 
generated cannot solely be attributed to the effect of ERK5 inhibition. 
2.9.5 Synthesis and NMR Studies of 4-cyclopropyl-6-(difluoro(thiophen-2-
ylsulfonyl)methyl)-1H-indazole (211) 
2.9.5.1 Synthesis of 4-cyclopropyl-6-(difluoro(thiophen-2-ylsulfonyl)methyl)-1H-indazole 
(211) 
In a bid to determine the metabolites of 199 a fluorinated derivative of this compound 
was synthesised. Orally dosing mice with a fluorinated compound and running an F19-
NMR experiment with the collected animal material is often used to determine several 
properties such as where a compound accumulates, where it is metabolised and the 
biological halflife.171-173 Determining the structure of metabolites in this manner is 
difficult as gaining a spectrum with which the structure can be determined (i.e. C13/H1-
NMR) requires a large amount of sample. Alternatively, once a fluorine NMR is 
obtained using animal urine the shift of the metabolite peaks are recorded and 
oxidation reactions upon the parent compound can be performed in an effort to match 
shifts and thus predict metabolites. 
In the case of establishing the metabolism of 199 the F19-NMR spectra collected was 
proposed to be used to identify the number of major metabolites and the quantity in 
which each is formed. At this time the nature of 199 metabolism was unknown and 
therefore the desired synthetic target for this experiment would reveal all metabolites 
regardless of which area of the parent compound was affected. Potential targets 
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(Figure 66) were proposed based on synthetic feasibility and availability of starting 
materials utilising adapted versions of Scheme 19. 
 
Figure 66. Proposed fluorinated targets 207-211 and the proposed forward synthesis from a commercially available 
starting material or intermediate of Scheme 19. 
4-Fluoro (207) and fluorophenyl (209) targets were disregarded because of their 
significant structural difference to 199. Both the thiophene and cyclopropyl units could 
be sites of metabolism and therefore exclusion of these groups would not give a true 
picture of metabolism in the F19-NMR. Fluorinated compound 210 was not synthesised 
as the addition of three fluorines in two different environments will not only affect the 
complexity of the spectra but also the properties of the molecule, more so than 
desired. A silver mediated, radical procedure was found which allows fluorination of 
benzyl positions, two of which are present on 199 and therefore it was assumed 
selectivity would not be obtained.174 This target may be more attractive if synthesised 
in the sulphonamide series as a pose to the sulphone as only one benzylic centre is 
present. 
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Due to the central location of the fluorinated centre, compound 211 (fluorinated 
sulphone) was chosen for synthesis. It was postulated that metabolism of the indazole 
or thiophene would both perturb the chemical shift of the fluorine signal of compound 
211, which would most likely not be the case with compound 208. 
The synthesis of 211 was adapted from a literature procedure describing the 
fluorination of benzyl sulphonic acids and phosphonates using NaHMDS and either 
diethylaminosulfur trifluoride (DAST) or N-fluorobenzenesulfonimide (NFSI).172 Both 
reactions are driven by the breaking of a weak heteroatom (N or S) to fluorine bond 
and formation of a strong C-F bond. In this case the carbon centre is activated by 
deprotonation by a strong base. Both NaHMDS and n-butyl lithium were tested for the 
deprotonation with better results derived from the latter, stronger base. NFSI was 
used as the fluorinating agent which gave satisfactory results and was not further 
investigated (Scheme 21). The pure product was obtained and tested for enzymatic 
and cellular activity as well as mouse microsomal clearance and solubility (Table 45). 
 
Scheme 21. Synthesis of 211; Reagents and conditions; a) n-Buli, NFSI, THF, -78 
o
C-RT, 18 h, 49%. 
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Table 45. Potency, Clearance and Lipophilicity data regarding 199 and 211. 
Structure 
  
Compound 199 211 
ERK5 Enzymatic IC50 (μM) 0.012 ± 0.007 0.019 ± 0.003 
ERK5 Cellular IC50 (μM) 0.04 ± 0.04
a 0.003 ± 0.04b 
Mouse Microsomal 
Clearance (µl/min/mg) 
378 604 
cLogp 4.83 5.45 
Caco-2 A2B/B2A 
Efflux Ratio 
39/20 
0.52 
 11.8/10.7 
1.11 
a HeLa western blot assay; b MEF2D reporter assay 
Both 211 and the parent compound 199 possess excellent enzymatic and cellular 
potency against ERK5. As potency is maintained it suggests there is room for a small 
group at the sulphone position which may improve potency. However, it is crucial to 
recall the N-ethyl sulphonamides synthesised in Chapter 2.5.1.2 which showed a 
reduction. 
The fluorination of the sulphone resulted in an increase in microsomal metabolism 
indicating that the benzyl position is not a centre of metabolism, as fluorination of this 
centre removes any possibility of oxidation. It is most likely that this increase in the 
rate of metabolism is caused by the increase in lipophilicity and therefore better 
recognition by CYP enzymes. The increased lipophilicity also means that compound 
211 has inferior solubility to the parent (199) but remains sufficiently soluble for both 
activity assays to be completed and an in vivo formulation to be prepared. 
Isolation of a racemic mixture of mono-fluorinated 199 derivatives (rac-212) was 
possible upon scale up of the synthesis expected to yield 211 (Scheme 21). This 
mixture was tested for ERK5 activity in the enzymatic assay measuring a similar 
potency of 0.015 ± 0.006 μM to 199 and 211 (Figure 67). The activity of this compound 
(rac-212) reflects the same SAR generated for 211, tentatively indicating there is some 
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space for substitution at the sulphone. This compound was not used in any subsequent 
analysis due to the limited amount isolated. The mixture has not been chirally resolved. 
 
Figure 67. Structure of monofluorinated compound 212.  
2.9.5.2 F19-NMR experiments with 211 
A formulation of 211 was made up and mice were dosed via IP at 100 mg/Kg and kept 
in a metabolic cage for 24 hrs. Urine of both test and control mice was collected during 
this time and stored at -20 oC. This work was conducted by Dr Huw Thomas in the NICR, 
Newcastle-upon-Tyne. 
After calibration of the NMR to the fluorine signal of the positive control both urine 
samples were run giving the spectra shown in Figure 68. The NMR data shows that 211 
is almost entirely metabolised inside the 24 hour time period to one major metabolite. 
A remnant of un-metabolised sample is visible in the dosed animal urine but indicating 
rapid clearance. Only one new peak appears in the dosed animal urine which is unlikely 
to refer to two or more metabolites with the same chemical shift. 
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Figure 68. F
19
-NMR Spectra A) positive control (200 µL DMSO-d6, 200 µL H2O, 44 µL TFA H2O; green); B) dosed 
mouse urine (200 µL DMSO-d6, 200 µL dosed animal urine, 44 µL TFA H2O; red); C) negative control (200 µL DMSO-
d6, 200 µL negative control urine, 44 µL TFA H2O; blue). 
This data suggests only one metabolite exits which would simplify optimising the 
metabolic profile of the series, however, an out-sourced metabolite identification 
study showed that this data was not representative of 199 metabolism (Chapter 2.9.6). 
It is known from microsomal data that 211 is less metabolically stable than 199 and it 
is therefore expected that that sensitivity to different routes differs between the two 
molecules. 
Although the findings here have not improved knowledge of 199 pharmacokinetics, 
the discovery of an equipotent compound with rapid, but simple metabolism may 
prove important later in the development of indazole ERK5 inhibitors. 
2.9.6 Metabolite Identification Study of 199 
A metabolite identification experiment was outsourced to Cyprotex for 199 revealing 
five major metabolites. The study was conducted by incubating the compound (199) 
with mouse liver microsomes for 15 minutes and analysis of the resulting solution by 
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LCMS.  Mouse liver microsomes contain a mixture of CYP and other membrane bound 
metabolising enzymes found in hepatocytes. The findings of the study are summarised 
in Table 46. This study reconfirms the initial microsomal clearance data which showed 
the rapid clearance of the compound. This is made clear by the fact that almost 80% of 
the sample is metabolised in the 15 minute time frame. 
Table 46. Metabolite ID study of 199. 
Type/location Peak Area at 15 
mins (%) m/z Found 
Retention Time 
(min) 
Parent compound 199 32.4 319.0570 8.14 
 Indazole Oxidation 
 
 
12.5 335.0519 6.00 
11.4 335.0518 6.62 
17.5 335.0511 6.92 
Indazole di-oxidation 
 
 
19.4 351.0473 5.40 
Thiophene oxidation 
 
 
6.9 335.0513 7.54 
 
The study identified single oxidation of the indazole as the major metabolite. The 
experiment is not able to distinguish between the five different possible sites of 
oxidation on the cyclopropyl indazole. Metabolites are identified by mass 
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spectrometry fragmentation patterns. Compound 199 typically fragments across the 
sulphone bond which means the location of metabolites can only be determined to be 
on either the indazole or thiophene halves of the molecule. A second oxidation occurs 
on the indazole in 20% of the sample and interestingly only one metabolite is shown. 
As three singly oxidised metabolites are present it would be expected that three 
doubly oxidised metabolites would also exist. The fact that only one exists may mean 
that oxidation at certain positions on the indazole prevents further (second) oxidation. 
It is also possible that the doubly oxidised metabolite is oxidised at one or more 
different positions to the singly metabolised peaks. There are six positions which could 
potentially be oxidised on the indazole portion of the molecule highlighted in Table 46, 
not including N-oxidation (Figure 69).  
 
Figure 69. Potential oxidation sites on the indazole core. 
Position D has been discounted as an oxidation site due to synthesis of di-fluoro 
sulphone compound 211 which did not improve the metabolic profile (Chapter 2.9.5). 
Rapid oxidation of benzylic positions such as E (Figure 69) is well documented and is 
likely to have been oxidised in this case.  
Oxidation on the thiophene occurs in 7% of the sample which is the smallest portion of 
metabolites. This data only shows the effects of phase 1 metabolism caused by CYP 
enzymes but this is not necessarily the limit of compound modifications. Once oxidised 
thiophenes are susceptible to nucleophilic attack producing toxicophores depending 
on the nature of the nucleophile. If thiophene-glutathione conjugates form, renal 
excretion is increased. However, if protein or CYP enzymes act as the nucleophile 
toxicity generally increases. The real danger posed by the thiophene ring is the nature 
of the metabolites. Production of epoxides, thiols, thials and aldehydes by ring opening 
or other pathways and the formation of Michael acceptors via S-oxidation means 
numerous highly reactive species are released (Figure 70). 
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Figure 70. Biotransformations of the thiophene ring, adapted from Dolenc Et al.
124, 175
 
The most common reason for a drug to be withdrawn from the market is idiosyncratic 
toxicity derived from formation of reactive metabolites.176 Numerous drugs on the 
market contain the thiophene moiety testifying to its suitability to drug-like structure. 
In some examples the thiophene is the major source of metabolic changes to the 
molecule and is associated with various toxicities (Table 47). Oxidation of the sulphur is 
common across these drug structures with some evidence for epoxidation also. 
Toxicity is commonly associated with the liver and also the kidneys as these are the 
major sites of metabolism. CYP inhibition by Tienilic acid (213) metabolites is critical 
due to the prevalence of CYP2C9 which is speculated to metabolise 15% of all drugs.177, 
178 The chance of drug-drug interactions is significantly increased when a fundamental 
enzyme such as CYP2C9 is inactivated increasing the chance of adverse effects.179  
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Table 47. Drugs containing a thiophene ring, the metbolic pathway and any associated toxicity. Adapted from 
Dolenc et al.
175
 
# - Name Drug Structure 
Reactive 
Thiophene 
Metabolite 
Toxicity of Daily 
Dose 
Drugs containing metabolically labile thiophene: 
213-Tienilic 
acid 
 
S-oxide, epoxide CYP2C9 inactivator 
214-
Methapyrilene 
 
S-oxide 
Liver toxicity in 
rats, Periportal 
necrosis 
215-Tiaprofenic 
acid 
 
Not reported Acute cystitis 
216-Suprofen 
 
S-oxide, epoxide 
Renal toxicity in 
humans 
217-Zileuton 
 
S-oxide Hepatotoxic 
 
In every case of the drug examples included in Table 47 the thiophene is substituted in 
the 2-position and the 4-position is unoccupied. As seen in Figure 70 all five positions 
around the thiophene ring can be oxidised unless substituted meaning that only a 
completely masked thiophene, including S-oxidation, would attenuate the metabolism 
beyond doubt. Examples of both electron-rich and -deficient thiophenes are included 
in Table 47 with no clear distinction between the metabolism of either. 
Figure 71 shows thiophene containing drugs in which the thiophene is not the major 
route of metabolism. Structurally these compounds are unrelated and the properties 
cannot be correlated to aid design decisions regarding progression of 199 though it is 
encouraging that two cases of mono-substituted thiophenes exist without metabolic 
liability. 
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218-Dulxetine 
 
219-Eprosartan 
 
  
 
220-Olanzapine 221-Rivaroxaban 
Figure 71. Drugs containing a thiophene ring which are not metabolised via biotransformations of thiophene. 
Adapted from Dolenc et al
175
. 
Metabolism of the thiophene accounts for 10% of metabolites identified in the study 
and is known to produce reactive and therefore toxic metabolites. For this reason 
replacement heterocycle systems were investigated to improve the metabolic liability 
of the moiety and the overall LogP of the compound (see Chapter 2.11.1). 
2.9.6.1 Targets Arising from Metabolite Identification Study of 199 
The results of the metabolite ID study show that oxidation of the indazole and 
cyclopropyl are the major causes of fast excretion in mice. No indication is given in the 
study as to which positions on the structure are the most labile and at least three 
different positions are affected in almost equal measure. A 5-chloro indazole (222) 
derivative of 199 was proposed for synthesis to better understand the reactivity of the 
5-position. Introducing a halogen to the aromatic ring blocks any metabolism at that 
position thus if microsomal stability fluctuates a relationship can be established. A 
procedure to give compound 222 was found serendipitously when investigating 
thiophene replacement groups (Chapter 2.11.1). During thioether oxidation to 
sulphone, it was noted that a small amount of chlorination took place selectively at the 
5-position (Scheme 22). This transformation occurred due to the presence of both 
Oxone® and NaCl in the work up of the oxidation reaction.  
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Scheme 22. Hypothetical reaction of thioether 191 in Oxone®and brine to produce chlorinated derivative 222. 
2.9.6.2 Synthesis of Chlorinated Derivatives of 199 
The reaction was repeated on the sulphone compound 199 with an excess of brine in 
order to establish the limits of chlorination. Two equivalence of Oxone® in H2O, one 
equivalence of 199 in MeOH and brine were used to make a 1:1 ratio of aqueous and 
organic solvent. The solution was stirred overnight at room temperature and showed 
full conversion of the starting material to four products by LCMS after this time 
(Scheme 23). 
 
Scheme 23. Formation of chlorinated derivatives of 199 ; Reagents and conditions; a) Oxone, Brine, H2O, MeOH, RT, 
18 h, Quantative (222 36%, 223 24%, 224 21%, 225 21%). 
All four products (222-225) were separable by standard phase MPLC and produced in a 
quantative yield regarding starting material. The major product was the mono-
chlorinated compound 222 (36%) and the remaining doubly and triply chlorinated 
compounds were isolated in near equal measure. Substitution patterns were easily 
identifiable by H1-NMR after using 2D spectra to full assign 199 with high confidence. 
Proton peaks corresponding to chlorinated positions can be seen to disappear in Figure 
72 as the degree of chlorination increases. 
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Figure 72. H
1
-NMR spectra of 199 and 222-225 aromatic regions. 199  sample in CDCl3, 222-225 all in DMSO-d6.  
The chlorination is an electrophilic aromatic substitution (SEAr) caused by the 
formation of hypochlorous acid from the radical decomposition of peroxymonosulfate 
(active salt in Oxone®)(Figure 73).180 Hypochlorous acid is a highly reactive source of 
Cl+ and so the indazole positions conjugated to the NH are readily chlorinated, which 
are the unoccupied 3-, 5- and 7-positions. The electron withdrawing effects of 
halogenation of indazole are not so great that the nucleophilicity is completely 
diminished and therefore multiple chlorinations occur on one substrate leading to the 
di- and tri-halogenated compounds 222-225. 
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Figure 73. Mechanism of Oxone® mediated chlorination of 199. 
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2.9.6.3 Activity and Metabolism SARs of Chlorinated Derivatives of 199 
Indazoles 222-225 were tested for ERK5 activity and mouse liver microsome stability. 
As expected potency was diminished particularly in compounds 224 and 225 which 
both present 3-chloro groups (Table 48). 
Table 48. ERK5 activity, microsomal stability and lipophilicty of compounds 222-225. 
 Structure 
ERK5 enzymatic 
IC50 (µM)
a 
Mouse liver 
microsomal stability 
(µl/min/mg) 
CLogP 
199 
 
0.012 ± 0.007 378 4.83 
222 
 
0.28 ± 0.14 604 5.45 
223 
 
0.18 ± 0.05 696 6.07 
224 
 
4.6 ± 1.9 390 6.47 
225 
 
3.4 ± 0.3 148 7.09 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP). 
Metabolism data shows that all compounds are rapidly cleared, however, this was not 
unexpected due to increase made to LogP and the fact that some susceptible parts of 
the molecule remain exposed. Comparison of 199 and 222 indicates that the 5-position 
152 
 
is not a major site of oxidation due to the large increase in clearance. A similar 
difference in clearance is seen between 223 and 224 indicating that the occupation of 
the 3-position has a larger effect on metabolism than substitution of the 7-position. 
This conclusion is further confirmed by the clearance result of 225 which is significantly 
superior to 224 and therefore oxidation at the 3-position of 199 is more prevalent than 
the 5- or 7-positions. 
This data suggests that substitution at the indazole 3-position may yield an 
improvement to metabolism. A large number of compounds have been synthesised 
exploring the 3-position (Chapter 2.10) and the metabolic trends of these compounds 
are discussed in Chapter 2.11. 
2.10 3,6-Substituted Indazoles 
Substitution of the indazole 3-position presents a potentially fruitful vector along the 
hinge region of the ERK5 active site. As discussed previously, many drug molecules 
include 3-substituted  indazoles. The indazole structure is capable of making two close 
proximity hydrogen bonds and therefore is commonly seen to interact with the amino 
acid backbone in the kinase hinge region. Frequently an extra interaction can be 
gained by introducing a further hydrogen bonding group at the 3-position.  
2.10.1 Molecular Modelling of 3,6-Substituted Indazoles 
Using the published crystal structure of ERK5, potential synthetic targets were docked 
into the active site using docking software ‘GOLD’.164 The compounds were chosen to 
assess which linker system may be preferred (sulphone or N-methyl sulphonamide) 
and what type of group would be best tolerated in the 3-position. In total 33 
speculative compounds were proposed, 6 of which have direct relevance to the 3-
position (Table 49). Compound 226 is included for reference as a compound that was 
synthesised and tested for activity. Therefore the docking score can be related to a real 
ERK5 activity value. The docking study was run to a high efficiency with ca. 12 solutions 
predicted for each compound. The active site was treated as rigid for the study with 
the exception of Lys39 which was permitted free rotation. Whilst results generated in 
this way are not as accurate as measured activity they serve as a guide to prioritise 
synthesis. The GOLD fitness score is an amalgamation of all scoring functions provided 
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by the program giving a high score that should in theory be comparable to binding 
enthalpy (see Chapter 2.8.1 for details). All compounds chosen are synthetically 
plausible and represent 3 classes of targets, namely; alkyl (227/228) amide (229/230) 
and amine (231/232). 
Table 49. Molecular docking data gathered for compounds 226-232 in the ERK5 active site using GOLD. 
 
Compound X R3 R4 
GOLD Fitness score 
(ERK5 IC50) 
226 NMe H Et 64.4 (43 nM)  
227 CH2 
Me H 
59.6 
228 NMe 55.1 
229 CH2 
CONHMe H 
61.3 
230 NMe 56.3 
231 CH2 
NHMe H 
67.9 
232 NMe 59.3 
 
There is a clear trend in this data set suggesting that the sulphone linker is superior to 
the N-methyl sulphonamide. This conclusion is entirely due to the ligand torsion and 
ligand clash scores given by the programme which predict that the N-methyl group on 
compounds 226, 228, 230 and 232 prevents compounds adopting the binding 
conformation without a steric penalty. The results also show that the introduction of 
small amine groups at the 3-position is the most promising compound set of three due 
to an improved hydrogen bonding profile. All scores are in a range suitable for 
synthesis and the visualisations show reason to believe that larger groups will also be 
tolerated (Figure 74). 
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Figure 74. Best scoring docking pose of compound 231 (blue) in the ERK5 active site. A) ERK5 protein surface shown, 
B) Key interacting residues of ERK5 (green) with Compound 231 (blue). (PDB: 4IC8) 
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2.10.2 Synthetic 3,6-Substituted Indazole Targets 
Three compound sets were designed for investigating interactions at the 3-position; 
alkyl, amine and amide. It is hypothesised that all three can be made from one 
common halogenated intermediate using various synthetic procedures (Figure 75). 
 
Figure 75. Retrosynthetic analysis of 3-substituted indazoles, X = CH2 or NMe, R
1
 = Ph, 2-thiophene or 4-MeOPh, 
Alkyl = Me, Et, 
Cyc
Pr, Ph. 
Synthesis of both linker types was investigated and it was decided that this series of 
compounds would be made with the N-Me sulphonamide linker due to the availability 
of 3-bromo-6-nitro-1H-indazole starting material. The guidance of molecular modelling 
data means that sulphone compounds are expected to be superior to the alkylated 
sulphonamide, however, a parallel SAR is expected for 3-position substituents for both 
linkers.  
The key intermediates 237/238 were synthesised in 4 steps commencing with a THP 
protection (Scheme 24). The nitro reduction was conducted using Pd/C and H2 in a 
Thales H-cube flow reactor which gave complete conversion to 234 without the need 
for optimisation or purification. The sulphonamide formation was conducted using 
previously optimised conditions in pyridine and was methylated using methyl iodide in 
DMF with Cs2CO3. For these compound sets only phenyl and 2-thiophene R
1 groups 
were included with the major focus on 2-thiophene derivatives. 
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Scheme 24. Synthesis of key intermediates 237/238. Reagents and conditions: a) DHP, p-TSA, DCM, RT, 6 h, 86%; b) 
Pd/C, H2, EtOAc, 40 
o
C, 6 h, 99%; c) R
1
-SOOCl, Pyr, RT, 16 h, 90%; d) MeI, K2CO3, DMF, RT, 4 h, 90-98%. 
 
2.10.3 Synthesis and evaluation of 3-Alkyl-6-Sulphonamide Indazoles 
2.10.3.1 3-Alkyl-6-Sulphonamide Indazole Targets 
Synthetic targets are shown in Figure 76 all of which are accessible via Suzuki reaction 
on the key intermediate 237/238. Small probing groups have been chosen up to a large 
phenyl group which is predicted to be too large for the space. This data set revealed 
the volume of space open to the 3-position vector and some encouraging potency 
results. 
 
Figure 76. Synthetic targets for 3-alkyl indazole sulphonamides. 
2.10.3.2 Synthesis of 3-Alkyl-6-Sulphonamide Indazole Targets 
Using the Suzuki conditions employed to install alkyl groups at the indazole 4-position 
(Chapter 2.8.3) followed by THP deprotection (Scheme 25) all targets were synthesised 
in high yields (Table 50). 
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Scheme 25. Reagents and conditions: a) Pd(dppf)Cl2, R
3
-B(OH)2, Cs2CO3, 1,4-dioxane, MW, 150 
o
C, , 0.5 h, 67-99%; b) 
MeOH.HCl, RT, 6 h, 31-92%. 
Table 51. Yields of Suzuki reactions to form compounds 239-244. 
 
Compound R1 R3 Boron Species Yield 
239 
 
Me Trimethyl boroxine 85% 
240 Et EtB(OH)2 67% 
241 CycPr 
Cyc
PrB(OH)
2
 96% 
242 Ph PhB(OH)2 99% 
243 
 
Me Trimethyl boroxine 99% 
244 CycPr 
Cyc
PrB(OH)
2
 80% 
 
Two non-methylated sulphonamide targets were synthesised to maintain confidence 
in the linker SAR developed in Chapter 2.5.1 which concluded the N-methyl 
sulphonamide was superior. Targets were synthesised using the same procedures as 
Schemes 24 and 25 but the order was changed to avoid the presence of protonated 
nitrogen in the Suzuki reaction (Scheme 26). Unexpectedly, during the Suzuki reaction 
significant deprotection was witnessed resulting in the isolation of compound 253 as 
the major product in an approximately 3:2 ratio with the protected derivative. This 
synthesis yielded both final compounds, however, yields were reduced in the final step 
due to formation of 6-disulphonamide and 1,6-sulphonamides  (Figure 77) in small 
quantities. Had the THP deprotection been conducted last as initially planned this 
formation would have been limited. 
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Scheme 26. Reagents and conditions: a) DHP, p-TSA, DCM, RT, 6 h, 86%; b) Pd(dppf)Cl2, 
cyc
Pr-B(OH)2, Cs2CO3, 1,4-
dioxane, MW, 150 
o
C, , 0.5 h, 58%;  c) Pd/C, H2, EtOAc, 40 
o
C, 6 h, 93%; d) R1-SOOCl, Pyr, RT, 16 h, 17-46%. 
 
 
Figure 77. By-products of sulphonamide formation reaction 
2.10.3.3 SAR of 3-Alkyl-6-Sulphonamide Indazole Compounds 
Compounds were tested for activity against ERK5 and p38α showing a mixed range of 
potency. As was seen with the 4-substituted series, the bromine is not tolerated in 
either matched pair (Table 52). An increase in potency is seen when small alkyl groups 
are introduced, most profoundly in the complete 2-thiophene data set. Ethyl 
compound 247 shows excellent activity, however, potency dropped when a slightly 
larger cyclopropyl group (248) was introduced. This data set suggests there is room for 
a small group at the three position with alkyl properties. Compound 249 with a phenyl 
group also has good potency at 100 nM suggesting aromatic groups may also be 
tolerated. 
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Table 52. Enzymatic activity data of compounds 245-250 against ERK5 and p38α. 
 
   IC50 (μM) 
Compound R1 R3 ERK5a p38αb 
82 
 
H 1.1 ± 0.6 >120 
250 Br 2.4 ± 0.1 >120 
251 Me 0.48 ± 0.05 >120 
252 CycPr 0.32 ± 0.18 >120 
84 
 
H 0.45 ± 0.09 >120 
245 Br 3.6 ± 0.6 >120 
246 Me 0.16 ± 0.05 >120 
247 Et 0.05 ± 0.05 >120 
248 CycPr 0.29 ± 0.05 >120 
249 Ph 0.10 ± 0.01 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
Cellular data collected in the HeLa cell Western blot assay shows 3-ethyl compound 
247 to have an IC50 of 0.17 μM and 3-phenyl 249 an IC50 of 0.09 μM. Correlation 
between the enzymatic and cellular data is good in this case and both compounds have 
reasonable potency in cells. 
Overall, potency has increased over unsubstituted 3-position compounds (82 and 84) 
and therefore this substitution could be combined with substitution at the 4-position 
which may further increase potency. The sulphonamide linker targets 255-256 showed 
a consistent SAR as potency was found to be inferior to the methylated match pairs 30 
and 38 (Table 53).  
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Table 53. Enzymatic activity data of compounds 253-254 against ERK5 and p38α. 
 
    IC50 (μM) 
Compound R1 R2 ERK5a p38αb 
255 
 
H 1.3 ± 0.1 >120 
252 Me 0.32 ± 0.18 >120 
256 
 
H 1.2 ± 0.6 >120 
248 Me 0.29 ± 0.05 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
2.10.4 Synthesis and evaluation of 3-Carboxyl and Hydroxyl-6-Sulphonamide 
Indazoles 
2.10.4.1 3-Carboxyl and Hydroxyl-6-Sulphonamide Indazole Targets 
Targets in this set are polar in nature and therefore will benefit from a good LogP and 
solubility profile. This small set of compounds will help establish the hydrogen bonding 
capability in the extended hinge region of the kinase active site. Typically acidic groups 
are not desirable in a drug molecule as ionised drugs cannot pass through the cell 
membrane thus limiting the bioavailability. The functionality is also a known substrate 
for glucuronidation. Carboxylic acid target 257 is a useful intermediate for the 
synthesis of the remaining targets and therefore was also tested for activity. 
 
Figure 78. Synthetic targets exploring the 3-position with carbonyl and hydroxyl groups. 
2.10.4.2 Synthesis of 3-Carboxyl /Hydroxyl-6-Sulphonamide Indazole Targets 
There are numerous examples of carbonylation reactions in the literature describing 
conditions amenable to a halogenated substrate.181-184 To avoid the use of gaseous 
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carbon monoxide, a procedure was selected which included the in situ formation of 
the reagent from Ac2O. Bromo indazole 237 was dissolved in THF with a palladium 
catalyst and phosphor ligand, xantphos, and lithium formate. Addition of Ac2O causes 
the release of gas and is added through a septum to the sealed flask. The reaction 
proceeds though bond insertion by the palladium complex in the C-Br bond of the 
indazole and addition of the formate, the Ac2O triggers the formation of carbon 
monoxide which then follows a typical palladium-mediated carbonylation mechanism 
(Figure 79).185 This modified carbonylation procedure facilitated the conversion of the 
3-bromo-indazole intermediate 237, to the carboxylic acid 261 in a 95% yield (Scheme 
27).  
 
Figure 79. Mechanism of palladium mediated carbonylation using in situ generated CO from Ac2O and lithium 
formate; adapted from Cacchi et al.
185
 
 
Deprotection of the indazole using a low concentration of HCl gave the desired acid 
target. By using a strong acid, H2SO4, at a high concentration in MeOH a simultaneous 
esterification/deprotection reaction was performed giving the desired methyl ester 
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compound 258 (Scheme 27). The ester product (258) was reduced using LiAlH4 to yield 
the hydroxyl target 259. 
 
Scheme 27. Synthesis of final compounds 257, 258, 259. Reagents and conditions: a) Pd(OAc)2, Xantphos, Et3N, 
HCO2Li.H2O, Ac2O DMF, 90 
o
C, 2 h, 95%; b) MeOH.HCl, RT, 6 h, 69%; c) MeOH, H2SO4, RT, 18h 47%. iv) LiAlH4, THF, 4 
h 90%; 
To synthesise dimethyl-carbinol 260, a modified version of the palladium-mediated 
carbonylation was conducted using methylformate in place of lithium formate to give 
methyl 6-(N-methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-
indazole-3-carboxylate 262 (Scheme 28). The ester was formed in a satisfactory yield 
(53%) and importantly retained the THP protecting group. Compound 262 was exposed 
to a small excess of methyl magnesium bromide to give the tertiary alcohol in an 
excellent yield. Deprotection of this product was not trivial and it was found that a 
strong acid and a long reaction time was required to remove the THP group due to the 
now electron rich 3-position. 
 
Scheme 28. Synthesis of final compounds 260. Reagents and conditions: a) Pd(OAc)2, Xantphos, Et3N, HCO2Me, Ac2O 
DMF, 90 
o
C, 2 h, 53%; b) MeMgBr, THF, 0 
o
C - RT, 2 h, 87%; c) H2SO4, THF, RT, 72 h, 39%. 
2.10.4.3 SAR of 3-Carboxyl and Hydroxyl-6-Sulphonamide Indazole Compounds 
Compounds show a range of potencies from poor to moderate. The carboxylic acid 
(257) has poor ERK5 affinity whilst the methyl ester (258) analogue shows ten-fold 
superiority at 1.7 μM. The ester 258 is equipotent with the unsubstituted 3-H 
compound 84 indicating no benefit is associated with the addition of the hydrogen 
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bond acceptor functionality. Neither the carbinol (260) nor hydroxyl (259) make an 
improvement to potency, however, the result of the ester 258 and acid 257 
compounds suggests that ether versions of these compounds may confer extra 
potency. 
Table 54. Enzymatic activity data of compounds 257-260 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R3 ERK5a p38αb 
84 H 0.45 ± 0.09 >120 
257 COOH 16 ± 0.2 >120 
258 COOMe 1.7 ± 0.1 >120 
259 CH2OH 3.7 ± 0.2 >120 
260 C(CH3)2OH 2.8 ± 0.5 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
A potential problem with the synthesis of the suggested ether targets is their potential 
for elimination. The indazole is an electron rich aromatic and elimination of groups has 
been seen at the 4-position when a potential leaving group such as an amine is present 
in acidic reaction conditions. This elimination is also possible at the 3-position by a 
similar mechanism (Figure 80). Aqueous acidic conditions are likely to yield compound 
259.  
 
Figure 80. Elimination mechanism of conjugated 3,6-substituted Indazole sulphonamides 
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2.10.5 Synthesis and Evaluation of 3-Amide-6-Sulphonamide Indazoles 
2.10.5.1 3-Amide-6-Sulphonamide Indazole Targets 
A set of simple amides were designed to investigate the hydrogen bonding potential at 
the amide. Progressive alkylation of a primary amide will show if a hydrogen bond 
donor is beneficial at the 3-position, three bonds away from the indazole hinge binding 
motif. This target set represents similar chemical space to the acid and ester 
compounds 257 and 258 but amides are more ‘drug like’ as rapid metabolism is a 
lesser concern. Flexibility of these targets is expected to be limited due to the 
conjugation between the amide and aromatic indazole.  
 
Figure 81. Synthetic targets in the 3-position; amide data set. 
2.10.5.2 Synthesis of 3-Amide-6-Sulphonamide Indazole Compounds 
From the previously synthesised 3-carboxylic acid 261 a number of amide coupling 
reactions followed by an elongated deprotection reaction gave the products in a facile 
manner (Scheme 29). Carbonyldiimidazole (CDI) was used as the acid activating 
reagent in the amide coupling, giving satisfactory yields of 263-265 without rigorous 
optimisation. 
 
Scheme 29. Synthesis of final compounds 263-265 Reagents and conditions: a) Pd(OAc)2, Xantphos, Et3N, 
HCO2Li.H2O, Ac2O DMF, 90 
o
C, 2 h, 90%; b) CDI, NHR
3
2, THF, 70 
o
C , 18 h, 27-99%; c) MeOH.HCl, RT, 72 h, 34-47%. 
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2.10.5.3 SAR of 3-Amide-6-Sulphonamide Indazole Compounds 
ERK5 assay results of the amide data set show a drop in potency over the 
unsubstituted indazole matched pair 84. Methylated amides 264 and 265 have 
superior ERK5 activity to the primary amide 263 indicating that no benefit is gained by 
the hydrogen bond donor. These values can be compared with those for the methyl 
ester compound 258 which has an IC50 value of 1.7 ± 0.1 μM and is therefore 
equipotent to the alkylated amides. 
Table 55. Enzymatic activity data of compounds 263-265 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R3 ERK5a p38αb 
84 H 0.45 ± 0.09 >120 
263 CONH2 >30 >120 
264 CONHMe 3.5 ± 0.1 >120 
265 CONMe2 3.8 ± 0.7 >120 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
Similarly to the targets arising from carboxyl and hydroxyl compound sets, the removal 
of the carbonyl group to leave the alkylated amines appears to be most promising. 
Again it is expected that these targets may be unstable due to the potential for 
elimination.  
2.10.6 Synthesis and Evaluation 3-Amino-6-Sulphonamide Indazoles 
2.10.6.1 3-Amino-6-Sulphonamide Indazole Targets 
Simple synthetic targets were chosen in this data set to represent all possible 
hydrogen bonding profiles immediately adjacent to the core, at the 3-position (Figure 
82). Introduction of these groups is predicted to decrease the hydrogen bond strength 
of the indazole H-bond donor and increase the effect of the H-bond acceptor through 
the conjugation of the amine lone electron pair. The SAR of this effect is very difficult 
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to conclude as two parameters are changed simultaneously. It is known that both 
heteroatoms in the indazole core form hydrogen bonds and it is therefore predicted 
that the change in electronics will have little effect on the overall hinge binding. 
 
Figure 82. Synthetic targets in the 3-position; amine data set. 
2.10.6.2 Synthesis of 3-Amino-6-Sulphonamide Indazole Targets 
The synthesis of the amine compounds was conceived incorporating a Buchwald-
Hartwig reaction upon bromo intermediate 237. Investigation of this reaction was 
conducted on the 6-nitro,3-bromo, THP protected, indazole 233 to optimise conditions 
before application to the sulphonamide intermediate 237 (Table 56). 
Table 56. Optimisation of Buchwald-Hartwig reaction on 3-bromo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole, 
233. 
 
Reaction  Catalyst Amine/R3 Conversion 
1 Pd(OAc)2, Xantphos Me2NH No reaction  
2 Pd(OAc)2, Xantphos MeNH2 Major product is 273 
3 Pd(OAc)
2
, Xantphos PMB-NH
2
 53% 272 
4 Pd(dppf)Cl
2
.DCM PMB-NH
2
 No reaction  
5 Pd
2
(dba)
3
, Johnphos PMB-NH
2
 61% 272, 15% 273  
6 Pd(OAc)
2
, Johnphos PMB-NH
2
 No reaction  
7 Pd(PPh
3
)
4
 PMB-NH
2
 43% 273 
8 Pd
2
(dba)
3
, Brettphos PMB-NH
2
 91% 272 
PMB = Para-methoxybenzyl 
Palladium acetate and Xantphos ligand were used according to a procedure developed 
in house. Reactions (1 and 2) with simple methylated amines failed to give the desired 
product at the 3-position. The loss of the bromine in the reaction was common 
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resulting in an unusable product, 273. Microwave irradiation was employed as an 
alternative to conventional heating but it was found that vials were susceptible to 
rupture and yields were not improved. Significant improvements were made to the 
yield once the para-methoxybenzylamine(PMB-NH2) was used. Further improvements 
were made by changing the catalyst to Pd2(dba)3 and the phosphine ligand to 
Brettphos (Table 56, Reaction 8). Buchwald reactions require a phosphorous ligand on 
palladium, this usually comes as a palladium (0) catalyst and a specific phosphine 
ligand such as those listed in the Table; Xantphos, JohnPhos and BrettPhos (Figure 83). 
Reactions 4 and 7 in Table 56 do not include separate Pd catalyst and phosphine ligand 
and, interestingly, no product formation was seen in either example, although there 
was evidence for initial oxidative addition by the formation of the de-halogenated 
product 273. 
Selection of the phosphine catalyst is crucial as subtleties in the structure effect 
different stages of the Buchwald-Hartwig catalytic cycle (Figure 83 & 84). Only two of 
the dialkylbiaryl phosphine ligand class were used before a suitable yield was achieved 
so a relationship between the substitution pattern of the ligand and the progress of 
the reaction could not be established for this particular transformation on an indazole. 
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Figure 83. Structural features of dialkylbiaryl phosphine ligands adapted from Buchwald et al
186
 and the structures 
of ligands used in optimisation. 
 
 
Figure 84. Generalised Buchwald-Hartwig catalytic cycle adapted from Buchwald et al
186
. 
After the success of the Buchwald reaction (8, Table 56) on a test substrate the same 
conditions were applied to the more elaborate intermediate 237 (Scheme 30). This 
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gave the PMB protected amine 274 in a reduced yield of 51% which was deemed 
satisfactory. The THP deprotection was modified to give compound 275 as a final 
target retaining the large 3-position group. 
 
Scheme 30. Synthesis of final compound 275. Reagents and conditions: a) Pd2(dba)3, Brettphos, Cs2CO3, 1,4-dioxane, 
100 
o
C, 18 h, 51%; b) AcOH, MeOH, 70 
o
C, 2 h, 43%. 
Compound 275 was subjected to hydrogenation in an attempt to selectively remove 
the PMB group however this resulted in over cleavage giving the 3-H indazole 
sulphonamide 84. The use of MeOH.HCl, commonly used for THP deprotection, also 
gave this product. Methylation of intermediate 274 was found to be incredibly slow 
and poor yielding.  Exchanging the PMB for the more labile dimethoxy benzyl (DMB) 
did not solve the deprotection issue. It became apparent that this strategy would not 
yield the desired compounds in a repeatable manner, which was desired for the 
broadening of this target library at a later date. Therefore an alternate scheme was 
devised. 
A scheme was proposed using literature procedures which would give 3-amino targets 
in three steps without the use of a protection strategy (Scheme 31).187-189 The scheme 
was embarked upon using benzenesulfonyl chloride to maintain conditions as close to 
those given by Deng et al in the second step which was identified as key.187 Formation 
of the methyl sulphonamide 276 was conducted in a high yield, however, the following 
copper mediated coupling was found to be unrepeatable.189 This is presumably 
because of the presence of the cyano or fluorine group which are not represented in 
the test step of compounds for this reaction. This scheme was abandoned and a more 
simplistic but longer route was adopted. 
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Scheme 31. Reagents and conditions: a) MeNH2, DCM, 60 
o
C, 2 h, 94%
189
; b) 4-bromo-2-fluorobenzonitrile, CuI, N,N-
dimethylglycine, K3PO4, DMF, reflux, 48 h
187
; c) N2H4.H2O, THF, reflux, 48 h
188
. 
A route to the products via an analogous ring closing strategy was completed using 
more conventional methods to form the methylated sulphonamide (Scheme 32). 
 
Scheme 32. Synthesis of final compound 269. Reagents and conditions: a) Zn, AcOH, MeOH, 50 
o
C, 4 h, RT, 61%; b) 
2-thiophene sulphonyl chloride, Pyr, RT, 3 h, 54%; c) MeI, K2CO3, DMF, RT, 4 h, 99%; d) NHNH2, THF, RT, 18 h, 59%;  
Reduction of nitro starting material followed by sulphonamide formation and 
alkylation gave intermediate 279 in good yields. When N-(4-cyano-3-fluorophenyl)-N-
methylthiophene-2-sulfonamide 279 was treated with hydrazine the ring closing 
reaction is facilitated by an SNAr on the fluoroaromatic and nucleophilic attack by the 
hydrazine on the nitrile group to form the imidamide. Final product 269 was obtained 
from this scheme, however, alkylation of the primary amine could not be completed 
selectively without the protection of the indazole NH. Incidentally, the protection of 
this material (269) would not progress selectively using standard conditions for THP 
protection. Attempts were made to install a pre-protected indazole functionality in the 
hydrazine ring closing step by use of t-butylcarbazate in a copper mediated reaction. 
This reaction would not proceed, presumably due to the strong F-C bond preventing 
bond insertion by the copper reagent. To solve this problem bromo intermediate 281 
was proposed which complies better with literature conditions for this transformation 
and was easily synthesised. The procedures in Scheme 33 were used upon a 
brominated starting material to give Boc protected indazole 282. 
A strong base (NaH) was required to facilitate the methylation of the secondary amine 
which was attributed to the effect of the carbamate formed on the indazole drawing 
171 
 
electron density away from the nucleophilic group. The scheme allows the synthesis of 
a wide range of amines or amine derived compounds to be made by further reactions 
on intermediate 282. 
 
Scheme 33. Synthesis of final compounds 270-271. Reagents and conditions: a) 2-thiophene-SO2Cl, Pyr, RT, 3 h, 60%; 
b) MeI, K2CO3, DMF, RT, 4 h, 99%; c) CuBr, Boc-NHNH2, K2CO3, DMSO, 80 
o
C, 18 h, 43%; d) NaH, MeI, DMF, 0 
o
C-RT, 
6h 23-37% (eq varied to acquire products 283 and 284 selectively); e) TFA, DCM, RT, 2 h, 57-66%.  
2.10.6.3 SAR of 3-Amino-6-Sulphonamide Indazole Compounds 
The primary amine (269) shows moderate potency (Table 57) which is comparable to 
the unsubstituted derivative (84, ERK5 IC50 = 0.45 ± 0.09 μM), however, the dimethyl 
(271) and mono-methyl (270) show significantly worse activity. These results suggest 
neither the presence of a hydrogen bond acceptor or donor is beneficial adjacent to 
the pyrazole functionality as potency is either lost or unchanged.  Intermediate 275, 
which was also sent for testing, showing that space at this position is not limited. 
However it is possible that this compound, due to its significant differences in size and 
properties, adopts a different binding mode. The most likely conformation of 275 is 
with the ring folded back to accommodate the lipophilic space at the 4-position. 
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Table 57. Enzymatic activity data of compounds 269-271 & 275 against ERK5 and p38α. 
 
  IC50 (μM) 
Compound R3 ERK5a p38αb 
84 H 0.45 ± 0.09 >120 
269 NH2 0.79 ± 0.08 >30 
270 NHMe >30 >30 
271 NMe2 7.2 ± 0.2 >30 
275 NH-PMB 0.73 ± 0.3 >30 
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP).  
2.10.15 SAR Summary of 3-Substituted-6-Sulphonamide Indazole Compounds 
A set of 17 compounds possessing the 2-thiophene R1 group and variation at the 3-
position is compared in Table 58. The data clearly shows, by colour coding, that 
lipophilic groups at the 3-position confer the best potency and largely the polar groups 
included showed poor ERK5 affinity. 
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Table 58. Enzymatic activity data of 3-Substituted-6-Sulphonamide Indazole compounds against ERK5 and p38α. 
 
  IC50 (μM)  
Compound R3 ERK5a p38αb  
84 H 0.45 ± 0.09 >120  
269 NH2 0.79 ± 0.08 >30  
270 NHMe >30 >30  
271 NMe2 7.2 ± 0.2 >30  
275 NH-PMB 0.73 ± 0.3 >30  
257 COOH 16 ± 0.2 >120  
258 COOMe 1.7 ± 0.1 >120  
259 CH2OH 3.7 ± 0.2 >120  
260 C(CH3)2OH 2.8 ± 0.5 >120  
263 CONH2 >30 >120  
264 CONHMe 3.5 ± 0.1 >120  
265 CONMe2 3.8 ± 0.7 >120  
245 Br 3.6 ± 0.6 >120  
246 Me 0.16 ± 0.05 >120  
247 Et 0.05 ± 0.05 >120  
248 CycPr 0.29 ± 0.05 >120  
249 Ph 0.10 ± 0.01 >120  
a ERK5 IC50 values generated by IMAP cell free assay (350 μM ATP); 
b p38α IC50 values 
generated by Lance assay (350 μM ATP). Colour code base on ERK5 IC50: green < 1 μM; orange > 
1, < 10 μM; red > 10 μM. 
Substitution of the 3-position has produced significant benefits to ERK5 activity with 
two compounds reaching sub 100 nM IC50 (247 and 249). All compounds in Table 58 
contain the sulphonamide linker and it is possible that further potency could be gained 
by synthesising matched pairs of 247 and 249 with a sulphone linker. 
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2.11 Metabolism SAR of the Indazole series 
Metabolism data has been collected thus far in the form of microsomal clearance 
which determines the magnitude of metabolism caused by cytochrome p450 (CYP) 
enzymes. This is a good measure of how susceptible a compound is to phase 1 
metabolism reactions. 
Metabolism data has been collected on selected compounds where matched pairs 
exist or where significant changes to physiochemical properties have been made. 
Initially the simple compounds synthesised with a sulphonamide linker displaying 
moderate µM potency showed good clearance data, below the criteria of <48 
µl/min/mg (Table 59). Once the N-methylated linker was identified as beneficial for 
potency a faster rate of metabolism is observed (Table 59). This may be because of a 
demethylation process or better recognition by CYP enzymes due to the increase in 
LogP. Metabolism is clearly affected by the R1 ring system in this data set but no 
correlation exits between LogP and microsomal stability.  
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Table 59. Mouse microsomal clearance data of sulphonamide linker compounds. 
 
Compound  R1 R2 
Mouse Microsomal Clearance 
(µl/min/mg) 
XLogP 
38 
 
H 21 3.60 
30 
 
H 41 3.16 
83 
 
Me 24 2.44 
82 
 
Me 47 3.34 
84 
 
Me 81 3.78 
87 
 
Me 102 3.30 
85 
 
Me 174 3.48 
 
Further metabolism data was collected on the sulphone linker and 4-substituted 
compounds along with 4-substituted sulphonamide compounds 285 - 288 which were 
synthesised by Dr Stephanie Myers. This data shows a clear trend in substitution at the 
4-position causing a significant increase in the rate of metabolism (Table 60). 
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Table 60. Metabolism data of various linkers and substitution in the 2-thiophene and phenyl data sets. 
 
Compound  R1 R4 X 
Mouse Microsomal 
Clearance 
(µl/min/mg) 
 ERK5 
Enzymatic IC50 
(μM) 
XLogP 
38 
 
H NH 21 2.2 ± 1.1 3.60 
84 H NMe 81 0.45 ± 0.09 3.78 
120 H CH2 86 1.1 ± 0.2 4.05 
285 CycPr NH 126 0.09 ± 0.03 4.38 
286 CycPr NMe 432 0.43 ± 0.05 4.56 
199 CycPr CH2 378 0.01 ± 0.01 4.83 
30 
 
H NH 41 4.7 ± 0.04 3.16 
82 H NMe 47 1.1 ± 0.6 3.34 
122 H CH2 83 0.91 ± 0.15 3.61 
287 CycPr NH 94 0.20 ± 0.06 3.95 
288 CycPr NMe 200 0.99 ± 0.08 4.12 
197 CycPr CH2 319 0.03 ± 0.01 4.40 
 
A convincing trend exists between clearance and XLogP (Figure 85) showing that 
increases in lipophilicity, giving better potency in some cases, results in a higher rate of 
metabolism in almost all cases.  This finding means that a strategy could be put in 
place to improve this parameter and therefore the metabolic profile of the series. 
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Figure 85. Graph showing the relationship between microsomal clearance in mice and XLogP. 
2.11.1 Re-optimisation of the Sulphonamide Aromatic 
2.11.1.1 Decreasing the LogP by variation of the sulphonamide aryl group 
The most straightforward position to vary is the sulphonamide aromatic system whilst 
maintaining the potent cyclopropyl group at the 4-position. Chapter 2.3 describes the 
synthesis of a library of sulphonamide aromatics which exhausted viable commercially 
available sulphonyl chlorides. The sulphone linker has since been identified as 
equipotent to the N-methyl sulphonamides and therefore a novel reagent pool was 
available in the form of aromatic thiols. The groups chosen lower the overall 
lipophilicity of the molecule over matched pairs 199 and compound 197 (phenyl) 
which are two of the most potent, but metabolically labile compounds. Small 
heterocycles are not typically metabolically unstable, due to polarity and strong 
aromatic systems and therefore if this portion of the molecule is causing the high rate 
of metabolism, these modifications would alleviate it. Thiol starting materials were 
sourced and synthesis completed according to Scheme 34. 
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Scheme 34. Reagents and conditions; a) DBI, H2SO4, 60 
o
C, 3h, 98%. b) MeOH, H2SO4, 60 
o
C, 18h, 92%. c) Zn, AcOH, 
MeOH, 50 
o
C, 1h, 98%. d) AcOH, NaNO2, H2O, RT, 15 mins, 94%. e) DHP, p-TSA, DCM, RT, 6h  82%. f) 
Pd[(P(Ph)2C5H4)2Fe]Cl2.DCM, 
Cyc
Pr-B(OH)2, Cs2CO3,1,4-dioxane, 150 
o
C, MW, 0.5 h. 71%.  g) LiAlH4, THF, 0 
o
C-RT, 4h, 
93%. h) SOBr2, DMF, DCM, 0 
o
C-RT, 4h. i) MeOH.HCl (1.25 M), 18 h, 91% (over two steps). j) R
1
-SH, CsCO3, DMF, RT, 
6h, 83-99%. k) KHSO5, MeOH, H2O, RT, 18h, 56-80%. 
Compound synthesis was completed using the same scheme used in the synthesis of 
199 and was completed in high yields. Some complications occurred in the final 
oxidation step as residual oxone was present during a brine wash of the organic layer 
during work up. This caused an unwanted chlorination of indazole and the synthesis 
had to be repeated for those compounds (302, 298 & 305) with the omission of brine 
from the work up. This unwanted chlorination was later used to investigate the 
metabolism of 199 (See Chapter 2.9.6.2). 
Isolated products were tested for ERK5 activity and metabolism data was also collected 
on selected compounds based on potency or unique properties (Table 61). 
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Table 61. Activity data for re-optimisation of the sulphonamide aromatic group. 
 
Compound R1 
ERK5 Enzymatic IC50 
(μM) 
Mouse Microsomal 
Clearance 
(µl/min/mg) 
XLogP 
199 
 
0.01 ± 0.47 378 4.83 
197 
 
0.03 ± 0.01 319 4.40 
201 
 
0.08 ± 0.01 342 4.36 
298 
 
0.06 ± 0.02 - 4.33 
299 
 
0.08 ± 0.01 200 3.49 
300 
 
0.10 ± 0.09 160 2.99 
301 
 
0.36 ± 0.15 335 4.01 
302 
 
0.46 ± 0.14 - 3.99 
303 
 
0.60 ± 0.16 - 3.09 
304 
 
0.88 ± 0.48 398 2.21 
305 
 
2.2 ± 0.1 - 4.29 
306 
 
2.6 ± 1.4 190 3.53 
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No significant improvements were made to potency. However, compounds 298 and 
299 possess <100 nM potency which means the thiazole and pyridine groups will be 
considered as thiophene replacements due to the improved LogP of the compounds.  
Similarly, metabolism data has not revealed a useable improvement as values are 
higher than that required to retain a good drug concentration in an in vivo model 
(typically < 50 µl/min/mg). There is no visible correlation between predicted LogP and 
clearance data indicating that this position of the molecule is not a metabolic hot spot 
and that CYP enzyme recognition is not greatly affected by these modifications. 
2.11.1.2 Extension from the Sulphone Aromatic 
To further investigate the space around the sulphone aromatic position a set of 
elongated groups were selected for synthesis. It was proposed that potential for 
maintaining or improving potency would be possible by extending from two vectors on 
triazole 305 and phenyl 197 to probe new space with a polar moiety. Despite the poor 
activity of 305 this ring was chosen for further development because it gives chemical 
accessibility to a desirable vector towards the edge of the active site (Figure 81). 
Targets were based on synthetic feasibility with potential to expand the library to 
include ethers and amines should promising results be obtained (Figure 82). 
 
Figure 81. Synthetic targets extension from the sulphonamide aromatic. 
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Figure 82. A)Overlay of compounds 308 (blue) and 310 (orange) in the ERK5 active site (grey) showing the opposed 
vectors each provides; B) with ERK5 removed and colour coded arrows to denote each vector. 
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2.11.1.2.1 Synthesis of Extended Phenyl and Triazole Sulphone Compounds 
Phenyl derivatives 310 and 311 were synthesised by varying the thiol species in the SN2 
reaction of Scheme 35. The unprotected indazole compound 312 was then oxidised 
and the carboxylic acid reduced using borane to give both desired products. 
 
Scheme 35. Reagents and conditions; a) 3-mercaptobenzoic acid, CsCO3, DMF, RT, 6h, 92%; b) KHSO5, MeOH, H2O, 
RT, 18h, 30%; c) Borane.THF, THF, 0
o
C, 4 h, 33%. 
Triazole targets 307-309 proved more difficult to synthesise as an alkylation reaction 
was conducted on the unprotected indazole which inherently lead to selectivity issues. 
Final compounds were synthesised according to Scheme 36, however, insufficient 
material remained to complete the reduction of the ester to the hydroxyl target 309. 
 
Scheme 36. Reagents and conditions; a) 3-mercaptobenzoic acid, CsCO3, DMF, RT, 6h, 92%; b) Cs2CO3, MeI or 
methylbromoacetate, DMF, RT, 8h, 9-18%; c) KHSO5, MeOH, H2O, RT, 18h, 30-63% 
2.11.1.2.2 SAR of Extended Phenyl and Triazole Sulphone Compounds 
Compounds were tested in the enzymatic assay for activity against ERK5 however no 
major improvements were made to activity. The N-methylated triazole 307 is over 2-
fold more active than the non-methylated derivative 305 (Table 62) but potency is not 
improved over the current lead compound 199. 
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Table 62. Activity data for Sulphonamide Aromatic Extension Compounds. 
 
Compound  R1 ERK5 Enzymatic IC50 (μM) XLogP 
197 
 
0.03 ± 0.01 4.40 
310 
 
1.5 ± 0.8 3.60 
311 
 
0.29 ± 0.05 3.77 
305 
 
2.2 ± 0.1 4.29 
307 
 
0.77 ± 0.05 3.67 
308 
 
 6.8b 3.40 
b n=1. 
2.11.2 4-Position Metabolism SAR 
A number of compounds synthesised by Dr Stephanie Myers were submitted for 
mouse liver microsome, metabolic stability assessment with the sulphonamide linkers 
and variation in the 4-position (Table 63). Pyrazole and pyridine heterocycles did not 
show an advantageous improvement to clearance when compared to current lead 199 
(378 µl/min/mg). Similarly the ethyl hydroxyl compound 317b is cleared at the same 
rate as ethyl compound 321b. Di-fluoro compound 320b is cleared at a slower rate 
than 321b and therefore highlights the alkyl group as a metabolic site. This finding is 
backed up by the clearance of trifluoromethyl compound 318b but contradicted by 
319b. It is highly likely that the 4-position alkyl groups are centres for metabolism but 
based on this data it is not confirmed. 
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Comparison of N-methyl and non-methylated sulphonamides show the latter to be 
much more stable to CYP enzymes. This suggests that N-demethylation is a metabolic 
pathway for these compounds. 
Table 63. Metabolism of selected 4,6-substituted indazole sulphonamides. 
 
 
 
 
R4 
MLM Clint (µl/min/mg) 
R2 = H                                        R2 = Me 
315a/b 
NHN
 
- 327 
316a/b 
N
 
- 238 
317a/b 
OH
 
- 412 
318a/b 
CF3
 
46 161 
319a/b 
F F
 
65 409 
320a/b 
F
F
 
- 225 
321a/b Et - 436 
 
2.11.3 Metabolism SAR of 3,6-Substituted Indazoles 
Clearance of compounds substituted in the 4-position is poor, however, the effects of 
substitution at the 3-position on metabolism are not known. Microsomal clearance 
data was collected on a number of compounds with various interesting 3-position 
substituents. Table 64 shows the activity and clearance data of selected compounds.  
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Table 64. ERK5 activity and metabolism data of selected 3,6-substitued indazole sulphonamides 
 
Compound  R3 
ERK5 Enzymatic 
IC50 (μM) 
Mouse 
Microsomal 
Clearance 
(µl/min/mg) 
XLogP 
84 H 0.45 ± 0.09 81 3.78 
247 Et 0.05 ± 0.05 1010 4.39 
248 CycPr 0.29 ± 0.05 287 4.47 
269 NH2 0.79 ± 0.08 8.3 3.43 
 
Amine compound 269 has an excellent clearance value and is the most metabolically 
stable compound made and measured in the series so far. 269 Is 10-fold more stable 
than the unsubstituted compound 84 and is well within the acceptable range of 
microsomal clearance values desired (<48 µl/min/mg). The drop in clearance may be 
attributed to the net reduction in LogP. However, this does not seem significant and 
previously has not correlated with clearance (Chapter 2.11.1.1). The stability of 269 
may be due to the placement of the solubilising group which affects the CYP enzyme’s 
ability to act upon the 3-position or other positions on the indazole. Typically, 
increasing the nucleophilicity of a ring system results in an increase in metabolism due 
to the increase in reactivity. With this in mind it is therefore most likely that the 
compound’s affinity for the CYP enzyme is lost due to the placement of this amine 
group. Unfortunately, compound 269 does not possess good potency, but the concept 
of increasing polarity at the 3-position of the molecule is incorporated into future 
targets to retain the good clearance profile and improve potency. 
It is proposed that during CYP oxidation a proton is first abstracted from the substrate 
before the introduction of the hydroxyl group and therefore the rate is dependent on 
the strength of the bond being broken and the nucleophilicity of the resulting 
structure.190 Ethyl compound 247 has the worst microsomal stability of all compounds 
tested and is cleared over 3-fold quicker than the cyclopropyl compound 248.  This 
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relationship between ethyl and cycloproply groups is expected due to the comparative 
bond strength of C-H bonds in each group. Cyclopropyl C-H bonds have an energy of 
109.0 kcal mol-1 compared to ethane at 101.2 kcal mol-1. This translates to the 
metabolic stability witnessed.191 
Both ethyl and cyclopropyl groups have also been incorporated in the 4-position of the 
indazole in a separate data set and a similar relationship is seen (Table 65). Although 
the difference in clearance is less pronounced, ethyl compound 198 is metabolised at a 
higher rate (513 µl/min/mg) than the cyclopropyl analogue 199 (378 µl/min/mg). This 
conserved relationship indicates than in both the 3- and 4-substituted indazoles the 
alkyl appendage is a metabolic centre. 
Table 65. ERK5 activity and metabolism data of selected 4,6-substitued indazole sulphones 
 
Compound R4 
ERK5 Enzymatic 
IC50 (μM) 
Mouse 
Microsomal 
Clearance 
(µl/min/mg) 
XLogP 
198 Et 0.08 ± 0.01 513 4.75 
199 CycPr 0.01 ± 0.01 378 4.83 
 
 
2.11.3.1 Synthesis and metabolism of N-(3-(difluoromethyl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (322) 
Although the metabolism of 3-substituted compounds was improved drastically by the 
introduction of an amino group there was no associated benefit to potency. 
Introduction of alkyl groups did improve potency but the metabolic profile of these 
compounds was disappointing. In order to remove the liability of the introduced 
metabolic centres synthesis of the fluorinated derivatives was attempted. Compound 
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322, the 3-CHF2 compound (Figure 83) was the only example synthesized due to the 
relative ease by which it could be made from intermediates already in hand. 
 
Figure 83. Difluoro compound 322. 
The synthesis of compound 322 was achieved by the successful fluorination of 3-C(O)H 
compound 323 (Scheme 37). Repetition of the palladium mediated carbonylation of 
key intermediate 237 was conducted and the methyl ester product 262 was reduced to 
the hydroxyl 324 using DIBAL-H in a 90% yield. Compound 324 was then oxidised using 
Dess-Martin Periodinane to the corresponding aldehyde 323 in a high yield (96%) with 
no observed oxidation of the thiophene moiety. The resulting aldehyde 323 was taken 
in DCM with diethylaminosulfur trifluoride (DAST) and stirred overnight for 18 hours at 
room temperature. The starting material was recovered in its entirety from this 
reaction but upon repetition an alternate fluorine source was used in the form of 
Deoxo-Fluor®.  The solvent was also switched to toluene which gave the di-fluoro 
methyl compound 325 in an acceptable yield. The THP protecting group was removed 
in the next step to give the desired final product 322 (Scheme 37). 
 
Scheme 37. Synthesis of difluoro-methyl compound 322. Reagents and conditions: a) Pd(OAc)2, Xantphos, Et3N, 
HCO2Me, Ac2O DMF, 90 
o
C, 2 h, 53%; b) DIBAL-H, THF, -78 
o
C , 2 h, 90%; c) DMP (0.3M), DCM, RT, 3 h, 96%; d) 
Deoxo-Fluor®, 18 h, 60 
o
C, 37%; e) MeOH.HCl, RT, 6 h, 95%. 
 
 
188 
 
2.11.3.2 ERK5 activity and metabolism of N-(3-(difluoromethyl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (322) 
The di-flouromethyl compound 322 was subjected to the ERK5 enzymatic assay as well 
as the mouse liver microsome screen (Table 66). The collected data shows that the di-
fluoro compound 322 has lost potency when compared to the methyl analogue 246 (7-
fold decrease). When comparing the metabolism value of the highly cleared ethyl 
compound 247 with the difluoro 322 a significant improvement is made, however, the 
compound is outside the desired value for this assay type. Further fluorinated 
analogues at the 3-position have not been synthesised due to the tenuous benefit this 
result indicates and instead future focus is around 3-amino compounds which showed 
excellent metabolism properties. 
Table 66. ERK5 activity and metabolism data of fluorinated 3,6-substitued indazole sulphonamide 322 and 
corresponding matched pairs. 
 
Compound  R3 
ERK5 Enzymatic 
IC50 (μM) 
Mouse 
Microsomal 
Clearance 
(µl/min/mg) 
XLogP 
84 H 0.45 ± 0.09 81 3.78 
247 Et 0.05 ± 0.05 1010 4.39 
322 CHF2 1.1 ± 0.2 157 4.32 
246 Me 0.15 ± 0.03 - 3.97 
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Chapter 3: The Pyrrole Series 
3.1 Initiation of the Pyrrole carboxamide series and early SARs 
A HTS campaign of 48,500 and 9,000 compounds from diverse and kinase focussed 
compound libraries revealed three ERK5 inhibitory chemotypes, one of which was a 
pyrrole carboxamide. Hits such as 326 (Figure 89) were validated by resynthesis and 
retesting and consistently displayed potency below 10 µM (IC50) in the ERK5 enzymatic 
assay. This series of compounds was developed by colleagues; Dr Sandrine Vidot, Dr 
Ruth Bawn, Dr Stephanie Myers and Dr Lauren Molyneux to reveal SARs and lead 
compound 17 (Figure 89). 
 
Figure 89. Structures of 326 and 17 and relevant SARs of the pyrrole carboxamide series. 
Molecular modelling has shown that the compounds interact with the ERK5 active site 
through the ketone to Lys39, pyrrole NH to Asp93 and amide carbonyl to Met95. The 
presence of the 2,6 disubstitution pattern on the phenyl group of 17 induces a twist on 
the geometry so the ketone and aromatic group are out of plane allowing both to be  
accommodated in the ERK5 active site (Figure 90). 
190 
 
 
Figure 90. Proposed binding of 17 (blue) in the ERK5 active site. A) showing the ERK5 protein and surface of active 
site. B) select ERK5 hinge residues (green) and interactions with 17 (blue). 
3.2 Pyrrole carboxamides 17 and 327 
3.2.1 Resynthesis of Pyrrole Carboxamides 17 and 327 
Compound 17 and close analogue 327 were desired for use in pharmacokinetic and 
pharmacodynamics studies and therefore a scale up synthesis was conducted. The 
synthesis of these compounds was achieved in four steps  beginning with the 
activation of 2-bromo-6-fluorobenzoic acid for a Friedel-Crafts acylation which 
proceeded in an 85% yield over the two steps (Scheme 38). The resulting pyrrole ester 
(328) was hydrolysed to the carboxylic acid 329 and then subjected to an amide 
coupling reaction using PCl3 and the desired amino-pyridine. The route has been 
optimised via the synthesis of numerous related compounds and the final compounds 
were obtained in high yields. 
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Scheme 38. Reagents and conditions; a) SOCl2, DMF (cat.), THF, RT, 3h, (not isolated); b) AlCl3, methyl 1H-pyrrole-2-
carboxylate, DCM, RT, 18h, 85% (over 2 steps); c) LiOH, H2O, THF, 65 
o
C, 16 h, 99%; d) 3/4-aminopyridine, PCl3, 
MeCN, 150 
o
C MW, 5 mins, 69-74%. 
3.2.2 In vitro Pharmacokinetics of 17 and 327 
Both compounds displayed good properties and potency at that point of the project 
(Table 67). At the time 17 was the most promising compound synthesised and was 
therefore subjected to further selectivity and metabolism screening. The data 
collected shows the compound was of some promise but is hindered by CYP inhibition 
results. It is an extremely undesirable characteristic in a drug to exhibit CYP enzyme 
inhibition as it leads to drug-drug interactions and toxicity. As maybe expected 
compound 327 has very similar properties to 17 and is only inferior in solubility which 
was the primary reason this molecule (327) was not pursued into further in vitro and in 
vivo assays.  
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Table 67. Medicinal chemistry profile of  17 and 327. For 17 only: good results are highlighted in green, undesirable 
in amber and poor in red. Solubility and metabolism data supplied by Cyprotex. 
Criteria 
Desired value 
for lead 
 
327 
 
17 
ERK5 IC50 (cell free) < 0.1 µM 0.67 ± 0.15 0.82 ± 0.07   
ERK5 cellular 
potency (Hela) 
<1 µM - 1.9 (n=1) 
 
ERK5 cellular 
potency (HEK293) 
<1 µM 4.0 ± 2.8 3.8 ± 2.2 
 
Selectivity >10-fold p38α IC50 >120 µM p38α IC50 >120 µM  
ERK5 Ligand 
Efficiency 
>0.3 0.35 0.35 
 
xLogP <5 3.15 3.15  
TPSA 75-100 75 75  
MW <500 388 388  
Plasma Protein 
binding 
<99% 99.9 99.9 
 
Caco-2 A2B/B2A 
Efflux Ratio 
>1 x10-6 cm/s 
<2 
- 
34/28 
0.82 
 
Solubility 
(Lower/Upper) 
>50 µM 30/100 100/100 
 
Mouse microsomal 
clearance 
<48 
µl/min/mg 
36.9 25.7 
 
hERG inhibition IC50 >25 µM - 38% at 25 µM  
CYP1A inhibition IC50 >10 µM - 6.0  
CYP2C19 inhibition IC50 >10 µM - 8.5  
CYP2C9 inhibition IC50 >10 µM - 13.8  
CYP2D6 inhibition IC50 >10 µM - 9.2  
CYP3A inhibition IC50 >10 µM - 8.4  
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3.2.3 In vivo Pharmacokinetics and Pharmacodynamics of 17 
17 Was dosed at 10 mg/kg in mice and pharmacokinetic data collected (Table 68) this 
shows the compound behaves favourably in animals as it has a respectable biological 
half-life and clearance resulting in a good bioavailability value of 68%. Animal studies 
were all conducted by Dr Huw Thomas. 
Table 68. Pharmacokinetic data for 17 
Parameter Intravenous Dose (IV) Oral Dose (PO) 
Intraperitoneal Dose 
(IP) 
Dose (mg/kg) 10 10 10 
AUC (µg/ml.min) 372 254 398 
Cmax (µg/ml) 25 6 12 
tmax (min) 5 15 15 
t1/2 (min) 38 65 43 
Clearance (ml/min/kg) 27 - 25 
Vdss (L/kg) 1.2 - - 
Bioavailability (%) - 68 - 
AUC = Area under curve; Vdss = volume of distribution at steady state. 
3.2.3.1 Matrigel plug assay 
17 Was used in a Matrigel plug assay to deduce the effect of ERK5 inhibition on 
angiogenesis.192 Matrigel plugs doped with fibroblast growth factor (bFGF) were 
implanted subcutaneously in mice and animals were dosed over 7 days. After this time 
mice were euthanized, plugs were removed and assessed for blood content by 
colorimetric analysis of haemoglobin levels (Figure 91). 
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Figure 91. Haemoglobin levels in matrigel plugs retrieved from mice after 7 days dosing twice daily with either 
vehicle (control), 50 mg/kg XMD8-92 12 (IP) and 17 50 mg/kg (PO). 
Data gathered from matrigel plugs reveals a notable antiangiogenic effect of ERK5 
inhibition by 17 which is comparable to the positive control, XMD8-92 (12). 
3.2.3.2 Human tumour xenograft models 
17 Was assessed for tumour growth inhibition with XMD8-92 (12) as a positive control. Mice 
were inoculated with human ovarian carcinoma cells (A2780) and after 7 days without any 
drug, tumours were established subcutaneously at an average volume of 72 mm3.  Mice were 
dosed with vehicle control, XMD8-92 or 17 over 11 days and the tumour volumes measured 
(RTV). The data (Figure 92) shows 17 to produce the same growth inhibitory effect as XMD8-92, 
although at twice the dose. During the study no animal weight loss was associated with 
administration of 17 indicating a good tolerance for the high dose of compound and therefore 
good toxicity profile. 
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Figure 92. Xenograft tumour volume vs time for subcutaneous A2780 xenografts in mice dosed with vehicle 
(control), XMD8-92 (12) 50 mg/kg and 17 100 mg/kg. 
 
3.3 Summary of Pyrroles Carboxamide SARs 
Further development of this series of compounds by Dr Lauren Molyneux, Dr Duncan 
Miller and Dr Tristan Reuillon improved the potency of the lead compound extensively. 
Figure 93 shows the structure of 331 which has been used in further pharmacokinetic 
and pharmacodynamics experiments. 
 
Figure 93. SARs of the pyrrole carboxamide series around compounds 330 and 331. 
The series now exhibits excellent potency and physiochemical properties, however, 
progression to a clinical candidate has been impeded by the poor efflux of lead 
compounds. During development the CYP inhibition witnessed for 17 was designed out. 
Efforts to remove the poor efflux properties have not been successful and included 
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biological experiments to identify SAR between pyrrole carboxamides and P-gp 
expression (Chapter 3.4). The Indazole series development was run simultaneously to 
the pyrrole series and both ran into different problems at a similar time point. It is 
possible that combination of the two series may aid both the efflux and metabolism 
problems that each series faces. 
3.3.1 Potential Combination of Indazole and Pyrrole Carboxamide Series 
Developments on the pyrrole carboxamide series have shown potency can be derived 
from the portion of the active site beyond the hinge, towards solvent. Molecular 
modelling of both indazole and pyrrole series shows that the 3-position of the indazole 
directs towards the space in which potency is gained in the pyrrole series (Figure 94). 
Inclusion of an aromatic ring and basic centre beyond it at the indazole 3-position 
would simulate the potent groups discovered on the pyrrole series. It has been shown 
that substitution at the 3-position can boost potency and 3-amino compound 269 has 
excellent metabolic stability. For these reasons it is plausible that a suitable in vivo tool 
compound may be identified through further exploitation of the 3-position. 
Interestingly compound 275, which was originally a synthetic intermediate serves as a 
suitable mimic for 17 and is equipotent (ERK5 IC50 = 0.73 ± 0.3 µM) (Figure 95).  
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Figure 94. A) Overlay of indazole 30 (red) and pyrrole carboxamide 332 (blue) docked in the ERK5 active site; B) 
Overlay of indazole 30 (red) and pyrrole carboxamide 332 (blue); C) Chemical structure of pyrrole carboxamide 
compound 332. 
 
Figure 95. Equivalent compounds in the pyrrole carboxamide (17) and indazole sulphonamide (275) 
series. 
Combination of the two series may improve potency but it has been shown that the 
potent basic chain incorporated into pyrrole compounds is associated with poor efflux. 
It is therefore reasonable to believe that this property would also be introduced when 
the same functionality is incorporated in the indazole 3-position (Figure 96A). Although 
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it is possible that the indazole compound 334 may not suffer the same efflux effects 
due to the subtle differences in the structure and the positioning of polar groups. A 
synthetic campaign to reach this compound would systematically build the molecule as 
was originally done in the Pyrrole series. Synthesis of the Boc-protected 3-amino 
indazole 282 has been shown previously and would allow for a series of SNAr reactions 
to be conducted to install the various required groups (Figure 96B). Alternately in the 
same manner that compound 275 was synthesised, an optimised Buchwald-Hartwig 
reaction would enable the introduction of the desired amine groups. 
 
Figure 96. A) potential targets combining the indazole and pyrrole carboxmide series 333 and 334; B 
Potential synthetic routes to compound 334. 
Inclusion of potent indazole moieties would lead to alkylation of the pyrrole 
carboxamide core at the 3-position (Figure 97).  This modification has been 
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investigated and the compounds lost potency, presumably because of the congested 
space and the orientation of the adjacent systems.  
 
Figure 97. Pyrrole carboxamide target 336 incorporating potent indazole series moities. 
Combination of the two series has not been thoroughly investigated to date as it 
requires a crystal structure of both chemotypes in the ERK5 active site before any 
accurately informed design decisions can be made. A more coalescent pathway to 
develop the indazole series would be to combine the SARs developed at the 3- and 4-
positions of the molecule (Chapter 4). 
3.4 Investigating the Efflux of Lead Pyrrole Carboxamide Compounds 
Experiments were conducted to determine if a cellular presence of selected pyrrole 
carboxamide compounds causes an increase in the expression of transporter protein P-
gp. Resistance to drugs can be caused by efficient efflux of a drug molecule from the 
cell, preventing it from reaching its target. This resistance can be caused by a high 
affinity between the efflux protein and the drug which is generally associated with up-
regulated expression. Ten pyrrole carboxamide compounds were chosen displaying 
high potency but poor cell permeability properties, in particularly poor efflux. 
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3.4.1 ABC Transporters 
Membrane transporter proteins are an abundant family of proteins in living organisms.  
They span biological membranes and facilitate the passage of vital materials, such as 
ions, small molecules and macromolecules across the membrane. The movement of 
substances is mediated either by passive diffusion (high to a low concentration) or by 
active transport (from low to high concentration) which normally requires energy in 
the form of ATP. 
ATP binding cassette (ABC) transporters are primary active transporters; they utilize 
ATP to transport substrates across extra-and intra-cellular membranes.  Their role 
within the human body serves to remove foreign or unrecognised material from the 
cell. This process aids the body by eliminating toxic entities from cells and eventually 
from the body.  
 
Figure 98. Generic structure of ABC transporters. 
These proteins are made up of a transmembrane domain (TMD) and a nucleotide 
binding domain (NBD)193,194. The TMD, largely made up of α–helices, has a high affinity 
site on the cell interior which binds to the substrate, and a low affinity site on the 
exterior which permits dissociation of the material after transfer to the extracellular 
Transmembrane domain (TMD) Nucleotide-binding domain (NBD) 
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face. When ATP binds to the NBD, the conformation of the transporter changes such 
that any substrate bound to the interior of the TMD passes to the low affinity site on 
the other side of the membrane and is released. The release of ADP from the NBD 
resets the transporter to its ground state, ready to bind another substrate. The system 
consumes two ATP molecules per cycle and therefore has poor energy economy, 
though this does imply a high importance in the cellular hierarchy. 
3.4.2 P-glycoproteins and Multidrug Resistance 
P-glycoprotein (P-gp) also known as multidrug resistance 1 (MDR1) and ABCB1 is a 170 
kDa protein present in endothelial and epithelial cells of the liver, lungs kidneys, testes 
and brain, among others. P-gp is the most studied member of the ABC transporter 
family accounting for over 400 related publications in 2012 alone. This is largely due to 
P-gp’s implication in multidrug resistance (MDR). Many drug compounds are 
substrates of P-gp and are expelled from cells. This lowers the drug’s overall 
bioavailability, as it reduces the total time an effective drug concentration is present in 
the cell. Such a drug will have a poor pharmacokinetic profile as a result.  
Expression of P-gp is not necessarily intrinsic to the cell and expression can be induced 
by exposure to a compound or a mutation. The conventional chemotherapeutic agents, 
taxanes, epipodophyllotoxins and vinca alkaloids, are all known substrates for P-gp. 
Chemotherapy regimens involving these (and other compounds) become much less 
effective following P-gp overexpression195. This phenomenon is a contributing factor to 
a patient developing MDR and also identifies P-gp as a therapeutic target. Thus, 
combinatorial therapy of a P-gp inhibitor such as verapamil, 337, and a 
chemotherapeutic agent can potentially negate the drugs efflux and restore the intra-
cellular concentration of the desired agent.  
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Figure 99. Chemical structures of Verapamil, 337 and NSC73306, 338. 
3.4.3 Agents that Target P-gp  
A P-gp inhibitor, like any drug compound, must meet certain safety criteria and so far 
toxicity has limited development of a clinical compound specifically designed for P-gp 
inhibition.195 A study in 2006 identified a novel compound, NSC73306 (338) (Figure 99), 
which increased the cytotoxicity of various tumour cell lines to cytotoxic agents in 
correlation to P-gp over-expression.194 However, the mode of action appears to bypass 
an interaction between the intended transporter and 338, presenting another, so far 
unidentified, target to combat MDR. 
Verapamil is an FDA approved calcium channel inhibitor used as a treatment for 
various conditions of the cardiovascular system. It has also become widely used as a 
tool compound in cell biology for the inhibition of P-gp (IC50 = 0.5 µM).
196 The 
compound has been shown to reduce the passage of materials by P-gp whilst 
remaining relatively non-toxic to the cell, the primary reason for its widespread use. 
Verapamil itself has a moderate bioavailability and a biological half-life of less than 12 
hours because of metabolism in the liver. The side effects attributed to P-gp inhibition 
are currently unknown however verapamil is known to cause headaches, nausea and 
dizziness. 
3.4.4 Designing drugs that do not interact with P-gps 
The substrate binding domain of P-gp does not contain a conserved binding motif: this 
fact means that designing compounds to avoid efflux is very difficult. Ambudkar et al 
demonstrated a limited number of SARs by making small structural modifications to 
known P-gp substrates. 197 This exposed planar lipophilic groups and lipophilic, tertiary 
amines as common moieties causing drug efflux. However, these groups are present 
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on many drug compounds that do not suffer from accelerated cell elimination, 
highlighting the difficulty in defining the parameters of P-gp-substrate binding.  
It has also been reported that moderating hydrogen bond strength can have a 
profound impact on P-gp recognition; this is typically done by the introduction of a 
fluorine atom to withdraw electron density.198  The strategy is to identify and disrupt a 
key hydrogen bond between the transporter and the molecule by reducing its strength. 
Maintaining high potency for the therapeutic target whilst altering the electronics of 
key functionality to prevent efflux presents a difficult challenge. 
Another strategy to combat P-gp elimination is to improve the pharmacokinetic 
properties and potency of the compound so that elimination by P-gp no longer has a 
significant effect on the therapeutic concentration obtained in the body. This is 
perhaps the most difficult method to employ as many parameters need to be 
addressed at once. 
3.4.5 Methods to Deduce Drug P-gp Interaction 
To satisfy the specification of a clinical candidate compound, cell permeability must 
provide an in cell concentration sufficient for a therapeutic effect at a tolerable dose. A 
widely used indicator of cell permeability is the Caco-2 assay; this provides data on 
both influx and efflux of material. Caco-2 is a colon carcinoma cell line which has tight 
junctions and expresses a comprehensive variety of transporter proteins including P-gp. 
The compound in question is added in solution on top of the Caco-2 membrane and 
the concentration of compound is measured on the other side to give a value of 
permeability. Because of the tight junctions between the cells it is deemed that any 
amount of compound measured on the other side must have passed through the cell. 
Results are routinely quoted as an efflux ratio which takes the values of B to A (the 
reverse of the assay) over A to B giving a value proportional to excretion. When this 
assay is run on a compound in the presence of a P-gp inhibitor any increase in the 
efflux ratio eludes to an interaction with P-gp.  
To determine the activity of an ATP consuming transporter, an ATPase assay can be 
conducted. This quantifies activity by measuring the phosphate level produced as a 
result of ATP hydrolysis, typically by colorimetry. A vesicular transport assay 
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determines the amount of drug remaining in a system after a given time by using 
inverted vesicles possessing ABC transporters. Any drug that is a transporter substrate 
is taken up into the vesicles which can be filtered off and the concentration of the 
remaining media analysed. 
3.4.6 Effects of Selected Pyrrole carboxamides on P-gp Expression 
A number of potent compounds from the pyrrole core series were selected for in vitro 
pharmacokinetic screening consisting of: solubility assessment, mouse microsomal 
clearance and Caco-2 assessment (Table 69). The results showed only one compound is 
not completely soluble (344 (10/65)) with generally good microsomal clearance. As we 
already know, the efflux ratios across a Caco-2 membrane gave cause for concern for 
pyrrole carboxamides. The potency of these compounds in the enzymatic ERK5 IMAP 
assay is good (65-4.8 nM). However, since the inclusion of the tri-halogenated 
aromatic ring and extension of the scaffold with multiple heterocycles off the pyrrole 
amide, a decrease in cell permeability has been witnessed. These groups have 
increased ERK5 inhibition but it is now crucial to understand, firstly if the reason for 
the poor Caco-2 profile is due to a transporter protein and secondly which, if any 
group is the source of this activity. Typically a Caco-2 efflux ratio less than 2 is desired 
as it indicates that material is not ejected from the cell at a great rate. However, all but 
two compounds (330 and 345) gave poor results indicating that a transporter protein 
may be identifying and transferring the molecules out of the cell.  
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Table 69. Pharmacokinetic and potency data for selected pyrrole compounds (Caco-2 ratio = amount 
eliminated/amount absorbed) 
 
Structure 
Caco-2 
Ratio 
Mouse 
Microsomal 
Clearance 
( µl/min/mg) 
xLog P 
IMAP ERK5 
IC50 (nM) 
339 
 
5.42 4.3 4.0 4.8 
340 
 
28.3 34 4.5 5.9 
341 
 
4.52 0.3 3.6 7.3 
342 
 
8.22 50 4.0 13.4 
330 
 
0.94 28 3.6 18.4 
343 
 
18.4 8.2 3.3 18.7 
344 
 
38.3 20 3.5 23.3 
345 
 
0.66 46.8 3.8 65.6 
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Another reason to suspect that compounds are being ejected from the cell is the 
cellular assay data. Although the curves generated have a steep gradient, as expected 
for a potent compound, the maximal inhibition remains very high (Figure 100).  A 
potential cause for the early plateau could be an induction of P-gp expression and 
therefore excretion due to the presence of the compound at higher concentrations. To 
ascertain whether selected compounds in the pyrrole series are substrates for P-gp a 
number of protocols were devised.  
 
Figure 100. Cellular inhibition curve for compound 345. 
The ERK5 cellular assay was conducted in HEK293 cells with and without a known P-gp 
inhibitor (verapamil, 337). There is no variation in the curves with both showing poor 
maximum inhibition (Figure 101). This suggests that P-gp is not responsible for the 
reduced activity. To control for verapamil (337) activity, paclitaxel resistant MCF7 cells 
were used.  This breast cancer cell line has elevated P-gp levels in response to chronic 
exposure to paclitaxel; this underlines resistance to paclitaxel in this cell line.  
Treatment of paclitaxel resistant MCF7 cells with paclitaxel in the presence or absence 
of verapamil for 24h shows that inhibition of P-gp with verapamil reduces cell 
proliferation due to inhibition of P-gp, thus demonstrating that the verapamil used in 
this study is active (Figure 102). 
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Figure 101. Activity curve of compound 341 with (green) and without (blue) verapamil, 337. 
 
 
Figure 102. Verapamil, 337 sensitises paclitaxel Resistant MCF7 cells to paclitaxel treatment. 
P-gp expression can be induced by the presence of a drug; therefore we monitored the 
level of P-gp in cells in the presence of a number of selected ERK5 inhibitors. Using 
HEK293 cells, as they are used in the cellular IC50 determination assay, a dose of 10 µM 
inhibitor was added and incubated overnight. This concentration, in all cases is enough 
to cause significant inhibition of ERK5 and assumed to be high enough to induce P-gp 
expression, if the event occurs. This is also a dose tolerated by the cells so toxicity 
should not lead to a false result. After incubation the cells are lysed, the lysate 
separated by SDS-PAGE and then visualised by Western blotting. ERK1 expression is 
used to verify the amount of protein loaded on the gel and an MDR1 polyclonal 
antibody is used to show the amount of P-gp expressed. MCF7 cells showing resistance 
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to paclitaxel (MCF7TaxR) are known to up-regulate P-gp expression when grown in the 
presence of Taxol and were therefore used as a positive control with HEK293 cultured 
in the absence of a drug fulfilling the negative control (Figure 103).  These results show 
that P-gp was detected in all lanes and that there was no substantial induction of P-gp 
expression following incubation with any of the compounds tested. 
 
Figure 103. Transferred and visualised 10% SDS poly acrylamide gel (SDS-PAGE), showing (left to right); -ve control 
(HEK293 cell lysate in the absence of drug), compounds 3-9 (HEK293 cells cultured with corresponding compound), 
+ve control (MCF7TaxR cells grown in 6 nM palitaxcel to over express P-gp). ERK1 bands show variation in sample 
loading. 
These results show that HEK293 cells, which are used for the ERK5 in-cell luciferase 
assay, express P-gp.  However, P-gp expression was not altered with any of the 
selected inhibitors. No correlation is witnessed between poor Caco-2 efflux and P-gp 
expression. However, one limitation of this experiment is that only induction of P-gp 
expression is monitored and it may be that select compounds in this series are 
substrates for P-gp without increasing expression. 
3.4.7 Summary of Pyrrole Carboxamide Efflux 
With regard to both experiments run it is deemed that the pyrrole pharmacophore 
does not suffer from low maximum inhibition due to the action of P-gp. There is no 
change whatsoever to the cellular inhibition isotherm when P-gp is eliminated through 
inhibition which suggests it is not the reason for the poor profile. This suggests that 
compounds are not eliminated from the cell by P-gp. Western blotting of P-gp 
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expression showed that the HEK293 cell line does express P-gp, however, a significant 
variation in expression was not seen between positive/negative controls and the 
compounds under investigation. Induction of P-gp does not correlate to the efflux ratio 
witnessed in the Caco-2 assay but elimination from the cell by P-gp needn’t, in all cases, 
induce P-gp expression. Susceptibility to P-gp transport alone could be investigated by 
running a Caco-2 membrane assay in the presence of a P-gp inhibitor. A decrease in 
the efflux ratio in this case would indicate that P-gp was responsible for the poor 
pharmacokinetics. It is also possible that another member of the ABC transporter 
family acts on the pharmacophore but an experiment to investigate this theory is not 
being pursued. 
The data generated suggests P-gp does not interact with compounds in the pyrrole 
series and therefore the findings cannot aid the design of further compounds. To 
eliminate P-gp from the investigation into the poor Caco-2 permeability, the Caco-2 
assay should be repeated with a P-gp inhibitor present. 
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Chapter 4: Conclusions and Future work 
4.1 Summary of Further Indazole 4-position Exploration 
A large library of 4-substituted indazole compounds have been synthesised with the 
sulphonamide linker as a pose to the sulphone compounds discussed in Chapter 2.8. 
Compound sets were devised to investigate the difference between the sulphone and 
sulphonamide linkers by introducing small heterocycles and polar systems. 
4.1.1 Comparison of lead Sulphone Indazole Compounds with Sulphonamide 
Analogues 
The first sulphone compounds synthesised were equipotent to N-methyl 
sulphonamide matched pairs when unsubstituted in the 4-position (Chapter 2.5.5). The 
sole reason for selecting the sulphone series for progression was the simplicity of 
synthesis of 4-position analogues. Subsequently sulphonamide matched pairs have 
been synthesised by Dr Stephanie Myers. Sulphonamide analogues of sulphones 179, 
198 and 199 all show inferior potency in both N-methyl and unmethylated 
sulphonamide (Table 70). Interestingly the previously established activity hierarchy of 
N-methyl sulphonamide lending higher potency than the un-substituted is 
contradicted by compound 348a and 348b in which the relationship is reversed. Lead 
compound 199 is between 10 and 40-fold more potent than the sulphonamide 
matched pairs indicating that the sulphone linker is superior on the elaborated 
indazole scaffold. 
Table 70. Activity results of Indazole sulphonamide compounds.  
 
 
   
 R4 Enzymatic ERK5 IC50 (µM) 
346a/b, 179 Me 1.1 ± 0.02 0.27 ± 0.10 0.14 ± 0.04 
347a/b, 198 Et 1.1 ± 0.2 0.10 ± 0.01 0.08 ± 0.01 
348a/b, 199 CycPr 0.11 ± 0.01 0.43 ± 0.05 0.01 ± 0.01 
349a/b Ph 6.2 ± 4.5 2.3 ± 0.7 - 
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4.1.2 4-Substituted, 6-sulphonamide Indazoles – Heterocyclic Substituents 
Heterocyclic rings were installed in the indazole 4-position to improve the solubility 
profile of the series, a limitation of lead compound 199.  Although good potency was 
obtained and properties improved, ligand efficiency is not improved and therefore 
inclusion of these groups holds no net benefit. 
Table 71. Activity results of compounds 350a/b – 355a/b 
 
 
  
 R4 ERK5 IC50 (µM) 
350a/b 
N
HN
 
1.87 ± 1.2 0.21 ± 0.10 
351a/b 
NHN
 
1.46 ± 0.28 0.11 ± 0.01 
352a/b 
O
 
0.72 ± 0.07 0.13 ± 0.01 
353a/b 
O
 
1.32 ± 0.18 0.18 ± 0.03 
354a/b 
N
 
0.45 ± 0.06 0.13 ± 0.05 
355a/b N
 
1.75 ± 0.5 1.05 ± 0.06 
 
4.1.3 4-Substituted, 6-Sulphonamide Indazoles – Polar Substituents 
Numerous carbonyl possessing groups were introduced to the indazole to improve 
solubility however potency significantly suffered. With the exception of ester 
compound 359b all results are over 1 µM.  Alkyne 356b is 4-fold more potent than the 
cyano 357b indicating that a lone pair of electrons cannot make a favourable 
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interaction in the enzyme at this location. Compounds 366a/b are the only compounds 
tested so far which have a benzylic sp3 centre but no benzylic hydrogen. The poor 
potency of compound 366b suggests that space at this position is confined. 
Table 72. Summary of ERK5 SARs for indazoles 356a/b-366a/b. 
 
 
  
 R4 ERK5 IC50 (µM) 
356a/b 
 
2. 5 ± 0.2 1.3 ± 0.0 
357a/b 
 
5.9 ± 0.6 4.4 ± 0.2 
358a/b 
O
 
2.5 ± 0.7 1.1  ± 0.02 
359a/b O O
 
1.6 ± 0.4 0.43 ± 0.1 
360a/b 
HO O
 
>120 20.3 ± 0.5 
361a/b 
H2N O
 
8.1 ± 1.0 1.9 ± 0.02 
362a/b 
H
N O
 
9.2 ± 0.05 1.8 ± 0.1 
363a/b N O
 
10.5 ± 4.9 4.3 ± 0.1 
364a/b 
HO
 
2.8 ± 0.3 0.52 ± 0.08 
365a/b 
OH
 
- 0.12 ± 0.02 
366a/b 
OH
 
1.8 ± 0.5 3.3 ± 0.5 
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4.2 Future work 
4.2.1 Future Work at the Indazole 4-Position 
To understand the SAR of the benzylic 4-position of the indazole, groups have been 
categorised by hybridisation of this carbon, and in the case of sp3 centres by degree of 
substitution.  It has been observed that tertiary sp3 benzylic centres have poor potency 
when compared to primary and secondary centres.  Sp2 and aromatic groups are 
tolerated with regard to potency and it is possible that the reason for the loss in 
potency is the polarity of these groups not the hybridisation. The 4-position vector is 
out towards the solvent and into the roof of the active site at the glycine rich loop. 
Figure 103 shows the binding of lead compound 199 and a hypothetical 4-tbutyl 
indazole 367 illustrating a subtle change in the angle of the indazole core, which will 
affect the hinge binding. Hydrogen bonds are strongest when the lone pair and proton 
align at 180o. By affecting the angle of the hinge binding motif through substitution of 
the 4-position the strength of the hydrogen bonds is likely to be affected and may well 
be the reason for the sharp drop in potency.  
214 
 
 
Figure 103. Molecular modelling of compound 199 (A, cyan) and hypothetical 
t
butyl compound 367 (B, Orange) in 
the ERK5 active site. 
Considering modelling images in Figure 103 and all activity data generated from the 
sulphonamide series it is proposed that a ‘good substituent’ at the 4-position must 
satisfy two requirements: 
1. The benzylic carbon of the 4-position groups must either be an sp3 with at least 
one proton attached or an sp2 centre. 
Although most of the substituents with an sp2 centre at this position have shown poor 
activity (Table 72) these groups are all highly polar. It is known that a small lipophilic 
group gives excellent potency at this position and therefore compounds 358a/b - 
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365a/b in Table 72 have poor ERK5 affinity because of polarity not the planarity of the 
group. 
2. 4-position substituents must make a contribution to LogP within the first 3-4 
bond lengths. 
Figure 104 shows the limits of potency obtained by only alkyl substituents revealing 
the cyclopropyl to be the frontier of this positive SAR. This means that introducing 
solubility beyond this point should improve potency further. Heterocyclic compounds 
shown in Table 71 agree with the above statement. Comparison of pyrazole 
compounds 350b and 351b shows that positioning the heteroatoms 3 bond lengths 
from the indazole lends more potency than the nearest heteroatom being situated 2 
bond lengths away. This translates to a 2-fold difference in potency.  Pyridine 
compounds 354b and 355b show the same relationship as the 4-pyridyl group is 
almost 10-fold more potent than the 2-pyridyl. 
 
Figure 104. Graph of ERK5 pIC50 vs Molecular weight for 2-thiophene sulphone compounds with alkyl 4-substituents. 
3-Tetrahydrofuran compound 352b (Table 71) shows good potency but it is proposed 
that the heteroatom is still too close to the indazole to make the most of the lipophilic 
relationship. Proposed targets are shown in Figure 105 and aim to establish the 
optimum proximity of a heteroatom to the core. 
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Figure 105. Proposed future targets to explore the properties of the 4-position. 
Synthesis of these compounds is possible by introducing a vinyl group to the 4-position by the 
same Suzuki reaction used to obtain the 4-alkyl targets (scheme 38) and hydroxylation of this 
material via hydroboration and oxidation. 
 
Scheme 38. Key steps involved in the synthesis of 4-position future targets. 
4.2.2 Future Targets at the 3-Position   
A number of targets have arisen from the 3-substituted indazole sulphonamide data 
set. Lipophilic compounds 247-249 show good potency but also reach the limit of the 
lipophilic interaction and therefore new targets need to incorporate polarity (Figure 
106). A new data set systematically moving hydrogen bond acceptor/donor motifs 
away from the indazole core should reveal a new interaction and therefore 
improvement in potency and potentially properties of the compound. 
 
Figure 106. Future synthetic targets at the indazole 3-position. 
Synthesis of these targets with a sulphone linker as a pose to the sulphonamide should 
also improve potency. 
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4.2.3 Substitution of 4,3 and 6 Positions 
Substitution at the 4-position with alkyl groups has given the best potency and current lead 
compound 199. Exploration of the 3-position also revealed potential for more potency and 
possibly the attenuation of the metabolic problem the series faces (Figure 107). Combination 
of these groups has yet to be attempted.  
 
Figure 107. Significant results of compounds 199, 247 and 269 
To date, substitution of the 3, 4 and 6-position of the indazole has not been 
undertaken due the lengthy synthesis. Targets shown in Figure 108 show both cyclised 
and separate 3,4-substituents. It is expected that due to the proximity of the 3 and 4-
position independent substituents will affect the orientation of potent functionalities 
and therefore optimisation may be required. Targets 368 and 370 do not appear 
particularly drug-like and will almost undoubtedly show very high clearance, however 
ERK5 potency is predicted to be very good. The incorporation of a hetero atom to 
targets 369 and 371 may balance potency and metabolism or at least give a starting 
point for further investigation. 
 
Figure 108. Potential targets combining potent groups in both the 3 and 4 position. 
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4.3 Conclusion 
Investigations conducted on the Indazole series have moved from hit validation 
through hit to lead and into lead optimisation with the synthesis of over 130 final 
compounds. An array of SARs have been developed revealing the likely binding mode 
of indazole compounds in the ERK5 active site. Activity for ERK5 has been increased 
1000-fold between the original hits and lead compound 199. Compound 199 has good 
solubility and potency but suffers from rapid metabolism by CYP enzymes and 
undesirable selectivity among other kinases. In vivo pharmacokinetic studies with 199 
revealed a bioavailability of 24% which requires improvement before the role of ERK5 
inhibition in cancer can be proven in an animal model. Synthesis of 4-substituted 
indazoles has been heavily optimised to give a high yielding scheme over nine steps 
 
Figure 109. Progression of the indazole series activity. 
Efforts to improve the metabolic profile of the series has led to 3-aminoindazole 
compound 269 which exhibits excellent metabolic stability and will be used to inform 
further compound design to retain both metabolic stability and potency. 
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Chapter 5: Experimental  
5.1  ERK5 and p38α Assay Protocols 
The ERK5 biological assays were performed by Ms Ai Ching Wong at Cancer Research 
Technology Discovery Research Laboratories, London, by Dr Pamela Lochhead at the 
Babraham Institute, Cambridge, by Ms Lan-Zhen Wang and Dr Noel Edwards at the Paul 
O’Gorman Building, Newcastle Cancer Centre, Newcastle upon Tyne. 
5.1.1 ERK5 IMAPTM Assay Protocol 
Preparation of assay buffer (1x) 
The assay buffer was prepared using 0.01% Tween®-20 5x stock, supplied as part of IMAPTM FP 
Progressive Binding System Kit (Molecular Devices R7436) and diluted to 1x using milliQ H2O. 1 
μL of a 1 M DTT stock was added for every 1 mL of 1x assay buffer to give a final concentration 
of 1 mM DTT. 
Preparation of ERK5 working solution 
The final dilution was dependent on activity of the enzyme batches. The initial batch (08/08/08) 
was used at a 1 in 1 in 350 final dilution in assay buffer. A 1:175 dilution of ERK5 stock was 
performed in 1x assay buffer. For 1 plate, 13 μL of ERK5 stock was added to 2262 μL of 1x 
assay buffer. ERK5 was expressed and purified at CRT by Leon Pang and Sue Young. Aliquots 
were stored at -80 °C. Batch PO080808 was used at a stock concentration of 73.4 ng/μL. 
Preparation of ATP/substrate working solution 
For one plate, ATP disodium salt (90 μL, 20 mM) (Sigma A7699) and FAM-EGFR-derived 
peptide (15 μL, 100 μM) (LVEPLTPSGEAPNQ(K-5FAM)-COOH) (Molecular Devices RP7129; 
reconstituted in milliQ H2O to a stock concentration of 100 μM; stored at -20 
oC) was added to 
2295 μL of 1x assay buffer. 
Preparation of IMAPTM binding solution 
For one plate, 20.5 μL of IMAP™ binding reagent stock, 1476 μL of 1x binding buffer A (60%), 
and 984 μL of binding buffer B (40%) (IMAP™ FP Progressive screening express kit (Molecular 
Devices R8127) was added to 9819.5 μL of milliQ H2O. 
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Assay procedure 
1 μL of inhibitor (in 60:40 H2O/DMSO) or control/blanks (60:40 H2O/DMSO) were dry-spotted 
into the relevant wells of a 384-well assay plate using the MATRIX PlateMate® Plus. 5 μL of 
ERK5 working solution was added to test and control wells, and 5 μL of 1x assay buffer added 
to blanks; 4 μL of ATP/substrate working solution was added to all wells using a Matrix 
multichannel pipette. The plate was sealed using DMSO resistant clear seal and incubated for 2 
h at 37 oC. 1 μL of the kinase reaction mixture from the first plate was dry spotted into a 
second 384-well assay plate using the MATRIX PlateMate® Plus. 9 μL of assay buffer was added, 
followed by 30 μL of IMAP™ binding solution using a multichannel pipette. The plate was 
incubated at RT in darkness for 2 h. The assay plate was then read on an Analyst HT plate 
reader (Molecular Devices) using the settings described below: 
Measurement mode = Fluorescence polarisation; Method ID = ERK5; Integration time = 100 ms; 
Excitation filter = Fluorescein 485-20; Emission filter = 530-25; Dichroic mirror = 505 nm; Plate 
definition file = Corning 384 black fb; Z-height = 5.715 mm (middle); G-factor = 1; Attenuator = 
out; Detector counting = Smartread+; Sensitivity = 2. 
5.1.2  p38α LANCE Assay 
Preparation of assay buffer (1x) 
1x assay buffer was prepared consisting of the following reagents; 250 mM 
tris(hydroxymethyl)aminomethane (Tris) pH 7.5, 25 mM MgCl2, 2.5 mM ethylene glycol 
tetraacetic acid (EGTA), 10 mM DTT and 0.05% Triton X100 in milliQ H2O (NB: 1x buffer final 
assay concentrations were 5x lower than stated above). 
Preparation of p38α/SAPK2 working solution 
The p38α/SAPK2 working solution was prepared using active N-terminal GST-tagged 
recombinant full length protein (Millipore 14-251) supplied as a 10 μg/4 μL stock. This was 
diluted to a 10 μg/40 μL (1 μM) concentration by addition of 156 μL of Tris/HCl (pH 7.5, 50 
mM), NaCl (150 mM), EGTA (0.1 mM), Brij-35 surfactant (0.03%), glycerol (50%) and 0.1% 
2-mercaptoethanol (0.1%). The final dilution was dependent on activity of the enzyme 
batches. The p38α concentration used in the assay was 1 nM. A 2x working stock solution 
(2 nM, 500 fold dilution of 1 μM stock) in 1x assay buffer was prepared. For one plate, 9.4 
μL of p38α (1 μM) was added to 1870.6 μL of milliQ H2O. 
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Preparation of ATP/substrate working solution 
For one plate, ATP disodium salt (17.5 μL, 200 mM stock), (Sigma A7699) and Ulight-MBP 
Peptide (50 μL, 5 μM stock) (Perkin Elmer TRF0109), which were added to 400 μL of 5x assay 
buffer and 1532.5 μL of milliQ H2O. 
Preparation of EDTA/antibody detection reagent  
For one plate, 84 μL of ethylenediaminetetraacetic acid (EDTA) (0.5 M) (Sigma E4378-100G) 
and 27 μL of Europium-anti-phospho-MBP antibody (0.625 μM) (Perkin Elmer) was added to 
420 μL of LANCE detection buffer (1x) and 3669 of milliQ H2O. 
Assay procedure 
1 μL of compound (in 80:20 H2O/DMSO) or control/blank (80:20 H2O/DMSO) was dry-spotted 
into the relevant wells of a 384-well assay plate using the MATRIX PlateMate Plus. 5 μL of p38α 
working solution was added to test and control wells, and 5 μL of assay buffer added to blanks; 
4 μL of ATP/substrate working solution was added to all wells using a Thermo Multidrop Combi 
or Matrix multichannel pipette. The plate was sealed using DMSO resistant clear seal and 
incubated for 1 h at 37 oC. 10 μL of the EDTA/antibody working solution was added to all wells 
using a Thermo Multidrop Combi or Matrix multichannel pipette. The plate was incubated at 
RT in darkness for 2 h. The assay plate was then read on a PheraStar microplate reader using 
the settings described below: 
Pherastar: Measurement mode = TRF; Method ID = LANCE HTRF ERK5; Optic Module: 337, 665, 
620 nm. Focal Height = 6.0, Positioning delay, 0.1 sec, Number of flashes per well = 100, 
Integration start = 60 μs, Integration time = 200 μs, Simultaneous dual emission, Ratio 
multiplicator = 1000. 
5.1.3 Hela cell-based densitometry assay protocol 
HeLa cells were serum starved overnight followed by treatment with ERK5 inhibitors for 1 h. 
Cells were then stimulated with 100 ng/ml EGF for 10 min. The cells were harvested and lysed 
at 4 oC for 5–10 min in Laemmli buffer containing Halt protease and phosphate inhibitors 
(Pierce). The lysates were boiled for 10 min at 100 oC. Twenty microliters samples were run on 
6% Tris–glycine gels and transferred to nitrocellulose. Western blotting was done with ERK5 
antibody (Cell signalling #3372S). The IC50 was calculated from densitometry of top bands. 
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5.1.4 Cellular Dual-Luciferase Reporter Assay 
Cell Trypsinisation 
Cell stocks of HEK293 and MCF7 were removed from incubation and the media was removed. 
Cells were washed with PBS (15 mL) and trypsinised using 0.05% Trypsin EDTA solution (1 mL). 
Cells were then counted under a microscope and the media solution was diluted with DMEM 
accordingly to give 80 mL of 0.2 x 106 cells/mL solution which was transferred to 8 x 96 well 
plates (84µL/well) which were incubated overnight.  
Lipofection 
A lipofection solution made up of Lipofectamine™ 2000 transfection reagent (Invitrogen 
11668019)  was combined with a solution of DNA master mix A (61.5 µL) in 1500 µL Opti-
MEM® growth media (reduced serum medium, Invitrogen 31985070) and left for twenty 
minutes before 16 µL was added to each of the wells (except for controls) previously prepared. 
The control experiment was set up in the same way but with DNA master mix B in 250 µL of 
Opti-MEM® growth media, plates were then incubated for 4 hours. 
DNA master mix A: MEF2D-Gal4 (15 µL, 0.25mg/mL stock), Gal4-Luc (15 µL, 1.25 mg/mL stock), 
Renilla Luciferase (15 µL, 0.1 mg/mL stock), EGFP-MEK5D construct (1.5 µL, 0.5 mg/mL stock), 
HA-ERK5 wt (wild type)(15 µL, 0.5 mg/mL stock). 
DNA master mix B: MEF2D-Gal4 (2.5 µL, 0.25 mg/mL stock), Gal4-Luc (2.5 µL, 1.25 mg/mL 
stock), Renilla Luciferase (2.5 µL, 0.1 mg/mL stock), EGFP construct, containing no MEK5D (0.25 
µL, 0.5 mg/mL stock), and HA-ERK5 wt (2.5 µL, 0.5 mg/mL stock) 
Addition of drugs 
Compounds were prepared as a 10 mM solution in DMSO, from which serial dilutions were 
conducted to give concentrations of 10 mM, 1 mM, 0.1 mM, 3 mM, 0.3 mM and 0.03 mM. 3 uL 
of each of these solutions was added to 0.5 mL of DMEM and 100 uL of each of these solutions 
was added to corresponding wells in a 96-well plate containing 100 uL of transfected cell 
media to give final drug concentrations of; 30 µM, 3 µM, 0.3 µM, 10 µM, 1 µM and 0.1 µM. 
Controls of C3 and 5D were made up using only DMSO instead of drug plus DMSO. A further 
control using BIX02189 in equal drug concentrations was also prepared. 
Cell Lysis 
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The media was removed from the assay plates by aspiration and 20 µL of passive lysis buffer 
(PLB) was dispensed into each well, the plates were then shaken for 10 min. 
Quantification of cellular ERK5 Inhibition 
A Dual-Luciferase® Reporter Assay System (Promega® E1960)  kit was prepared according to 
the manufacturer’s guidelines by combining Luciferase assay buffer and Luciferase assay 
substrate separately to a combination of  Stop and Glo® assay buffer and Stop and Glo®. 50 µL 
of the Luciferase system was added to each well of a 96 well plate using a multichannel pipette 
and luminescence was quantified by an EG&G Berthold Microlumat Plus luminometer. A 
further addition of Stop and Glo® system (50 µL) was added and the analysis repeated.  The 
technical replicates generated were transformed in Excel and data was then transformed using 
GraphPad Prism to a curve and absolute IC50. 
5.2 P-gp induction assessment 
Cell preparation and compound addition 
Cell stocks of HEK293 and MCF7 were removed from incubation and the media was removed. 
Cells were washed with PBS (15 mL) and trypsinised using Trypsin/EDTA solution (1 mL).  
MCF7TaxR cells were suspended in DMEM-TaxR media and counted on glass slip under a 
microscope showing 1.37x106 cells/mL. A cell count of 1.5x105 is required per plate therefore 
1.1 mL of cell solution was combined with 8.9 mL of DMEM-TaxR on a 10 cm circular cell plate 
and incubated overnight.  
HEK293 cells were suspended in DMEM (19 mL) after trypsinisation and counted, showing 
1.06x106 cells/mL therefore 16 ml of cell solution was combined with 64 mL of DMEM to give a 
1.5x105 cells/mL which was used to make 9x10 mL circular cell plates which were incubated 
overnight. After this time drug was added to the cells to a final concentration of 10 µM, the 
cells were then returned to the incubator for a further 18 hours.  
Cell lysate preparation 
The media was then removed and the cells washed with PBS solution (5 mL). Cells were lysed 
using TG lysis buffer (250 µL) and this solution was transferred to a 1.25 mL eppendorf tube 
and centrifuged at 13000 rpm, 4oC for 10 minutes to remove cell debris, and the supernatant 
collected. A Bradford assay was performed to ensure equal protein loading whilst the 
supernatant (150 µL) was combined with loading buffer (50 µL) and heated to 95oC for 5 
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minutes. Equal amount of protein was loaded for each sample according to the Bradford assay 
results. Dual colour protein ladder (10µL) was loaded in the final well. 
 
Bradford Assay 
The supernatant (5 µL) was added to Bradford assay solution (995 µL) and this mixture (200 µL) 
was added to a 96 well plate in duplicate. The absorbance was measured at 595 nm and 
protein loading volumes calibrated to the lowest absorbing sample to give 45 µg in each well. 
SDS-Polyacrylamide gel electrophoresis 
A 6% stacking gel and either 8 or 10% resolving gels were made up and poured according to 
the quantities shown (Table 72).Gels were run at 25 mA for 2-4 hours, until the dye present in 
the loading buffer elutes off the gel. 
Table 72. Material quantities (in order of addition) for making up gels of specified strength. 
Resolving Gel 8% 10%  Stacking Gel 6% 
Deionised H2O / mL 27.6 24  Deionised H2O / mL 10.6 
1.5 M Tris pH 8.8 (ml) 15 15  0.5 M Tris pH 6.8 (ml) 5 
30% Acrylamide/Bis (ml) 16.2 19.8  
30% Acrylamide/Bis 
(ml) 
4 
20% SDS (ml) 0.6 0.6  20% SDS (ml) 0.2 
APS (ml) 0.6 0.6  APS (ml) 0.2 
TEMED (µl) 60 60  TEMED (µl) 25 
 
Protein Transfer 
 A Polyvinylidene fluoride (PVDF) membranes activated in methanol and washed in transfer 
buffer was layed on the gel and electroblotted in a Biorad mini-transblot tank for ca. 80 
minutes at 300 mA. 
Immunodetection 
Membranes were washed in TBST solution and blocked for 1 hour at room temperature in 5% 
(W/V) milk-TBST solution. The Primary polyclonal antibodies; P-gp (P-gp, Santa Cruz 
biotechnology, inc. MDR (H-241): sc-8313) and ERK1 (BD transduction labs 610031) were 
added (6 µL in 6 mL 5% (W/V) milk-TBST solution)  to the membrane and incubated overnight 
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at 4oC. Following this membranes were washed in TBST solution and the secondary antibodies 
(mouse for visualising ERK1, Rabbit for visualising P-gp (2 µL in 6 mL 5% (W/V) milk-TBST 
solution) were added. The membranes were left for one hour then washed in TBST and 
subjected to immunodetection solution (ECL, peroxide and luminol enhancer) according to the 
manufacturer’s instructions. Film exposures were made for various durations in complete 
darkness and digital files made by scanning marked films. 
Cell lines: 
HEK293 
HEK293 cells are an epithelial-like human embryonic kidney cell line transformed with 
adenovirus 5 DNA and were a kind gift from Dr Nicholas Ktistakis, The Babraham Institute. 
HEK293 growth media: DMEM-HEK293 (Dulbecco's Modified Eagle Medium): 100 µg ml-1 
penicillin, 100 μg ml-1 streptomycin, 1 mM L-glutamine, 10% (v/v) foetal bovine serum. 
MCF7TaxR 
MCF7TaxR cells are an epithelial-like breast adenocarcinoma cell line established from a 69 
year old female Caucasian patient with acquired resistance to 6 nM paclitaxel (Taxol)7. Cells 
were kindly provided by Dr Helen Coley, University of Surrey. 
MCF7TaxR(Taxol resistant) growth media: DMEM-TaxR (Dulbecco's Modified Eagle Medium): 
100 U ml-1 penicillin, 100 μg ml-1 streptomycin, 1mM L-glutamine, 10% (v/v) foetal bovine 
serum, 6 nM paclitaxel. 
Cell Maintenance 
All cells were incubated at 37°C in a humidified incubator with 95% (v/v) air and 5% (v/v) 
carbon dioxide. Cells were generally passaged every three days when the density reaches ca. 
80% confluency. Media is removed by aspiration and cells rinsed with PBS (4 mL) then 
detached by Trypsin/EDTA (2 mL). Cells were counted and resuspended in the appropriate 
media at a concentration of 0.2x106 cells/mL. 
Solutions: 
Bradford assay solution: 795 µl distilled water, 200 µl Bradford reagent 
Phosphate buffer solution (PBS (10x)): NaCl (4% w/v), KCl (0.1% w/v), Na2HPO4.7H2O (0.6% w/v), 
KH2PO4 (0.1% w/v), NaN3 (0.01% w/v) in distilled H2O. 
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Trypsin/EDTA: (0.5% Trypsin-EDTA (1x), Gibco®) 
Loading Buffer: Tris-Cl (50 mM), sodium dodecyl sulphate (SDS, 2% w/v), bromophenol blue 
(0.1% w/v), glycerol (10% v/v), dithiothreitol (100 mM) in distilled H2O. 
TG lysis buffer: 20 mM Tris-Cl, pH 7.5, 137 mM NaCl, 1 mM EGTA, 1% (v/v) Triton X-100, 10% 
(v/v) glycerol, 1.5 mM MgCl2, 1 mM Na3VO4, 1 mM PMSF, 10 µg ml
-1 leupeptin, 10 μg ml-1 
aprotinin, 50 mM NaF. 
Transfer buffer:  192 mM glycine, 25 mM Tris base, 20% (v/v) methanol. 
Running buffer: 192 mM glycine, 25 mM Tris base, 0.1% (w/v) SDS. 
TBS-T: 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% (v/v) Tween 20, Tris-Buffered Saline Tween-
20  
Passive lysis buffer: PLB (Dual-LuciferaseReporter Assay System (5x), Promega®) in  H2O, (1:5) 
5.3 Molecular Docking Procedure 
Molecular docking was conducting using GOLD software. Selected structures were 
drawn in ChemDraw, saved in .SDF format and docked in the active site of ERK5 (PDB: 
4IC7). A 12 Å radius sphere centred on Met93 (C2) was defined as the docking space 
and free rotation was permitted on Lys39(all other residues were treated as rigid). 
Water was eliminated from the structure. The Chemscore docinkg protocol was run at 
the highest level of efficiency. 
5.4 Analytical Techniques 
All commercial reagents were purchased from Sigma-Aldrich Chemical Company, Alfa 
Aesar, Apollo Scientific, Tokyo Chemical Industry UK Ltd or Fluorchem. Unless otherwise 
stated, chemicals were used as supplied without further purification. Anhydrous solvents 
were obtained from AcroSealTM or Aldrich SureSeal™ bottles and were stored under 
nitrogen. Petrol refers to the fraction with a boiling point between 40 and 60 °C. 
NMR samples were run on a Bruker Avance III (500 MHz) NMR spectrometer in deuterated 
solvent. Chemical shifts are reported in parts per million (ppm) and coupling constants in Hertz 
(Hz). Spin multiplicity is denoted in the following format: s = singlet, d = doublet, t = triplet, q = 
quartet, quint = quintet, m = multiplet and br = broad. Notations can also be found combined 
to denote the following dt = doublet of triplets, dd = doublet of doublets etc. Homonuclear and 
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heteronuclear two dimensional NMR experiments were used where appropriate to facilitate 
assignment of chemical shifts. 
Low resolution mass spectrometry data were collected from a Waters Acquity UPLC system, 
through a Aquity UPLC® BEH C18 1.7µm, 2.1 x 50mm column with PDA and ELSD with both 
positive and negative electrospray ionisation. High resolution mass spectra were obtained 
from EPSRC UK National Mass Spectrometry Facility (NMSF), University of Wales, Singleton 
Park, Swansea, SAZ 8PP.  
Liquid chromatography purification was performed by medium pressure liquid 
chromatography (MPLC) using Davisil silica gel (40 -63µm) on a Biotage SP4 system using pre-
packed Aligent Si 50, Si 35 or Graceresolve Si 40 columns. Thin layer chromatography (TLC) was 
perfomed on aluminium backed Merck TLC silica gel 60 F254 plates and visualised under short 
wave ultraviolet light (254nm). 
All samples submitted for biological assay were greater than 95% purity by integration. 
Analytical HPLC values were acquired from a Waters XTerra RP18, 5 M (4.6 x 150 mm) column 
at 1 ml/min. Both acidic and basic values were taken using 0.1% aqueous formic acid and 0.1% 
aqueous ammonia in acetonitrile respectively on a gradient of 5-100% over 15 minutes.  
All FTIR (fourier transform infrared) spectra where run on a Bio-Rad FTS 3000MX diamond ATR 
as a neat sample or an Agilent Cary 630 FTIR as a neat sample. 
Melting points were obtained on a Stuart Scientific SMP3. 
Ultraviolet spectra were gathered on a Hitachi UV-U2800A spectrophotometer in ethanol. 
 Microwave reactions were carried out in a Biotage initiator with Sixty robot. 
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5.5 General Procedures: 
Except where water was included in the reaction mixture, all reactions were carried 
out under strict anhydrous conditions with oven-dried glassware and cooled under 
nitrogen. Temperatures quoted refer to heating block temperatures. 
General procedure A: The preparation of Sulphonamides: 
Sulphonyl chloride (1.1 eq) was dissolved in pyridine and added dropwise to amino 
indazole (1 eq) in pyridine (1.5 mL per 100 mg) at 0 oC. The reaction mixture was 
stirred for 4 h under N2 and allowed to warm to RT. After this time the solution was 
reduced under vacuum and resuspended in saturated NaHCO3 solution and extracted 
with EtOAc. Combined organic fractions were washed with brine, dried over Na2SO4 
and purified by MPLC (0-80% EtOAc in petroleum ether) giving the pure product. 
General procedure B: Sulphonamide Alkylation: 
In oven dried glassware, a sulphonamide (1 eq) was dissolved in DMF (1 mL per 0.18 
mmol) and  potassium carbonate (1 eq) was added and the mixture stirred at 0 oC 
under N2 for 15 mins. After this time ethyl/methyliodide (1.5 eq) was added and the 
reaction was allowed to warm to RT. This was left to stir overnight before being 
reduced to a residue in vacuo and suspended  in water before extraction with EtOAc. 
Organic fractions were combined and washed with brine. The pure product was 
obtained by MPLC (10 - 60% EtOAc in petroleum ether). 
General procedure C: Indazole-THP protection 
The indazole derivative (1 eq) was dissolved in DCM (3 mL/mmol) and DHP (3 eq) 
added followed by p-TSA (0.1 eq). The solution was stirred at RT for ca. 6 h then 
saturated aqueous sodium hydrogen carbonate solution (2 mL/mmol) was added and 
the solution extracted with DCM (3 x 1.5 mL/mmol). Organic fractions were combined 
and dried using a phase separator. The solution was reduced in vacuo and the pure 
product obtained by MPLC (0-80% EtOAc in petroleum ether). 
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General procedure D: Indazole-THP Deprotection 
THP protected indazole (1 eq) is dissolved in an excess of methanolic HCl (1.25 M) 
solution and stirred at room temperature for ca. 3 h before evaporation of the 
volatiles and redissolving in EtOAc. The organic solution was washed with saturated 
NaHCO3 solution (aq) and dried over Na2SO4. The pure product was obtained by MPLC 
(0-80% EtOAc in petroleum ether). 
General procedure E: Aromatic Nitro reduction 
A nitro-indazole compound (1 eq) was dissolved in EtOAc to a maximum concentration 
of 0.05 M and cycled through a Thales ‘H-Cube’ instrument with a 10% Pd/C catalyst 
cartridge on full H2 mode at 40
oC with a flow rate of 1 mL/min until complete 
conversion was witnessed by TLC/LCMS. The volatiles were removed and the clean 
product isolated without purification. 
General procedure F: Suzuki reaction 
A bromo-indazole compound (1 eq), a boronic acid species (3 eq), Cs2CO3 (1.5 eq) and 
Pd(dppf)Cl2.DCM (0.1 eq) were deposited in a dry microwave vial under N2 and 
dissolved in 1,4-dioxane (12 mL/ mmol). The solution was degassed with N2 for ca. 10 
minutes before being subjected to microwave irradiation for 30 minutes, to a 
temperature of 150 oC. The solution was allowed to cool, filtered through Celite® and 
the reduced to a residue under vacuum. The pure product was obtained by reversed 
phase MPLC (0-80% MeCN (0.1% HCOOH) in H2O (0.1% HCOOH)). 
General procedure G: LiAlH4 Ester Reduction 
Methylester-indazole (1 eq) was dissolved in anhydrous THF (10 mL/mmol) under N2 at 
0 oC and LiAlH4 (1 M in THF, 2 eq) added dropwise. The reaction was stirred for 3 h 
before addition of EtOAc (5 mL/mmol) and a further stirring period of 15 minutes. 
Water was added dropwise until effervescence ceased. The reaction mix was then 
filtered through Celite® and washed with MeOH. The solution was reduced to a 
residue by rotary evaporator and resuspended in DCM, partitioned with water, washed 
with brine and dried by phase separator before purification by MPLC (0-80% EtOAc in 
petroleum ether). 
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General procedure H: Bromination and Simultaneous Indazole-THP Deprotection 
A Methanol-indazole derivative (1 eq) was dissolved in anhydrous DCM (20 mL/mmol) 
under N2 at 0 
oC and DMF (0.1 eq) was added. SOBr2 (2 eq) was added dropwise and 
the reaction allowed to reach room temperature over 6 h with stirring. After this time 
the reaction mix was concentrated in vacuo and resuspended in methanolic HCl (1.25 
M, 10 eq). This mixture was stirred for 3 h before volatiles were removed in vacuo and 
the residue redissolved in EtOAc. The organic solution was washed with saturated 
NaHCO3 solution (aq) and dried over Na2SO4. The pure product was obtained by MPLC 
(0-80% EtOAc in petroleum ether). 
General procedure I: Thiol-Alkyl Bromide SN2 
A Thiol species (1.5 eq) was dissolved in anhydrous DMF (10 mL/mmol) under N2 and 
Cs2CO3 (1.1 eq) added. This mixture was stirred for 5 minutes before the addition of 
the bromomethyl-indazole species (1 eq). The reaction was stirred at room 
temperature for 6 h then reduced to a residue on by high vacuum and heat (Biotage 
V10 instrument), resuspended in DCM and partitioned with H2O. The aqueous layer 
was extracted with DCM (3 x 10 mL) and combined organic fractions were washed with 
brine and dried via phase separator. The product was obtained by MPLC (0-80% EtOAc 
in petroleum ether). 
General procedure J: Secondary Sulphonamide Formation 
Methylamine (2 M in THF, 2.1 eq) was added to a solution of a sulphonylchloride (1 eq) 
in DCM (3 mL/mmol) and heated at reflux for 2 h whilst stirring. After this time water 
(2 mL/mmol) was added and the organic fraction separated, washed with brine (2 
mL/mmol) and dried using a phase separator. The product was obtained by MPLC (0-
80% EtOAc in petroleum ether). 
General procedure K: Oxone® Thioether Oxidation 
Indazole-thioether was dissolved in MeOH (20 mL/mmol) and a solution of Oxone® (6 
eq) in H2O (20 mL/mmol) was added in one portion. The reaction mix was stirred for 18 
h then volatiles were removed by rotary evaporator. The remaining solution was 
diluted with H2O and extracted with DCM (3 x 10 mL) and the combined organic 
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fractions dried via phase separator. The product was obtained by MPLC (0-80% EtOAc 
in petroleum ether). 
General procedure L: Suzuki and THP Deprotection 
Bromo-indazole compound (1 eq), a boronic acid species (3 eq), Cs2CO3 (1.5 eq) and 
Pd(dppf)Cl2.DCM (0.1 eq) were deposited in a dry microwave vial under nitrogen and 
subsequently dissolved in dioxane (12 mL/ mmol). The solution was degassed with N2 
for ca. 10 minutes before being subjected to microwave irradiation for 30 minutes, to a 
temperature of 150oC. The solution was allowed to cool, filtered through Celite® and 
the filtrate reduced to a residue under vacuum. This resulting material was dissolved in 
an excess of methanolic HCl (1.25 M) solution and stirred at room temperature for ca. 
3 h before volatiles were removed in vacuo and the residue redissolved in EtOAc. The 
organic solution was washed with a saturated NaHCO3 solution (aq) and dried over 
Na2SO4. The product was obtained by semi-preparative HPLC (MeCN:H20 (0.1% 
CHOOH). 
General procedure M: Sequential Diazotisation, Sulphonylchloride and sulphonamide 
formation 
6-Aminoindazole (100 mg, 0.75 mmol) was dissolved in concentrated hydrochloric acid 
(0.25 mL, 3.00 mmol) and water (1 mL) and stirred at 0 oC. A solution of sodium nitrite 
(62 mg, 9.0 mmol) in water (0.5 mL) was added drop wise over 10 minutes. After 30 
minutes this reaction mixture was added drop wise to a solution of copper (II) chloride 
(300 mg, 2.25 mmol) in concentrated acetic acid (12 mL) under SO2 over 5 minutes. 
Sulphur dioxide was vigorously bubbled through this mixture for 40 minutes at RT 
before being diluted with DCM (40 mL) and cooled in ice. Cold water (20 mL) was 
added and the organic layer was isolated, dried and reduced in vacuo, this gave the 
intermediate sulphonyl chloride which was used directly without purification. The 
residue was taken in pyridine (2 mL) and the relevant aromatic amine (0.75 mmol) in 
pyridine (1 mL) was added slowly under N2. This was stirred at RT for 18h before being 
reduced to a residue under vacuum and suspended in saturated sodium bicarbonate 
solution. This was extracted with EtOAc (3 x 10 mL) and combined organic extracts 
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were washed with brine (10 mL) then dried over Na2SO4. Desired products were 
isolated by MPLC (0-80% EtOAc in petroleum ether). 
SO2 is a toxic gas and therefore release to the environment is prohibited; this was 
managed by allowing excess gas from the reaction to pass through water and a 
separate sodium hydroxide solution to convert SO2 to safer substances namely 
sulfourous acid and sodium sulphite which can be neutralised and disposed of in a 
typical manor for aqueous solutions (Scheme 39). 
 
Scheme 39. Quenching methods for the sanitation of SO2 gas. 
General procedure N: Palladium Mediated Carboxylation 
A bromo-indazole compound (1 eq), Pd(OAc)2 (0.1 eq), XantPhos (4,5-
Bis(diphenylphosphino)-9,9-dimethylxanthene, 0.2 eq) and lithium/methyl formate (4 
eq)  were deposited in a dry microwave vial under N2 and dissolved in DMF (12 mL/ 
mmol). After addition of Et3N (4 eq) the solution was degassed with N2 for ca. 10 
minutes and Ac2O (4 eq) added then reaction vessel was sealed. The solution was 
heated to 90 oC for 18 hours then allowed to cool, filtered through Celite® and reduced 
to a residue under vacuum. The pure product was obtained by MPLC (0-80% EtOAc in 
petrol). 
General procedure O: CDI Mediated Amide Coupling  
A solution of carbonyldiimidazole (2.0 eq.) and the relevant carboxylic acid (1.0 eq.) in 
THF (5 mL/mmol) was heated to 70 oC for 3 h. The appropriate amine (2.5 eq.) was 
added and the mixture heated at 50 °C for 3 h then RT for 16 h. The solution was 
diluted with H2O (10 mL), extracted with EtOAc (2 x 10 mL), washed with brine (10 mL) 
and dried over Na2SO4. The desired product was purified by MPLC (0-80% EtOAc in 
petrol). 
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General procedure P: Amine Alkylation: 
In oven dried glassware an amino indazole (1 eq) was taken in DMF (1 mL per 0.18 
mmol) with NaH (1 eq/ 2 eq) and stirred at 0 oC under N2 for 30 mins. After this time 
methyliodide (1 eq/2 eq) was added and the reaction was allowed to warm to RT. This 
was left to stir overnight before being reduced in vacuo and taken up in water (15 mL) 
and extracted with EtOAc (3 x 15 mL). Organic fractions were combine, washed with 
brine and reduced by rotary evpourator. The pure product was obtained by MPLC (10 - 
60% EtOAc in petroleum ether). 
General procedure Q: Indazole-BOC Deprotection 
A Boc protected indazole (1 eq) was dissolved in DCM (10 mL/0.1 mmol) and TFA (1 
mL/0.05 mmol) and stirred at room temperature for 2 hours before evaporating off 
the volatiles and redissolving in EtOAc. The organic solution was washed with a 
saturated NaHCO3 solution (aq) and dried over Na2SO4. The product was obtained by 
MPLC (0-80% EtOAc in petroleum ether). 
General Procedure R: PCl3 Mediated Amide Coupling  
A microwave vial was charged with the relevant carboxylic acid (1 eq.), the desired 
amine (2.5 eq), MeCN (2 mL/mmol) and PCl3 (1 eq.). The resulting mixture was heated 
at 150 oC by microwave irradiation for 5 mins. The mixture was then quenched with a 
saturated NaHCO3 Solution and diluted with H2O. The the solution was extracted with 
EtOAc (3 x 30 mL) and combined organic layers were washed with brine (50 mL), dried 
over Na2SO4, and concentrated in vacuo. The pure product was obtained by MPLC (10-
80% EtOAc in petroleum ether). 
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5.6 Synthetic Procedures 
N-(1H-Indazol-6-yl)-2-methoxybenzenesulfonamide (31) 
 
2-methoxybenzenethiol (0.24 ml, 2 mmol) was dissolved in acetonitrile (3 mL) and 
Hydrogen peroxide (30% in water, 6 mmol, 0.68ml) was added, the vessel was cooled 
in ice whilst thionyl chloride (2 mmol, 0.15 ml) was added dropwise. The mixture was 
stirred until conversion to the sulfonyl chloride was complete by TLC. 6-Amino-
indazole (266 mg, 2 mmol) dissolved in pyridine (3 ml) was added to the solution and 
stirred for a further 16 h. The resulting solution was acidified with hydrochloric acid 
solution (2 M, 10 mL) and extracted with EtOAc (3 x 10ml). The combined organic 
fractions were washed with brine and evaporated under low pressure. The resulting 
residue was purified by medium pressure liquid chromatography (0-70% EtOAc in 
petroleum spirit over 30 column volumes) to give a white solid (43.4 mg, 7%). 
Rf 0.35 (EtOAc /Petrol, 1:1); m.p. 221
oC; UV λmax (EtOH/nm) 286.0, 213.5; IR νmax/cm
-1: 
3353 (SO2NH), 1590, 1479; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 3.89 (3H, s, H-18), 6.91 
(1H, d, J = 8.6 Hz, H-6), 7.01 (1H, dd, J = 7.4, 7.4 Hz, H-16), 7.15 (1H, d, J =8.2 Hz, H-14), 
7.22 (1H, s, H-8), 7.51-7.56 (2H, m, H-15, H-5), 7.77 (1H, d, J = 7.4 Hz, H-17), 7.89 (1H, s, 
H-3), 10.13 (1H, s-br, SOONH), 12.80 (1H, s-br, N-1); 13C-NMR (125 MHz, DMSO-d6) δ 
ppm 56.1 (C-18), 99.1 (C-8), 112.8 (C-14), 114.4 (C-6), 119.5 (C-4), 120.0 (C-16), 120.9 
(C-5), 126.2 (C-12), 130.3 (C-17), 133.3 (C-3), 135.0 (C-15), 136.2 (C-7), 140.1 (C-9), 
156.3 (C-13);  MS (ES+) m/z 304.2 [M+H]+; HRMS calcd for C14H14N3O3S 304.0750 
[M+H]+ found 304.0750. 
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N-(1H-Indazol-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide (34) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 1,4-
benzodioxan-6-sulfonyl chloride  (194 mg, 0.75 mmol) to give a white solid (37.1 mg, 
15%).  
Rf 0.39 (EtOAc /Petrol, 1:1). m.p.  196
oC. UV λmax (EtOH/nm) 288, 207. IR νmax/cm
-1 3384 
(SO2NH) 2111, 1633, 1495, 1142. 
1H-NMR (500 MHz, DMSO-d6) δ ppm 4.24-4.27 (4H, m, 
H-162 ,H-172), ), 6.89 (1H, d, J = 8.7, 1.6 Hz, H-6), 6.97 (1H, d, J = 8.9 Hz, H-20), 7.23-7.26 
(1H, m, H-21, H-8, H-13), 7.61 (1H, d, J = 8.7 Hz, H-5), 7.94 (1H, s,H-3), 10.33 (1H, br, 
SOONH), 12.87 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 63.9 (C-17), 64.3 
(C-16), 99.4 (C-8), 114.5 (C-6), 115.6 (C-13), 117.6 (C-20), 119.6 (C-4), 120.3 (C-21), 
121.2 (C-5), 131.8 (C-12), 133.4 (C-3), 136.1 (7CH), 140.1 (C-9), 143.2 (C-19), 147.2 (C-
14); MS (ES+) m/z 332.2 [M+H]+. HRMS calcd for C15H14N3O4S [M+H]
+ 332.700 found 
332.0703 
N-(1H-Indazol-6-yl)pyridine-3-sulfonamide (37) 
 
Pyridine-3-sulfonic acid (1g, 6.28 mmol) was dissolved in phosphorousoxychloride (7 
ml) with phosphorouspentachloride (1.96 g, 9.42 mmol) and was heated at 135 oC for 
c.a. 18 h. After this time the solution was reduced to a residue under low pressure and 
taken in ice cold water (c.a. 20 ml). This was then baseified with saturated sodium 
hydrogencarbonate solution (20 ml) and extracted with diethylether. This was reduced 
under low pressure and used in the next reaction without purification. 6-
aminoindazole (837 mg, 6.28 mmol) in anhydrous pyridine (5 ml) was added to the 
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sulphonyl chloride, previously taken in 5ml THF. The solution was stirred at RT under 
nitrogen for c.a. 3 h before being reduced to a residue and taken in sodium 
hydrogencarbonate (20 ml) and extracted with EtOAc (3 x 15ml). Combined organic 
fractions were washed with brine, reduced under low pressure and purified by 
medium pressure liquid chromatography (0-70% EtOAc in petroleum ether) giving the 
title compound as an off white solid (284.3 mg, 16%). 
Rf 0.28 (EtOAc /Petrol, 1:1); m.p.  216
oC; UV λmax (EtOH/nm) 267, 209, 199.5; IR 
νmax/cm
-1  2745 (NNH), 1636, 1467, 1416; 1H-NMR (500 MHz, DMSO-d6) δ ppm 6.88 
(1H, dd, J = 8.6, 1.7  Hz, H-6), 7.27 (1H, s, H-8) 7.59 (1H, dd, J = 8.1, 4.7 Hz H-16), 7.63 
(1H, d, J = 8.6 Hz, H-5), 7.97 (1H, s, H-3), 8.11 (1H, dt, J = 8.1, 1.6 Hz, H-17), 8.76 (1H, dd, 
J = 4.7, 1.6 Hz, H-15) 8.89 (1H, d, J =  1.9 Hz, H-13) 10.62 (1H, s-br, SOONH), 12.26 (1H, 
s-br, N-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 100.7 (C-8), 115.1 (C-6), 120.1 (C-4), 
120.4 (C-5), 124.4 (C-16), 133.5 (C-3), 134.6 (C-17), 135.3 (C-7), 135.6 (C-12), 140.0 (C-
9), 147.0 (C-13), 153.5 (C-15); MS (ES+) m/z 275.2 [M+H]+; HRMS calcd for C12H11N4O2S 
[M+H]+  275.0602 found 275.0602. 
N-(1H-Indazol-6-yl)thiophene-2-sulfonamide (38) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 2-
thiophenesulfonyl chloride (137 mg, 0.75 mmol) to give a light pink solid (32.8 mg, 
16%). 
Rf 0.39 (EtOAc /Petrol, 1:1). m.p.  169-170
oC. UV λmax (EtOH/nm) 298, 258, 213. IR 
νmax/cm
-1 3341 (SO2NH) 3139 (NNH), 1628, 1497, 1332, 1146, 853. 
1H-NMR (500MHz, 
DMSO-d6) δ ppm 6.91 (1H, d, J = 8.6 Hz, H-6), 7.09 (1H, dd, J = 3.7 & 4.7 Hz, H-15), 7.32 
(1H, s, H-8), 7.53 (1H, d, J = 3.7 Hz, H-16), 7.64 (1H, d, J =8.7  Hz, H-5), 7.86 (1H, d, J= 
4.7 Hz, H-14), 7.90 (1H,s, H-3), 10.54 (1H, s-br, SOONH), 12.91 (1H, s-br, N-1). 13C-NMR 
(125 MHz, DMSO-d6) δ ppm 100.4 (C-8), 115.0 (C-6), 120.0 (C-4), 121.2 (C-5), 127.6 (C-
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15), 132.3 (C-16), 133.3 (C-14), 133.4 (C-3), 135.7 (C-7), 139.8 (C-12), 140.1 (C-9); MS 
(ES+) m/z 280.2 [M+H]+; HRMS calcd for C11H10N3O2S2 280.01 [M+H]
+ 280.0205 found 
280.0205. 
N-(1H-Indazol-6-yl)-1-methyl-1H-imidazole-5-sulfonamide (40) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 1-methyl-1H-
imidazole-5-sulfonyl chloride (181 mg, 0.75 mmol) to give an off white solid (50.9 mg, 
25%). 
Rf 0.34 (EtOAc /Petrol, 1:1). m.p.  262
oC; UV λmax (EtOH/nm) 297.5, 285.5, 208.5; IR 
νmax/cm
-1 3427 (SO2NH), 1631, 1531, 1326, 1146, 991, 945, 798. 
1H-NMR (500 MHz, 
DMSO-d6) δ ppm 3.63 (3H, s, H-17), 6.93 (1H, d, J = 8.6  Hz, H-6), 7.33 (1H, s, H-8), 7.57 
(1H, d, J = 8.6 Hz, H-5), 7.73 (1H, s, H-14), 7.98 (1H, s, H-16), 7.93 (1H, s, H-3), 10.31 (1H, 
s-br, SOONH), 12.84 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 33.4 (C-17), 
98.9 (C-8), 114.4 (C-6), 119.3 (C-4), 120.8 (C-5), 125.2 (C-16), 133.3 (C-3), 136.5 (C-7), 
138.4 (C-12), 139.7 (C-14), 140.2 (C-9); MS (ES+) m/z 378.2 [M+H]+; HRMS calcd for 
C11H12N5O2S 278.0706 [M+H]
+ found 278.0706. 
5-Chloro-N-(1H-indazol-6-yl)-1,3-dimethyl-1H-pyrazole-4-sulfonamide (41) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 5-chloro-1,3-
dimethyl-1H-pyrazole-4-sulfonyl chloride (172 mg, 0.75 mmol)  followed by semi-
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preprative HPLC (50% MeCN in H2O with 1% formic acid) to give a white solid (121.7 
mg, 50%). 
Rf 0.41 (EtOAc /Petrol, 1:1); m.p.  221
oC; UV λmax (EtOH/nm) 298, 286.5, 212;  IR 
νmax/cm
-1 3374 (SO2NH), 1635, 1501, 1333, 1126, 941, 910, 855, 686. 
1H-NMR (500 
MHz, DMSO-d6) δ ppm 2.27 (3H, s, H-17), 3.69 (3H, s, H-18), 6.89 (1H, dd, J = 8.7, 1.8  
Hz, H-6), 7.33 (1H, d, J = 1.8 Hz, H-8), 7.63 (1H, d, J = 8.7 Hz, H-5), 7.96 (1H, s, H-3), 
10.56 (1H, s-br, SOONH), 12.91 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 
13.3 (C-17), 36.4 (C-18), 99.1 (C-8), 114.3 (C-6), 114.3 (C-16), 119.6 (C-4), 121.3 (C-5), 
128.9 (C-9), 133.4 (C-3), 135.7 (C-12), 140.1 (C-7), 147.6 (C-13); MS (ES+) m/z 326.2 
[M+H]+; HRMS calcd for C12H13
35ClN5O2S  326.0473 [M+H]
+ 326.0479. 
N-(1H-Indazol-6-yl)-5-(pyridin-2-yl)thiophene-2-sulfonamide (42) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 5-(pyridin-2-
yl)thiophene-2-sulfonyl chloride  (195 mg, 0.75 mmol)  followed by semi-preprative 
HPLC (60% MeCN in H2O) to give a white solid (47.5 mg, 18%). 
Rf 0.44 (EtOAc /Petrol, 1:1); m.p.  220
oC; UV λmax (EtOH/nm) 363.5, 311, 211.5;  IR 
νmax/cm
-1 3253 (SO2NH), 1634, 1427, 1350, 1149, 943, 773, 661; 
1H-NMR (500 MHz, 
DMSO-d6) δ ppm 6.95 (1H, dd, J = 8.7, 1.7  Hz, H-6), 7.35-7.37 (1H, m, H-8), 7.35-7.37 
(1H, m, H-20), 7.54 (1H, d, J = 4.0 Hz, H-16), 7.65 (1H, d, J = 8.7 Hz, H-5), 7.76 (1H, d, J = 
4.0 Hz, H-15), 7.87 (1H, dd, J = 7.8, 1.6 Hz, H-21), 7.96-7.98 (1H, m, H-3), 7.96-7.98 (1H, 
m, H-22), 8.53 (1H, d, J = 4.3 Hz, H-19), 10.65 (1H, s-br, SOONH), 12.93 (1H, s-br, N-1). 
13C-NMR (125 MHz, DMSO-d6) δ ppm 100.4 (C-8), 115.0 (C-6), 119.4 (C-22), 120.0 (C-4), 
121.3 (C-5), 123.8 (C-20), 124.7 (C-15), 133.3(C-16), 133.5 (C-3), 135.6 (C-9), 137.5 (C-
21), 140.1 (C-7), 140.6 (C-12), 149.6 (C-19), 150.1 (C-17), 150.6 (C-14); MS (ES+) m/z 
357.2 [M+H]+; HRMS calcd for C16H13N4O2S2 357.0474 [M+H]
+ found 357.0479. 
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5-Chloro-N-(1H-indazol-6-yl)thiophene-2-sulfonamide (43) 
 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 4-
chlorothiophene-2-sulfonyl chloride  (163 mg, 0.75 mmol)  to give an orange solid 
(28.8 mg, 12%). 
Rf 0.32 (EtOAc /Petrol, 1:1). m.p.  180
oC. UV λmax (EtOH/nm) 271, 210.5. IR νmax/cm
-1 
3401 (SO2NH) 2723 (NNH), 1632, 1488, 1406, 1078, 992, 947. 
1H-NMR (500 MHz, 
DMSO-d6) δ ppm 6.90 (1H, d, J = 8.2  Hz, H-6), 7.16 (1H, d, J =4.9 Hz, H-15) 7.31 (1H, s, 
H-8), 7.39 (1H, d, J = 4.9 Hz, H-16), 7.66 (1H, d, J = 8.2 Hz, H-5), 7.98 (1H, s, H-3), 10.67 
(1H, s-br, SOONH), 12.94 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 100.8 (C-
8), 115.2 (C-6), 120.2 (C-4), 121.4 (C-5), 127.96 (C-15), 132.3 (C-16), 133.5 (C-3), 135.1 
(C-12), 135.2 (C-7), 138.0 (C-14), 140.0 (C-9). MS (ES+) m/z 314.2 [M+H]+; HRMS calcd 
for C11H9
35ClN3O2S 313.9819 [M+H]
+ found 313.9820. 
N-(1H-indazol-6-yl)benzo[b]thiophene-2-sulfonamide (44) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 
benzo[b]thiophene-2-sulfonyl chloride (175 mg, 0.75 mmol) to give a white solid (94.5 
mg, 38%). 
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Rf 0.37 (EtOAc /Petrol, 1:1). m.p. 193 
oC. UV λmax (EtOH/nm) 270.5, 212.5. IR νmax/cm
-1 
3403 (SO2NH), 1634, 1501, 1325, 1241, 1142, 1070, 946, 746. 
1H-NMR (500 MHz, 
DMSO-d6) δ ppm  6.97 (1H, d, J=8.6 Hz, H-6), 7.37 (1H, s, H-8), 7.44 (1H, dd, J = 7.0 Hz, 
H-17), 7.49 (1H, dd, J = 7.0 Hz, H-16), 7.65 (1H, d, J=8.6 Hz, H-5), 7.97 (1H, s, H-3), 7.97 
(1H, s, H-20), 7.98 (1H, d, J=7.9 Hz H-18), 7.98 (1H, d, J=8.1 Hz H-15), 10.79 (1H, s-br, 
SOONH), 12.93 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 100.6 (C-8), 115.1 
(C-6), 120.1 (C-4), 121.3 (C-5), 123.0 (C-15), 125.5 (C-17), 125.8 (C-18), 127.4 (C-16), 
129.5 (C-20), 133.4 (C-3), 135.4 (C-7), 137.1 (C-19), 140.0 (C-9), 140.3 (C-12), 140.8 (C-
14);  MS (ES+) m/z 330.2 [M+H]+; HRMS calcd for C15H12N3O2S2 330.0365 [M+H]
+ found 
330.0370. 
4,5-Dichloro-N-(1H-indazol-6-yl)thiophene-2-sulfonamide (45) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 4,5-
dichlorothiophene-2-sulfonyl chloride  (187 mg, 0.75 mmol)  to give a off white solid 
(24 mg, 9%). 
Rf 0.35 (EtOAc /Petrol, 1:1). m.p.  234
oC. UV λmax (EtOH/nm) 269, 212. IR νmax/cm
-1 3423 
(SO2NH) 3062 (NNH), 1633, 1320, 1162, 1022, 974, 853. 
1H-NMR (500 MHz, DMSO-d6) 
δ ppm 6.94 (1H, d, J = 7.9  Hz, H-6), 7.34 (1H, s, H-8), 7.64 (1H, s, H-16), 7.71 (1H, d, J = 
7.9 Hz, H-5), 8.02 (1H, s, H-3), 10.84 (1H, s-br, SOONH), 12.98 (1H, s-br, N-1). 13C-NMR 
(125 MHz, DMSO-d6) δ ppm 101.4 (C-8), 115.3 (C-6), 120.4 (C-4), 121.6 (C-5), 123.9 (C-
15), 130.1 (C-14), 131.0 (C-16), 133.5 (C-12), 134.7 (C-3), 137.1 (C-9), 140.0 (C-7); MS 
(ES+) m/z 348.1 [M+H]+; HRMS calcd for C11H8
35Cl2N3O2S2  347.9435 [M+H]
+  found 
347.9435. 
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2,5-Dichloro-N-(1H-indazol-6-yl)thiophene-3-sulfonamide (46) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 2,5-
dichlorothiophene-3-sulfonyl chloride  (187 mg, 0.75 mmol) to give a light pink solid 
(96 mg, 37%). 
Rf 0.34 (EtOAc /Petrol, 1:1); m.p. 197-198
oC; UV λmax (EtOH/nm) 264.5; IR νmax/cm
-1 
3408 (SO2NH) 3104 (NNH), 3354, 1632, 1354, 1154, 1130, 1041, 851. 
1H-NMR (500 
MHz, DMSO-d6) δ ppm 6.92 (1H, d, J = 7.7  Hz, H-6), 7.27 (1H, s, H-8), 7.31 (1H, s, H-16), 
7.67 (1H, d, J = 7.7 Hz, H-5), 7.98 (1H, s, H-3), 10.82 (1H, s-br, SOONH), 12.92 (1H, s-br, 
N-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 100.4 (C-8), 114.8 (C-6), 120.1 (C-4), 121.4 
(C-5), 126.5 (C-15), 126.7 (C-16), 129.7 (13CCl), 133.4 (C-3), 134.9 (12CH), 135.5 (C-7), 
140.1 (C-9); MS (ES+) m/z 348.1 [M+H]+; HRMS calcd for C11H8
35Cl2N3O2S2  348. [M+H]
+ 
347.9427 found 347.9427. 
5-Chloro-N-(1H-indazol-6-yl)-3-methylbenzo[b]thiophene-2-sulfonamide (47) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 5-chloro-3-
methylbenzo[b]thiophene-2-sulfonyl chloride (211 mg, 0.75 mmol) to give a grey solid 
(122.4 mg, 43%). 
Rf 0.37 (EtOAc /Petrol, 1:1;. m.p. 232 
oC; UV λmax (EtOH/nm) 285.0, 240.5, 209.5; IR 
νmax/cm
-1 3359 (SO2NH), 1631, 1329, 1150, 1077, 944, 859; 
1H-NMR (500 MHz, DMSO-
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d6) δ ppm  2.51 (3H, s, H-21), 6.94 (1H, d, J=8.1 Hz, H-6), 7.34 (1H, s, H-8), 7.51 (1H, d, J 
=7.8 Hz, H-16), 7.63 (1H, d, J=8.1 Hz H-5), 7.97 (1H, s, H-3), 7.97 (1H, s, H-18), 8.02 
(1H,d, J=7.8 Hz , H-15), 10.89 (1H, s-br, SOONH), 12.93 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm 11.9 (C-21) 100.8 (C-8), 115.7 (C-6), 120.1 (C-4), 121.3 (C-5), 
123.4 (C-18), 124.6 (C-15), 127.6 (C-16), 130.5 (C-17), 133.4 (C-3), 135.0 (C-7), 136.3 (C-
20), 136.4 (C-12), 137.1 (C-14), 140.0 (C-9), 140.3 (C-19); MS (ES+) m/z 378.2 [M+H]+; 
HRMS calcd for C16H13
35ClN3O2S2 378.0132 [M+H]
+ found 378.0136. 
N-(1H-Indazol-6-yl)quinoline-8-sulfonamide (48) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 8-
quinolinesulfonyl chloride (171 mg, 0.75 mmol) to give a grey solid (110.7 mg, 45%). 
Rf 0.34 (EtOAc /Petrol, 1:1) m.p.  237
oC. UV λmax (EtOH/nm) 274.5, 214. IR νmax/cm
-1 
1633, 1492, 1135, 939, 900, 785, 685. 1H-NMR (500 MHz, DMSO-d6) δ ppm 6.88 (1H, 
dd, J = 8.6, 1.7  Hz, H-6), 7.20 (1H, s, H-8) 7.47 (1H, d, J = 8.6 Hz, H-5), 7.70 (1H, dd, J = 
7.8, 7.8 Hz, H-20), 7.73 (1H, dd, J = 8.4, 4.2, Hz, H-16)   7.84 (1H, s, H-3), 8.25 (1H, dd, J 
= 7.8, 1.1 Hz, H-19), 8.25 (1H, dd, J = 7.8, 1.1 Hz, H-21), 8.50 (1H, dd, J = 8.4, 1.6, Hz, H-
17), 9.17 (1H, dd, J = 4.2, 1.6 Hz, H-15),  10.22 (1H, s-br, SOONH), 12.75 (1H, s-br, N-1). 
13C-NMR (125 MHz, DMSO-d6) δ ppm 99.5 (C-8), 114.7 (C-6), 119.5 (C-4), 120.8 (C-5), 
122.6 (C-16), 125.6 (C-20), 128.4 (18C), 132.1 (C-21), 133.2 (C-3), 134.3 (C-19). 135.1 
(C-12), 136.0 (C-7), 137.0 (C-17), 139.9 (C-9), 142.7 (13C), 151.45 (C-15);  MS (ES+) m/z 
325.3 [M+H]+ ;HRMS calcd for C11H8ClN3O2S2 [M+H]
+ 325.0753 found 325.0753. 
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N-(1H-Indazol-6-yl)benzo[d][1,3]dioxole-5-sulfonamide (50) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 1,3-
benzodioxole-5-sulfonylchloride  (166 mg, 0.75 mmol) to give a off white solid (106.2 
mg, 45%).  
Rf 0.37 (EtOAc /Petrol, 1:1). m.p.  196
oC. UV λmax (EtOH/nm) 289.5, 207.5, 197.5. IR 
νmax/cm
-1 3358 (SO2NH), 2899 (NNH), 1630, 1482, 1249, 1140, 1037, 914, 805, 702. 
1H-
NMR (500 MHz, DMSO-d6) δ ppm 6.11 (2H, s, H-162), 6.90 (1H, d, J = 7.7 Hz, H-6), 7.00 
(1H, d, J = 6.7 Hz, H-19), 7.23 (1H, s, H-13),  7.26 (1H, s, H-8), 7.31 (1H, d, J = 6.7 Hz, H-
20), 7.61 (1H, d, J = 7.7 Hz, H-5), 7.95 (1H, s, H-3), 10.23 (1H,s- br, SOONH), 12.87 (1H, 
s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 99.8 (C-8), 102.5 (C-16), 106.3 (C-13), 
108.2 (C-19), 114.7 (C-6), 119.7 (C-4), 121.2 (C-5), 122.5 (C-20), 132.6 (C-12), 133.4 (C-
3), 136.0 (C-7), 140.1 (C-9), 147.8 (C-14), 151.0 (18C); MS (ES+) m/z 318.3 [M+H]+; 
HRMS calcd for C14H12N3O4S 318.0543 [M+H]
+ found 318.0548. 
N-(1H-Indazol-6-yl)-2,3-dihydrobenzofuran-5-sulfonamide (51) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 2,3-
dihydrobenzo[b]furan-5-sulfonylchloride  (164 mg, 0.75 mmol) to give an off white 
solid (121.8 mg, 51%).  
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Rf 0.35 (EtOAc /Petrol, 1:1). m.p.  194
oC. UV λmax (EtOH/nm) 298, 287.5, 250, 200. IR 
νmax/cm
-1 3314 (SO2NH), 1633, 1445, 1354, 1244, 1144, 1113, 1065, 921, 687. 
1H-NMR 
(500 MHz, DMSO-d6) δ ppm 3.18 (2H, t, J=9.0 Hz, H-15), 4.58 (2H, t, J=9.0 Hz, H-162), 
6.85 (1H, d, J=8.5 Hz, H-19), 6.89 (1H, d, J = 8.9 Hz, H-6), 7.26 (1H, s, H-8), 7.54 (1H, d, J 
= 8.5 Hz, H-20), 7.60 (1H, d, J = 9.0 Hz, H-5), 7.63 (1H, s, H-13), 7.94 (1H, s, H-3), 10.23 
(1H, s-br, SOONH), 12.85 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 28.3 (C-
15), 72.2 (C-16), 99.4 (C-8), 109.0 (C-19), 114.6 (C-6), 119.6 (C-4), 121.2 (C-5), 124.0 (C-
13), 128.1 (C-20), 128.1 (C-12), 131.0 (C-7), 133.4 (C-3), 136.3 (C-14), 140.1 (C-9), 163.2 
(18C); MS (ES+) m/z 316.3 [M+H]+; HRMS calcd for C15H14N3O3S 316.0750 [M+H]
+ found 
316.0755. 
N-(1H-Indazol-6-yl)-2-oxoindoline-5-sulfonamide (52) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 2-oxindole-5-
sulfonylchloride (174 mg, 0.75 mmol) to give a pure product as a white solid (172.6 mg, 
70%).  
Rf 0.38 (EtOAc /Petrol, 1:1). m.p.  268
oC; UV λmax (EtOH/nm) 265.5, 207; IR νmax/cm
-1 
3377 (SO2NH), 2891 (NNH), 1707 (C=O), 1611, 1617, 1480. 
1H-NMR (500MHz, DMSO-d6) 
δ ppm 3.53 (2H, s, CH2), 6.88 (1H, d, J = 8.2 Hz, H-6), 6.89 (1H, dd, J = 8.7 & 1.7 Hz H19), 
7.25 (1H, s, H-8), 7.59 (1H, d, J = 8.6 Hz, H-5), 7.56 (1H, s, H-13),  7.62 (1H, d, J = 8.7 Hz, 
H-20), 7.93 (1H, s, H-3), 10.30 (1H, s-br, SO2NH), 10.75 ( 1H, s-br, CONH) 12.84 (1H, br s, 
H-1). 13C-NMR (125MHz, DMSO-d6) δ ppm 35.5 (C-15), 99.4 (C-8), 108.9 (C-19) 114.5 
(C-6), 119.6 (C-4), 121.2 (C-5), 122.7 (C-13), 126.7 (C-14), 127.5 (C-20), 131.8 (C-12), 
133.4 (C-3), 136.2 (C-7), 140.1 (C-9), 147.8 (C-18), 176.3 (C-16);  MS (ES+) m/z 329.3 
[M+H]+; HRMS calcd for C15H13N4O3S 329.0708 [M+H]
+ found 329.0703. 
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N-(1H-Indazol-6-yl)-2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide (53) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 2-oxo-2,3-
dihydro-1,3-benzoxazole-6-sulfonyl chloride  (176 mg, 0.75 mmol) to give a white solid 
(84.4 mg, 34%). 
Rf 0.41 (EtOAc /Petrol, 1:1). m.p.  308
oC. UV λmax (EtOH/nm) 280.5, 248 IR νmax/cm
-1 
3372 (SO2NH), 2898 (NNH), 1765 (C=O), 1488, 1347, 1151, 942, 700. 
1H-NMR (500 MHz, 
DMSO-d6) δ ppm6.89 (1H, dd, J = 8.6, 1.8  Hz, H-6), 7.18 (1H, d, J = 8.2 Hz H-19), 7.26 
(1H, s, H-8) 7.56 (1H, dd, J = 8.2, 1.8 Hz H-20), 7.60 (1H, d, J = 8.6 Hz, H-5),  7.63 (1H, d, 
J = 1.8 Hz, H-13), 7.94 (1H, s, H-3), 10.38 (1H, s-br, SOONH), 12.11 ( 1H, s-br, NHCOO) 
12.86 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 99.9 (C-8), 107.8 (C-13), 
109.8 (C-19), 114.8 (C-6), 119.8 (C-4), 121.3 (C-5), 123.4 (C-20), 132.7 (C-12), 133.4 (C-
3), 134.5 (18C). 135.9 (C-7), 140.1 (C-9), 142.8 (C-14), 154.0 (C-16);  MS (ES+) m/z 331.2 
[M+H]+; HRMS calcd for C14H11N4O4S 331.0500 [M+H]
+ found 331.0496. 
N-(1H-indazol-6-yl)dibenzo[b,d]furan-3-sulfonamide (54) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 
dibenzo[b,d]furan-3-sulfonyl chloride (200 mg, 0.75 mmol) to give a white solid (40.7 
mg, 15%). 
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Rf 0.42 (EtOAc /Petrol, 1:1). m.p. 310 
oC; UV λmax (EtOH/nm) 287.5, 209.0; IR νmax/cm
-1 
3314 (SO2NH), 1632, 1500,; 
1H-NMR (500 MHz, DMSO-d6) δ ppm  6.93 (1H, d, J=8.6 Hz, 
H-6), 7.28 (1H, s, H-8), 7.46 (1H, t, J = 7.5 Hz, H-18), 7.60 (1H, d, J = 8.60 Hz, H-5), 7.60 
(1H, m, H-19), 7.75 (1H, d, J = 78.2 Hz, H-20), 7.90 (1H, m, H-23), 7.90 (1H, m, H-24H),  
7.90 (1H, s, H-3), 8.27 (1H, d, J = 7.5 Hz, H-17), 8.65 (1H, s, H-13) 10.46 (1H, s-br, 
SOONH), 12.83 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm 100.3 (C-8), 112.0 
(C-20), 112.6 (C-23), 115.0 (C-6), 119.8 (C-4), 120.8 (C-13), 121.3 (C-5), 121.9 (C-17), 
122.4 (21C), 123.9 (C-18), 123.9 (22C), 126.0 (C-24), 128.9 (C-19), 133.4 (C-3), 134.5 (C-
12), 136.0 (C-7), 140.0 (C-9), 156.2 (C-16), 157.2 (C-14);  MS (ES+) m/z 364.2 [M+H]+; 
HRMS calcd for C19H14N3O3S 364.0750 [M+H]
+ found 364.0754. 
N-(1H-Indazol-6-yl)-6-morpholinopyridine-3-sulfonamide (67) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 6-(morpholin-
4-yl)pyridine-3-sulfonyl chloride (198 mg, 0.75 mmol)  to give a grey solid (165.6 mg, 
61%). 
Rf 0.39 (EtOAc /Petrol, 1:1); m.p.  218-219
oC. UV λmax (EtOH/nm) 274.5, 210.5 IR 
νmax/cm
-1 3237 (SO2NH) 2856 (NNH), 1633, 1586, 1491, 1141, 1103, 941. 
1H-NMR (500 
MHz, DMSO-d6) δ ppm 3.53 (4H, t, J = 4.8 Hz, H-19),  3.62 (4H, t, J = 4.8 Hz, H-20), 6.85 
(1H, d, J= 9.2 Hz, H-16), 6.91 (1H, dd, J = 8.7, 1.8  Hz, H-6), 7.29 (1H, s, H-8) 7.61 (1H, d, 
J = 8.7 Hz, H-5), 7.70 (1H, dd, J = 9.2, 2.5 Hz, H-17), 7.94 (1H, s, H-3), 8.39 (1H, d, J = 2.5 
Hz, H-13), 10.27 (1H, s-br, SOONH), 12.87 (1H, s-br, N-1). 13C-NMR (125 MHz, DMSO-d6) 
δ ppm 44.3 (C-19), 65.7 (C-20), 99.4 (C-8), 106.0 (C-16), 114.6 (C-6), 119.7 (C-4), 121.3 
(C-5), 122.9 (C-12), 133.4 (C-3), 135.7 (C-17), 136.2 (C-7), 140.2 (C-9), 147.3 (C-13), 
159.8 (C-15); MS (ES+) m/z 360.3 [M+H]+; HRMS calcd for C16H18N5O3S 360.1125 [M+H]
+ 
found 360.1116. 
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N-(1H-Indazol-6-yl)-2,5-dimethylfuran-3-sulfonamide (372) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 2,5-
dimethylfuran-3-sulfonyl chloride (146 mg, 0.75 mmol)  to give a white solid (83 mg, 
38%). 
Rf 0.36 (EtOAc /Petrol, 1:1). m.p. 163 
oC; UV λmax (EtOH/nm) 298.0, 286.0, 214.5; IR 
νmax/cm
-1 3330 (SO2NH), 1633, 1500; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 2.16 (3H, s, 
H-18), 2.33 (3H, s, H-17), 6.18 (1H, s, H-16),  6.91 (1H, d, J=8.6 Hz, H-6), 7.27 (1H, s, H-8), 
7.64 (1H, d, J=8.6 Hz, H-5), 7.97 (1H, s, H-3), 10.29 (1H, s-br, SOONH), 12.90 (1H, s-br, 
N-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 12.3 (C-17), 12.8 (C-18), 99.6 (C-8), 105.1 
(C-16), 114.7 (C-6), 119.7 (C-4), 120.7 (C-12), 121.2 (C-5), 133.4 (C-3), 136.1 (C-7), 140.1 
(C-9), 150.7 (C-15), 153.8 (13C);  MS (ES+) m/z 292.2 [M+H]+; HRMS calcd for 
C13H14N3O3S 292.0750 [M+H]
+ found 292.0755. 
N-(1H-Indazol-6-yl)-6-phenoxypyridine-3-sulfonamide (373) 
 
Prepared according to general procedure A with following reagents and quantities: 6-
amino-indazole (100 mg, 0.75 mmol), pyridine (1.5 mL), THF (2 mL) and 6-
phenoxypyridine-3-sulfonyl chloride (203 mg, 0.75 mmol) to give a white solid (114.3 
mg, 42%). 
Rf 0.24 (EtOAc /Petrol, 1:1); m.p.  178
oC; UV λmax (EtOH/nm) 210.5, 198; IR νmax/cm
-1 
3082 (SO2NH), 1635, 1581, 1463; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 6.91 (1H, dd, J = 
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8.6, 1.8  Hz, H-6), 7.15 (2H, d, J = 7.8 Hz H-20), 7.15 (1H, d, J = 7.8 Hz H-16) 7.26 (1H, t, J 
= 7.5 Hz H-22)  7.29 (1H, s, H-8) 7.42 (2H, t, J = 7.8 Hz, H-21), 7.64 (1H, d, J = 8.6 Hz, H-
5), 7.97 (1H, s, H-3), 8.12 (1H, dd, J = 8.8, 2.5 Hz, H-17), 8.47 (1H, d, J = 2.5 Hz, H-13),  
10.54 (1H, s-br, SOONH), 12.90 (1H, s-br, N-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 
100.3 (C-8), 111.9 (C-16) 114.9 (C-6), 120 (C-4), 121.5 (C-5), 121.6 (C-20), 125.5 (C-22), 
129.8 (C-21), 130.5 (C-12), 133.4 (C-3), 135.4 (C-7). 138.6 (C-17), 140.1 (C-9), 146.6 (C-
13), 152.6 (C-19), 165.4 (C-15); MS (ES+) m/z 367.2 [M+H]+; HRMS calcd for 
C18H15N4O3S 367.0863 [M+H]
+ found 367.0859. 
N-(1H-Indazol-6-yl)-N-methyl-2-oxoindoline-5-sulfonamide (83) 
 
Prepared according to general procedure A with following reagents and quantities: N-
methyl-1H-indazol-6-amine (32 mg, 0.22 mmol), pyridine (1.5 mL), THF (2 mL) and 2-
oxindole-5-sulfonylchloride (50 mg, 0.22 mmol) to give a light pink solid (32 mg, 43%). 
Rf 0.34 (EtOAc /Petrol, 1:1); m.p. 229-231
oC; UV λmax (EtOH/nm) 262.0, 207.5; IR 
νmax/cm
-1 3398 (SO2N), 2873, 1699 (C=O), 1618, 1478, 1326, 1240, 1152; 
1H-NMR (500 
MHz, DMSO-d6) δ ppm 3.53 (2H, s, H-15), 6.88 (1H, d, J = 8.4Hz, H-6), 6.89 (1H, dd, J = 
8.7, 1.7Hz H-19), 7.25 (1H, s, H-8), 7.59 (1H, d, J = 8.4Hz, H-5), 7.56 (1H, s, H-13),  7.62 
(1H, d, J = 8.7Hz, H-20), 7.93 (1H, s, H-3), 10.30 (1H, s-br, SOONH), 10.75 ( 1H, s-br, H-
17) 12.84 (1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 35.5 (C-15), 99.4 (C-8), 
108.9 (C-19) 114.5 (C-6), 119.6 (C-4), 121.2 (C-5), 122.7 (C-13), 126.7 (C-14), 127.5 (C-
20), 131.8 (C-12), 133.4 (C-3), 136.2 (C-7), 140.1 (C-9), 147.8 (C-18), 176.3 (C-16);  MS 
(ES+) m/z 329.3 [M+H]+; HRMS calcd for C16H15N4O3S 343.0859 [M+H]
+ found 343.0858. 
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N-(1H-Indazol-6-yl)-N-methylthiophene-2-sulfonamide (84) 
 
Prepared according to general procedure A with following reagents and quantities: N-
methyl-1H-indazol-6-amine (41 mg, 0.27 mmol), pyridine (1.5 mL), THF (2 mL) and 2-
thiophenesulfonyl chloride (50 mg, 0.27 mmol) to give a white solid (30 mg, 38%). 
Rf 0.37 (EtOAc /Petrol, 1:1); m.p. 172-173 
oC; UV λmax (EtOH/nm) 255.5, 210.0; IR 
νmax/cm
-1 3360 (SO2N) 3106, 1627, 1343, 1162; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 
6.87 (1H, d, J = 8.6 Hz, H-6), 7.24 (1H, dd, J = 3.7, 4.9Hz, H-15), 7.26 (1H, s,H-8), 7.49 
(1H, d, J = 3.7Hz, H-16), 7.73 (1H, d, J =8.6 Hz, H-5), 8.01 (1H, d, J= 4.9Hz, H-14), 8.08 
(1H, s, H-3), 13.13 (1H, s-br, H-1) ; 13C-NMR (125 MHz, DMSO-d6) δ ppm 38.4 (C-17), 
108.0 (C-8), 119.2 (C-6), 120.8 (C-5), 121.8 (C-4), 128.0 (C-15), 133.2 (C-16), 133.5 (C-3), 
134.0 (C-14), 138.9 (C-7), 139.5 (C-9), 153.2 (C-12);  MS (ES+) m/z 294.2 [M+H]+; HRMS 
calcd for C12H12N3O2S2 294.0365 [M+H]
+ found 294.0364. 
N-(1H-Indazol-6-yl)-N-methylquinoline-8-sulfonamide (85) 
 
Prepared according to general procedure B with following reagents and quantities: 
methyliodide (13 µL, 0.22 mmol), K2CO3 (20 mg, 0.15 mmol) and N-(1H-indazol-6-yl)-
quinoline-8-sulfonamide (47 mg, 0.15 mmol) in DMF (4 mL) this gave the title 
compound as a grey solid (13.6 mg, 28%). 
Rf 0.35 (EtOAc /Petrol, 1:1); m.p. 158
oC; UV λmax (EtOH/nm) 288.0, 213.0; IR νmax/cm
-1 
3318 (SO2NH), 1626, 1474; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 3.69 (3H, s, H-22), 6.78 
(1H, dd, J = 8.6, 1.7  Hz, H-6), 7.22 (1H, s, H-8) 7.53 (1H, d, J = 8.6 Hz, H-5), 7.63 (1H, dd, 
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J = 7.8, 7.8 Hz, H-20), 7.75 (1H, dd, J = 8.4, 4.2, Hz, H-16),  7.95 (1H, s, H-3), 8.21 (1H, dd, 
J = 7.8, 1.1 Hz, H-19), 8.26 (1H, dd, J = 7.8, 1.1 Hz, H-21), 8.55 (1H, dd, J = 8.4, 1.6, Hz, 
H-17), 9.15 (1H, dd, J = 4.2, 1.6 Hz, H-15),  12.92 (1H, s-br, N-1); 13C-NMR (125 MHz, 
DMSO-d6) δ ppm 40.2 (C-22), 107.2 (C-8), 118.7 (C-6), 120.7 (C-5), 121.1 (C-4), 122.6 (C-
16), 125.6 (C-20), 128.6 (18C), 132.9 (C-19), 133.3 (C-3), 134.2 (C-21), 136.6 (C-12), 
136.9 (C-17), 139.2 (C-7), 139.6 (C-9), 143.3 (13C), 151.5 (C-15); MS (ES+) m/z 339.2 
[M+H]+; HRMS calcd for C17H15N4O2S 339.0910 [M+H]
+ found 339.0916. 
N-(1H-Indazol-6-yl)-3-methoxy-N-methylbenzenesulfonamide (86) 
 
 
Prepared according to general procedure B with following reagents and quantities: 
Methyliodide (12 µL, 0.20 mmol), K2CO3 (18 mg, 0.13 mmol) and N-(1H-indazol-6-yl)-3-
methoxybenzenesulfonamide (40 mg, 0.13 mmol) in DMF (3 mL) this gave the title 
compound as a grey solid (17 mg, 41%). 
Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 84-86 
oC; UV λmax (EtOH/nm) 289.5; IR νmax/cm
-1: 3356 
(SO2NH), 1627, 1479; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 3.21 (3H, s, H-19), 3.70 (3H, 
s, H-18), 6.85 (1H, dd, J = 8.6, 1.7  Hz, H-6), 6.93 (1H, s, H-13), 7.10 (1H, d, J = 7.7 Hz, H-
15), 7.23 (1H, s, H-8), 7.28 (1H, dd, J = 8.2, 2.3 Hz, H-17), 7.53 (1H, dd, J = 8.0 Hz, H-16), 
7.72 (1H, d, J = 8.6 Hz, H-5), 8.08 (1H, s, H-3), 13.10 (1H, s-br, N-1); 13C-NMR (125 MHz, 
DMSO-d6) δ ppm 38.42 (C-19) 55.46 (C-18), 107.9 (C-8), 112.1 (C-13), 119.2 (C-6), 119.3 
(C-17), 119.6 (C-15), 120.7 (C-5), 121.7 (C-4), 130.4 (C-16), 133.5 (C-3), 137.1 (C-12), 
139.1 (C-7), 139.5 (C-9), 159.2 (C-14);  MS (ES+) m/z 318.2 [M+H]+; HRMS calcd for 
C15H16N3O3S 318.0907 [M+H]
+ found 318.0911. 
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N-(1H-indazol-6-yl)-4-methoxy-N-methylbenzenesulfonamide (87) 
 
Prepared according to general procedure A with following reagents and quantities: N-
methyl-1H-indazol-6-amine (36 mg, 0.24 mmol), pyridine (1.5 mL), THF (2 mL) and 2-
thiophenesulfonyl chloride (50 mg, 0.24 mmol) to give a white solid (31 mg, 42%). 
Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 162-164 
oC; UV λmax (EtOH/nm) 244.0; IR νmax/cm
-1 
3350 (SO2N), 3042, 1626, 1593, 1500, 1307; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 3.18 
(3H, s, H-17), 3.83 (3H, s, H-16), 6.91 (1H, d, J = 8.6 Hz, H-6), 7.15 (2H, d, J =8.2 Hz, H-
14), 7.22 (1H, s, H-8), 7.15 (2H, d, J =8.2 Hz, H-13), 7.70 (1H, d, J = 8.6 Hz, H-5), 7.89 (1H, 
s, H-3), 12.80 (1H, br, H-1) ; 13C-NMR (125 MHz, DMSO-d6) δ ppm 38.3 (C-17) 56.1 (C-
16), 99.1 (C-8), 112.8 (C-14), 114.4 (C-6), 119.5 (C-4), 120.9 (C-5), 126.2 (C-12), 133.3 
(C-3), 135.0 (C-13), 136.2 (C-7), 140.1 (C-9) 162.7 (C-15);  MS (ES+) m/z 317.3 [M+H]+; 
HRMS calcd for C15H16N3O3S 318.0907 [M+H]
+ found 318.0906. 
2,6-Difluoro-N-(1H-indazol-6-yl)-N-methylbenzenesulfonamide (88) 
 
 
Prepared according to general procedure B with following reagents and quantities: 
Methyliodide (12 µL, 0.22 mmol), K2CO3 (18 mg, 0.13 mmol) and 2,6-difluoro-N-(1H-
indazol-6-yl)-benzenesulfonamide (40 mg, 0.13 mmol) in DMF (4 mL) this gave the title 
compound as a grey solid (10.2 mg, 24%). 
Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 170
oC; UV λmax (EtOH/nm) 271.0, 211.0; IR νmax/cm
-1: 
3328 (SO2NH), 1611, 1464; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 3.38 (3H, s, H-163), 
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6.96 (1H, dd, J = 8.6, 1.7  Hz, H-6), 7.29 (2H, t, J = 8.8 Hz, 2xH-14), 7.38 (1H, s, H-8), 7.75 
(1H, d, J = 8.6 Hz, H-5), 7.76 (1H, dddd, J = 6.1, 6.1, 8.5, 8.5, H-15), 8.08 (1H, s, H-3), 
13.14 (1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 38.5 (C-16), 108.0 (C-8), 113.5 
(d, JFC = 27 Hz, C-14), 114.7 (C-12), 118.8 (C-6), 121.1 (C-15), 121.8 (C-4), 133.5 (C-3), 
136 (t, JFC = 11.1 Hz, C-15), 138.1 (C-7), 139.6 (C-9), 158.87 (d, JFC = 257 Hz, C-13), 
158.91 (d, JFC = 257 Hz, C-13); 
19F NMR (470 MHz, DMSO-d6) δ -105.9; MS (ES
+) m/z 
324.2 [M+H]+; HRMS calcd for C14H12F2N3O2S 324.0613 [M+H]
+ found 324.0611. 
N-(1H-Indazol-6-yl)-N-methyl-2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide (89) 
 
Prepared according to general procedure A with following reagents and quantities: N-
methyl-1H-indazol-6-amine (50 mg, 0.34 mmol), pyridine (1.5 mL), THF (2 mL) and 2-
thiophenesulfonyl chloride (80 mg, 0.34 mmol) to give a white solid (50 mg, 43%). 
Rf 0.41 (EtOAc /Petrol, 1:1); m.p. 271-273 
oC; UV λmax (EtOH/nm) 287.5, 251.5; IR 
νmax/cm
-1 3237 (SO2N), 1762 (C=O), 1620, 1482, 1346; 
1H-NMR (500 MHz, DMSO-d6) δ 
ppm 3.21 (3H, s, H-213), 6.83 (1H, dd, J = 8.5 Hz, H-6), 7.22 (1H, d, J = 8.3 Hz, H-19), 
7.23 (1H, s, H-8) 7.27 (1H, dd, J = 8.3, 1.7 Hz H-20), 7.46 (1H, d, J = 1.7 Hz, H-13), 7.70 
(1H, d, J = 8.5 Hz, H-5), 8.08 (1H, s, H-3), 12.21 ( 1H, br, H-17) 13.08 (1H, br, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm 39.1(C-21), 108.1(C-8), 108.7 (C-13), 109.7 (C-19), 
119.4 (C-6), 120.7 (C-5), 121.7(C-4), 124.4 (C-20), 129.2 (C-12), 133.5 (C-3), 134.8 (C-18). 
139.1 (C-7), 139.6 (C-9), 142.9 (C-14), 154.1 (C-16); MS (ES+) m/z 345.2 [M+H]+; HRMS 
calcd for C15H13N4O4S 345.0652 [M+H]
+ found 345.0650. 
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N-Methyl-1H-indazol-6-amine (90) 
 
6-Aminoindazole (1.0 g, 7.5 mmol) was taken in freshly prepared sodium methoxide 
solution (900 mg of sodium in 20 mL MeOH) followed by paraformaldehyde (340mg, 
10.5 mmol) and stirred at room temperature for 5 hours. After this time sodium 
borohydride (280 mg, 7.5 mmol) was added and the mixture refluxed at 80 oC for 2 
hours. The solution was hydrolysed in sodium hydroxide (1 M, 10 mL) and extracted 
with ethyl acetate (3 x 10 mL). Combined organic fractions were washed with brine (10 
mL) and dried over Na2SO4. The compound was purified MPLC (0-60% EtOAc in 
petroleum spirit over 20 column volumes). The pure product was isolated as a light 
brown solid (423 mg, 38%). 
Rf 0.25 (EtOAc /Petrol, 1:1); m.p. 137-138
oC; UV λmax (EtOH/nm) 306.4, 267.0, 236.4, 
218.8, 217.0; IR νmax/cm
-1 3409, 3188,  1613, 1357, 948, 802; 1H-NMR (500 MHz, 
DMSO-d6) δ ppm; 2.71 (3H, d, J = 4.7 Hz, H-11), 5.87 (1H, d, J = 4.7 Hz, H-10), 6.29 (1H, 
s, H-8), 6.49 (1H, d, J = 8.7 Hz H-6), 7.38 (1H, d, J = 8.7 Hz, H-5), 7.74 (1H, s, H-3), 12.35 
(1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 29.8 (C-11), 86.3 (C-8), 111.9 (C-6), 
115.0 (C-4), 120.3 (C-5), 133.1 (C-3), 142.2 (C-9), 149.0 (C-7); MS (ES+) m/z 148.2 
[M+H]+; HRMS calcd for C8H10N3 148.0869 [M+H]
+ found 148.0866. 
N-(1H-Indazol-6-yl)-N-methylfuran-2-sulfonamide (91) 
 
Prepared according to general procedure A with the following reagents and quantities: 
N-methyl-1H-indazol-6-amine (34 mg, 0.24 mmol), pyridine (1.5 mL) and 2-
furansulfonyl chloride (48 μL, 0.29 mmol) to give a light brown solid (41 mg, 62%). 
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Rf 0.37 (Et2O); m.p. 152-154 
oC; UV λmax (EtOH/nm) 288.8, 216.0; IR νmax/cm
-1 3337, 
3126, 1356, 1151 ; 1H-NMR (500 MHz, CDCl3) δ ppm 3.39 (1H, s, H-17), 6.49 (1H, s, H-
16), 6.90-6.91 (2H, m, H-6, H-15), 7.44 (1H, s, H-8), 7.59 (1H, s, H-14), 7.67 (1H, d, J = 
8.2 Hz, H-5), 8.04 (1H,s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm 39.2 (C-17), 109.3 (C-8), 
111.3 (C-16), 113.0 (C-4), 117.6 (C-15), 119.8 (C-6), 121.5 (C-5), 134.7 (C-3), 139.7 (C-7), 
146.4 (C-14), 147.2 (C-12);  MS (ES+) m/z 278.2 [M+H]+; HRMS calcd for C12H12N3O3S 
278.0594 [M+H]+ found 278.0594 
N-(1H-indazol-6-yl)-N-methylcyclopropanesulfonamide (92) 
 
Prepared according to general procedure B with following reagents and quantities: 
methyliodide (9.6 µL, 0.22 mmol), K2CO3 (38 mg, 0.27 mmol) and N-(1H-indazol-6-
yl)cyclopropanesulfonamide (43 mg, 0.18 mmol) in DMF (8 mL) this gave the title 
compound as a clear yellow  oil (26 mg, 57%). 
Rf 0.37 (Et2O); UV λmax (EtOH/nm) 287.8, 265.8, 210.0; IR νmax/cm
-1 3333, 3183, 1330, 
1137 ; 1H-NMR (500 MHz, CDCl3) δ ppm 0.92-0.96 (2H, m, H-13), 1.08-1.12 (2H, m, H-
13), 2.41-2.45 (1H, m, H-12), 3.41 (1H, s, H-17),   6.85 (1H, dd, J = 8.7, 1.7 Hz, H-6), 7.60 
(1H, s, H-8), 7.73 (1H, d, J = 8.7 Hz, H-5), 8.07 (1H,s, H-3); 13C-NMR (125 MHz, CDCl3) δ 
ppm 4.8 (C-13), 27.0 (C-12), 39.0 (C-14), 109.0 (C-8), 119.8 (C-6), 121.4 (C-5), 122.2 (C-
4), 134.7 (C-3), 140.2 (C-7), 140.5 (C-9);  MS (ES+) m/z  252.3 [M+H]+; HRMS calcd for 
C11H14N3O2S 252.0801 [M+H]
+ found 252.0801. 
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N-(1H-indazol-6-yl)-N-methyl-1-phenylmethanesulfonamide (93) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-6-amine (60 mg, 
0.41 mmol) and phenylmethanesulfonyl chloride (93 mg, 0.49 mmol) in pyridine (2.5 
mL). The product was isolated as a white solid (97 mg, 79%). 
Rf 0.44 (Et2O); m.p. 134-136 
oC; UV λmax (EtOH/nm) 310.2, 244.2, 215.6; IR νmax/cm
-1 
3345, 3109, 3037, 2921, 2863, 2811, 1614; 1H-NMR (500 MHz, CDCl3) δ ppm; 2.76 (3H, 
s, H-17), 4.57 (2H, s, H-12), 6.51 (1H, dd, J = 8.7, 2.0 Hz, H-6), 6.06 (1H, d, J = 2.0 Hz, H-
8), 7.03 (2H, d, J = 7.4 Hz, H-14), 7.11 (2H, dd, J = 7.4, Hz, 7.5 H-15), 7.21 (1H, t, J = 7.5 
Hz, H-16), 7.36 (1H, d, J =  8.7 Hz, H-5), 8.04 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ 
ppm; 30.4 (C-17), 59.6 (C-12), 91.6 (C-8), 113.6 (C-6), 118.6 (C-4), 121.3 (C-5), 126.8 (C-
13), 128.5 (C-15), 129.1 (C-16), 130.8 (C-14), 141.2 (C-3), 144.2 (C-9), 150.8 (C-7);  MS 
(ES+) m/z 302.2 [M+H]+. 
N-Isopropyl-1H-indazol-6-amine (95) 
 
6-Aminoindazole (100 mg, 0.75 mmol) was dissolved in acetonitrile (3 mL) and 
potassium iodide (12 mg, 0.08 mmol) added whilst under N2. 2-Bromopropane (24 µL, 
0.25 mmol) was added and the reaction was subjected to microwave radiation to a 
temperature of 150 oC for 10 minutes and then a further 10 minutes to 170oC. The 
resulting mixture was diluted with water (10 mL) and extracted with EtOAc (3 x 10 mL), 
combined organic fractions were washed with brine (10 mL) and dried over Na2SO4. 
The resulting solution was reduced to a residue under vacuum and purified by MPLC 
(0-60% EtOAc in petroleum ether). The pure product was isolated as a brown solid (17 
mg, 39%).  
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Rf 0.61 (Et2O);  m.p. 83-84 
oC; UV λmax (EtOH/nm) 309.2, 268.2, 236.8, 220.4; IR νmax/cm
-
1 3303, 3191, 1633, 1358, 1128, 846; 1H-NMR (500 MHz, DMSO-d6) δ ppm 1.17 (6H, d, J 
= 6.2 Hz, H-12), 3.35 (1H, m, J = 6.2 Hz, H-11), 5.59 (1H, d, J = 7.2, H-10), 6.34 (1H, s, H-
8), 6.51 (1H, d, J = 8.3 Hz, H-6), 7.37 (1H, d, J = 8.3 Hz, H-5), 7.71 (1H, s, H-3), 12.28 (1H, 
br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 22.2 (C-12), 43.2 (C-11), 87.3 (C-8), 112.3 
(C-6), 114.9 (C-4), 120.4 (C-5), 133.2 (C-3), 142.3 (C-7), 147.1 (C-9); MS (ES+) m/z 176.2 
[M+H]+ 
N-Ethyl-N-(1H-indazol-6-yl)benzenesulfonamide (97) 
 
Prepared according to general procedure A using 1H-indazol-6-amine (100 mg, 0.75 
mmol) and benzenesulfonyl chloride (96 µL, 0.75 mmol) in pyridine (2 mL). The 
material generated (N-(1H-indazol-6-yl)benzenesulfonamide)  was used directly 
without purification according to general procedure B with the following reagents and 
quantities: ethyliodide (60 µL, 0.75 mmol) and K2CO3 (104 mg, 0.75 mmol) in DMF (4 
mL) this gave the title compound as a grey solid (74 mg, 35%). 
Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 149-151 
oC; UV λmax (EtOH/nm) 208.0; IR νmax/cm
-1 
3298, 1625, 1334, 1156, 1057, 937, 726; 1H-NMR (500 MHz, DMSO-d6) δ ppm 1.00 (3H, 
t, J  = 7.1 Hz, H-17), 3.67 (2H, q, J = 7.1 Hz, H-16), 6.72 (1H, dd, J =  8.6, 1.7 Hz, H-6), 
7.20 (1H, s, H-8), 7.59-7.60 (4H, m, H-14, H-13), 7.70-7.72 (2H, m, H-5, H-15), 8.09 (1H, 
s, H-3), 13.12 (1H, s-br(1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 13.9 (C-17), 
45.5 (C-16), 110.5 (C-8), 120.7 (C-6), 120.8 (C-5), 122.1 (C-4), 127.2 (C-13), 129.2 (C-14), 
133.1 (C-15), 133.5 (C-3), 136.2 (C-7), 137.9 (C-12), 139.7 (C-9);  MS (ES+) m/z 302.3 
[M+H]+; HRMS calcd for C15H16N3O2S 302.0958 [M+H]
+ found 302.0956. 
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N-Ethyl-N-(1H-indazol-6-yl)-2-oxoindoline-5-sulfonamide (98) 
 
Prepared according to general procedure B with following reagents and quantities: 
ethyliodide (10 µL, 0.12 mmol), K2CO3 (17 mg, 0.12 mmol) and N-(1H-indazol-6-yl)-2-
oxoindoline-5-sulfonamide (40 mg, 0.12 mmol) in DMF (2 mL) this gave the title 
compound as a grey solid (19.2 mg, 44%). 
Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 128-130 
oC; UV λmax (EtOH/nm) 266.4, 208.2; IR 
νmax/cm
-1 3218, 2928,1703, 1617, 1480, 1332, 1141, 1061; 1H-NMR (500 MHz, DMSO-
d6) δ ppm 0.98, (3H, t, J = 7.0 Hz, H-22), 3.57 (2H, s, H-15), 3.62 (2H, q, J = 7.0 Hz, H-21), 
6.75 (1H, dd, J = 8.5, 1.6 Hz, H-6), 6.92 (1H, d, J = 8.2 Hz, H-19), 7.18 (1H, s, H-8), 7.37 
(1H, d, J = 8.2 Hz, H-20), 7.45 (1H, s, H-13), 7.71 (1H, d, J = 8.5 Hz, H-5), 8.09 (1H, s, H-3), 
10.85 ( 1H, br, H-17) 13.11 (1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 13.8 (C-
22), 35.6 (C-15), 45.4 (C-21), 108.9 (C-19), 110.5 (C-8), 120.7 (C-5), 121.0 (C-6), 122.0 
(C-4), 123.5 (C-13), 126.7 (C-14), 128.2 (C-20), 133.5 (C-3), 136.6 (C-7), 139.7 (C-9), 
147.9 (C-18), 153.2 (C-12), 176.4 (C-16);  MS (ES+) m/z 357.4 [M+H]+; HRMS calcd for 
C17H17N4O3S 357.1016 [M+H]
+ found 357.1016. 
N-Ethyl-N-(1H-indazol-6-yl)thiophene-2-sulfonamide (99) 
 
Prepared according to general procedure A using 1H-indazol-6-amine (100 mg, 0.75 
mmol) and thiophene-2-sulfonyl chloride (137 mg, 0.75 mmol) in pyridine (2 mL). The 
material generated (N-(1H-indazol-6-yl)thiophene-2-sulfonamide)  was used directly 
without purification according to general procedure B with the following reagents and 
quantities: ethyliodide (60 µL, 0.75 mmol) and  K2CO3 (104 mg, 0.75 mmol) in DMF (4 
mL) this gave the title compound as a grey solid (44.8 mg, 20% (over two steps)). 
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Rf 0.33 (EtOAc /Petrol, 1:1); m.p. 174-176 
oC; UV λmax (EtOH/nm) 253.4, 210.4; IR 
νmax/cm
-1 3317, 1333, 1157, 938; 1H-NMR (500MHz, DMSO-d6) δ ppm 1.03 (3H, t, J = 
7.1 Hz, H-18), 3.69 (2H, q, J = 7.1 Hz, H-17), 6.89 (1H, dd, J = 8.6, 1.7 Hz, H-6), 7.23-7.25 
(2H, m, H-15, H-8), 7.52 (1H, dd, J = 1.3, 3.7 Hz, H-16), 7.74 (1H, d, J = 8.6 Hz, H-5), 8.02 
(1H, dd, J = 5.0, 1.3 Hz, H-14), 8.10 (1H,s, H-3), 13.16 (1H, s-br, H-1). 13C-NMR (125 MHz, 
DMSO-d6) δ ppm 13.9 (C-18), 45.6 (C-17), 110.4 (C-8), 120.7 (C-6), 120.9 (C-5), 122.2 (C-
4), 128.0 (C-15), 132.8 (C-16), 133.5 (C-3), 133.7 (C-14), 136.0 (C-7), 137.8 (C-12), 139.6 
(C-9); MS (ES+) m/z 308.3 [M+H]+; HRMS calcd for C13H14N3O2S2 308.0522 [M+H]
+ found 
308.0520. 
N-Ethyl-N-(1H-indazol-6-yl)quinoline-8-sulfonamide (100) 
 
Prepared according to general procedure B with following reagents and quantities: 
ethyliodide (10 µL, 0.12 mmol), K2CO3 (17 mg, 0.12 mmol) and N-(1H-indazol-6-yl)-
quinoline-8-sulfonamide (40 mg, 0.12 mmol) in DMF (3 mL) this gave the title 
compound as a grey solid (22.3 mg, 51%). 
Rf 0.37 (EtOAc /Petrol, 1:1); m.p. 168-169 
oC; UV λmax (EtOH/nm) 289.2, 212.2; IR 
νmax/cm
-1 3307, 2931, 1493, 1324, 1128, 941, 704; 1H-NMR (500 MHz, DMSO-d6) δ ppm 
1.09 (3H, t, J = 7.2 Hz, H-23), 4.24 (2H, q, J = 7.2 Hz, H-22), 6.61 (1H, dd, J = 8.7, 1.6  Hz, 
H-6), 7.14 (1H, s, H-8), 7.54 (1H, d, J = 8.7 Hz, H-5), 7.59 (1H, dd, J = 7.7, 7.7 Hz, H-20), 
7.78 (1H, dd, J = 8.4, 4.2, Hz, H-16),  7.98 (1H, s, H-3), 8.09 (1H, dd, J = 7.7, 1.2 Hz, H-19), 
8.27 (1H, dd, J = 7.7, 1.1 Hz, H-21), 8.58 (1H, dd, J = 8.4, 1.7, Hz, H-17), 9.18 (1H, dd, J = 
4.2, 1.6 Hz, H-15),  12.98 (1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 15.0 (C-23), 
47.9 (C-22), 110.7 (C-8), 120.8 (C-5), 121.0 (C-6), 121.8 (C-4), 122.6 (C-16), 125.6 (C-20), 
128.6 (C-18), 132.7 (C-19), 133.4 (C-3), 134.0 (C-21), 136.4 (C-7), 136.7 (C-12), 137.0 (C-
17), 139.6 (C-9), 143.2 (13C), 151.5 (C-15); MS (ES+) m/z 353.4 [M+H]+; HRMS calcd for 
C18H17N4O2S 353.1067 [M+H]
+ found 353.1064. 
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N-Ethyl-N-(1H-indazol-6-yl)-3-methoxybenzenesulfonamide (101) 
 
 
Prepared according to general procedure B with following reagents and quantities: 
ethyliodide (11 µL, 0.13 mmol), K2CO3 (18 mg, 0.13 mmol) and N-(1H-indazol-6-yl)-3-
methoxybenzenesulfonamide (40 mg, 0.13 mmol) in DMF (3 mL) this gave the title 
compound as a grey solid (24.5 mg, 56%). 
Rf 0.37 (EtOAc /Petrol, 1:1); m.p. 63-64 
oC; UV λmax (EtOH/nm) 285.0, 203.6; IR νmax/cm
-
1: 3352, 2935, 1595, 1477, 1319, 1239, 1159, 941; 1H-NMR (500 MHz, DMSO-d6) δ ppm 
0.99 (3H, t, J = 7.0 Hz, H-20), 3.66 (2H, q, J = 7.0 Hz, H-19), 3.74 (3H, s, H-18), 6.74 (1H, 
dd, J = 8.7, 1.8  Hz, H-6), 6.93 (1H, dd, J = 2.3, 2.3 Hz, H-13), 7.16 (1H, ddd, J = 8.0, 1.9, 
2.3 Hz, H-15), 7.22 (1H, s, H-8), 7.28 (1H, ddd, J = 8.0, 2.3, 1.9 Hz, H-17), 7.51 (1H, dd, J 
= 8.0, 8.0 Hz, H-16), 7.72 (1H, d, J = 8.7 Hz, H-5), 8.09 (1H, s, H-3), 13.15 (1H, br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm 13.9 (C-20), 45.4 (C-19), 55.5 (C-18), 110.5 (C-8), 
111.9 (C-13), 119.1 (C-17), 119.4 (C-15), 120.8 (C-5), 121.4 (C-4), 122.1 (C-6), 130.5 (C-
16), 133.6 (C-3), 136.2 (C-7), 138.0 (C-12), 139.0 (C-9), 159.3 (C-14);  MS (ES+) m/z 
332.4 [M+H]+; HRMS calcd for C16H18N3O3S 332.1063 [M+H]
+ found 332.1062. 
N-Ethyl-N-(1H-indazol-6-yl)-4-methoxybenzenesulfonamide (102) 
 
Prepared according to general procedure B using N-ethyl-1H-indazol-6-amine (40 mg, 
0.24 mmol) and 4-methoxybenzene-1-sulfonyl chloride (51 mg, 0.24 mmol) in pyridine 
(2 mL). The title compound was obtained as a light green solid (21 mg, 25%). 
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Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 146-148 
oC; UV λmax (EtOH/nm) 245.6, 202.0; IR 
νmax/cm
-1 3400, 2937, 1593, 1326, 1260, 1154, 939; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 0.98 (3H, t, J = 7.1 Hz, H-19), 3.63 (2H, q, J = 7.1 Hz, H-18), 3.85, (3H, s, H-17), 6.73 
(1H, dd, J = 8.5, 1.7 Hz, H-6), 7.10 (2H, d, J =  8.9 Hz H-14), 7.12 (1H, s, H-8), 7.51 (2H, d, 
J = 8.9 Hz, H-13), 7.71 (1H, d, J = 8.5 Hz, H-5), 8.08 (1H, s, H-3), 13.11 (1H, br, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm 13.9 (C-19), 45.1 (C-18), 55.7 (C-17), 110.8 (C-8), 
114.3 (C-14), 120.8 (C-6), 120.9 (C-5), 125.1 (C-4), 129.4 (C-12), 129.5 (C-13), 133.6 (C-
3), 136.5 (C-7), 139.7 (C-9), 162.6 (C-18);  MS (ES+) m/z 332.3 [M+H]+; HRMS calcd for 
C16H18N3O3S 332.1063 [M+H]
+ found 332.1060. 
N-Ethyl-2,6-difluoro-N-(1H-indazol-6-yl)benzenesulfonamide (103) 
 
Prepared according to general procedure A using 1H-indazol-6-amine (100 mg, 0.75 
mmol) and 2,6-difluorobenzene-1-sulfonyl chloride (102 µL, 0.75 mmol) in pyridine (2 
mL). The material generated (N-(1H-indazol-6-yl)benzenesulfonamide) was used 
directly without purification according to general procedure B with the following 
reagents and quantities: ethyliodide (60 µL, 0.75 mmol) and  K2CO3 (104 mg, 0.75 
mmol) in DMF (4 mL) this gave the title compound as a grey solid (12 mg, 10%). 
Rf 0.39 (EtOAc /Petrol, 1:1); m.p. 83-85 
oC; UV λmax (EtOH/nm) 289.2, 264.0, 209.0; IR 
νmax/cm
-1 3362, 2882, 1610, 1464, 1362, 1171, 1002, 939 ; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm 1.05 (3H, t, J =7.0 Hz, H-17), 3.85 (2H, q, J = 7.0 Hz, H-16), 6.86 (1H, d, J = 8.4 Hz, 
H-6), 7.28 (2H, dd, J = 9.15 Hz, H-14), 7.36 (1H, s, H-8), 7.73-7.79 (2H, m, H-15, H-5), 
8.10 (1H, s, H-3), 13.17 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 14.1 (C-17), 
46.0 (C-16), 110.7 (C-8), 113.5 (d, JFC = 23.5 Hz, C-14), 113.5 (d, JFC = 23.5 Hz, C-14’), 
120.4 (C-6), 121.2 (C-5), 122.2 (C-4), 133.6 (C-3), 133.6 (C-12), 135.1 (C-7), 136.1 (t, JFC 
= 11.4 Hz, C-15), 139.7 (C-9), 158.8 (d, JFC = 257.3 Hz, C-13), 158.8 (d, JFC = 257.3 Hz, C-
13’); 19F NMR (470 MHz, DMSO-d6) δ -106.2;  MS (ES
+) m/z 338.3 [M+H]+; HRMS calcd 
for C15H14F2N3O2S 338.0769 [M+H]
+ found 338.0764. 
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N-Ethyl-N-(1H-indazol-6-yl)-2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide (104) 
 
Prepared according to general procedure B with following reagents and quantities: 
ethyliodide (10 µL, 0.12mmol), K2CO3 (17 mg, 0.12 mmol) and N-(1H-indazol-6-yl)-2-
oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide (40 mg, 0.12 mmol) in DMF (2 mL) this 
gave the title compound as a grey solid (16.8 mg, 43%). 
Rf 0.37 (EtOAc /Petrol, 1:1); m.p. 239-241
oC; UV λmax (EtOH/nm) 252.2, 203.8; IR 
νmax/cm
-1 3370, 3072, 1775, 1631, 1487, 1329, 1147, 940; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm 1.21 (3H, t, J = 7.2 Hz, H-22), 3.81 (2H, q, J = 7.2 Hz, H-21), 6.91 (1H, dd, J = 8.7, 
1.7 Hz, H-6), 7.28 (1H, s, H-8), 7.44 (1H, d, J =  8.3 Hz, H-19), 7.60 (1H, d, J = 8.7 Hz, H-5), 
7.65 (1H, dd, J = 8.3, 1.7 Hz, H-20), 7.70 (1H, d, J = 1.7 Hz, H-13), 7.93 (1H, s, H-3), 10.44 
( 1H, br, H-17), 12.86 (1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 12.6 (C-22), 
37.1 (C-21), 99.7 (C-8), 107.9 (C-13), 109.1 (C-19), 114.6 (C-6), 119.8 (C-4), 121.3 (C-5), 
123.4 (C-20), 132.9 (C-12), 133.4 (C-3), 134.8 (C-18), 135.9 (C-7), 140.1 (C-9), 141.5 (C-
14), 153.2 (C-18);  MS (ES+) m/z 359.4 [M+H]+; HRMS calcd for C16H15N4O4S 359.0809 
[M+H]+ found 359.0809. 
6-(Benzo[b]thiophen-2-yl)-1H-indazole  (111) 
 
6-Bromoindazole (100 mg, 0.51 mmol), benzo[b]thiophen-2-ylboronic acid (90 mg, 
0.51 mmol) and Na2CO3 (64 mg, 0.61 mmol) in water (0.3 mL) were added to dioxane 
(2.7 mL) and the solution was degassed with nitrogen for ca. 15 minutes. Palladium 
tetrakis (6 mg, 0.05 mmol) was added and the solution degassed again for a further 15 
minutes. After this time the reaction was subjected to microwave radiation to a 
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temperature of 110 oC for 30 minutes. After this time further equivalence of 
benzo[b]thiophen-2-ylboronic acid (90 mg, 0.51 mmol), Na2CO3 (64 mg, 0.61 mmol) 
and Palladium tetrakis (6 mg, 0.05 mmol) with repeated 15 minute degassing. This was 
again heated in a microwave initiator at 110oC for 30 minutes before being filtered 
through Celite® (washing with EtOAc (15 mL)) and being diluted in water (15 mL). The 
aqueous was extracted with EtOAc (3 x 10 mL) and the combined organic extraction 
was washed with brine, dried over Na2SO4 and purified by MPLC (0-50% EtOAc in 
petroleum ether over 20 CV). 97.7 mg (77%) of pure orange solid was isolated.   
Rf 0.30 (EtOAc /Petrol, 1:1); m.p. 254-255
oC; UV λmax (EtOH/nm) 319.8, 257.4, 234.0, 
214.8; IR νmax/cm
-1 3296, 1620, 1073, 943, 836, 751; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 7.36 (1H, dd, J =8.9, 8.9 Hz, H-15), 7.42 (1H, dd, J = 8.9, 8.9 Hz, H-14), 7.60 (1H, d, J 
= 8.7, H-6), 7.87-7.89 (3H, m, H-8, H-13, H16), 7.97 (1H, s, H-18), 8.00 (1H, d, J = 8.7, H-
5), 8.12 (1H, s, H-3), 13.21 (1H, br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 107.9 (C-
8), 118.5 (C-6), 121.4 (C-13), 122.0 (C-5), 123.3 (C-4), 124.4 (C-17), 125.4 (C-18), 125.9 
(C-16), 130.5 (C-15), 130.8 (C-10), 133.9 (C-3), 134.5 (C-14), 136.3 (C-12), 139.6 (C-9), 
141.4(C-7); MS (ES+) m/z 251.2 [M+H]+. 
2-(1H-Indazol-6-yl)benzo[b]thiophene 1,1-dioxide (112)  and 2-(1H-indazol-6-
yl)benzo[b]thiophene 1-oxide (113) 
 
 
6-(Benzo[b]thiophen-2-yl)-1H-indazole (66 mg, 0.26 mmol) was dissolved in anhydrous 
DCM (2 mL) and m-CPBA (84 mg, 0.36 mmol, 0.74%) was added at 0 oC in portions over 
5 minutes whilst under N2. This was left at RT overnight before being filtered through 
Celite® (washing with DCM), the filtrate was washed with Na2SO3 solution, NaHCO3 
solution and dried over Na2SO4. This solution was reduced to a residue under vacuum 
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and purified by MPLC (0-70% EtOAc in petroleum ether) to give 112 as a dull orange 
solid (41 mg, 55%) and 113 as a grey solid (11 mg, 15%).    
112 - Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 224-225 
oC; UV λmax (EtOH/nm) 339.2, 313.6, 
240.2, 202.8; IR νmax/cm
-1 3169, 3128, 2867, 1284, 1145, 834, 755; 1H-NMR (500 MHz, 
DMSO-d6) δ ppm 7.60 (1H, d, J = 8.7, H-6), 7.65 (1H, dd, J =8.9, 8.9 Hz, H-15), 7.68 (1H, 
d, J = 8.9, H-16), 7.77 (1H, dd, J = 8.9, 8.9 Hz, H-14), 7.96 (1H, d, J =8.7Hz, H-5), 7.98 (1H, 
J = 8.9 Hz, H-13), 8.07 (1H, s, H-8), 8.11 (1H, s, H-18), 8.19 (1H, s, H-3), 13.38 (1H, br, H-
1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 107.9 (C-8), 118.5 (C-6), 121.4 (C-13), 122.0 
(C-5), 123.3 (C-4), 124.4 (C-17), 125.4 (C-18), 125.9 (C-16), 130.5 (C-15), 130.8 (C-10), 
133.9 (C-3), 134.5 (C-14), 136.3 (C-12), 139.6 (C-9), 141.4(C-7); MS (ES+) m/z 283.3 
[M+H]+; HRMS calcd for C15H11N2O2S 285.0536 [M+H]
+ found 285.0536. 
113 - Rf 0.33 (EtOAc /Petrol, 1:1); m.p. 206-208 
oC; UV λmax (EtOH/nm) 352.6, 241.4, 
201.2; IR νmax/cm
-1 3252, 2921, 1061, 998, 845, 752; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 7.55 (1H, dd, J =8.9, 8.9 Hz, H-15), 7.60 (1H, d, J = 8.7, H-6), 7.66 (1H, dd, J = 8.9, 
8.9 Hz, H-14), 7.71 (1H, d, J = 8.9, H-16), 7.91 (1H, s, H-18), 7.92 (1H, d, J =8.7Hz, H-5), 
8.04 (1H, s, H-8), 8.06 (1H, J = 8.9 Hz, H-13), 8.16 (1H, s, H-3), 13.32 (1H, br, H-1);  MS 
(ES+) m/z 267.3 [M+H]+;HRMS calcd for C15H11N2OS 267.0587 [M+H]
+ found 267.0587. 
N-phenyl-1H-indazole-6-sulfonamide (114) 
 
Prepared according to general procedure M using the following varyied reagents and 
quantities: aniline (70 mg, 0.75 mmol); giving a dark grey solid (12 mg, 6%). 
Rf 0.33 (EtOAc /Petrol, 1:1); m.p. 152-154
oC; UV λmax (EtOH/nm) 299.0, 263.2, 216.6; IR 
νmax/cm
-1 3248, 1315, 1150, 938, 715; 1H-NMR (500 MHz, DMSO-d6) δ ppm 7.09 (1H, t, 
J = 7.3 Hz, H-15), 7.18 (2H, d, J =7.9 Hz, H-13), 7.29 (2H, dd, J =7.9, 7.3 Hz, H-14), 7.55 
(1H, d, J =8.5 Hz, H-6), 8.01-8.04 (2H, m, H-5, H-8), 8.30 (1H, s, H-3), 10.44 (1H, s-br, H-
11), 13.61 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 110.0 (C-8), 117.5 (C-6), 
120.1 (C-13), 121.9 (C-5), 124.1 (C-15), 124.6 (C-4), 129.1 (C-14), 134.0 (C-3), 136.9 (C-
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7), 137.6 (C-12), 138.3 (C-9);  MS (ES+) m/z 274.3 [M+H]+; HRMS calcd for C13H12N3O2S 
274.0645 [M+H]+ found 274.0646. 
N-(4-methoxyphenyl)-1H-indazole-6-sulfonamide (115) 
 
Prepared according to general procedure M using the following varyied reagents and 
quantities: 4-methoxyaniline (80 mg, 0.64 mmol); giving a grey solid (25 mg, 11%). 
Rf 0.28 (EtOAc /Petrol, 1:1); m.p. 157-159 
oC; UV λmax (EtOH/nm) 217.5; IR νmax/cm
-1 
3259, 1615, 1508, 1318, 1148, 943, 717; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.64 (3H, 
s, H-17), 6.77 (2H, d, J =8.7 Hz, H-14), 6.97 (2H, d, J =8.7 Hz, H-13), 7.42 (1H, d, J =8.5Hz, 
H-6), 7.85 (1H, s, H-8), 7.93 (1H, d, J = 8.5Hz, H-5), 8.21 (1H, s, H-3), 9.95 (1H, s-br, H-
11), 13.47 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 55.1 (C-17), 109.9 (C-8), 
114.2 (C-14), 117.7 (C-6), 121.7 (C-5), 123.5 (C-13), 124.6 (C-4), 130.0 (C-12), 134.0 (C-
3), 136.9 (C-7), 138.4 (C-9) 156.5 (C-15);  MS (ES+) m/z 304.3 [M+H]+; HRMS calcd for 
C14H14N3O3S 304.0750 [M+H]
+ found 304.0753. 
N-(quinolin-8-yl)-1H-indazole-6-sulfonamide (116) 
 
Prepared according to general procedure M using the following varied reagents and 
quantities: quinolin-8-amine (108 mg, 0.75 mmol); giving a grey solid (11.3 mg, 5%). 
Rf 0.46 (EtOAc /Petrol, 1:1); m.p. 201-203 
oC; UV λmax (EtOH/nm) 304.0, 228.6, 200.0; IR 
νmax/cm
-1 3355, 3268, 2924, 1504, 1253, 1054,713; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 7.52 (1H, dd, J = 7.9, 7.9 Hz, H-20), 7.57 (1H, dd, J = 8.3, 4.2, Hz, H-16), 7.60 (1H, d, 
J = 8.6  Hz, H-6), 7.65 (1H, dd, J = 7.9, 1.0 Hz,  H-19), 7.72 (1H, dd, J = 7.9, 1.0 Hz, H-21), 
7.86 (1H, d, J = 8.6  Hz, H-5), 8.14 (1H, s, H-8), 8.16 (1H, s, H-3), 8.33 (1H, dd, J = 8.3, 1.7, 
Hz, H-17),  8.84 (1H, dd, J = 4.2, 1.7 Hz, H-15),  13.51 (1H, s-br, H-1); 13C-NMR (125 MHz, 
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DMSO-d6) δ ppm 110.2 (C-8), 116.8 (C-12), 117.7 (C-6), 121.8 (C5), 122.3 (C-16), 123.1 
(C-21), 124.7 (C-4), 126.6 (C-20), 128.1 (C-18), 133.6 (C-19), 133.9 (C-3), 136.5 (C-17), 
137.0 (C-7), 138.2(C-9), 138.8 (C-13), 149.4 (C-15);  MS (ES+) m/z 325.3 [M+H]+; HRMS 
calcd for C16H13N4O2S 325.0754 [M+H]
+ found 325.0753. 
(1H-Indazol-6-yl)methanol (125) 
 
 
 
1H-indazole-6-carbaldehyde (100 mg, 0.68 mmol) was dissolved in ethanol (4 mL) and 
sodium borohydride (32 mg, 0.85mmol) was added and the solution was stirred at RT 
for c.a. 3 h. NaOH solutuion (2 M in H2O, 10ml) was added and the solution extracted 
with EtOAc (3 x 10ml). Combined organic fractions were washed with brine and dried 
over NaSO4. This solution was reduced to a residue under reduced pressure and 
purified by MPLC (0-70% EtOAc in petroleum spirit over 30 column volumes) to give 
the title product as a white solid (87 mg, 89%). 
Rf 0.32 (Et2O); m.p. 156-158 
oC; IR νmax/cm
-1 3121, 2861, 1354, 1028, 1007, 946, 848; 
1H-NMR (500 MHz, DMSO-d6) δ ppm 4.62 (2H, d, J = 5.4 Hz, H-10), 5.26 (1H, t, J = 5.4 Hz, 
H-11), 7.04 (1H, d, J = 8.4 Hz, H-6), 7.46 (1H, s, H-8), 7.67 (1H, d, J = 8.4 Hz H-5), 8.00 
(1H, s, H-3), 12.95 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 63.1 (C-10), 
106.9 (C-8), 119.5 (C-6), 120.0 (C-5), 121.8 (C-4), 133.2 (C-3), 140.1 (C-9), 140.8 (C-7); 
MS (ES+) m/z 149.3 [M+H]+. 
6-(bromomethyl)-1H-indazole (126) 
 
(1H-Indazol-6-yl)methanol (200 mg, 1.3 mmol) was dissolved in anhydrous DCM in dry 
glassware, under an inert atmosphere. Thionylbromide (0.21ml, 2.7mmol) was added 
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via syringe followed by DMF (0.01 mL, 0.13 mmol). The reaction was stirred at 0oC and 
warmed to RT over 4 h. The reaction mix was evaporated to a residue and purified by 
MPLC (0-10% methanol in DCM) to give the title product as an orange solid (244 mg, 
86%). 
Rf 0.44 (Et2O); m.p. >300 
oC; UV λmax (EtOH/nm) 262.8, 217.8; IR νmax/cm
-1 2766, 2615, 
1635, 1353, 1146, 828, 661; 1H-NMR (500 MHz, DMSO-d6) δ ppm 4.88 (2H, s, H-10), 
7.18 (1H, d, J = 8.4 Hz, H-6), 7.65 (1H, s, H-8), 7.75 (1H, d, J = 8.4 Hz H-5), 8.07 (1H, s, H-
3), 13.40 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 63.5 (C-10), 107.6 (C-8), 
120.3 (C-6), 120.6 (C-5), 122.1 (C-4), 133.4 (C-3), 140.6 (C-9), 140.8 (C-7); MS (ES+) m/z 
211.2 [M+H]+.  
6-((Phenylthio)methyl)-1H-indazole (127) 
 
Thiophenol sodium salt (1M in THF, 0.38 mL, 0.42 mmol) was dissolved in EtOH (2 mL) 
and 6-(bromomethyl)-1H-indazole (80 mg. 0.38 mmol) was added, this was stirred at 
RT for 4 h. The reaction was diluted with water (10 mL) and extracted with EtOAc (3 x 
10 mL), combined organic fractions were washed with brine and dried over Na2SO4. 
The material was purified by MPLC (0-80% EtOAc in petroleum ether) giving the title 
compound as an off white solid (40 mg, 40%). 
Rf 0.49 (EtOAc /Petrol, 1:1); m.p. 147-149
oC; UV λmax (EtOH/nm) 254.0, 210.5; IR 
νmax/cm
-1 3269, 1578, 1483, 1068, 943; 1H-NMR (500 MHz, DMSO-d6) δ ppm 4.39 (2H, s, 
H-10), 7.13 (1H, d, J =8.4 Hz, H-6), 7.18 (1H, t, J = 7.4 Hz, H-15), 7.28 (2H, t, J = 8.0Hz, H-
14), 7.35 (2H, d, J = 8.0 Hz, H-13), 7.48 (1H, s, H-8), 7.68 (1H, d, J = 8.4 Hz, H-5), 8.05 
(1H, s, H-3), 12.98 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 37.0 (C-10), 
109.7 (C-8), 120.4 (C-5), 121.7 (C-6), 121.9 (C-5), 125.8 (C-15), 128.3 (C-13), 128.9 (C-
14), 133.3 (C-3), 135.5 (C-7), 136.0 (C-12) 139.9 (C-9);  MS (ES+) m/z 241.2 [M+H]+; 
HRMS calcd for C14H13N2S 241.0794 [M+H]
+ found 241.0797. 
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6-(((4-Methoxyphenyl)thio)methyl)-1H-indazole (128) 
 
Sodium hydroxide (22 mg, 0.56 mmol) was dissolved in EtOH (2.5 mL), 4-
methoxybenzenethiol (0.046 mL, 0.38mmol) was added followed by 6-(bromomethyl)-
1H-indazole (80 mg, 0.38 mmol) this was stirred at RT for 4 h. The reaction was diluted 
with water (10 mL) and extracted with EtOAc (3 x 10 mL), combined organic fractions 
were washed with brine and dried over Na2SO4. The material was purified by MPLC (0-
80% EtOAc in petroleum ether) giving the title compound as light brown solid (40 mg, 
40%). 
Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 117-119
oC; UV λmax (EtOH/nm) 211.5, 348.0; IR 
νmax/cm
-1 3182, 1588, 1491, 1241, 1027, 944; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.72 
(3H, s, H-17), 4.24 (2H, s, H-10), 6.86 (2H, d, J = 8.9Hz, H-14), 7.06 (1H, d, J =8.2Hz, H-6), 
7.28 (2H, d, J =8.9Hz, H-13), 7.34 (1H, s, H-8), 7.66 (1H, d, J = 8.2Hz, H-5), 8.00 (1H, s, H-
3), 12.95 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 39.7 (C-10) 55.1 (C-17), 
109.6 (C-8), 114.6 (C-14), 120.3 (C-5), 121.7 (C-4, C-6), 125.6 (C-12), 132.4 (C-13), 133.3 
(C-3), 136.0 (C-7), 139.9 (C-9) 158.4 (C-15);  MS (ES+) m/z 271.2 [M+H]+; HRMS calcd for 
C15H15N2OS 271.0900 [M+H]
+ found 271.0904. 
6-(((3-Methoxyphenyl)thio)methyl)-1H-indazole (129) 
 
 
Sodium hydroxide (21 mg, 0.47 mmol) was dissolved in water (1 mL) and added to a 
solution of 3-methoxybenzenethiol (0.059 mL, 0.47mmol) and 6-(bromomethyl)-1H-
indazole (100 mg, 0.47 mmol) in toluene (3 mL). Tetra-n-butylammonium bromide (15 
mg, 0.05 mmol) was added to the mixture which was then then stirred vigourously for 
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18 h at RT. The reaction was diluted with water (10 mL) and extracted with EtOAc (3 x 
10 mL), combined organic fractions were washed with brine (10 mL) and dried over 
Na2SO4. The material was purified by MPLC (0-80% EtOAc in petroleum ether) giving 
the title compound as a yellow solid (25 mg, 20%). 
Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 96-98
oC; UV λmax (EtOH/nm) 287.0, 254.5, 214.0; IR 
νmax/cm
-1 3128, 2935, 1573, 1245, 1035, 850; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.71 
(3H, s, H-19), 4.40 (2H, s, H-10), 6.73 (1H, d, J = 8.2 Hz, H-15), 6.89 (1H, s, H-13), 6.91 
(1H, d, J = 8.2 Hz, H-17), 7.14 (1H, d, J = 8.4 Hz, H-6), 7.46 (1H, dd, J = 8.0, 8.0 Hz, H-16), 
7.51 (1H, s, H-8), 7.69 (1H, d, J = 8.4 Hz, H-5), 8.01 (1H, s, H-3), 13.00 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm 36.6 (C-10), 55.0 (C-19), 109.8 (C-8), 111.6 (C-15), 
113.2 (C-13), 120.1 (C-17), 120.4 (C-5), 121.7 (C-6), 121.9 (C-4), 129.8 (C-16), 133.3 (C-
3), 135.5 (C-7), 137.5 (C-12), 139.9 (C-9), 159.5 (C-14);  MS (ES+) m/z 271.4 [M+H]+; 
HRMS calcd for C15H15N2OS 271.0900 [M+H]
+ found 271.0896. 
8-(((1H-Indazol-6-yl)methyl)thio)quinoline (130) 
 
Sodium hydroxide (42 mg, 1.03 mmol) was dissolved in water (2 mL) and added to a 
solution of 3- quinoline-8-thiol HCl salt ( 94 mg, 0.47 mmol) and 6-(bromomethyl)-1H-
indazole (100 mg, 0.47 mmol) in toluene (3 mL). Tetra-n-butylammonium bromide (15 
mg, 0.05 mmol) was added to the mixture which was then then stirred vigourously for 
18 h at RT. The reaction was diluted with water (10 mL) and extracted with EtOAc (3 x 
10 mL), combined organic fractions were washed with brine (10 mL) and dried over 
Na2SO4. The material was purified by MPLC (0-80% EtOAc in petroleum ether) giving 
the title compound as an off white solid (49 mg, 36%). 
Rf 0.50 (EtOAc /Petrol, 1:1); m.p. 187-190
oC; UV λmax (EtOH/nm) 340.5, 290.0, 251.5; IR 
νmax/cm
-1 3293, 3055,  1490, 1350, 936, 832; 1H-NMR (500 MHz, DMSO-d6) δ ppm 4.50 
(2H, s, H-10), 7.25 (1H, d, J = 8.3  Hz, H-6), 7.52 (1H, dd, J = 7.8, 7.8 Hz, H-20), 7.82 (1H, 
dd, J = 8.4, 4.3, Hz, H-16), 7.64-7.67 (2H, m, H-8, H-19), 7.72 (1H, dd, J = 8.1, 1.0 Hz, H-
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21), 7.72 (1H, d, J = 8.3  Hz, H-5), 8.03 (1H, s, H-3), 8.36 (1H, dd, J = 8.3, 1.7, Hz, H-17),  
8.90 (1H, dd, J = 4.2, 1.7 Hz, H-15),  13.00 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) 
δ ppm 34.5 (C-10), 109.8 (C-8), 120.2 (C-5), 121.9 (C-5), 122.0 (C-4), 122.1 (C-16), 123.9 
(C-21), 124.1 (C-19), 126.7 (C-20), 127.8 (C-18), 133.3 (C-3), 135.1 (C-7), 136.5 (C-17), 
138.1 (C-12), 140.1 (C-9), 144.4 (C-13), 149.3 (C-15);  MS (ES+) m/z 292.3 [M+H]+; HRMS 
calcd for C17H14N3S 292.0903 [M+H]
+ found 292.0901. 
6-((Thiophen-2-ylthio)methyl)-1H-indazole (131) 
 
Cs2CO3 (109 mg, 0.57 mmol) was dissolved in THF (2 mL), thiophene-2-thiol ( 0.036 mL, 
0.38 mmol) was added followed by 6-(bromomethyl)-1H-indazole (80 mg, 0.38 mmol) 
this was stirred at RT for 4 h. The reaction was diluted with water (10 mL) and 
extracted with EtOAc (3 x 10 mL), combined organic fractions were washed with brine 
and dried over Na2SO4. The material was purified by MPLC (0-80% EtOAc in petroleum 
ether) giving the title compound as a light pink solid (33 mg, 35%). 
Rf 0.39 (EtOAc /Petrol, 1:1). m.p. 104-107
oC. UV λmax (EtOH/nm) 212.5; IR νmax/cm
-1 
3266, 1625, 1346, 1346, 944, 855, 696. 1H-NMR (500MHz, DMSO-d6) δ ppm 4.19 (2H, s, 
H-10), 6.98 (1H, dd, J = 5.2, 3.5 Hz, H-15), 7.01-7.04 (2H, m, H-6, H-14), 7.27 (1H, s, H-8), 
7.56 (1H, dd, J = 1.3, 5.2 Hz, H-16), 7.67 (1H, d, J =8.3  Hz, H-5), 8.02 (1H,s, H-3), 12.98 
(1H, s-br, H-1); ). 13C-NMR (125 MHz, DMSO-d6) δ ppm 42.9 (C-10), 110.0 (C-8), 120.4 
(C-5), 121.8 (C-6), 127.8 (C-15), 130.2 (C-16), 133.7 (C-3), 135.6 (C-14); MS (ES+) m/z 
247.2 [M+H]+; HRMS calcd for C12H11N2S2 247.0358 [M+H]
+ found 247.0361. 
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6-((Thiophen-2-ylsulfonyl)methyl)-1H-indazole (120) 
 
6-((Thiophen-2-ylthio)methyl)-1H-indazole (12.5 mg, 0.05 mmol) was dissolved in 
MeOH (1 mL) and Oxone® solution  (0.07 mL, 0.15 mmol, 1.5 M in H2O:MeOH(1:1)) 
was added. This was stirred for c.a. 18 h before dilution with water (10 mL) and 
extraction with EtOAc (3 x 10 mL), combined organic fractions were washed with brine 
and dried over Na2SO4. The material was purified by MPLC (0-80% EtOAc in petroleum 
ether) giving the title compound as a pink solid (9 mg, 63%). 
Rf 0.31 (EtOAc /Petrol, 1:1). m.p. 201-203
oC. UV λmax (EtOH/nm) 291.5, 255.5, 213.0; IR 
νmax/cm
-1 3359, 1398, 1295, 1140, 942, 673; 1H-NMR (500MHz, DMSO-d6) δ ppm 4.90 
(2H, s, H-10), 6.89 (1H, d, J = 8.3 Hz, H-6), 7.21 (1H, dd, J = 3.8, 4.9 Hz, H-15), 7.38 (1H, s, 
H-8), 7.57 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.67 (1H, d, J =8.3 Hz, H-5), 8.03 (1H, dd, J = 
4.9, 1.3 Hz, H-14), 8.05 (1H,s, H-3), 13.12 (1H, s-br, H-1); MS (ES+) m/z 279.2 [M+H]+; 
HRMS calcd for C12H11N2O2S2 279.0256 [M+H]
+ found 279.0261. 
8-(((1H-Indazol-6-yl)methyl)sulfonyl)quinoline (121) 
 
 
8-(((1H-Indazol-6-yl)methyl)thio)quinoline  (15 mg, 0.05 mmol) was dissolved in MeOH 
(2 mL) and Oxone® solution (0.1 mL, 0.15 mmol, 1.5 M in H2O:MeOH(1:1))  was added 
and the mixture stirred for 18 h. After this time the reaction was diluted with water (10 
mL) and extracted with EtOAc (3 x 10 mL), combined organic fractions were washed 
with brine (10 mL) and dried over Na2SO4. The material was purified by MPLC (0-80% 
EtOAc in petroleum ether) giving the title compound as a yellow solid (8 mg, 47%). 
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Rf 0.44 (EtOAc /Petrol, 1:1); m.p. 178-180
oC; UV λmax (EtOH/nm) 282.0, 214.5; IR 
νmax/cm
-1 3309, 2929, 1493, 1296, 1113, 832; 1H-NMR (500 MHz, DMSO-d6) δ ppm 5.37 
(2H, s, H-10), 6.74 (1H, d, J = 8.3  Hz, H-6), 7.25 (1H, s, H-8) 7.54 (1H, d, J = 8.3 Hz, H-5), 
7.67 (1H, dd, J = 8.0, 8.0 Hz, H-20), 7.82 (1H, dd, J = 8.4, 4.3, Hz, H-16),  7.97 (1H, s, H-3), 
8.14 (1H, dd, J = 7.4, 1.5 Hz, H-19), 8.35 (1H, dd, J = 8.0, 1.5 Hz, H-21), 8.63 (1H, dd, J = 
8.5, 1.8, Hz, H-17), 9.27 (1H, dd, J = 4.3, 1.8 Hz, H-15),  12.98 (1H, s-br, H-1); 13C-NMR 
(125 MHz, DMSO-d6) δ ppm 40.2 (C-10), 107.2 (C-8), 118.7 (C-6), 120.7 (C-5), 121.1 (C-
4), 122.6 (C-16), 125.6 (C-20), 128.6 (18C), 132.9 (C-19), 133.3 (C-3), 134.2 (C-21), 136.6 
(C-12), 136.9 (C-17), 139.2 (C-7), 139.6 (C-9), 143.3 (13C), 151.5 (C-15);  MS (ES+) m/z 
273.3 [M+H]+; HRMS calcd for C17H14N3O2S 324.0801 [M+H]
+ found 324.0806. 
6-((Phenylsulfonyl)methyl)-1H-indazole (122) and 6-((phenylsulfinyl)methyl)-1H-
indazole (132) 
 
    
 
6-((Phenylthio)methyl)-1H-indazole (50 mg, 0.21 mmol) was dissolved in MeOH (1 mL) 
and Oxone® solution (0.41 mL, 0.63 mmol, 1.5 M in H2O:MeOH(1:1))  was added. This 
was stirred for c.a. 18 h before dilution with water (10 mL) and extraction with EtOAc 
(3 x 10 mL), combined organic fractions were washed with brine and dried over Na2SO4. 
The material was purified by MPLC (0-80% EtOAc in petroleum ether) giving the 15 as a 
white solid (11 mg, 19%) and 20 as a white solid (24 mg, 45%). 
122 - Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 195-197
oC; UV λmax (EtOH/nm) 291.5, 258.5, 
212.0; IR νmax/cm
-1 3397, 1281, 1149, 1083, 937; 1H-NMR (500 MHz, DMSO-d6) δ ppm 
4.83 (2H, s, H-10), 6.87 (1H, d, J =8.3Hz, H-6), 7.35 (1H, s, H-8), 7.58 (2H, dd, J = 7.4, 
8.2Hz, H-14), 7.65 (1H, d, J = 8.3Hz, H-5), 7.69-7.72 (3H, m, H-15, H-13), 8.05 (1H, s, H-
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3), 13.09 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 60.9 (C-10), 112.6 (C-8), 
120.1 (C-5), 122.5 (C-4), 123.1 (C-6), 126.4 (C-7), 128.0 (C-13), 129.1 (C-14), 133.4 (C-3), 
133.7 (C-15), 138.4 (C-12) 139.6 (C-9);  MS (ES+) m/z 273.3 [M+H]+; HRMS calcd for 
C14H12N2O2S 273.0692 [M+H]
+ found 273.0697. 
132 - Rf 0.42 (EtOAc /Petrol, 1:1); m.p. 184-186
oC; UV λmax (EtOH/nm) 379.5, 259.0, 
212.0; IR νmax/cm
-1 3169, 1626, 1357, 1012, 938; 1H-NMR (500 MHz, DMSO-d6) δ ppm 
4.21 (1H,d, J = 13.1 Hz, H-10A), 4.40 (1H,d, J = 13.1 Hz, H-10B) 6.82 (1H, d, J =8.2 Hz, H-
6), 7.31 (1H, s, H-8), 7.52 (5H, m, H-15, H-14, H-13), 7.63 (1H, d, J = 8.2Hz, H-5), 8.04 
(1H, s, H-3), 13.07 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 62.0 (C-10), 
111.9 (C-8), 120.0 (C-5), 122.3 (C-4), 122.8 (C-6), 124.4 (C-13), 128.2 (C-7), 128.9 (C-14), 
130.8 (C-15), 133.3 (C-3), 139.0 (C-12) 143.4 (C-9);  MS (ES+) m/z 257.3 [M+H]+; HRMS 
calcd for C14H12N2OS 257.0743 [M+H]
+ found 257.0747. 
6-(((3-Methoxyphenyl)sulfonyl)methyl)-1H-indazole (123) 
 
6-(((3Methoxyphenyl)thio)methyl)-1H-indazole (13.5 mg, 0.05mmol) was dissolved in 
MeOH (2 mL) and Oxone® solution (0.1 mL, 0.15 mmol, 1.5M in H2O:MeOH(1:1))  was 
added and the mixture stirred for 18 h. After this time the reaction was diluted with 
water (10 mL) and extracted with EtOAc (3 x 10 mL), combined organic fractions were 
washed with brine (10 mL) and dried over Na2SO4. The material was purified by MPLC 
(0-80% EtOAc in petroleum ether) giving the title compound as an off white solid (6 mg, 
42%). 
Rf 0.30 (EtOAc /Petrol, 1:1); m.p. 160-162
oC; UV λmax (EtOH/nm) 290.5, 258.0; IR 
νmax/cm
-1 3350, 2929, 1596, 1481, 1300, 1143, 854; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 3.74 (3H, s, H-19), 4.83 (2H, s, H-10), 6.91 (1H, d, J = 8.3Hz, H-6), 7.21 (1H, dd, J = 
2.3, 1.8 Hz, H-13), 7.24-7.28 (2H, m, H-15, H-17), 7.37 (1H, s, H-8), 7.48 (1H, dd, J = 7.9, 
7.9 Hz, H-16), 7.66 (1H, d, J = 8.3 Hz, H-5), 8.05 (1H, s, H-3), 13.10 (1H, s-br, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm 55.5 (C-19), 60.8 (C-10), 112.5 (C-13), 112.7 (C-8), 
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120.0 (C-17), 120.1 (C-15), 120.1 (C-5), 122.5 (C-4), 123.2 (C-6), 126.4 (C-7), 130.3 (C-
16), 133.4 (C-3), 139.6 (C-12), 139.6 (C-9) 159.2 (C-15);  MS (ES+) m/z 303.3 [M+H]+; 
HRMS calcd for C15H15N2O3S 303.0798 [M+H]
+ found 303.0803. 
6-(((4-Methoxyphenyl)sulfonyl)methyl)-1H-indazole (124) 
 
6-(((4-Methoxyphenyl)thio)methyl)-1H-indazole (27.5 mg, 0.1mmol) was dissolved in 
MeOH (2 mL) and Oxone® solution (0.2 mL, 0.3 mmol, 1.5M in H2O:MeOH(1:1)) was 
added. This was stirred for c.a. 18 h before a further addition of Oxone® solution was 
made (0.2 mL, 0.3 mmol, 1.5 M). The reaction was stirred for 1.5 h more before 
dilution with water (10 mL) and extraction with EtOAc (3 x 10 mL), combined organic 
fractions were washed with brine and dried over Na2SO4. The material was purified by 
MPLC (0-80% EtOAc in petroleum ether) giving the title compound as a white solid (22 
mg, 72%). 
Rf 0.32 (EtOAc /Petrol, 1:1); m.p. 156-158
oC; UV λmax (EtOH/nm) 291.0, 242.0; IR 
νmax/cm
-1 3396, 2590, 1595, 1260, 1143, 827; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.83 
(3H, s, H-17), 4.75 (2H, s, H-10), 6.87 (1H, d, J = 8.3 Hz, H-6), 7.08 (2H, d, J = 8.9 Hz, H-
14), 7.33 (1H, s, H-8), 7.61 (2H, d, J = 8.9 Hz, H-13), 7.65 (1H, d, J = 8.3 Hz, H-5), 8.05 
(1H, s, H-3), 13.08 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 55.7 (C-17), 
61.2 (C-10), 112.5 (C-8), 114.2 (C-14), 120.1 (C-5), 122.4 (C-4), 123.1 (C-6), 126.7 (C-7), 
130.0 (C-12), 130.3 (C-13), 133.4 (C-3), 139.6 (C-9) 163.1 (C-15);  MS (ES+) m/z 303.3 
[M+H]+; HRMS calcd for C15H15N2O3S 303.0798 [M+H]
+ found 303.0800. 
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6-(((4-Methoxyphenyl)sulfinyl)methyl)-1H-indazole (133) 
 
 
6-(((4-methoxyphenyl)thio)methyl)-1H-indazole (84 mg, 0.31 mmol) was dissolved in 
MeOH (1.5 mL) and cooled to 0oC with stirring, sodium periodate (74 mg, 0.34 mmol) 
was added in portions over 3 minutes and the reaction mixture was allowed to warm 
to RT overnight.  Water (10 mL) was added and the mixture extracted with EtOAc (3 x 
10 mL), combined organic fractions were washed with brine and dried over Na2SO4. 
The material was purified by MPLC (0-80% EtOAc in petroleum ether) giving the title 
compound as a white solid (71 mg, 80%). 
Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 167-168
oC; UV λmax (EtOH/nm) 251.4, 203.6; IR 
νmax/cm
-1 3171, 2957, 1593, 1494, 1248, 1019, 832; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 3.81 (3H, s, H-17), 4.21 (1H, d,  J = 12.4 Hz, H-10), 4.32 (1H,d, J = 12.4 Hz, H-10) 
6.83 (1H, d, J = 8.3Hz, H-6), 7.07 (2H, d, J = 8.9 Hz, H-14), 7.28 (1H, s, H-8), 7.47 (2H, d, J 
= 8.9 Hz, H-13), 7.64 (1H, d, J = 8.3Hz, H-5), 8.04 (1H, s, H-3), 13.06 (1H, s-br, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm 55.5 (C-17), 62.3 (C-10), 111.8 (C-8), 114.4 (C-14),  
120.0 (C-5), 122.2 (C-4), 122.8 (C-6), 126.2 (C-13), 128.4 (C-7), 133.3 (C-3), 134.3 (C-12), 
139.8 (C-9), 161.3 (C-15);  MS (ES+) m/z 287.3 [M+H]+; HRMS calcd for C15H15N2O2S 
287.0849 [M+H]+ found 287.0848. 
N-(1H-Indazol-5-yl)benzenesulfonamide (134) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and benzenesulfonyl chloride (96 µL, 0.75 mmol). The title compound was 
obtained as a grey solid (48 mg, 30%). 
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Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 176-178 
oC; UV λmax (EtOH/nm) 299.0, 207.6; IR 
νmax/cm
-1 3437, 3361, 1734, 1449, 1151, 945, 687; 1H-NMR (500 MHz, DMSO-d6) δ ppm 
7.07 (1H, dd, J =9.0, 1.8 Hz, H-7), 7.40-7.42 (2H, m, H-5, H-8), 7.50 (2H, dd, J =7.7, 7.7 
Hz, H-14), 7.56 (1H, tt, J = 7.7, 1.4 Hz, H-15), 7.69 (2H, dd, J =7.7, 1.4 Hz H-13),7.98 (1H, 
s, H-3), 10.07 (1H, s-br, H-10), 13.02 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ 
ppm 110.6 (C-8), 112.8 (C-5), 122.2 (C-7), 122.8 (C-4), 126.6 (C-13), 129.1 (C-14), 130.2 
(C-6), 132.7 (C-15), 133.4 (C-3), 137.6 (C-12), 139.4 (C-9);  MS (ES+) m/z 274.3 [M+H]+; 
HRMS calcd for C13H12N3O2S 274.0645 [M+H]
+ found 274.0643. 
N-(1H-Indazol-5-yl)-2-oxoindoline-5-sulfonamide (135) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and 2-oxoindoline-5-sulfonyl chloride (173 mg, 0.75 mmol). The title compound 
was obtained as a green solid (12 mg, 5%). 
Rf 0.25 (EtOAc /Petrol, 1:1); m.p. 230-232 
oC; UV λmax (EtOH/nm) 263.6, 204.4; IR 
νmax/cm
-1 3286, 2844, 1703, 1617, 1481, 1138, 1067; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 3.52 (2H, s, H-15), 6.85 (1H, d, J = 8.2 Hz, H-19), 7.09 (1H, dd, J = 8.9, 1.9 Hz, H-7), 
7.40-7.42(2H, m, H-5, H-8), 7.51-7.54 (2H, m, H-13, H-20), 7.98 (1H, s, H-3), 9.95 (1H, s-
br, H-17), 10.71 (1H, s-br, H-10), 13.01 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ 
ppm 35.5 (C-15), 108.8 (C-19), 110.6 (C-8), 112.3 (C-5), 122.0 (C-7), 122.8 (C-13), 122.8 
(C-4), 126.5 (C-14), 127.5 (C-20), 130.4 (C-6), 131.9 (C-12), 133.4 (C-3), 137.5 (C-9), 
147.6 (C-18), 176.4 (C-16);  MS (ES+) m/z 329.3 [M+H]+; HRMS calcd for C15H13N4O3S 
329.0703 [M+H]+ found 329.0754. 
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N-(1H-Indazol-5-yl)thiophene-2-sulfonamide (136) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and thiophene-2-sulfonyl chloride (136 mg, 0.75 mmol). The title compound 
was obtained as a light orange solid (166 mg, 79%). 
Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 170-172 
oC; UV λmax (EtOH/nm) 283.4, 235.8, 200.0; IR 
νmax/cm
-1 3443, 3384, 2730, 1738, 1495, 1139,728; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 7.08 (1H, dd, J = 3.8, 5.0 Hz, H-15), 7.12 (1H, dd, J =2.6, 8.9 Hz, H-7), 7.43-7.47 (3H, 
m, H-5, H-8, H-16), 7.85 (1H, dd, J = 1.4, 5.0 Hz, H-14), 8.03 (1H, s, H-3), 10.19 (1H, s-br, 
H-10), 13.06 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 110.6 (C-8), 113.2 (C-
5), 122.4 (C-7), 122.8 (C-4),  127.5 (C-15), 129.9 (C-6), 132.1 (C-16), 133.06 (C-14), 133.5 
(C-3), 137.8 (C-9), 139.8 (C-12);  MS (ES+) m/z 280.3 [M+H]+; HRMS calcd for C11H10N3O-
2S2 280.0209 [M+H]
+ found 280.0209. 
N-(1H-Indazol-5-yl)quinoline-8-sulfonamide (137) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and quinoline-8-sulfonyl chloride (171 mg, 0.75 mmol). The title compound was 
obtained as a grey solid (15 mg, 6%). 
Rf 0.46 (EtOAc /Petrol, 1:1); m.p. 258-260 
oC; UV λmax (EtOH/nm) 278.8, 215.4; IR 
νmax/cm
-1 3259, 2927, 1493, 1318, 1163, 1140, 830; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 7.01 (1H, dd, J = 8.9, 1.6 Hz, H-7), 7.25 (1H, d, J = 8.9 Hz, H-8), 7.32 (1H, d, J = 1.6  
Hz, H-5), 7.64 (1H, dd, J = 7.6, 7.6 Hz,  H-20), 7.76 (1H, dd, J = 8.3, 4.2 Hz, H-16), 7.87 
(1H, s, H-3), 8.23 (1H, dd, J = 7.6, 1.4 Hz, H-19),  8.26 (1H, dd, J = 7.6, 1.4 Hz, H-21), 8.53 
(1H, dd, J = 8.3, 1.8 Hz, H-17), 9.20 (1H, dd, J = 4.2, 1.8 Hz, H-15), 9.84 (1H, s-br, H-10), 
12.90 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 110.3 (C-8), 112.1 (C-5), 
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121.9 (C-7), 122.5 (C-4), 122.6 (C-16), 128.3 (C-19), 130.3 (C-6), 131.9 (C-21), 133.2 (C-
3), 134.0 (C-18), 135.1 (C-13), 137.0 (C-17), 137.4 (C-9), 142.7 (C-12), 151.5 (C-15); MS 
(ES+) m/z 325.4 [M+H]+; HRMS calcd for C16H13N4O2S 325.0754 [M+H]
+ found 325.0752. 
N-(1H-Indazol-5-yl)-3-methoxybenzenesulfonamide (138) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and 3-methoxybenzene-1-sulfonyl chloride (106 µL, 0.75 mmol). The title 
compound was obtained as a white solid (139 mg, 63%). 
Rf 0.34 (EtOAc /Petrol, 1:1); m.p. 170-172 
oC; UV λmax (EtOH/nm) 284.4, 202.0; IR 
νmax/cm
-1 3368, 3243, 1484, 1311, 1157, 809; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.73 
(3H, s, H-19), 7.09 (1H, dd, J =9.0, 1.8 Hz, H-7), 7.13 (1H, ddd, J = 0.8, 2.5, 8.3 Hz, H-15), 
7.50 (1H, dd, J =1.7, 2.5 Hz, H-13), 7.24 (1H, ddd, J = 7.7, 1.7, 0.8 Hz, H-17), 7.39-7.43 
(3H, m, H-5, H-8, H-16), 8.00 (1H, s, H-3), 10.06 (1H, s-br, H-10), 13.03 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm 55.5 (C-19), 110.6 (C-8), 111.7 (C-13), 112.9 (C-5), 
118.5 (C-15), 118.8 (C-17), 122.2 (C-7), 122.8 (C-4), 130.1 (C-6), 130.3 (C-16), 133.4 (C-
3), 137.6 (C-9), 140.6 (C-12), 159.2 (C-14);  MS (ES+) m/z 304.4 [M+H]+; HRMS calcd for 
C14H14N3O3S 304.0750 [M+H]
+ found 304.0751. 
N-(1H-Indazol-5-yl)-4-methoxybenzenesulfonamide (139) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and 4-methoxybenzene-1-sulfonyl chloride (155 mg, 0.75 mmol). The title 
compound was obtained as a white solid (143 mg, 63%). 
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Rf 0.35 (EtOAc /Petrol, 1:1); m.p. 187-189 
oC; UV λmax (EtOH/nm) 299.6, 241.6, 202.2; IR 
νmax/cm
-1 3357, 3238, 1592, 1498, 1259, 1151, 811; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 3.77 ( 3H, s, H-17), 7.01 (2H, d, J = 8.9 Hz, H-14), 7.07 (1H, dd. J = 9.0, 1.8 Hz, H-7), 
7.40-7.41 (2H, m, H-5, H-8), 7.61 (2H, d, J = 8.9 Hz, H-13), 7.99 (1H, s, H-3), 9.91 (1H, s-
br, H-10), 13.00 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 55.5 (C-17), 110.6 
(C-8), 112.5 (C-5), 114.2 (C-14),  122.1 (C-7), 122.8 (C-4), 128.8 (C-13), 130.4 (C-6), 
131.0 (C-12), 133.4 (C-3), 137.6 (C-9), 162.2 (C-15);  MS (ES+) m/z 304.3 [M+H]+; HRMS 
calcd for C14H14N3O3S 304.0750 [M+H]
+ found 304.0749. 
2,6-Difluoro-N-(1H-indazol-5-yl)benzenesulfonamide (140) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and 2,6-difluorobenzene-1-sulfonyl chloride ( 101 µL, 0.75 mmol). The title 
compound was obtained as a yellow solid (58 mg, 25%). 
Rf 0.37 (EtOAc /Petrol, 1:1); m.p.243-245 
oC; UV λmax (EtOH/nm) 299.2, 255.6, 210.2; IR 
νmax/cm
-1 3386, 2981, 1613, 1467, 1353, 1169,  1002, 772; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm 7.16 (1H, dd, J = 8.6, 1.6  Hz, H-7), 7.22 (2H, dd, J = 9.0, 9.0 Hz, H-14), 7.46 (1H, d, 
J = 8.6 Hz, H-8), 7.49 (1H, d, J = 1.6 Hz, H-5), 7.76 (1H, dddd, J = 6.1, 6.1, 8.5, 8.5, H-15), 
8.02 (1H, s, H-3), 10.66 (1H, s-br, H-10), 13.08 (1H, s-br, H-1); 13C-NMR (125 MHz, 
DMSO-d6) δ ppm 110.9 (C-8), 112.4 (C-5), 113.3 (d, JFC = 23.4 Hz, C-14), 113.3 (d, JFC = 
23.4 Hz, C-14’), 116.4 (C-12), 121.7 (C-7), 122.7 (C-4), 129.2 (C-6), 133.5 (C-3) 135.8 (t, 
JFC = 11.1 Hz, C-15), 137.7 (C-9), 158.9 (d, JFC = 256.8 Hz, C-13), 158.9 (d, JFC = 256.8 Hz, 
C-13); 19F NMR (470 MHz, DMSO-d6) δ -107.5; MS (ES
+) m/z 310.3 [M+H]+; HRMS calcd 
for C13H10F2N3O2S 310.0456 [M+H]
+ found 310.0457. 
 
 
 
279 
 
N-(1H-Indazol-5-yl)-2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide (141) 
 
Prepared according to general procedure A using 1H-indazol-5-amine (100 mg, 0.75 
mmol) and 2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonyl chloride ( 175 mg, 0.75 mmol). 
The title compound was obtained as a grey solid (24 mg, 10%). 
Rf 0.24 (EtOAc /Petrol, 1:1); m.p. >300 
oC; UV λmax (EtOH/nm) 286.8, 247.8, 202.8; IR 
νmax/cm
-1 3382, 3242, 1770, 1484, 1347, 1168, 947; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 7.08 (1H, dd, J = 8.9, 2.0 Hz, H-7), 7.15 (1H, d, J = 8.2 Hz, H-19), 7.40-7.42 (2H, m, 
H-5, H-8), 7.46 (1H, dd, J = 8.2, 1.6 Hz, H-20), 7.56 (1H, d, J = 1.6 Hz, H-13), 8.00 (1H, s, 
H-3), 10.04 (1H, s-br, H-10), 12.10 (1H, s-br, H-17), 13.03 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm 107.8 (C-13), 109.7 (C-19), 110.7 (C-8), 112.8 (C-5), 122.2 (C-7), 
122.8 (C-4), 123.5 (C-20),  130.1 (C-6), 132.6 (C-18), 133.4 (C-3), 137.6 (C-9), 140.4 (C-
12), 142.8 (C-14), 154.1 (C-16);  MS (ES+) m/z 331.4 [M+H]+; HRMS calcd for C14H11N4O-
4S 331.0496 [M+H]
+ found 331.0497. 
N-Methyl-1H-indazol-5-amine (150) 
 
5-Aminoindazole (1.0 g, 7.5 mmol) was taken in freshly prepared sodium methoxide 
solution (sodium (900 mg) in MeOH (20 mL)) followed by paraformaldehyde (340 mg, 
10.5 mmol) and stirred at RT for 5 h. After this time sodium borohydride (280 mg, 7.5 
mmol) was added and the mixture refluxed at 80oC for 2 h. The solution was 
hydrolysed in sodium hydroxide (1 M, 10 mL) and extracted with EtOAc (3 x 10 mL). 
Combined organic fractions were washed with brine (10 mL) and dried over Na2SO4. 
The compound was purified by MPLC (0-60% EtOAc in petroleum ether). The pure 
product was isolated as a brown solid (622 mg, 62%). 
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Rf 0.23 (EtOAc /Petrol, 1:1); m.p. 144-145 
oC (lit: 144-146 oC)199; UV λmax (EtOH/nm) 
334.0, 216.2; IR νmax/cm
-1 3432, 3137,  1500, 954, 853, 797; 1H-NMR (500 MHz, DMSO-
d6) δ ppm 2.68 (3H, d, J = 5.2 Hz, H-11), 5.39 (1H, d, J = 5.2 Hz, H-10), 6.57 (1H, s, H-5), 
6.79 (1H, d, J = 8.9 Hz H-7), 7.27 (1H, d, J = 8.9 Hz, H-8), 7.77 (1H, s, H-3), 12.59 (1H, br, 
H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 30.5 (C-11), 96.0 (C-5), 110.4 (C-7), 117.8 (C-
8), 123.9 (C-4), 131.7 (C-3), 134.3 (C-6), 144.4 (C-9); MS (ES+) m/z 148.02 [M+H]+;  
N-(1H-Indazol-5-yl)-N-methylbenzenesulfonamide (142) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and benzenesulfonyl chloride (70 µL, 0.54 mmol). The title compound was 
obtained as an off white solid (68 mg, 44%). 
Rf 0.38 (EtOAc /Petrol, 1:1); m.p. 154.5-155.3
oC; UV λmax (EtOH/nm) 292.4, 209.0; IR 
νmax/cm
-1 3145, 2948, 1504, 1446, 1345,1158, 954, 726; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm 3.19 (3H, s, H-16), 7.05 (1H, dd, J =9.0, 2.0 Hz, H-7), 7.42 (1H, d, J = 2.0 Hz, H-5), 
7.48 (1H, d, J = 9.0 Hz, H-8), 7.51 (2H, dd, J = 8.3, 1.6 Hz, H-13), 7.57 (2H, dd, J = 8.3, 8.3 
Hz, H-14), 7.69 (1H, tt, J =8.3, 1.6 Hz H-15), 8.05 (1H, s, H-3), 13.19 (1H, s-br, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm 38.6 (C-16), 110.3 (C-8), 118.5 (C-5), 122.6 (C-4), 
125.4 (C-7), 127.5 (C-13), 129.2 (C-14), 133.2 (C-15), 133.8 (C-3), 133.9 (C-6), 135.9 (C-
12), 138.6 (C-9);  MS (ES+) m/z 288.3 [M+H]+; HRMS calcd for C14H14N3O2S 288.0801 
[M+H]+ found 288.0801. 
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N-(1H-Indazol-5-yl)-N-methyl-2-oxoindoline-5-sulfonamide (143) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and 2-oxoindoline-5-sulfonyl chloride (126 mg, 0.54 mmol). The title 
compound was obtained as a dull white solid (9 mg, 4%). 
Rf 0.26 (EtOAc /Petrol, 1:1); m.p. 249-251 
oC; UV λmax (EtOH/nm) 263.0, 210.4; IR 
νmax/cm
-1 3186, 2861, 1711, 1618, 1480, 1340, 1237, 1147; 1H-NMR (500 MHz, DMSO-
d6) δ ppm 3.15 (3H, s, H-21), 3.55 (2H, s, H-15), 6.91 (1H, d, J = 8.3 Hz, H-19), 7.06 (1H, 
dd, J = 8.7, 2.0 Hz, H-7), 7.78 (1H, dd, J = 8.3, 1.7 Hz, H-20),  7.38 (1H, s, H-13), 7.45 (1H, 
d, J = 2.0 Hz, H-5), 7.48 (1H, d, J = 8.7 Hz, H-8), 8.06 (1H, s, H-3), 10.84 (1H, s-br, H-17),  
13.17 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 35.6 (C-15), 38.6 (C-21),  
108.9 (C-19), 110.2 (C-8), 118.5 (C-5), 122.6 (C-4), 123.7 (C-13), 125.6 (C-7), 126.6 (C-
14), 128.2 (C-12), 128.4 (C-20), 133.9 (C-3), 134.1 (C-6), 138.6 (C-9), 148.0 (C-18), 176.4 
(C-16);  MS (ES+) m/z 343.4 [M+H]+; HRMS calcd for C16H15N4O3S 343.0859 [M+H]
+ 
found 343.0858. 
N-(1H-Indazol-5-yl)-N-methylthiophene-2-sulfonamide (144) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and thiophene-2-sulfonyl chloride (99 mg, 0.54 mmol). The title compound 
was obtained as a pink solid (74 mg, 74%). 
Rf 0.37 (EtOAc /Petrol, 1:1); m.p. 164-165 
oC; UV λmax (EtOH/nm) 212.0; IR νmax/cm
-1 
3260, 3150, 1506, 1341, 1160, 942, 708; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.23 (3H, 
s, H-17), 7.09 (1H, dd, J =2.0, 8.8 Hz, H-7), 7.24 (1H, dd, J = 3.8, 5.0 Hz, H-15), 7.46 (1H, 
dd, J = 3.8, 1.3 Hz, H-16), 7.48 (1H, d, J = 2.0 Hz, H-5), 7.51 (1H, d, J = 8.8 Hz, H-8), 8.01 
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(1H, dd, J = 1.3, 5.0 Hz, H-14), 8.07 (1H, s, H-3), 13.20 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm 38.6 (C-17), 110.3 (C-8), 118.5 (C-5), 122.6 (C-4), 125.4 (C-7), 
128.0 (C-15), 133.1 (C-16), 133.6 (C-3), 133.9 (C-6, C-14), 135.6 (C-12), 138.7 (C-9);  MS 
(ES+) m/z 294.3 [M+H]+; HRMS calcd for C12H12N3O2S2 294.0365 [M+H]
+ found 294.0365. 
N-(1H-Indazol-5-yl)-N-methylquinoline-8-sulfonamide (145) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and quinoline-8-sulfonyl chloride (124 mg, 0.54 mmol). The title compound 
was obtained as a white solid (105 mg, 56%). 
Rf 0.49 (EtOAc /Petrol, 1:1); m.p. 164-166 
oC; UV λmax (EtOH/nm) 286.6, 214.6; IR 
νmax/cm
-1 3304, 2943, 1495, 1325, 1158, 1127, 938, 786; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm 3.66 (3H, s, H-22), 6.97 (1H, dd, J = 8.9, 1.6 Hz, H-7), 7.33 (1H, d, J = 8.9 Hz, H-8), 
7.42 (1H, d, J = 1.6  Hz, H-5), 7.60 (1H, dd, J = 7.7, 7.7 Hz,  H-20), 7.75 (1H, dd, J = 8.4, 
4.2 Hz, H-16), 7.95 (1H, s, H-3), 8.13 (1H, dd, J = 7.7, 1.4 Hz, H-19),  8.25 (1H, dd, J = 7.7, 
1.4 Hz, H-21), 8.56 (1H, dd, J = 8.4, 1.8 Hz, H-17), 9.16 (1H, dd, J = 4.2, 1.8 Hz, H-15), 
13.08 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 40.9 (C-22), 110.4 (C-8), 
118.9 (C-5), 122.5 (C-16), 122.7 (C-4), 125.4 (C-7), 125.6 (C-20), 128.6 (C-13), 132.8 (C-
19), 133.7 (C-3, C-18), 134.0 (C-21), 136.7 (C-6), 136.9 (C-17), 138.3 (C-9), 143.4 (C-12), 
151.5 (C-15); MS (ES+) m/z 339.3 [M+H]+; HRMS calcd for C17H15N4O2S 339.0910 [M+H]
+ 
found 339.0909. 
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N-(1H-Indazol-5-yl)-3-methoxy-N-methylbenzenesulfonamide (146) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and 3-methoxybenzene-1-sulfonyl chloride (77 µL, 0.54 mmol). The title 
compound was obtained as a white solid (67 mg, 38%). 
Rf 0.36 (EtOAc /Petrol, 1:1); m.p. 158-160 
oC; UV λmax (EtOH/nm) 285.4, 203.4; IR 
νmax/cm
-1 3150, 2953, 1428, 1344, 1243, 1053, 956,  848, 712; 1H-NMR (500 MHz, 
DMSO-d6) δ ppm 3.19 (3H, s, H-20), 3.71 (3H, s, H-19), 7.09 (1H, dd, J =9.0, 1.8 Hz, H-7), 
6.92 (1H, dd, J =1.8, 2.3 Hz, H-13), 7.06-7.08 (2H, m, H-7, H-17), 7.13 (1H, ddd, J =0.7, 
2.3, 8.3 Hz, H-15), 7.46 (1H, d, J = 2.0 Hz, H-5), 7.48-7.51 (2H, m, H-8, H-16), 8.07 (1H, s, 
H-3), 13.19 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 38.6 (C-20), 55.4 (C-
18), 110.2 (C-8), 112.2 (C-13), 118.5 (C-5), 119.2 (C-15), 119.7 (C-17), 122.6 (C-4), 125.4 
(C-7), 130.4 (C-16), 133.8 (C-3), 133.9 (C-6), 137.1 (C-12), 138.6 (C-9), 159.2 (C-14);  MS 
(ES+) m/z 318.3 [M+H]+; HRMS calcd for C15H16N3O3S 318.0907 [M+H]
+ found 318.0905. 
N-(1H-Indazol-5-yl)-4-methoxy-N-methylbenzenesulfonamide (147) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and 4-methoxybenzene-1-sulfonyl chloride (112 mg, 0.54 mmol). The title 
compound was obtained as a light green solid (19 mg, 11%).  
Rf 0.34 (EtOAc /Petrol, 1:1); m.p. 66-68 
oC; UV λmax (EtOH/nm) 247.8, 201.6; IR νmax/cm
-
1 3349, 2945, 1594, 1496, 1336, 1256, 1155, 939, 832; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm 3.15 (3H, s, H-18), 3.84 (3H, s, H-17), 7.05-7.09 (3H, m, H-7, H-14), 7.42-7.43 (3H, 
m, H-5, H13), 7.49 (1H, d, J = 8.8 Hz, H-8), 8.06 (1H, s, H-3), 13.18 (1H, s-br, H-1); 13C-
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NMR (125 MHz, DMSO-d6) δ ppm 38.5 (C-18), 55.6 (C-17),  110.2 (C-8), 114.3 (C-14), 
118.4 (C-5), 122.6 (C-4), 125.5 (C-7), 127.5 (C-6), 129.7 (C-13), 133.9 (C-3), 134.0 (C-12), 
138.6 (C-9), 162.7 (C-15 );  MS (ES+) m/z 318.4 [M+H]+; HRMS calcd for C15H16N3O3S 
318.0907 [M+H]+ found 318.0908. 
2,6-Difluoro-N-(1H-indazol-5-yl)-N-methylbenzenesulfonamide (148) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and 2,6-difluorobenzene-1-sulfonyl chloride (74 µL, 0.54 mmol). The title 
compound was obtained as a grey solid (89 mg, 48%). 
Rf 0.40 (EtOAc /Petrol, 1:1); m.p. 216.8-217.1 
oC; UV λmax (EtOH/nm) 209.0; IR νmax/cm
-1 
3327, 1609, 1462, 1361, 1170,  941, 799; 1H-NMR (500 MHz, DMSO-d6) δ ppm 3.35 (3H, 
s, H-16), 7.18 (1H, dd, J = 8.8, 1.9  Hz, H-7), 7.28 (2H, dd, J = 8.9, 8.9 Hz, H-14), 7.51 (1H, 
d, J = 8.8 Hz, H-8), 7.60 (1H, d, J = 1.9 Hz, H-5), 7.76 (1H, dddd, J = 6.1, 6.1, 8.5, 8.5, H-
15), 8.07 (1H, s, H-3), 13.21 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 38.8 
(C-16), 110.6 (C-8), 113.6 (d, JFC = 23.5 Hz, C-14), 113.6 (d, JFC = 23.2 Hz, C-14’), 114.6 
(C-12), 118.8 (C-5), 122.7 (C-4), 125.3 (C-7), 132.7 (C-6), 134.0 (C-3) 136.2 (t, JFC = 11.2 
Hz, C-15), 138.7 (C-9), 158.9 (d, JFC = 257.6 Hz, C-13), 158.9 (d, JFC = 257.3 Hz, C-13);
 19F 
NMR (470 MHz, DMSO-d6) δ -105.7  MS (ES
+) m/z 324.3 [M+H]+; HRMS calcd for 
C14H12F2N3O2S 324.0613 [M+H]
+ found 324.0611. 
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N-(1H-Indazol-5-yl)-N-methyl-2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonamide (149) 
 
Prepared according to general procedure A using N-methyl-1H-indazol-5-amine (80 mg, 
0.54 mmol) and 2-oxo-2,3-dihydrobenzo[d]oxazole-6-sulfonyl chloride ( 127 mg, 0.54 
mmol). The title compound was obtained as a grey solid (32 mg, 26%). 
Rf 0.25 (EtOAc /Petrol, 1:1); m.p. 256-257
oC; UV λmax (EtOH/nm) 281.6, 253.0, 205.6; IR 
νmax/cm
-1 3633, 2991, 2725, 1772, 1485, 1348, 1168, 706; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm 3.18 (3H, s, H-21), 7.05 (1H, dd, J =8.9, 2.0 Hz, H-7), 7.21 (1H, d, J = 8.1 Hz, H-19), 
7.24 (1H, dd, J = 8.1, 1.6 Hz, H-20), 7.43 (1H, d, J = 1.6 Hz, H-13), 7.45 (1H, d, J = 2.0 Hz, 
H-5), 7.48 (1H, d, J = 8.8 Hz, H-8), 8.05 (1H, s, H-3), 12.21 (1H, s-br, H-17), 13.18 (1H, s-
br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm 38.7 (C-21), 108.7 (C-5), 109.7 (C-19), 
110.3 (C-8), 118.7 (C-13), 122.6 (C-4), 124.4 (C-20), 125.5 (C-7), 129.1 (C-12), 133.8 (C-
3), 133.9 (C-6), 134.8 (C-14), 138.6 (C-9), 142.9 (C-18),154.2 (C-16);  MS (ES+) m/z 345.3 
[M+H]+; HRMS calcd for C15H13N4O4S 345.0652 [M+H]
+ found 345.0653. 
3-Bromo-4-methyl-5-nitrobenzoic acid (161)  
 
Dibromisocyanuric acid (870 mg, 3.0 mmol) was dissolved in sulphuric acid (20 mL) and 
added in portions to a solution of 4-methyl-3-nitrobenzoic acid (1.00 g, 5.5 mmol) in 
concentrated sulphuric acid (15 mL) over ca. 5 minutes. This solution was stirred 
overnight before addition of ice (100 g) and extraction with ethyl acetate (3 x 50 mL). 
Combined organic fractions were washed with brine (50 mL) and dried over Na2SO4. 
The pure product was isolated by MPLC (0-80% EtOAc in petroleum ether) giving the 
title compound as a pale yellow solid (1.34 g, 92%). 
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Rf 0.13 (Et2O); m.p. 188-189 
oC( Lit 184.5-185.5 oC)200; UV λmax (EtOH/nm) 229.2, 209.4; 
IR νmax/cm
-1 3086, 2815, 2539, 1696; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 2.54 (3H, s, 
H-9), 8.32 (1H, d, J = 1.6 Hz, H-4), 8.35 (1H, d, J = 1.6 Hz, H-6), 13.84 (1H, s-br, H-8); 13C-
NMR (125 MHz, DMSO-d6) δ ppm;  19.3 (C-9), 123.8 (C-4), 126.5 (C-2), 131.0 (C-1), 
136.0 (C-5), 136.3 (C-6), 150.8 (C-3), 164.4 (C-7);  MS (ES+) m/z 260.3 [M(79Br)+H]+.  
Methyl 3-bromo-4-methyl-5-nitrobenzoate (160) 
 
3-bromo-4-methyl-5-nitrobenzoic acid (200 mg, 0.38 mmol) was dissolved in methanol 
(3 mL) and concentrated sulphuric acid (0.5 mL) was added. This mixture was heated at 
60 oC for 18 hours then reduced under low pressure  giving a residue which was 
redissolved in EtOAc (15 mL) and washed with water (10 mL), saturated NaHCO3 
solution (aq, 10 mL), brine (10 mL) then dried over Na2SO4 and the solvent removed in 
vacuo giving the desired material as an orange solid (193 mg, 92 %). 
Rf 0.20 (Et2O); m.p. 56-58 
oC; UV λmax (EtOH/nm) 296.8, 230.6, 208.2; IR νmax/cm
-1 3423, 
3079, 1717, 1607; 1H-NMR (500 MHz, CDCl3) δ ppm; 2.61 (3H, s, H-9), 3.95 (3H, s, H-8), 
8.34 (1H, d, J = 1.4 Hz, H-4), 8.42 (1H, d, J = 1.4 Hz, H-6), 13C-NMR (125 MHz, CDCl3) δ 
ppm;  19.7 (C-9), 52.94 (C-8), 124.0 (C-4), 127.3 (C-1), 129.9 (C-5), 136.9 (C-6), 137.1 (C-
2), 151.2 (C-3), 163.9 (C-7); MS (ES+) m/z 274.3 [M(79Br)+H]+. 
Methyl 3-amino-5-bromo-4-methylbenzoate (162) 
 
3-bromo-4-methyl-5-nitrobenzoic acid (500 mg, 1.8 mmol) was dissolved in a 
methanol-acetic acid solution (4:1, 10:2.5 mL) under nitrogen and zinc powder (1.25 g, 
18.3 mmol) was added. This mixture was heated to 60 oC for 1 hour then filtered 
through Celite® and washed with MeOH (15 mL). The filtrate was reduced in vacuo and 
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purified by MPLC (0-80% EtOAc in petroleum ether) giving the desired material as an 
orange solid (424 mg, 95 %). 
Rf 0.21 (Et2O); m.p. 117-118 
oC; UV λmax (EtOH/nm) 325.4, 231.2; IR νmax/cm
-1 3468, 
3365, 3232, 1703, 1631; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 2.20 (3H, s, H-9), 3.80 
(3H, s, H-8), 5.56 (2H, s, H-10), 7.25 (1H, d, J  = 1.6 Hz, H-4), 7.29 (1H, d, J = 1.6 Hz, H-6); 
13C-NMR (125 MHz, DMSO-d6) δ ppm;  17.2 (C-9), 52.1 (C-8), 113.5 (C-4), 119.6 (C-6), 
124.7 (C-5), 125.0 (C-2), 128.8 (C-1), 148.4 (C-3), 165.5 (C-7);  MS (ES+) m/z 244.3 
[M(79Br)+H]+. 
Methyl 4-bromo-1H-indazole-6-carboxylate (163) 
 
Methyl 3-amino-5-bromo-4-methylbenzoate (30 mg, 0.12 mmol) was dissolved in 
acetic acid (2 mL) and NaNO2 (9.4 mg, 0.14 mmol) in H2O (0.5 mL) was added. The 
reaction was stirred for ca. 15 minutes then diluted with H2O (10 mL) and extracted 
with EtOAc (3 x 10 mL), combined organic fractions were washed with brine (10 mL) 
and dried over Na2SO4 before purification by MPLC (0-95% EtOAc in petroleum ether) 
giving the desired product as a pale orange solid (29.5 mg, 94%). 
Rf 0.59 (Et2O); m.p. 166-168
oC; UV λmax (EtOH/nm) 312.2, 266.6, 226.2; IR νmax/cm
-1 
3116, 3062, 2952, 2844, 1728, 1227; 1H-NMR (500 MHz, CDCl3) δ ppm; 3.97 (3H, s, H-
12),  8.00 (1H, s, H-8), 8.16 (1H, s, H-3),  8.22 (1H, s, H-6); 13C-NMR (125 MHz, CDCl3) δ 
ppm; 52.7 (C-12), 111.5 (C-8), 114.5 (C-5), 124.4 (C-4), 126.9 (C-6), 129.8 (C-7), 135.2 
(C-3), 139.9 (C-9), 166.1 (C-10) ; MS (ES+) m/z 253.3 [M(79Br)+H]+. 
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(4-Bromo-1H-indazol-6-yl)methanol (164) 
 
Prepared according to general procedure G using Methyl 4-bromo-1H-indazole-6-
carboxylate (1.565 g, 5.03 mmol) and LiAlH4 (2M in THF, 6.29 mL, 12.60 mmol). The 
product was isolated as a white solid (1.14 g, 82%). 
m.p. 210-212oC; UV λmax (EtOH/nm) 288.2, 267.8, 212.8; IR νmax/cm
-1 3122, 3078, 2881; 
1H-NMR (500 MHz, MeOD) δ ppm; 4.73 (2H, s, H-10), 7.35 (1H, s, H-6), 7.53 (1H, s, H-8),  
7.99 (1H, s, H-3); 13C-NMR (125 MHz, MeOD) δ ppm; 63.2 (C-10), 106.7 (C-8), 110.9 (C-
4), 113.4 (C-5), 122.7 (C-6), 133.2 (C-3), 135.2 (C-3), 142.3 (C-7), 143.4 (C-9) ; MS (ES+) 
m/z 227.3 [M(79Br)+H]+. 
4-Bromo-6-(bromomethyl)-1H-indazole (159) 
 
Prepared according to general procedure H using (4-bromo-1H-indazol-6-yl)methanol 
(1.14  g, 5.02 mmol), SOBr2 (0.78 mL, 10.03 mmol) and DMF (0.04 mL, 0.5 mmol). The 
product was isolated as an orange solid (838 mg, 58%). 
M.p. No clear m.p., decomposition range  222-225 oC; UV λmax (EtOH/nm) 296.2, 266.2, 
221.2; IR νmax/cm
-1 3149, 3110, 2967, 663; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 4.87 
(2H, s, H-10),  7.43 (1H, s, H-6), 7.69 (1H, s, H-8),  8.04 (1H, s, H-3), 13.55 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm; 34.0 (C-10), 113.0(C-8), 113.9 (C-5), 123.2 (C-4), 
124.5 (C-6), 133.1 (C-3), 137.6 (C-7), 140.3 (C-9); MS (ES+) m/z 291.3 [M(79Br)+H]+.  
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4-Bromo-6-((phenylthio)methyl)-1H-indazole (166) 
 
4-Bromo-6-(bromomethyl)-1H-indazole (200 mg, 0.69 mmol) was taken in anhydrous 
THF (15 mL) under N2 and lithium thiophenolate (0.76 mL, 0.76 mmol, 1.1 eq) was 
added. The solution was stirred for 4 hours at room temperature before dilution with 
NaOH solution (2 M, aq, 10 mL) and extraction with EtOAc (3 x 10 mL). Combined 
organic fractions were washed with brine (10 mL) and dried over Na2SO4. This material 
was reduced by rotary evaporator and purified by MPLC (0-80% EtOAc in petroleum 
ether) giving the desired product as an off white solid (201 mg, 91%). 
m.p. Not clear; decomposition range  280-282 oC; UV λmax (EtOH/nm) 298.2, 258.2; IR 
νmax/cm
-1 3150, 3108, 2964; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 4.87 (2H, s, H-10), 
7.11 (1H, s, H-6), 7.38 (1H, s, H-8), 7.60 (2H, dd, J = 7.8, 8.0 Hz, H-14), 7.73-7.75 (3H, m, 
H-15, H-13), 8.03 (1H, s, H-3), 13.49 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ 
ppm; 60.0 (C-10), 112.4 (C-8), 112.4 (C-5), 123.3 (C-4), 125.7 (C-6), 128.1 (C-13), 128.1 
(C-7), 129.2 (C-14), 133.0 (C-3), 133.9 (C-15), 138.1 (C-12) 140.1 (C-9);  MS (ES+) m/z 
319.2 [M(79Br)+H]+. 
4-Bromo-6-((phenylsulfonyl)methyl)-1H-indazole (169) 
 
 
Prepared according to general procedure K using 4-bromo-6-((phenylthio)methyl)-1H-
indazole (200 mg, 0.63 mmol) and Oxone® (1.15 g, 1.89 mmol). The product was 
isolated as an off white solid (142.3 mg, 65%). 
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Rf 0.41 (Et2O); m.p. 187-188 
oC; UV λmax (EtOH/nm) 293.8, 271.2, 264.0, 216.0; IR 
νmax/cm
-1 3119, 2921, 1303, 1144, 950,727; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 4.87 
(2H, s, H-10), 7.11 (1H, s, H-6), 7.37 (1H, s, H-8), 7.60 (2H, dd, J = 7.5, 8.0 Hz, H-14), 
7.73-7.75 (3H, m, H-15, H-13), 8.02 (1H, s, H-3), 13.49 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm; 60.1 (C-10), 112.4 (C-8), 112.4 (C-5), 123.3 (C-4), 125.7 (C-6), 
128.1 (C-13), 128.1 (C-7), 129.2 (C-14), 133.0 (C-3), 133.9 (C-15), 138.2 (C-12) 140.1 (C-
9);  MS (ES+) m/z 353.2 [M+H]+; HRMS calcd for C14H12BrN2O2S 350.9797 & 352.9776 
[M+H]+ found 350.9803 & 352.9777. 
4-Bromo-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (170) 
 
4-Bromo-6-(bromomethyl)-1H-indazole (100 mg, 0.34 mmol) was taken in anhydrous 
THF (2 mL) under N2 and was added dropwise to a solution of thiophene-2-thiol (0.065 
mL, 0.69 mmol, 2 eq) in pyridine (4 mL). The solution was stirred for 4 hours at room 
temperature before removal of solvent by V10. The resulting residue was suspended in 
NaOH solution (2 M, aq, 10 mL) and extracted into EtOAc (3 x10 mL). Combined 
organic fractions were washed with brine (10 mL) and dried over Na2SO4. This material 
was reduced by rotary evaporator and purified by MPLC (0-80% EtOAc in petroleum 
ether) giving 4-bromo-6-((thiophen-2-ylthio)methyl)-1H-indazole as an off white solid 
(89 mg, 73%). Isolated material was used directly in the next step with out 
characterisation according to general procedure K using: 4-bromo-6-((thiophen-2-
ylthio)methyl)-1H-indazole (139 mg, 0.43 mmol) and Oxone® (782 mg, 1.29 mmol). The 
product was isolated as an off white solid (152 mg, 77%). 
Rf 0.35 (Et2O). m.p. 182-183 
oC. UV λmax (EtOH/nm) 294.4, 216.0; IR νmax/cm
-1 3118, 
2925, 1307, 1146, 951, 686; 1H-NMR (500MHz, DMSO-d6) δ ppm; 4.95 (2H, s, H-10), 
7.14 (1H, s, H-6), 7.24 (1H, dd, J = 3.9, 4.9 Hz, H-15), 7.41 (1H, s, H-8), 7.61 (1H, dd, J = 
1.3, 3.9 Hz, H-16), 8.03 (1H,s, H-3), 8.06 (1H, dd, J = 4.9, 1.3 Hz, H-14), 13.51 (1H, s-br, 
H-1). 13C-NMR (125 MHz, DMSO-d6) δ ppm; 61.7 (C-10), 112.3 (C-8), 112.5 (C-5), 123.4 
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(C-4), 125.5 (C-6), 128.2 (C-15), 128.4 (C-12), 133.1 (C-3), 134.8 (C-16), 135.7 (C-14), 
138.6 (C-7), 140.1 (C-9); MS (ES+) m/z 359.1 [M(79Br)+H]+. 
4-Bromo-6-(((4-methoxyphenyl)sulfonyl)methyl)-1H-indazole (171) 
 
4-Bromo-6-(bromomethyl)-1H-indazole (200 mg, 0.69 mmol) was taken in anhydrous 
THF (2 mL) under N2 and was added dropwise to a solution of p-methoxythiophenol 
(0.17 mL, 1.38 mmol, 2 eq) in pyridine (4 mL). The solution was stirred for 4 hours at 
room temperature before removal of solvent by V10. The resulting residue was 
suspended in NaOH solution (2 M, aq, 10 mL) and extracted into EtOAc (3 x10 mL). 
Combined organic fractions were washed with brine (10 mL) and dried over Na2SO4. 
This material was reduced by rotary evaporator and purified by MPLC (0-80% EtOAc in 
petroleum ether) giving 4-bromo-6-(((4-methoxyphenyl)thio)methyl)-1H-indazole as an 
off white solid (61 mg, 25%). Isolated material was used directly in the next step 
without characterisation according to general procedure K using: 4-bromo-6-(((4-
methoxyphenyl)thio)methyl)-1H-indazole (61 mg, 0.17 mmol) and Oxone® (320 mg, 
0.52 mmol). The product was isolated as an off white solid (63 mg, 95%) 
Rf 0.36 (Et2O); m.p. 181-182
oC; UV λmax (EtOH/nm) 294.0, 242.0, 216.8, 202.4; IR 
νmax/cm
-1 3319, 2930, 1593, 1295, 1261, 1142, 1058, 833; 1H-NMR (500 MHz, DMSO-d6) 
δ ppm; 3.85 (3H, s, H-17), 4.79 (2H, s, H-10), 7.35 (3H, m, H-6, H-14), 7.35 (1H, s, H-8),  
7.63 (2H, d, J =8.8 Hz, H-13),  8.03 (1H, s, H-3), 13.48 (1H, s-br, H-1); 13C-NMR (125 MHz, 
DMSO-d6) δ ppm; 55.8 (C-17), 60.4 (C-10), 112.3 (C-8), 112.4 (C-5), 114.3 (C-14), 123.2 
(C-4), 125.7 (C-6), 128.5 (C-7), 129.7 (C-12), 130.4 (C-13), 133.0 (C-3), 140.1 (C-9) 163.3 
(C-15);  MS (ES+) m/z 383.2 [M(79Br)+H]+. 
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4-Bromo-6-((phenylsulfonyl)methyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (173 
 
Prepared according to general procedure C 4-bromo-6-((phenylsulfonyl)methyl)-1H-
indazole (60 mg, 0.17 mmol), p-TSA (3 mg, 0.02 mmol) and DHP (47 μL, 0.51 mmol). 
The product was isolated as an off white solid (103 mg, 71%). 
m.p. 151-153 oC; UV λmax (EtOH/nm) 296.5, 264.0, 219.5; IR νmax/cm
-1 3066, 2937, 2844, 
1304, 1156, 1080; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.64-1.75 (3H, m, H-4’, H-5’, H-5’), 
2.00-2.03 (1H, m, H-6’), 2.10-2.13 (1H, m, H-4’), 2.40-2.43 (1H, m, H-6’), 3.66-3.69 (1H, 
m, H-3’), 3.92-3.95 (1H, m, H-3’), 4.39 (2H, d, J = 5.1 Hz, H-10), 5.72 (1H, dd, J = 2.9, 9.1 
Hz, H-1’), 6.97 (1H, d, J = 1.1 Hz, H-6), 7.29 (1H, s, H-8), 7.48 (2H, dd, J = 7.5, 8.1 Hz, H-
14), 7.63 (1H, tt, J = 1.2, 7.5 Hz, H-15), 7.67 (2H, dd, J = 8.1, 1.2 Hz, H-13), 7.99 (1H, s, H-
3); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.3 (C-4’) 25.0 (C-5’), 29.3 (C-6’), 62.7 (C-10), 
67.4 (C-3’), 85.8 (C-1’), 112.0 (C-8), 114.5 (C-4), 126.5 (C-6), 127.7 (C-), 128.7 (C-13), 
129.1 (C-14), 133.8 (C-3), 133.9 (C-15); MS (ES+) m/z 435.2 [M+H]+; HRMS calcd for 
C19H20BrN2O3S 435.0373 & 437.0351 [M+H]
+ found 435.0371 & 437.0348. 
4-Bromo-1-(tetrahydro-2H-pyran-2-yl)-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole 
(174) 
 
Prepared according to general procedure C using 4-bromo-6-((thiophen-2-
ylsulfonyl)methyl)-1H-indazole (117 mg, 0.33 mmol), p-TSA (6 mg, 0.03 mmol) and DHP 
(84 μL, 0.99 mmol). The product was isolated as an off white solid (103 mg, 71%) 
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m.p. 64-66oC; UV λmax (EtOH/nm) 293.1, 260.2, 220.1; IR νmax/cm
-1 3374, 2928, 1355, 
1147; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.55-1.59 (2H, m, H-5’, H-4’), 1.73-1.76 (1H, 
m, H-4’), 1.93-1.96 (1H, m, H-5’), 1.99-2.03 (1H, m, H-6’), 2.27-2.30 (1H, m, H-6’), 3.66-
3.71 (1H, m, H-3’), 3.86-3.89 (1H, m, H-3’), 4.94 (2H, s, H-10), 5.72 (1H, dd, J = 2.0, 9.2 
Hz, H-1’), 7.25 (1H, s, H-6), 7.27 (1H, dd, J = 4.8, 3.6 Hz, H-15), 7.51 (1H, s, H-8), 7.34 
(1H, dd, J = 1.0, 3.6 Hz, H-16), 8.08-8.09 (2H, m, H-5, H-14); 13C-NMR (125 MHz, DMSO-
d6) δ ppm; 22.2 (C-4’) 25.1 (C-5’), 28.9 (C-6’), 62.6 (C-10), 67.4 (C-3’), 85.4 (C-1’), 62.3 
(C-10), 113.3 (C-8), 112.5 (C-5), 123.2 (C-4), 125.5 (C-6), 127.9 (C-15), 129.0 (C-12), 
133.3 (C-3), 134.7 (C-16), 136.0 (C-14), 139.1 (C-7), 140.2 (C-9); MS (ES+) m/z 442.4 
[M(79Br)+H]+. 
4-Methyl-6-((phenylsulfonyl)methyl)-1H-indazole (172) 
 
Prepared according to general procedure L using 4-bromo-6-((phenylsulfonyl)methyl)-
1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (45 mg, 0.10 mmol), Pd(dppf)Cl2.DCM (7 mg, 
0.01 mmol), Cs2CO3 (51 mg, 0.15 mmol) and methyboronic acid (19 mg, 0.31 mmol). 
The product was isolated as an off white solid (12.4 mg, 41%). 
Rf 0.40 (Et2O); m.p. 120-122 
oC; UV λmax (EtOH/nm) 293.8, 258.2, 216.0; IR νmax/cm
-1 
3337, 2357, 1625, 1446, 1305, 1148, 1083, 686; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 
2.46 (3H, s, H-16), 4.76 (2H, s, H-10), 6.65 (1H, s, H-6), 7.14 (1H, s, H-8), 7.59 (2H, dd, J 
= 7.5, 8.0 Hz, H-14), 7.71-7.74 (3H, m, H-15, H-13), 8.09 (1H, s, H-3), 13.04 (1H, s-br, H-
1); 13C-NMR (125 MHz, DMSO-d6) δ ppm;  18.3 (C-16), 61.0 (C-10), 110.2 (C-8), 122.9 
(C-6), 123.0 (C-4), 126.4 (C-5), 128.0 (C-13), 129.1 (C-14), 129.9 (C-7), 132.4 (C-3), 133.7 
(C-15), 138.5 (C-12), 139.6 (C-9);  MS (ES+) m/z 287.3 [M+H]+; HRMS calcd for 
C15H15N2O2S 287.0849 [M+H]
+ found 287.0852. 
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6-(((4-Methoxyphenyl)sulfonyl)methyl)-4-methyl-1H-indazole (180) 
 
 
Prepared according to general procedure C using 4-bromo-6-(((4-
methoxyphenyl)sulfonyl)methyl)-1H-indazole (63 mg, 0.17 mmol), p-TSA (3 mg, 0.02 
mmol) and DHP (42 μL, 0.50 mmol). 4-Bromo-6-(((4-methoxyphenyl)sulfonyl)methyl)-
1-(tetrahydro-2H-pyran-2-yl)-1H-indazole was isolated as an off white solid (44 mg, 
58%) and used in the next step without characterisation according to general 
procedure L using 4-bromo-6-(((4-methoxyphenyl)sulfonyl)methyl)-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole (44 mg, 0.09 mmol), Pd(dppf)Cl2.DCM (6 mg, 0.01 mmol), 
Cs2CO3 (46 mg, 0.14 mmol) and methyboronic acid (19 mg, 0.31 mmol). The product 
was isolated as an off white solid (15.8 mg, 52%). 
Rf 0.37 (Et2O); m.p. 189-191 
oC; UV λmax (EtOH/nm) 293.0, 242.0, 216.0; IR νmax/cm
-1 
3329, 2929, 1602, 1401, 1304, 1145, 1014, 854, 722; 1H-NMR (500 MHz, CDCl3) δ ppm; 
2.52 (3H, s, H-18), 3.85 (3H, s, H-17), 4.36 (2H, s, H-10), 6.67 (1H, s,H-6), 6.89 (2H, d, J = 
8.9 Hz, H-14), 7.09 (1H, s, H-8), 7.56 (2H, d, J =8.9 Hz, H-13), 8.09 (1H, s, H-3); 13C-NMR 
(125 MHz, CDCl3) δ ppm;  18.6 (C-18), 55.7 (C-17), 63.5 (C-10), 109.8 (C-8), 114.1 (C-14), 
120.1 (C-4), 123.9 (C-6), 127.3 (C-5), 129 (C-12), 130.3 (C-13), 133.4 (C-3), 139.6 (C-9), 
163.1 (C-15); MS (ES+) m/z 317.3 [M+H]+. 
4-Methyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (179) 
 
Prepared according to general procedure L using 4-bromo-1-(tetrahydro-2H-pyran-2-
yl)-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (50 mg, 0.11 mmol), 
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Pd(dppf)Cl2.DCM (6 mg, 0.01 mmol), Cs2CO3 (55 mg, 0.17 mmol) and methyboronic 
acid (21 mg, 0.34 mmol). The product was isolated as an off white solid (18 mg, 54%). 
Rf 0.34 (EtOAc /Petrol, 1:1). m.p. 115-117 
oC. UV λmax (EtOH/nm) 257.4, 215.8; IR 
νmax/cm
-1 3181, 1400, 1308, 1149, 849,738; 1H-NMR (500MHz, CDCl3) δ ppm; 2.54 (3H, 
s, H-17), 4.50 (2H, s, H-10), 6.70 (1H, s, H-6), 7.05 (1H, dd, J = 3.8, 4.9 Hz, H-15), 7.19 
(1H, s, H-8), 7.39 (1H, dd, J = 1.8, 3.8 Hz, H-16), 7.65 (1H, dd, J = 4.9, 1.8 Hz, H-14), 8.11 
(1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 18.6 (C-17), 64.4 (C-10), 109.7 (C-8), 
123.6 (C-6), 127.0 (C-4), 127.7 (C-15), 134.4 (C-14), 134.9 (C-16), 138.7 (C-3) N.B. not all 
are carbons visible; MS (ES+) m/z 293.3 [M+H]+; HRMS calcd for C13H13N2O2S2 293.0413 
[M+H]+ found 293.0415. 
Methyl 4-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (181) 
 
Crude methyl 4-bromo-1H-indazole-6-carboxylate (302 mg, 1.18 mmol) was dissolved 
in anhydrous DCM (20 mL) under N2 and p-TSA (0.1 eq, 23 mg, 0.12 mmol) was added 
followed by DHP (3 eq, 322 μL, 3.53 mmol). The solution was stirred at room 
temperature for ca. 18 hours then saturated NaHCO3 solution (aq, 15 mL) was added 
and the solution extracted with DCM (3 x 10 mL). Combined organic fractions were 
dried using a phase separator and reduced to a residue by rotary evaporator. This 
material was purified by MPLC (0-80% EtOAc in petroleum ether) giving the desired 
product as a pale orange solid (330 g, 82%). 
m.p. 110-112 oC; UV λmax (EtOH/nm) 314.6, 267.0, 227.4; IR νmax/cm
-1 3107, 2948, 2855, 
1715; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.45-1.50 (1H, m, H-4’), 1.59-1.62 (1H, m, 
H-4’), 1.76-1.79 (1H, m, H-5’) 2.00-2.06 (2H, m, H-5’, H-6’), 2.37-2.40 (1H, m, H-6’B), 
3.81-3.86 (2H, m, H-3’) 3.93 (3H, s, H-12), 6.08 (1H, dd, J = 2.0, 9.0 Hz, H-1’), 7.88 (1H, d, 
J = 1.0 Hz, H-6), 8.24 (1H, s, H-3), 8.41 (1H, s, H-8); 13C-NMR (125 MHz, DMSO-d6) δ 
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ppm;  21.8 (C-4’) 24.7 (C-5’), 28.8 (C-6’), 52.7 (C-12), 66.4 (C-3’), 84.1 (C-1’), 112.0 (C-8), 
113.5 (C-4), 123.6 (C-6), 127.1 (C-5), 128.9 (C-7), 133.3 (C-3), 139.2 (C-9), 165.3 (C-10);  
MS (ES+) m/z 339.2 [M+H]+; HRMS calcd for C14H16BrN2O3 339.0339 & 341.0318 [M+H]
+ 
found 339.0341 & 341.0315. 
Methyl 4-ethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (182) 
 
Prepared according to general procedure F using Methyl 4-bromo-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-6-carboxylate (250 mg, 0.74 mmol), ethylboronic acid (165 mg, 
2.21 mmol), Cs2CO3 (360 mg, 1.11 mmol) and Pd(dppf)Cl2.DCM (6 mg, 0.07 mmol) in 
1,4-dioxane (5 mL). The product was isolated as a white solid (184 mg, 87%). 
m.p. 88-90 oC; UV λmax (EtOH/nm) 314.8, 272.2, 263.8, 227.8; IR νmax/cm
-1 2943, 2850, 
1714, 1266; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.37 (3H, t, J = 7.6 Hz, H-14), 1.64-1.69 
(1H, m, H-5’), 1.74-1.80 (2H, m, H-4’, H-5’), 2.05-2.10 (1H, m, H-6’), 2.14-2.18 (1H, m, 
H-4’), 2.55-2.62 (1H, m, H-6’), 2.99 (2H, t, J = 7.6 Hz, H-13), 3.76-3.81 (1H, m, H-3’), 3.96 
(3H, s, H-12), 4.03-4.06 (1H, m, H-3’), 5.77 (1H, dd, J = 3.0, 9.8 Hz, H-1’), 7.64 (1H, s, H-
6), 8.10 (1H, s, H-8), 8.16 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 14.8 (C-14), 
22.7 (C-4’) 25.1 (C-5’), 26.2 (C-13), 29.5 (C-6’), 52.3 (C-12), 67.7 (C-3’), 85.4 (C-1’), 110.1 
(C-8), 120.0 (C-6), 127.0 (C-4), 128.5 (C-5), 132.7 (C-3), 137.9 (C-9), 139.2 (C-7), 167.6 
(C-10); MS (ES+) m/z 289.2 [M+H]+; HRMS calcd for C16H21N2O3 289.1547 [M+H]
+ found 
289.1549. 
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Methyl 4-cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (183) 
 
Prepared according to general procedure F using Methyl 4-bromo-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-6-carboxylate (250 mg, 0.74 mmol), cyclopropylboronic acid 
(185 mg, 2.21 mmol), Cs2CO3 (360 mg, 1.11 mmol) and Pd(dppf)Cl2.DCM (6 mg, 0.07 
mmol) in 1,4-dioxane (5 mL). The product was isolated as a white solid (157 mg, 71%). 
UV λmax (EtOH/nm) 320.6, 273.2, 265.2, 229.2; IR νmax/cm
-1 3083, 2945, 2851, 1714; 1H-
NMR (500 MHz, CDCl3) δ ppm; 0.91-0.94 (2H, m, H-14), 1.07-1.11 (2H, m, H-14), 1.65-
1.69 (1H, m, H-5’), 1.73-1.79 (2H, m, H-4’, H-5’), 2.05-2.08 (1H, m, H-6’), 2.15-2.18 (1H, 
m, H-4’), 2.23-2.28 (1H, m, H-13), 2.54-2.65 (1H, m, H-6’), 3.75-3.80 (1H, m, H-3’), 3.94 
(3H, s, H-12), 4.02-4.05 (1H, m, H-3’), 5.76 (1H, dd, J = 2.7, 9.6 Hz, H-1’), 7.41 (1H, s, H-
6), 8.11 (1H, s, H-8), 8.19 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.6 (C-14), 
13.4 (C-13), 22.8 (C-4’) 25.2 (C-5’), 29.6 (C-6’), 52.4 (C-12),  67.8 (C-3’), 85.5 (C-1’), 
109.8 (C-8), 117.0 (C-6), 127.7 (C-4), 128.6 (C-5), 132.9 (C-3), 138.1 (C-9), 139.6 (C-7), 
167.7 (C-10);  MS (ES+) m/z 301.3 [M+H]+; HRMS calcd for C17H21N2O3 301.1547 [M+H]
+ 
found 301.1546. 
 
 
 
 
 
 
 
298 
 
Methyl 4-cyclobutyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (374) 
 
Prepared according to general procedure F using Methyl 4-bromo-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-6-carboxylate (250 mg, 0.74 mmol), cyclobutylboronic acid 
(219 mg, 2.21 mmol), Cs2CO3 (360 mg, 1.11 mmol) and Pd(dppf)Cl2.DCM (60 mg, 0.07 
mmol) in 1,4-dioxane (5 mL). The product was isolated as a white solid (74 mg, 32%). 
m.p. 100-102 oC; UV λmax (EtOH/nm) 316.4, 272.6, 228.0; IR νmax/cm
-1 2943, 2856, 1717; 
1H-NMR (500 MHz, CDCl3) δ ppm; 1.65-1.69 (1H, m, H-5’), 1.73-1.80 (2H, m, H-4’, H-5’), 
1.91-1.97 (1H, m, H-15), 2.06-2.10 (1H, m, H-6’), 2.14-2.19 (2H, m, H-15, H-4’), 2.31-
2.39 (2H, m, H-14), 2.48-2.53 (2H, m, H-14), 2.57-2.60 (1H, m, H-6’), 3.76-3.81 (1H, m, 
H-3’), 3.93-3.99 (4H, m, H-12, H-13), 4.02-4.05 (1H, m, H-3’), 5.78 (1H, dd, J = 2.7, 9.6 
Hz, H-1’), 7.65 (1H, s, H-6), 8.06 (1H, s, H-3), 8.15 (1H, s, H-8); 13C-NMR (125 MHz, CDCl3) 
δ ppm;  18.7 (C-15), 22.7 (C-4’), 25.1 (C-5’), 29.1 (C-14), 29.5 (C-6’), 38.2 (C-13), 52.3 (C-
12), 67.7 (C-3’), 85.3 (C-1’), 110.0 (C-8), 118.0 (C-6), 126.0 (C-4), 128.4 (C-5),  133.0 (C-
3); MS (ES+) m/z 315.3 [M+H]+; HRMS calcd for C18H23N2O3 315.1703 [M+H]
+ found 
315.1703 
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Methyl 4-cyclohexyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-6-carboxylate (375) 
 
Prepared according to general procedure F using Methyl 4-bromo-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-6-carboxylate (250 mg, 0.74 mmol), cyclohexylboronic acid 
(283 mg, 2.21 mmol), Cs2CO3 (360 mg, 1.11 mmol) and Pd(dppf)Cl2.DCM (60 mg, 0.07 
mmol) in 1,4-dioxane (5 mL). The product was isolated as a white solid (83 mg, 33%). 
m.p. 96-98 oC; UV λmax (EtOH/nm) 316.2, 271.4, 264.0, 228.0; IR νmax/cm
-1 2936, 2852, 
1714; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.31-1.38 (1H, m, H-16), 1.44-1.54 (2H, m, H-
15), 1.58-1.67 (3H, m, H-14, H-5’), 1.76-1.82 (3H, m, H-4’, H-5’, H-16), 1.89-1.92 (2H, m, 
H-15), 1.97-2.01 (2H, m, H-14), 2.06-2.09 (1H, m, H-6’), 2.15-2.17 (1H, m, H-4’), 2.57-
2.61 (1H, m, H-6‘), 2.95-3.01 (1H, m, H-13), 3.76-3.81 (1H, m, H-3’), 3.96 (3H, s, H-12), 
4.03-4.06 (1H, m, H-3’), 5.77 (1H, dd, J = 2.7, 9.7 Hz, H-1’), 7.66 (1H, s, H-6), 8.13 (1H, s, 
H-8), 8.14 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.7 (C-4’) 25.1 (C-5’), 26.2 
(C-16), 26.9 (C-15), 29.5 (C-6’), 33.7 (C-14), 42.1 (C-13), 52.3 (C-12), 67.8 (C-3’), 85.3 (C-
1’), 110.0 (C-8), 118.1 (C-6), 126.6 (C-4), 128.5 (C-5), 132.7 (C-3), 139.2 (C-9), 141.8 (C-
7), 167.7 (C-10);  MS (ES+) m/z 343.2 [M+H]+; HRMS calcd for C20H27N2O3 343.2016 
[M+H]+ found 343.2015 
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(4-Ethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)methanol (184) 
 
Prepared according to general procedure G using Methyl 4-ethyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-6-carboxylate (368 mg, 1.28 mmol), LiAlH4 (1M in THF, 2.6 mL, 
2.21 mmol) in THF (30 mL). The product was isolated as a white solid (284 mg, 86%). 
UV λmax (EtOH/nm) 290.8, 256.4, 218.8; IR νmax/cm
-1 3368, 2932, 2855; 1H-NMR (500 
MHz, CDCl3) δ ppm; 1.38 (3H, t, J = 7.6 Hz, H-14), 1.62-1.66 (1H, m, H-5’), 1.70-1.80 (2H, 
m, H-4’, H-5’), 2.03-2.06 (1H, m, H-6’), 2.12-2.17 (1H, m, H-4’), 2.54-2.61 (1H, m, H-6’), 
2.94 (2H, q, J = 7.6 Hz, H-13), 3.71-3.76 (1H, m, H-3’), 4.02-4.05 (1H, m, H-3’), 4.80 (2H, 
s, H-10), 5.69 (1H, dd, J = 2.4, 9.7 Hz, H-1’), 6.94 (1H, s, H-6), 7.42 (1H, s, H-8), 8.03 (1H, 
s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 14.9 (C-14), 22.8 (C-4’) 25.1 (C-5’), 26.3 (C-
13), 29.5 (C-6’), 65.7 (C-10), 67.7 (C-3’), 85.3 (C-1’), 105.5 (C-8), 118.9 (C-6), 123.9 (C-4), 
132.6 (C-3), 138.1 (C-5), 139.9 (C-9), 140.2 (C-7);  MS (ES+) m/z 261.2 [M+H]+; HRMS 
calcd for C15H21N2O2 261.1598 [M+H]
+ found 261.1596. 
(4-Cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)methanol (185) 
 
Prepared according to general procedure G using methyl 4-cyclopropyl-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazole-6-carboxylate (900 mg, 3.00 mmol), LiAlH4 (1M in THF, 6 
mL, 5.99 mmol) in THF (40 mL). The product was isolated as a white solid (760 mg, 
93%).  
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UV λmax (EtOH/nm) 294.0, 259.8, 221.6; IR νmax/cm
-1 3353, 2935, 2853; 1H-NMR (500 
MHz, CDCl3) δ ppm; 0.87-0.91 (2H, m, H-14), 1.05-1.09 (2H, m, H-14), 1.64-1.69 (1H, m, 
H-5’), 1.72-1.81 (2H, m, H-4’, H-5’), 2.06-2.07 (1H, m, H-6’), 2.15-2.17 (1H, m, H-4’), 
2.21-2.27 (1H, m, H-13), 2.54-2.61 (1H, m, H-6’), 3.73-3.78 (1H, m, H-3’), 3.94 (3H, s, H-
12), 4.02-4.05 (1H, m, H-3’), 5.18 (2H, d, J = 5.6 Hz, H-10), 5.70 (1H, dd, J = 2.5, 9.4 Hz, 
H-1’), 7.76 (1H, s, H-6), 7.37 (1H, s, H-8), 8.12 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ 
ppm; 8.4 (C-14), 13.4 (C-13), 22.7 (C-4’) 25.1 (C-5’), 29.4 (C-6’), 66.8 (C-10), 67.6 (C-3’), 
85.2 (C-1’), 107.2 (C-8), 117.2 (C-6), 124.7 (C-4), 126.8 (C-5), 132.7 (C-3), 138.2 (C-9), 
139.6 (C-7);  MS (ES+) m/z 273.4 [M+H]+; HRMS calcd for C16H21N2O2 273.1598 [M+H]
+ 
found 273.1598. 
(4-Cyclobutyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)methanol (376) 
 
Prepared according to general procedure G using Methyl 4-cyclobutyl-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazole-6-carboxylate (101 mg, 0.32 mmol) and LiAlH4 (1M in THF, 
0.64 mL, 0.64 mmol). The product was isolated as an off white solid (58 mg, 64%). 
UV λmax (EtOH/nm) 297.0, 257.6; IR νmax/cm
-1 3349, 2940, 2877; 1H-NMR (500 MHz, 
CDCl3) δ ppm; 1.62-1.67 (1H, m, H-5’), 1.73-1.78 (2H, m, H-4’, H-5’), 1.88-1.95 (1H, m, 
H-15), 2.03-2.07 (1H, m, H-6’), 2.10-2.18 (2H, m, H-15, H-4’), 2.27-2.36 (2H, m, H-14), 
2.44-2.51 (2H, m, H-14), 2.55-2.61(1H, m, H-6’), 3.71-3.76 (1H, m, H-3’), 3.92 (1H, tt,  J 
= 8.6, 8.6 Hz,  H-13), 4.02-4.05 (1H, m, H-3’), 4.82 (2H, s, H-10), 5.69 (1H, dd, J = 2.8, 9.6 
Hz, H-1’), 6.96 (1H, s, H-6), 7.42 (1H, s, H-8), 7.98 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) 
δ ppm;  18.7 (C-15), 22.8 (C-4’), 25.1 (C-5’), 29.1 (C-14), 29.4 (C-6’), 38.3 (C-13), 65.8 (C-
10), 67.7 (C-3’), 85.3 (C-1’), 105.5 (C-8), 117.0 (C-6), 122.9 (C-4), 133.0 (C-3), 139.9 (C-5), 
140.0 (C-7), 140.2 (C-9);  MS (ES+) m/z 287.3 [M+H]+; HRMS calcd for C17H23N2O2 
287.1754 [M+H]+ found 287.1756 
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 (4-Cyclohexyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)methanol (377) 
 
Prepared according to general procedure G using Methyl 4-hexyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-6-carboxylate (125.7 mg, 0.37 mmol) and LiAlH4 (1M in THF, 
0.74 mL, 0.74 mmol). The product was isolated as an off white solid (95 mg, 82%). 
UV λmax (EtOH/nm) 298.4, 261.0, 222.3; IR νmax/cm
-1 3354, 2932, 2833; 1H-NMR (500 
MHz, CDCl3) δ ppm; 1.29-1.35 (1H, m, H-16), 1.44-1.52 (2H, m, H-15), 1.55-1.64 (3H, m, 
H-14, H-5’), 1.74-1.82 (3H, m, H-4’, H-5’, H-16), 1.88-1.90 (2H, m, H-15), 1.96-1.99 (2H, 
m, H-14), 2.04-2.07 (1H, m, H-6’), 2.14-2.16 (1H, m, H-4’), 2.57-2.60 (1H, m, H-6‘), 2.92-
2.97 (1H, m, H-13), 3.72-3.77 (1H, m, H-3’), 4.04-4.06 (1H, m, H-3’), 4.81 (2H, s, H-10), 
5.70 (1H, dd, J = 2.5, 9.5 Hz, H-1’), 7.00 (1H, s, H-6), 7.42 (1H, s, H-8), 8.06 (1H, s, H-3); 
13C-NMR (125 MHz, CDCl3) δ ppm; 22.8 (C-4’) 25.2 (C-5’), 26.3 (C-16), 26.9 (C-15), 29.4 
(C-6’), 33.8 (C-14), 42.6 (C-13), 65.9 (C-10), 67.7 (C-3’), 85.3 (C-1’), 105.5 (C-8), 117.1 (C-
6), 123.5 (C-4), 128.5 (C-5), 132.7 (C-3), 140.0 (C-9), 140.1 (C-7), 142.1 (C-5);  MS (ES+) 
m/z 315.3 [M+H]+; HRMS calcd for C19H27N2O2 315.2067 [M+H]
+ found 315.2069. 
6-(Bromomethyl)-4-ethyl-1H-indazole (186) 
 
Prepared according to general procedure H using (4-ethyl-1-(tetrahydro-2H-pyran-2-
yl)-1H-indazol-6-yl)methanol (258 mg, 0.99 mmol), SOBr2 (179 μL, 2.30 mmol), DMF (9 
μL, 0.12 mmol) in DCM (30 mL) followed by MeOH.HCl (1.25 M, 5 mL). The product 
was isolated as an off white solid (153 mg, 64%). 
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m.p. 104-106 oC; UV λmax (EtOH/nm) 263.6, 219.8, 292.2; IR νmax/cm
-1 3084, 2968, 2875; 
1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.29 (3H, t, J = 7.6 Hz, H-13), 2.92 (2H, q, J = 7.6 
Hz, H-12), 4.88 (2H, s, H-10), 6.97 (1H, s, H-6), 7.44 (1H, s, H-8), 8.14 (1H, s, H-3); 13C-
NMR (125 MHz, DMSO-d6) δ ppm;  15.3 (C-13), 26.6 (C-12), 63.6 (C-10), 105.2 (C-8), 
118.1 (C-6), 121.9 (C-4), 132.3 (C-3), 136.7 (C-5), 140.8 (C-9), 141.7 (C-7);  MS (ES+) m/z 
238.2 [M+H]+. 
6-(Bromomethyl)-4-cyclopropyl-1H-indazole (187) 
 
Prepared according to general procedure H using (4-cyclopropyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)methanol (720 mg, 2.65 mmol), SOBr2 (410 μL, 5.29 mmol), 
DMF (20 μL, 0.27 mmol) in DCM (65 mL) followed by MeOH.HCl (1.25 M, 10 mL). The 
product was isolated a white solid (573 mg, 91%). 
Rf 0.51 (Et2O); UV λmax (EtOH/nm) 296.4, 266.8, 220.2; IR νmax/cm
-1 3172, 3111, 2996, 
2855; 1H-NMR (500 MHz, CDCl3) δ ppm 0.91-0.95 (2H, m, H-13), 1.08-1.12 (2H, m, H-
13), 2.24-2.28 (1H, m, H-12), 4.58 (2H, s, H-10), 6.80 (1H, s, H-6), 7.32 (1H, s, H-8), 8.18 
(1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm;  8.5 (C-13),  13.5 (C-12), 34.2 (C-10), 
107.2 (C-8), 117.8 (C-6), 123.5 (C-4), 133.7 (C-3), 136.9 (C-7), 138.5 (C-5), 140.1 (C-9); 
MS (ES+) m/z 253.2 [M+H]+; HRMS calcd for C11H12BrN2 251.0178 & 253.0158 [M+H]
+ 
found 251.1018 & 253.0159. 
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4-Ethyl-6-((phenylthio)methyl)-1H-indazole (188) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-ethyl-1H-indazole 
(45 mg, 0.19 mmol) and lithium thiophenolate (1 M in THF, 0.28 mL, 0.28 mmol) in 
DMF (3 mL). The product was isolated a white solid (45 mg, 89%). 
UV λmax (EtOH/nm) 205.0, 264.2, 302.4; IR νmax/cm
-1 33186, 2965, 2931, 2870; 1H-NMR 
(500 MHz, CDCl3) δ ppm; 1.23 (3H, t, J = 7.7 Hz, H-17), 2.84 (2H, q, J = 7.7 Hz, H-16), 
4.15 (2H, s, H-10), 6.45 (1H, s, H-6), 7.16 (1H, s, H-8), 7.22 (1H, tt, J = 1.1, 8.1 Hz, H-15), 
7.28-7.1 (2H, m, H-14), 7.85 (1H, s, H-3), 7.46-7.50 (1H, m, H-13); 13C-NMR (125 MHz, 
CDCl3) δ ppm; 14.6 (C-17), 26.2 (C-16), 63.9 (C-10), 109.7 (C-8), 121.7 (C-6), 126.02 (C-
4), 127.2 (C-5), 127.5 (C-13), 129.0 (C-14), 130.9 (C-3), 131.3 (C-15), 135.4 (C-7), 137.0 
(C-12), 138.8 (C-9); MS (ES+) m/z 269.2 [M+H]+; HRMS calcd for C16H16N2S 269.1112 
[M+H]+ found 269.1109. 
4-Ethyl-6-((thiophen-2-ylthio)methyl)-1H-indazole (189) 
 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-ethyl-1H-indazole 
(45 mg, 0.19 mmol), Cs2CO3 (67 mg, 0.21 mmol) and 2-thiolthiophene (27 μL, 0.28 
mmol) in DMF (6 mL). The product was isolated a grey solid (33 mg, 63%). 
UV λmax (EtOH/nm) 219.1, 215.8; IR νmax/cm
-1 3172, 3101, 2962, 2972; 1H-NMR (500 
MHz, CDCl3) δ ppm; 1.34 (3H, t, J = 7.6 Hz, H-18) 2.94 (2H, q, J = 7.6Hz, H-17), 4.05 (2H, 
s, H-10), 6.86 (1H, s, H-6), 6.88-6.92 (2H, m, H-15, H-16), 7.05 (1H, s, H-8), 7.31 (1H, dd, 
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J = 1.2, 5.2 Hz, H-14), 8.10 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm;  14.7 (C-18), 
26.3 (C-17), 44.4 (C-10), 107.4 (C-8), 120.0 (C-6), 127.5 (C-15), 129.9 (C-14), 133.4 (C-3), 
134.5 (C-16), 137.3 (C-3), 137.8 (C-7), 140.4 (C-9);  MS (ES+) m/z 275.1 [M+H]+; HRMS 
calcd for C14H15N2S 275.0675 [M+H]
+ found 275.0671. 
4-Ethyl-6-(((4-methoxyphenyl)thio)methyl)-1H-indazole (190) 
 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-ethyl-1H-indazole 
(45 mg, 0.19 mmol), Cs2CO3 (67 mg, 0.21 mmol) and 4-methoxythiophenol (35 μL, 0.28 
mmol) in DMF (4 mL). The product was isolated as a white solid (34 mg, 61%). 
UV λmax (EtOH/nm) 263.6, 219.8, 292.2; IR νmax/cm
-1 3177, 3103, 2930, 1491, 1241; 1H-
NMR (500 MHz, CDCl3) δ ppm; 1.34 (3H, t, J = 7.6 Hz, H-19), 2.93 (2H, q, J = 7.6 Hz, H-
18), 3.77 (3H, s, H-17), 4.08 (2H, s, H-10), 6.77 (2H, d, J = 8.9 Hz, H-14), 6.87 (1H, s, H-6),  
7.08 (1H, s, H-8), 7.24 (2H, d, J = 8.9 Hz, H-13), 8.08 (1H, s, H-3); 13C-NMR (125 MHz, 
CDCl3) δ ppm;  14.7 (C-19), 26.3 (C-18), 41.8 (C-10), 55.5(C-17), 107.2 (C-8), 114.5 (C-
14), 121.0 (C-6), 122.0 (C-4), 125.8 (C-5), 126.3 (C-12), 133.1 (C-3), 134.3 (C-13), 137.9 
(C-7), 140.3 (C-9) 159.3 (C-15); MS (ES+) m/z 299.3 [M+H]+; HRMS calcd for C17H19N2OS 
299.1213 [M+H]+ found 299.1213. 
8-(((4-Ethyl-1H-indazol-6-yl)methyl)thio)quinoline (191) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-ethyl-1H-indazole 
(50 mg, 0.21 mmol), Cs2CO3 (143 mg, 0.44 mmol) and 8-quinolinethiol hydrochloride 
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(62 mg, 0.31 mmol) in DMF (2 mL). The product was isolated as a white solid (54 mg, 
81%). 
Rf 0.45 (EtOAc /Petrol, 1:1); UV λmax (EtOH/nm) 335.8, 292.0, 252.6, 205.8; 
1H-NMR 
(500 MHz, CDCl3) δ ppm; 1.33 (3H, t, J = 7.7 Hz,  H-23), 2.92 (2H, q, J = 7.2 Hz, H-22), 
4.42 (2H, s, H-10),  7.02 (1H, s, H-6), 7.44-7.47 (2H, m, H-8, H-20), 7.51 (1H, dd, J = 8.6, 
4.5 Hz, H-16), 8.05 (1H, dd, J = 7.0 Hz, H-19), 7.65 (1H, dd, J = 7.8 Hz, H-21), 8.22 (1H, 
dd, J = 8.6 Hz, H-17), 9.05 (1H, s, H-3); MS (ES+) m/z 320.3 [M+H]+. 
4-Cyclopropyl-6-((phenylthio)methyl)-1H-indazole (192) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (100 mg, 0.40 mmol) and lithium thiophenolate (1M in THF, 1.2 mL, 1.20 
mmol) in DMF (6 mL). The product was isolated a white solid (108 mg, 97%). 
Rf 0.69 (Et2O); m.p. 87-89 
oC; UV λmax (EtOH/nm) 292.4, 257.0, 218.8; IR νmax/cm
-1 3108, 
3049, 2996, 2851; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.86 (2H, m, H-17), 1.06 (2H, m, H-
17), 2.22 (1H, m, H-16), 4.18 (2H, s, H-10), 6.71 (1H, s, H-6), 7.18-7.20 (2H, m, H-8, H-
15), 7.24-7.26 (2H, m, H-14), 7.29-7.31 (2H, m, H-13), 8.16 (1H, s, H-3); 13C-NMR (125 
MHz, CDCl3) δ ppm; 8.4 (C-17), 13.4 (C-16), 39.7 (C-10), 106.8 (C-8), 117.9 (C-6), 122.5 
(C-4), 126.6 (C-15), 128.9 (C-13), 130.1 (C-14), 133.1 (C-3), 136.1 (C5-), 137.3 (C-7), 
137.9 (C-12), 140.2 (C-9);  MS (ES+) m/z 281.4 [M+H]+; HRMS calcd for C17H16N2S 
281.1107 [M+H]+ found 281.1107. 
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4-Cyclopropyl-6-((thiophen-2-ylthio)methyl)-1H-indazole (193) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (100 mg, 0.40 mmol), Cs2CO3 (143 mg, 0.44 mmol) and 2-thiolthiophene (56 
μL, 0.60 mmol) in DMF (6 mL). The product was isolated a grey solid (111 mg, 98%). 
Rf 0.63 (Et2O); m.p. 79-81 
oC; UV λmax (EtOH/nm)  217.6; IR νmax/cm
-1 3177, 3112, 3055, 
2997, 2925, 2883, 1620; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.84-0.87 (2H, m, H-18), 
1.04-1.07 (2H, m, H-18), 2.20-2.26 (1H, m, H-17), 4.02 (2H, s, H-10), 6.59 (1H, s, H-6), 
6.82-6.91 (2H, m, H-15, H-16), 7.02 (1H, s, H-8), 7.30 (1H, dd, J = 1.3, 5.1 Hz, H-14), 8.17 
(1H, s, H-3), 10.49 (1H, s-br, H-1); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.5 (C-18), 13.4 (C-
17), 44.4 (C-10), 107.0 (C-8), 117.7 (C-6), 122.7 (C-4), 127.5 (C-15), 129.9 (C-14), 133.4 
(C-3), 134.5 (C-16), 136.9 (C-7), 137.7 (C-5), 140.3 (C-9);  MS (ES+) m/z 287.2 [M+H]+; 
HRMS calcd for C15H14N2S2 287.0671 [M+H]
+ found 287.0671. 
4-Cyclopropyl-6-(((4-methoxyphenyl)thio)methyl)-1H-indazole (194) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (100 mg, 0.40 mmol), Cs2CO3 (143 mg, 0.44 mmol) and 4-methoxythiophenol 
(74 μL, 0.60 mmol) in DMF (6 mL). The product was isolated a white solid (105 mg, 
85%). 
Rf 0.64 (Et2O); IR νmax/cm
-1 3177, 3000, 1588, 1498, 1241; 1H-NMR (500 MHz, CDCl3) δ 
ppm; 0.84 (2H, m, H-19), 1.04 (2H, m, H-19), 2.21 (1H, m, H-18), 3.76 (3H, s, H-17), 4.04 
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(2H, s, H-10), 6.61 (1H, s, H-6), 6.79 (2H, d, J = 8.7 Hz, H-14), 7.04 (1H, s, H-8), 7.23 (2H, 
d, J = 8.9 Hz, H-13), 8.16 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm;  8.4 (C-19), 13.2 
(C-18), 41.8 (C-10), 55.4 (C-17), 106.8 (C-8), 114.5 (C-14), 117.8 (C-6), 122.5 (C-4), 125.9 
(C-5), 132.7 (C-12), 133.3 (C-3), 134.3 (C-13), 137.6 (C-7), 140.3 (C-9) 159.3 (C-15); MS 
(ES+) m/z 311.4 [M+H]+; HRMS calcd for C18H18N2OS 311.1213 [M+H]
+ found 311.1212. 
4-Ethyl-6-((phenylsulfonyl)methyl)-1H-indazole (196) 
 
 
Prepared according to general procedure K using 4-ethyl-6-((phenylthio)methyl)-1H-
indazole (35 mg, 0.13 mmol) and Oxone® (240 mg, 0.78 mmol) in MeOH (3 mL) and 
H2O (3 mL). The product was isolated as an off white solid (31 mg, 79%). 
Rf 0.42 (Et2O); m.p. 76-78 
oC; UV λmax (EtOH/nm) 294.2, 215.6; IR νmax/cm
-1 3341, 2966, 
1622, 1305, 1147, 1083, 686; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.15 (3H, t, J = 7.5 
Hz, H-17), 2.79 (2H, q, J = 7.5 Hz, H-16), 4.77 (2H, s, H-10), 6.54 (1H, s, H-6), 7.21 (1H, s, 
H-8), 7.57 (2H, dd, J = 7.4, 8.4 Hz, H-14), 7.70-7.73 (3H, m, H-15, H-13), 8.11 (1H, s, H-3), 
13.05 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 14.5 (C-17), 25.5 (C-16), 
61.1 (C-10), 110.3 (C-8), 121.1 (C-6), 122.2 (C-4), 126.5 (C-5), 128.1 (C-13), 129.0 (C-14), 
132.1 (C-3), 133.7 (C-15), 136.1 (C-7), 138.4 (C-12), 139.8 (C-9);  MS (ES+) m/z 301.3 
[M+H]+; HRMS calcd for C16H17N2O2S 301.1005 [M+H]
+ found 301.1008. 
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4-Ethyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (198) 
 
 
Prepared according to general procedure K using 4-ethyl-6-((thiophen-2-
ylthio)methyl)-1H-indazole (20 mg, 0.07 mmol) and Oxone® (134 mg, 0.44 mmol) in 
MeOH (2.5 mL) and H2O (2.5 mL). The product was isolated as a grey solid (17 mg, 
75%). 
Rf 0.37 (Et2O); m.p. 90-92 
oC; UV λmax (EtOH/nm) 294.2, 257.2, 215.8; IR νmax/cm
-1 3166, 
3103, 1593, 1496, 1252, 1136, 1084, 829, 696; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.26 
(3H, t, J = 7.5 Hz, H-18) 2.88 (2H, q, J = 7.5 Hz, H-17), 4.51 (2H, s, H-10), 6.63 (1H, s, H-6), 
7.03 (1H, dd, J = 3.9, 4.8 Hz, H-15), 7.23 (1H, s, H-8), 7.36 (1H, dd, J = 1.8, 3.9 Hz, H-16), 
7.64 (1H, dd, J = 4.8, 1.8 Hz, H-14), 8.16 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm;  
14.7 (C-18), 26.2 (C-17), 64.5 (C-10), 109.0 (C-8), 122.0 (C-6), 127.2 (C-4), 127.7 (C-15), 
134.4 (C-14), 134.9 (C-16), 138.6 (C-3), 140.4 (C-9) not all carbons visible;  MS (ES+) m/z 
307.3 [M+H]+. 
4-Ethyl-6-(((4-methoxyphenyl)sulfonyl)methyl)-1H-indazole (200) 
 
 
Prepared according to general procedure K using 4-ethyl-6-(((4-
methoxyphenyl)thio)methyl)-1H-indazole (20 mg, 0.07 mmol) and Oxone® (124 mg, 
0.40 mmol) in MeOH (2.5 mL) and H2O (2.5 mL). The product was isolated as a white 
solid (21 mg, 95%). 
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Rf 0.39 (Et2O); m.p. 169-171 
oC; UV λmax (EtOH/nm) 293.8, 241.8, 216.6; IR νmax/cm
-1 
3337, 2965, 1592; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.23 (3H, t, J = 7.6 Hz, H-19), 2.85 
(2H, q, J = 7.6 Hz, H-18), 3.83 (3H, s, H-17), 4.39 (2H, s, H-10), 6.54 (1H, s, H-6), 6.87 (2H, 
d, J = 8.9 Hz, H-14), 7.21 (1H, s, H-8), 7.54 (2H, d, J = 8.9 Hz, H-13), 8.08 (1H, s, H-3); 13C-
NMR (125 MHz, CDCl3) δ ppm;  14.7 (C-19), 26.1 (C-18), 55.7 (C-17), 63.5 (C-10), 109.9 
(C-8), 114.1 (C-14), 122.1 (C-6), 122.9 (C-4), 127.5 (C-5), 129.5 (C-12), 130.9 (C-13), 
133.4 (C-3), 137.8 (C-7), 140.1 (C-9) 163.8 (C-15); MS (ES+) m/z 331.4 [M+H]+. 
8-(((4-Ethyl-1H-indazol-6-yl)methyl)sulfonyl)quinoline (202) 
 
Prepared according to general procedure K using 8-(((4-ethyl-1H-indazol-6-
yl)methyl)thio)quinoline (44 mg, 0.14 mmol) and Oxone® (125 mg, 0.83 mmol) in 
MeOH (2.5 mL) and H2O (2.5 mL). The product was isolated as a white solid (39 mg, 
86%). 
m.p. 226-229 oC; UV λmax (EtOH/nm) 254.8, 215.8; IR νmax/cm
-1 3313, 2930, 1295, 1118; 
1H-NMR (500 MHz, CDCl3) δ ppm; 1.06 (3H, t, J = 7.6 Hz,  H-23), 2.74 (2H, q, J = 7.6 Hz, 
H-22), 5.26 (2H, s, H-10),  6.56 (1H, s, H-6), 7.20 (1H, s, H-8), 7.53 (1H, dd, J = 7.6, 8.1 Hz, 
H-20), 7.64 (1H, dd, J = 8.3, 4.3 Hz, H-16), 7.99 (1H, s, H-3), 8.05 (1H, dd, J = 1.4, 8.3 Hz, 
H-19), 8.25 (1H, dd, J = 7.6, 1.4 Hz, H-21), 8.31 (1H, dd, J = 8.3, 1.7 Hz, H-17), 9.26 (1H, 
dd, J = 4.3, 1.7 Hz, H-15); 13C-NMR (125 MHz, CDCl3) δ ppm 14.4 (C-23), 25.9 (C-22), 
62.0 (C-10), 109.7 (C-8), 121.8 (C-6), 122.3 (C-4), 122.9 (C-16), 125.7 (C-20), 127.5 (C-
12), 128.8 (C-18), 132.8 (C-21), 134.3 (C-19), 135.4 (C-3), 136.8 (C-17), 137.6 (C-5), 
144.4 (C-13), 151.6 (C-15);  MS (ES+) m/z 352.3 [M+H]+. 
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4-Cyclopropyl-6-((phenylsulfonyl)methyl)-1H-indazole (197) 
 
 
Prepared according to general procedure K using 4-cyclopropyl-6-((phenylthio)methyl)-
1H-indazole (92 mg, 0.33 mmol) and Oxone® (607 mg, 1.98 mmol) in MeOH (6 mL) and 
H2O (4 mL). The product was isolated as an off white solid (103 mg, 99%). 
Rf 0.35 (Et2O); m.p. 155-157 
oC; UV λmax (EtOH/nm) 297.4, 261.4, 225.2, 221.4; IR 
νmax/cm
-1 3348, 3178, 2924, 1620; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.63 (2H, m, H-17), 
1.00 (2H, m, H-17), 2.14 (1H, m, H-16), 4.38 (2H, s, H-10), 6.24 (1H, s, H-6), 7.17 (1H, s, 
H-8), 7.43 (2H, dd, J = 7.6, 7.9 Hz, H-14), 7.59-7.63 (3H, m, H-15, H-13), 8.17 (1H, s, H-3); 
13C-NMR (125 MHz, CDCl3) δ ppm; 8.5 (C-17), 13.1 (C-16), 63.3 (C-10), 109.5 (C-8), 
118.7 (C-6), 123.6 (C-4), 127.0 (C-5), 128.7 (C-13), 128.9 (C-14), 133.7 (C-3), 133.8 (C-
15), 137.9 (C-7), 139.0 (C-12), 139.9 (C-9);  MS (ES+) m/z 313.4 [M+H]+; HRMS calcd for 
C17H16N2O2S 313.1005 [M+H]
+ found 313.1004. 
4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (199) 
 
 
Prepared according to general procedure K using 4-cyclopropyl-6-((thiophen-2-
ylthio)methyl)-1H-indazole (110 mg, 0.38 mmol) and Oxone® (710 mg, 2.30 mmol) in 
MeOH (5 mL) and H2O (5 mL). The product was isolated as a pink solid (111 mg, 91%). 
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Rf 0.49 (Et2O); m.p. 114-116 
oC; UV λmax (EtOH/nm) 297.4, 258.8, 217.2; IR νmax/cm
-1 
3338, 3099, 2921,2852, 1620; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.70 (2H, m, H-18), 
1.02 (2H, m, H-18), 2.16 (1H, m, H-17), 4.47 (2H, s, H-10), 6.33 (1H, s, H-6), 7.03 (1H, dd, 
J = 3.8, 4.8 Hz, H-15), 7.22 (1H, s, H-8), 7.35 (1H, dd, J = 1.2, 3.8 Hz, H-16), 7.64 (1H, dd, 
J = 4.8, 1.2 Hz, H-14), 8.18 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.6 (C-18), 
13.2 (C-17), 64.5 (C-10), 109.6 (C-8), 118.5 (C-6), 123.6 (C-4), 127.0 (C-5) 127.7 (C-15), 
133.5 (C-3), 133.9 (C-14), 134.9 (C-16), 138.2 (C-7), 138.5 (C-12);  MS (ES+) m/z 319.3 
[M+H]+; HRMS calcd for C15H14N2O2S2 319.0569 [M+H]
+ found 319.0570. 
4-Cyclopropyl-6-(((4-methoxyphenyl)sulfonyl)methyl)-1H-indazole (201) 
 
 
Prepared according to general procedure K using 4-cyclopropyl-6-(((4-
methoxyphenyl)thio)methyl)-1H-indazole (84 mg, 0.27 mmol) and Oxone® (497 mg, 
1.62 mmol) in MeOH (6 mL) and H2O (4 mL). The product was isolated as a white solid 
(32 mg, 34%). 
Rf 0.34 (Et2O); m.p. 192-194 
oC; UV λmax (EtOH/nm) 296.4, 241.2, 217.2, 202.6; IR 
νmax/cm
-1 3345, 2922, 1591; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.66 (2H, m, H-19), 1.01 
(2H, m, H-19), 2.16 (1H, m, H-18), 3.85 (3H, s, H-17), 4.35 (2H, s, H-10), 6.26 (1H, s, H-6), 
6.88 (2H, d, J = 8.9 Hz, H-14), 7.15 (1H, s, H-8), 7.51 (2H, d, J = 8.9 Hz, H-13), 8.17 (1H, s, 
H-3); 13C-NMR (125 MHz, CDCl3) δ ppm;  8.5 (C-19), 13.1 (C-18), 55.7 (C-17), 63.5 (C-10), 
109.4 (C-8), 114.1 (C-14), 118.9 (C-6), 123.2 (C-4), 127.5 (C-5), 129.4 (C-12), 130.9 (C-
13), 133.6 (C-3), 137.9 (C-7), 139.8 (C-9) 163.8 (C-15); MS (ES+) m/z 343.4 [M+H]+; 
HRMS calcd for C18H18N2O3S 343.1111 [M+H]
+ found 343.1110. 
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8-(((4-cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)quinolone (203) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (100 mg, 0.40 mmol), Cs2CO3 (274 mg, 0.84 mmol) and 8-quinolinethiol 
hydrochloride (119 mg, 0.60 mmol) in DMF (4 mL). 8-(((4-cyclopropyl-1H-indazol-6-
yl)methyl)thio)quinoline was isolated as a white solid (94 mg, 70%). Isolated material 
was used in the next step without characterisation according to general procedure K 
using 8-(((4-cyclopropyl-1H-indazol-6-yl)methyl)thio)quinoline (84 mg, 0.28 mmol) and 
Oxone® (258 mg, 1.69 mmol) in MeOH (4 mL) and H2O (4 mL). The title product was 
isolated as a white solid (85 mg, 97%). 
m.p. 225-227 oC; UV λmax (EtOH/nm) 295.4, 252.4, 205.2; IR νmax/cm
-1 3174, 2995, 
1354, ; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.37-0.38 (2H, m, H-23), 0.85-0.88 (2H, m, H-
23), 2.01-2.04 (1H, m, H-22), 5.21 (2H, s, H-10),  6.23 (1H, s, H-6), 7.17 (1H, s, H-8), 7.52 
(1H, dd, J = 7.6, 7.6 Hz, H-20), 7.64 (1H, dd, J = 8.3, 4.2 Hz, H-16),  8.05-8.06 (1H, m, H-
19, H-3), 8.22 (1H, dd, J = 7.6, 1.4 Hz, H-21), 8.31 (1H, dd, J = 8.3, 1.7 Hz, H-17), 9.25 
(1H, dd, J = 4.2, 1.7 Hz, H-15); 13C-NMR (125 MHz, CDCl3) δ ppm 8.32 (C-23), 21.9 (C-22), 
62.0 (C-10), 109.4 (C-8), 118.5 (C-6), 122.3 (C-4, C-16), 125.7 (C-20), 127.5 (C-12), 128.8 
(C-18), 132.8 (C-21), 134.3 (C-19), 135.3 (C-3), 136.9 (C-17), 137.6 (C-5), 144.4 (C-13), 
151.6 (C-15);  MS (ES+) m/z 332.3 [M+H]+. 
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4-Cyclobutyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (204) 
 
 
Prepared according to general procedure H using: (4-Cyclobutyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)methanol (49 mg, 0.17 mmol), SOBr2 (27 µL, 0.34 mmol) 
and DMF (2 µL, 0.02 mmol) in DCM (10 mL). Crude material was engaged in general 
procedure I using:  Cs2CO3 (45 mg, 0.14 mmol) and 2-thiolthiophene (10 μL, 0.11 mmol) 
in DMF (4 mL). Crude material was engaged in general procedure K using: Oxone® (30 
mg, 0.05 mmol) in MeOH (2 mL) and H2O (2 mL). The product was isolated as a light 
grey solid (6 mg, 11% over three steps). 
UV λmax (EtOH/nm) 295.0, 257.0, 216.2; IR νmax/cm
-1 2952, 1035; 1H-NMR (500 MHz, 
CDCl3) δ ppm; 1.22-1.27 (1H, m, H-19), 1.90-1.93 (1H, m, H-19), 2.14-2.22 (3H, m, H-18, 
H-17), 2.44-2.49 (2H, m, H-18), 4.55 (2H, s, H-10), 6.94 (1H, s, H-6), 7.09 (1H, dd, J = 3.9, 
4.8 Hz, H-15), 7.37 (1H, s, H-8), 7.45 (1H, d, J =  3.9 Hz, H-16), 7.70 (1H, dd, J = 4.8 Hz, H-
14); 13C-NMR (125 MHz, CDCl3) δ ppm; 18.6 (C-19), 29.0 (C-18), 37.8 (C-17), 64.5 (C-10), 
127.9 (C-15), 134.8 (C-16), 135.0 (C-14);  MS (ES+) m/z 333.3 [M+H]+. 
4-Cyclohexyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (206) 
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Prepared according to general procedure H using: (4-Cyclobutyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)methanol (89 mg, 0.28 mmol), SOBr2 (44 µL, 0.34 mmol) 
and DMF (3 µL, 0.04 mmol) in DCM (10 mL). Crude material was engaged in general 
procedure I using:  Cs2CO3 (45 mg, 0.14 mmol) and 2-thiolthiophene (10 μL, 0.11 mmol) 
in DMF (4 mL). Crude material was engaged in general procedure K using: Oxone® (30 
mg, 0.05 mmol) in MeOH (2 mL) and H2O (2 mL). The product was isolated as a grey 
solid (9 mg, 9% over three steps). 
UV λmax (EtOH/nm) 304.5, 294.5, 256.5, 216.0; IR νmax/cm
-1 3363, 2924,2851, 1147, 
1009; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.28-1.32 (1H, m, H-20), 1.44-1.47 (4H, m, H-
18, H19), 1.79-1.82 (1H, m, H-20), 1.87-1.91 (4H, m, H-18, H-19), 2.87-2.91 (1H, m, H-
17), 4.53 (2H, s, H-10), 6.86 (1H, s, H-6), 7.06 (1H, dd, J = 3.8, 4.8 Hz, H-15), 7.38-7.40 
(2H, ms, H-8, H-16), 7.66 (1H, d, J = 4.8 Hz, H-14; 13C-NMR (125 MHz, CDCl3) δ ppm; 
26.1 (C-20), 26.7 (C-19), 33.7 (C-18), 42.1 (C-17), 64.5 (C-10), 111.5 (C-8), 121.8 (C-6), 
127.8 (C-15), 130.6 (C-5), 134.7 (C-14), 135.0 (C-16), 138.5 (C-12);  MS (ES+) m/z 361.2 
[M+H]+. 
4-Cyclopropyl-6-(difluoro(thiophen-2-ylsulfonyl)methyl)-1H-indazole (211) 
 
4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (85 mg, 0.27 mmol) was 
dissolved in anhydrous THF (3 mL) at -78 oC and N-fluorobenzenesulfonimide (NFSI) 
(185 mg, 0.59 mmol) was added followed by n-BuLi (2.5 M in hexanes, 342 μL, 0.86 
mmol) dropwise over ca. 10 minutes. The solution was stirred at -78 oC for 2 h then 
allowed to warm to room temperature and stirred for a further 16 h after which the 
reaction was quenched with NH4Cl solution (saturated aqueous, 5 mL) and extracted 
with EtOAc ( 3 x 10 mL). Combined organic fractions were washed with brine (10 mL), 
dryed over Na2SO4 and reduced in vacuo. Reverse phase flash chromatography (0-80 % 
MeCN (0.1% HCOOH) in H2O (0.1% HCOOH) was performed to give the title compound 
as a white solid (47 mg, 49%). 
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Rf 0.53 (Et2O); m.p. 170-172 
oC; UV λmax (EtOH/nm) 305.6, 262.8, 217.6; IR νmax/cm
-1 
3273, 3114, 1337, 1165; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.93 (2H, m, H-18), 1.13 (2H, 
m, H-18), 2.30 (1H, m, H-17), 6.98 (1H, s, H-6), 7.27 (1H, dd, J = 3.9, 5.0 Hz, H-15), 7.69 
(1H, s, H-8), 7.85 (1H, dd, J = 1.3, 3.9 Hz, H-16), 7.92 (1H, dd, J = 5.0, 1.3 Hz, H-14), 8.28 
(1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.8 (C-18), 13.6 (C-17), 107.7 (C-8), 
114.9 (C-6), 122.0 (C-4), 125.0 (C-7) 128.4 (C-15), 132.4 (C-12), 133.9 (C-3), 137.6 (C-14), 
138.3 (C-16), 138.8 (C-5); 19F NMR (470 MHz, CDCl3) δ -100.4;   MS (ES
+) m/z 355.3 
[M+H]+. 
4-Cyclopropyl-6-(difluoro(thiophen-2-ylsulfonyl)methyl)-1H-indazole (212) 
 
4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (200 mg, 0.63 mmol) was 
dissolved in anhydrous THF (7 mL) at -78 oC and N-fluorobenzenesulfonimide (NFSI) 
(435 mg, 1.38 mmol) was added followed by n-BuLi (2.5 M in hexanes, 880 μL, 0.22 
mmol) dropwise over ca. 10 minutes. The solution was stirred at -78 oC for 2 h then 
allowed to warm to room temperature and stirred for a further 16 h after which the 
reaction was cooled back down to -78 oC and N-fluorobenzenesulfonimide (NFSI) (197 
mg, 0.63 mmol) was added followed by n-BuLi (2.5 M in hexanes, 251 μL, 0.63 mmol) 
and stirred for a further 3 h. The reaction was quenched with NH4Cl solution (saturated 
aqueous, 5 mL) and extracted with EtOAc (3 x 10 mL). Combined organic fractions were 
washed with brine (10 mL), dryed over Na2SO4 and reduced in vacuo. Reverse phase 
flash chromatography (0-80 % MeCN (0.1% HCOOH) in H2O (0.1% HCOOH) was 
performed to give the title compound as a white solid (70 mg, 33%). 
m.p. 168-170 oC; UV λmax (EtOH/nm) 306.0, 262.8, 218.0; IR νmax/cm
-1 3268, 3110, 1335, 
1163; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.78-0.86 (2H, m, H-18), 1.07-1.09 (2H, m, H-
18), 2.23-2.24 (1H, m, H-17), 6.15 (1H, s, H-10A), 6.24 (1H, s, H-10B), 6.71 (1H, s, H-6), 
7.16 (1H, dd, J = 3.9, 5.0 Hz, H-15), 7.26 (1H, s, H-8), 7.61 (1H, d, J = 3.0 Hz, H-16), 7.79 
(1H, d, J = 4.9 Hz, H-14), 8.33 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.8 (C-18), 
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13.6 (C-17), 122.0 (C-4), 125.0 (C-7) 128.4 (C-15), 132.4 (C-12), 133.9 (C-3), 137.6 (C-14), 
138.3 (C-16), 138.8 (C-5); 19F NMR (470 MHz, CDCl3) δ -172.4;   MS (ES
+) m/z 337.3 
[M+H]+; HRMS calcd for C15H14N2O2FS2 337.0475 [M+H]
+ found 337.0477. 
5-Chloro-4-cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (222) 
 
4-Cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (100 mg, 0.32 mmol) was 
dissolved in MeOH (3 mL) and a solution of brine (1 mL) Oxone® (193 mg, 0.63 mmol) 
and H2O (2 mL) was added. The resulting mixture was stirred overnight before dilution 
with H2O (10 mL) and extraction with EtOAc (3 x 10 mL). Combined organic fractions 
were dried over Na2SO4 and purified by MPLC (0-60 % EtOAc in petroleum ether) to 
yield the title compound as a white solid (40 mg, 36%) and three further compounds 
shown below. 
m.p. 192-194 oC; UV λmax (EtOH/nm) 317.0, 306.4, 256.4, 221.8; IR νmax/cm
-1 3421, 3088, 
1302, 1150; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.86-0.89 (2H, m, H-18), 1.09-1.13 
(2H, m, H-18), 2.15-2.18 (1H, m, H-17), 5.02 (2H, s, H-10), 7.21 (1H, dd, J = 3.8, 5.1 Hz, 
H-15), 7.47 (1H, s, H-8), 7.51 (1H, dd, J = 1.3, 3.8 Hz, H-16), 8.08 (1H, dd, J = 5.1, 1.3 Hz, 
H-14), 8.16 (1H, s, H-3) 13.33 (1H, s, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 8.1 (C-
18), 14.0 (C-17), 61.1 (C-10), 113.2 (C-8), 123.5 (C-6), 124.9 (C-4), 126.8 (C-7) 127.8 (C-
5), 128.7 (C-15), 132.6 (C-3), 133.6 (C-3), 135.5 (C-16), 136.5 (C-14), 138.4 (C-12);  MS 
(ES+) m/z 353.2 [M+H]+; HRMS calcd for C15H14N2O2
35ClS2 353.0180 [M+H]
+ found 
353.0183. 
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5,7-Dichloro-4-cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (223) 
 
Isolated from procedure above (222) as a white solid (25 mg, 21%). 
m.p. 210-212 oC; UV λmax (EtOH/nm) 312.8, 257.4, 222.0; IR νmax/cm
-1 3214, 3115, 1311, 
1154; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.90-0.93 (2H, m, H-18), 1.14-1.17 (2H, m, 
H-18), 2.16-2.22 (1H, m, H-17), 5.13 (2H, s, H-10), 7.25 (1H, dd, J = 3.8, 4.9 Hz, H-15), 
7.62 (1H, dd, J = 1.3, 3.8 Hz, H-16), 8.15 (1H, dd, J = 4.9, 1.3 Hz, H-14), 8.30 (1H, s, H-3) 
13.83 (1H, s, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 8.2 (C-18), 14.1 (C-17), 59.7 
(C-10), 116.9 (C-8), 122.9 (C-6), 124.0 (C-4), 128.7 (C-7) 129.0 (C-15), 133.2 (C-5), 134.0 
(C-3), 135.9 (C-16), 137.0 (C-14), 137.2 (C-9), 140.1 (C-12);  MS (ES+) m/z 387.1 [M+H]+; 
HRMS calcd for C15H13N2O2
35Cl2S2 386.9790 [M+H]
+ found 386.9791. 
3,5-Dichloro-4-cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (224) 
 
Isolated from procedure above (222) as a white solid (30 mg, 24%). 
m.p. 200-202 oC; UV λmax (EtOH/nm) 322.6, 311.2, 226.4; IR νmax/cm
-1 3243, 3083, 1314, 
1127; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.63-0.64 (2H, m, H-18), 1.15-1.17 (2H, m, 
H-18), 1.98-2.02 (1H, m, H-17), 5.02 (2H, s, H-10), 7.21 (1H, dd, J = 3.8, 5.1 Hz, H-15), 
7.48 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.56 (1H, s, H-8), 8.09 (1H, dd, J = 5.1, 1.3 Hz, H-14), 
13.58 (1H, s, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 10.5 (C-18), 11.9 (C-17), 60.8 
(C-10), 114.7 (C-8), 120.6 (C-4), 126.8 (C-7), 128.7 (C-15) 129.9 (C-6), 132.4 (C-3), 133.3 
(C-5), 135.7 (C-16), 136.7 (C-14), 138.9 (C-12) 139.9 (C-9);  MS (ES+) m/z 387.1 [M+H]+; 
HRMS calcd for C15H13N2O2
35Cl2S2 386.9790 [M+H]
+ found 386.9793. 
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3,5,7-Trichloro-4-cyclopropyl-6-((thiophen-2-ylsulfonyl)methyl)-1H-indazole (225) 
 
Isolated from procedure above (222) as a white solid (28 mg, 21%). 
m.p. 247-249 oC; UV λmax (EtOH/nm) 329.4, 317.0, 226.6; IR νmax/cm
-1 3373, 3096, 1320, 
1132; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.69-0.70 (2H, m, H-18), 1.20-1.22 (2H, m, 
H-18), 2.01-2.04 (1H, m, H-17), 5.13 (2H, s, H-10), 7.25 (1H, dd, J = 3.8, 4.9 Hz, H-15), 
7.61 (1H, dd, J = 1.3, 3.8 Hz, H-16), 8.15 (1H, dd, J = 5.1, 1.3 Hz, H-14), 14.09 (1H, s, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm; 10.6 (C-18), 11.9 (C-17), 59.5 (C-10), 118.2 (C-8), 
121.3 (C-6), 124.7 (C-4), 129.1 (C-15) 130.7 (C-7), 132.9 (C-5), 133.6 (C-3), 136.1 (C-16), 
137.2 (C-14), 138.4 (C-9) 139.8 (C-12);  MS (ES+) m/z 423.1 [M+H]+; HRMS calcd for 
C15H12N2O2
35Cl3S2 420.9400 [M+H]
+ found 420.9400. 
3-Bromo-6-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole (233)  
 
Prepared according to general procedure C using 3-bromo-6-nitro-1H-indazole (4.5 g, 
18.7 mmol), DHP (4.75 mL, 56.0 mmol) and p-TSA (355 mg, 1.87 mmol) in DCM (80 mL). 
The product was isolated as a pure white solid (5.24 g, 86%). 
Rf 0.41 (Et2O); M.p. 124-126 
oC; UV λmax (EtOH/nm) 339.4, 255.4, 207.8; IR νmax/cm
-1  
3073, 2941, 2865, 1523; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.67-1.81 ( 3H, m, H-5’A, H-
5’, H-4’), 2.11-2.17 (2H, m, H-4’, H-6’), 2.48-2.54 (1H, m, H-6’) 3.76-3.81 (1H, m, H-3’), 
4.00-4.04 (1H, m, H-3’), 5.77 (1H, dd, J = 2.3, 8.7 Hz, H-1’), 8.09 (1H, d, J = 8.9 Hz, H-6), 
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7.73 (1H, d, J = 8.9 Hz, H-5), 8.55 (1H, s, H-8); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.0 
(C-4’), 24.9 (C-5’), 29.3 (C-6’), 67.5 (C-3’), 86.3 (C-1’), 107.6 (C-8), 116.7 (C-6), 121.5 (C-
5), 122.1 (C-3), 127.6 (C-4), 139.3 (C-9), 147.5 (C-7);  MS (ES+) m/z 326.4 [M-H]-; HRMS 
calcd for C12H13BrN3O3 326.0135 & 328.0114 [M+H]
+ found 326.0139 & 328.0118. 
3-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine (234)  
 
Prepared according to general procedure E using 3-bromo-6-nitro-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole (428 mg, 1.32 mmol) in EtOAc (50 mL, 0.05M). The product 
was isolated as a brown solid, (380 mg, 98%). 
Rf 0.34 (Et2O); m.p. <60 
oC; UV λmax (EtOH/nm) 303.0, 285.4, 239.8, 220.2; IR νmax/cm
-1 
3449, 3351, 3226, 2936, 2936, 2851, 1623; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.61-1.63 
(1H, m, H-5’), 1.70 (2H, m, H-5’, H-4’), 2.00-2.04 (1H, m, H-6’), 2.12-2.14 (1H, m, H-4’), 
2.49-2.52 (1H, m, H-6’), 3.67-3.72 (1H, m, H-3’), 4.00-4.03 (1H, m, H-3’), 5.51 (1H, dd, J 
=2.7, 9.2 Hz, H-1’), 6.61 (1H, dd, J = 1.5, 8.5 Hz, H-6), 6.69 (1H, d, J = 1.5 Hz, H-8), 7.33 
(1H, d,  J = 8.5 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.5 (C-5’), 25.1 (C-4’), 29.2 
(C-6’), 67.4 (C-3’), 85.3 (C-1’), 92.9 (C-8), 113.6 (C-6), 118.2 (C-4), 121.2 (C-5), 122.2 (C-
3), 142.4 (C-9), 147.0 (C-7); MS (ES+) m/z 296.2 [M+H]+; HRMS calcd for C12H15BrN3O 
296.0393 & 298.0373 [M+H]+ found 296.0398 & 298.0375. 
 
 
 
 
 
 
321 
 
N-(3-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylbenzenesulfonamide (238) 
 
Formic acid (184 µL, 4.88 mmol) was added drop wise to acetic anhydride (238 µL, 2.44 
mmol) at 0oC and stirred for ca. five minutes before heating to 60oC and stirred for a 
further hour. The solution was allowed to cool and 3-bromo-1-(tetrahydro-2H-pyran-2-
yl)-1H-indazol-6-amine (360 mg, 1.22 mmol) in THF (20 mL) was added in one portion 
and stirred for 1 hour. After this time the solution was reduced to a white solid under 
vacuum. The crude N-(3-bromo-1H-indazol-6-yl)formamide  was suspended in THF (20 
mL) and borane (3.05 mL, 1M in THF, 3.05 mmol) was added. The solution was stirred 
under reflux for 16 hours then allowed to cool, volatiles were removed by rotary 
evaporator. The residue was suspended in methanolic HCl (1.25M, 6 mL) and heated to 
reflux for 3 hours. The solution was reduced to a residue and purified using MPLC (0-80% 
EtOAc in petroleum ether) giving 3-bromo-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-
indazol-6-amine as a white solid 195 mg, 51%. Isolated material was used in the in the 
next step with out characterisation according to general procedure A using 3-bromo-N-
methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine (285 mg, 0.92 mmol) in 
pyridine (10 mL) and benzenesulphonyl chloride (176 µL, 1.38 mmol) to give the 
product as an off white solid (373 mg, 90%). 
m.p. 59-61 oC; UV λmax (EtOH/nm) 295.6, 272.8, 216.0; IR νmax/cm
-1 2937, 2854; 1H-
NMR (500 MHz, CDCl3) δ ppm; 1.61-1.75 (3H, m, H-4’, H-5’, H-5’), 2.01-2.05 (1H, m, H-
6’), 2.10-2.12 (1H, m, H-4’), 2.45-2.48 (1H, m, H-6’), 3.23 (3H, s, H-16), 3.65-3.70 (1H, m, 
H-3’), 3.96-3.99 (1H, m, H-3’), 5.59 (1H, dd, J = 2.8, 9.5 Hz, H-1’), 6.81 (1H, dd, J = 8.6, 
1.8 Hz, H-6), 7.11 (1H, d, J = 1.8 Hz, H-8), 7.45-7.47 (3H, m, H-14, H-5), 7.56 (2H, dd, J = 
1.5, 8.8 Hz, H-13), 7.89 (1H, tt, J = 1.5, 8.6, H-15); 13C-NMR (125 MHz, CDCl3) δ ppm; 
22.3 (C-4’) 24.9 (C-5’), 29.3 (C-6’), 38.6 (C-16), 67.4 (C-3’), 85.6 (C-1’), 109.7 (C-8), 120.5 
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(C-6), 120.7 (C-5), 121.9 (C-5), 123.4 (C-3), 127.9 (C-13), 128.9 (C-14), 132.9 (C-15), 
136.4 (C-12), 140.4 (C-7), 141.2 (C-9);  MS (ES+) m/z 449.2 [M(79Br)+H]+. 
N-(3-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-sulfonamide 
(235) 
 
Prepared according to general procedure A using 3-bromo-1-(tetrahydro-2H-pyran-2-
yl)-1H-indazol-6-amine (1 g, 3.38 mmol) and 2-thiophenesulphonyl chloride (920 mg, 
5.06 mmol) in pyridine (10 mL) and (THF 10 mL)  to give the product as an off white 
solid (1.46 g, 98%). 
m.p. 74-76 oC; UV λmax (EtOH/nm) 292.6, 218.8, 257.4; IR νmax/cm
-1 3342, 3099, 2937, 
2859, 1332, 1155; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.53-1.60 (2H, m, H-4’),  1.75-
1.77 (1H, m, H-5’), 1.95-2.00 (2H, m, H-5’, H-6’), 2.23-2.29 (1H, m, H-6’), 3.68-3.73 (1H, 
m, H-3’), 3.84-3.87 (1H, m, H-3’), 5.71 (1H, dd, J = 2.0, 9.0 Hz, H-1’), 7.06 (1H, dd, J = 8.9, 
1.5 Hz, H-6), 7.11 (1H, dd, J = 4.9, 3.8 Hz, H-15), 7.47-7.49 (2H, m, H-8, H-5), 7.61 (1H, 
dd, J = 1.3, 3.8 Hz, H-16), 7.89 (1H, dd, J = 1.3, 4.9, H-14), 10.77 (1H, s-br, H-10); 13C-
NMR (125 MHz, DMSO-d6) δ ppm; 21.7 (C-4’) 24.7 (C-5’), 28.6 (C-6’), 66.4 (C-3’), 84.5 
(C-1’), 100.1 (C-8), 116.7 (C-6), 120.1 (C-4), 120.5 (C-5), 120.6 (C-3), 127.5 (C-15), 132.6 
(C-14), 133.3 (C-16), 138.5 (C-12), 140.1 (C-9), 140.7 (C-7); MS (ES+) m/z 442.8 
[M(79Br)+H]+. 
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N-(3-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-
sulfonamide (237) 
 
 
Formic acid (184 µL, 4.88 mmol) was added drop wise to acetic anhydride (238 µL, 2.44 
mmol) at 0oC and stirred for ca. five minutes before heating to 60oC and stirred for a 
further hour. The solution was allowed to cool and 3-bromo-1-(tetrahydro-2H-pyran-2-
yl)-1H-indazol-6-amine (360 mg, 1.22 mmol) in THF (20 mL) was added in one portion 
and stirred for 1 hour. After this time the solution was reduced to a white solid under 
vacuum. The crude N-(3-bromo-1H-indazol-6-yl)formamide  was suspended in THF (20 
mL) and borane (3.05 mL, 1M in THF, 3.05 mmol) was added. The solution was stirred 
under reflux for 16 hours then allowed to cool, volatiles were removed by rotary 
evaporator. The residue was suspended in methanolic HCl (1.25M, 6 mL) and heated to 
reflux for 3 hours. The solution was reduced to a residue and purified using MPLC (0-80% 
EtOAc in petroleum ether) giving 3-bromo-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-
indazol-6-amine as a white solid 195 mg, 51%. Isolated material was used in the in the 
next step with out characterisation according to general procedure A using 3-bromo-N-
methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-amine (173 mg, 0.56 mmol) in 
pyridine (6 mL) and 2-thiophenesulphonyl chloride (122 mg, 0.67 mmol) to give the 
product as white solid (137 mg, 54%). 
Or 
Prepared according to general procedure B with following reagents and quantities: 
methyliodide (56 µL, 0.90 mmol), K2CO3 (75 mg, 0.54 mmol) and N-(3-Bromo-1-
(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-sulfonamide (200 mg, 0.45 
mmol) in DMF (3 mL) this gave the title compound as a white solid (201 mg, 98%). 
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m.p. 95-97 oC; UV λmax (EtOH/nm) 296.6, 263.8, 218.2; IR νmax/cm
-1 3070, 2935, 2866, 
1349, 1148; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.62-1.76 (3H, m, H-4’, H5’),  2.04-2.07 
(1H, m, H-6’), 2.11-2.14 (1H, m, H-5’), 3.31 (3H, s, H-17), 3.68-3.73 (1H, m, H-3’), 3.97-
4.00 (1H, m, H-3’), 5.61 (1H, dd, J = 2.7, 9.0 Hz, H-1’), 6.87 (1H, dd, J = 8.6, 1.7 Hz, H-6), 
7.08 (1H, dd, J = 4.9, 3.8 Hz, H-15), 7.34 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.47 (1H, d, J = 
1.7 Hz, H-8), 7.50 (1H, d, J = 8.6 Hz, H-5), 7.60 (1H, dd, J = 1.3, 4.9, H-14); 13C-NMR (125 
MHz, CDCl3) δ ppm; 22.3 (C-4’) 25.0 (C-5’), 29.2 (C-6’), 38.7 (C-17), 67.4 (C-3’), 85.6 (C-
1’), 110.0 (C-8), 120.3 (C-6), 120.8 (C-5), 122.0 (C-4), 123.6 (C-3), 127.4 (C-15), 132.3 (C-
14), 133.0 (C-16), 136.6 (C-12), 140.4 (C-9), 140.9 (C-7); MS (ES+) m/z 455.2 
[M(79Br)+H]+. 
N-methyl-N-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-
yl)benzenesulfonamide (243) 
 
Prepared according to general procedure F using N-(3-bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylbenzenesulfonamide (50 mg, 0.11 mmol), trimethyl 
boroxine (16 µL, 0.11 mmol), Cs2CO3 (54 mg, 0.16 mmol) and Pd(dppf)Cl2.DCM (9 mg, 
0.01 mmol) in 1,4-dioxane (2 mL). The product was isolated as a white solid (42 mg, 
99%). 
m.p. 62-64 oC; UV λmax (EtOH/nm) 295.0, 265.6, 219.8; IR νmax/cm
-1 2927, 2854, 1345, 
1169; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.60-1.62 (1H, m, H5’), 1.71-1.73 (2H, m, H-4’, 
H5’), 1.99-2.01 (1H, m, H-6’), 2.10-2.24 (1H, m, H-4’), 2.48-2.50 (1H, m, H-6’), 2.54 (3H, 
s, H-17), 3.24 (3H, s, H-16), 3.67-3.71 (1H, m, H-3’), 4.03-4.05 (1H, m, H-3’), 5.61 (1H, 
dd, J = 2.4, 10.0 Hz, H-1’), 6.72 (1H, dd, J = 8.5, 1.6 Hz, H-6), ), 7.31 (1H, d, J = 1.6 Hz, H-
8), 7.46 (2H, dd, J = 8.2, 8.2 Hz, H-14), 7.49 (1H, d, J = 8.5 Hz, H-5), 7.57-7.60 (3H, m, H-
15, H-13); 13C-NMR (125 MHz, CDCl3) δ ppm; 12.0 (C-17), 22.9 (C-4’) 25.1 (C-5’), 29.7 
(C-6’), 38.8 (C-16), 67.9 (C-3’), 85.1 (C-1’), 109.3 (C-8), 119.1 (C-6), 120.6 (C-5), 123.3 (C-
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4), 128.0 (C-13), 128.8 (C-14), 132.7 (C-15), 136.7 (C-12), 140.0 (C-9), 140.3 (C-7), 142.7 
(C-3); MS (ES+) m/z 386.1 [M+H]+. 
N-(3-Cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylbenzenesulfonamide (244) 
 
Prepared according to general procedure F using N-(3-bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylbenzenesulfonamide (50 mg, 0.11 mmol), cyclopropyl 
borinc acid (29 mg, 0.33 mmol), Cs2CO3 (54 mg, 0.16 mmol) and Pd(dppf)Cl2.DCM (9 
mg, 0.01 mmol) in 1,4-dioxane (3 mL). The product was isolated as a white solid (33 mg, 
80%). 
m.p. 67-69 oC; UV λmax (EtOH/nm) 300.4, 217.6; IR νmax/cm
-1 2936, 2856, 1345, 1169; 
1H-NMR (500 MHz, CDCl3) δ ppm; 0.99-1.05 (4H, m, H-18), 1.59-1.61 (1H, m, H5’), 1.66-
1.73 (2H, m, H-5’, H-4’), 1.95-1.98 (1H, m, H-6’), 2.08-2.11 (1H, m, H-4’), 2.15-2.18 (1H, 
m, H-17), 2.43-2.46 (1H, m, H-6’), 3.24 (3H, s, H-16), 3.63-3.69 (1H, m, H-3’), 3.99-4.01 
(1H, m, H-3’), 5.51 (1H, dd, J = 2.7, 9.8 Hz, H-1’), 6.72 (1H, dd, J = 8.6, 1.7 Hz, H-6), 7.28 
(1H, J = 1.7 Hz, H-8), 7.46 (2H, dd, J = 7.6, 7.6 Hz, H-14), 7.56-7.60 (4H, m, H-13, H-15, 
H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 7.1 (C-18), 8.3 (C-17), 22.7 (C-4’) 25.1 (C-5’), 
29.4 (C-6’), 38.8 (C-17), 67.7 (C-3’), 85.4 (C-1’), 109.5 (C-8), 119.2 (C-6), 120.5 (C-5), 
122.8 (C-4), 128.0 (C-13), 128.7 (C-14), 132.7 (C-15), 136.7 (C-12), 139.9 (C-9), 140.4 (C-
7), 147.5 (C-3); MS (ES+) m/z 412.3 [M+H]+. 
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N-Methyl-N-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-
sulfonamide (239) 
 
Prepared according to general procedure F using N-(3-Bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (80 mg, 0.18 mmol), trimethyl 
boroxine (25 µL, 0.18 mmol), Cs2CO3 (86 mg, 0.26 mmol) and Pd(dppf)Cl2.DCM (14 mg, 
0.02 mmol) in 1,4-dioxane (3 mL). The product was isolated as a white solid (50 mg, 
71%). 
m.p. 59-61oC; UV λmax (EtOH/nm) 295.1, 242.6, 218.6; IR νmax/cm
-1 33092, 2928, 2853, 
1349, 1148; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.59-1.62 (1H, m, H-5’), 1.72-1.76 (2H, m, 
H-4’, H-5’), 2.00-2.03 (1H, m, H-6’), 2.11-2.13 (1H, m, H-4’), 2.47-2.53 (1H, m, H-6’), 
2.54 (3H, s, H-18), 3.31 (3H, s, H-17), 3.68-3.73 (1H, m, H-3’), 4.03-4.05 (1H, m, H-3’), 
5.55 (1H, dd, J = 2.4, 10.0 Hz, H-1’), 6.78 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.08 (1H, dd, J = 
4.8, 3.8 Hz, H-15), 7.34 (1H, dd, J = 1.0, 3.8 Hz, H-16), 7.36 (1H, d, J = 1.4 Hz, H-8), 7.52 
(1H, d, J = 8.6 Hz, H-5), 7.59 (1H, dd, J = 1.0, 4.8, H-14); 13C-NMR (125 MHz, CDCl3) δ 
ppm; 12.0 (C-18), 22.5 (C-4’) 25.1 (C-5’), 29.6 (C-6’), 38.9 (C-17),  67.9 (C-3’), 85.1 (C-1’), 
109.4 (C-8), 118.9 (C-6), 120.7 (C-5), 123.5 (C-4), 127.3 (C-15), 132.1 (C-14), 132.9 (C-
16), 136.9 (C-12), 139.7 (C-9), 140.3 (C-7), 142.7 (C-3); MS (ES+) m/z 392.3 [M+H]+. 
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N-(3-Ethyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-
sulfonamide (240) 
 
Prepared according to general procedure F using N-(3-Bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (80 mg, 0.18 mmol), ethyl 
borinc acid (39 mg, 0.53 mmol), Cs2CO3 (86 mg, 0.26 mmol) and Pd(dppf)Cl2.DCM (14 
mg, 0.02 mmol) in 1,4-dioxane (3 mL). The product was isolated as a white solid (50 mg, 
71%). 
m.p. 63-65 oC; UV λmax (EtOH/nm) 294.8, 256.3, 218.2; IR νmax/cm
-1 3089, 2935, 2856, 
1349, 1050; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 1.37 (3H, t, J = 7.3 Hz, H-19), 1.61-1.63 
(1H, m, H-5’), 1.72-1.75 (2H, m, H-4’, H-5’), 1.99-2.02 (1H, m, H-6’), 2.11-2.13 (1H, m, 
H-4’), 2.48-2.51 (1H, m, H-6’), 2.96 (2H, q, J = 7.3 Hz, H-18), 3.31 (3H, s, H-17), 3.68-3.72 
(1H, m, H-3’), 4.01-4.05 (1H, m, H-3’), 5.55 (1H, dd, J = 2.4, 9.9 Hz, H-1’), 6.79 (1H, dd, J 
= 8.7, 1.7 Hz, H-6), 7.09 (1H, dd, J = 4.8, 3.8 Hz, H-15), 7.34-7.36 (2H, m, H-8, H-16), 
7.56-7.60 (2H, m, H-14, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 13.5 (C-19), 20.5 (C-18), 
22.8 (C-4’) 25.1 (C-5’), 29.6 (C-6’), 38.9 (C-17),  67.9 (C-3’), 85.4 (C-1’), 109.5 (C-8), 
118.9 (C-6), 120.8 (C-5), 122.7 (C-4), 127.3 (C-15), 132.0 (C-14), 132.9 (C-16), 137.0 (C-
12), 139.6 (C-9), 140.4 (C-7), 147.8 (C-3); MS (ES+) m/z 406.2 [M+H]+. 
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N-(3-Cyclopropyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-
2-sulfonamide (241) 
 
Prepared according to general procedure F using N-(3-Bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (75 mg, 0.16 mmol), 
cyclopropyl borinc acid (42 mg, 0.49 mmol), Cs2CO3 (80 mg, 0.25 mmol) and 
Pd(dppf)Cl2.DCM (13 mg, 0.02 mmol) in 1,4-dioxane (3 mL). The product was isolated 
as a white solid (66 mg, 96%). 
m.p. 63-65 oC; UV λmax (EtOH/nm) 298.8, 219.0; IR νmax/cm
-1 3068, 2927, 2854, 1347, 
1168; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 0.99-1.05 (4H, m, H-18), 1.59-1.62 (1H, m, 
H5’), 1.69-1.73 (2H, m, H-5’, H-4’), 1.96-1.99 (1H, m, H-6’), 2.10-2.12 (1H, m, H-4’), 
2.14-2.18 (1H, m, H-17), 2.45-2.47 (1H, m, H-6’), 3.31 (3H, s, H-16), 3.66-3.70 (1H, m, H-
3’), 3.99-4.02 (1H, m, H-3’), 5.53 (1H, dd, J = 2.6, 9.8 Hz, H-1’), 6.78 (1H, dd, J = 8.6, 1.6 
Hz, H-6), 7.08 (1H, dd, J = 4.9, 3.8 Hz, H-15), 7.35 (2H, m, H-8, H-16), 7.58-7.60 (2H, m, 
H-14, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 7.1 (C-18), 8.3 (C-17), 22.7 (C-4’) 25.1 (C-
5’), 29.4 (C-6’), 38.9 (C-17), 67.7 (C-3’), 85.4 (C-1’), 109.6 (C-8), 119.0 (C-6), 120.7 (C-5), 
122.9 (C-4), 127.3 (C-15), 132.0 (C-14), 132.9 (C-16), 137.0 (C-12), 139.6 (C-9), 140.4 (C-
7), 147.5 (C-3); MS (ES+) m/z 418.2 [M+H]+. 
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N-methyl-N-(3-phenyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-
sulfonamide (242) 
 
Prepared according to general procedure F using N-(3-Bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (80 mg, 0.18 mmol), phenyl 
borinc acid (64 mg, 0.53 mmol), Cs2CO3 (86 mg, 0.26 mmol) and Pd(dppf)Cl2.DCM (14 
mg, 0.02 mmol) in 1,4-dioxane (3 mL). The product was isolated as a white solid (79 mg, 
99%). 
m.p. 156-158 oC; UV λmax (EtOH/nm) 308.2, 246.4, 218.8; IR νmax/cm
-1 3087, 2926, 2852, 
1349, 1039; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.65-1.68 (1H, m, H-5’), 1.72-1.79 (2H, m, 
H-4’, H-5’), 2.09-2.12 (1H, m, H-6’), 2.16-2.19 (1H, m, H-4’), 2.57-2.63 (1H, m, H-6’), 
3.34 (3H, s, H-17), 3.73-3.77 (1H, m, H-3’), 4.02-4.04 (1H, m, H-3’), 5.72 (1H, dd, J = 2.6, 
9.3 Hz, H-1’), 6.88 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.09 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.37 
(1H, d, J = 1.4 Hz, H-8), 7.40 (1H, t, J = 7.3 Hz, H-21), 7.47-7.50 (3H, m, H-16, H-20), 7.60 
(1H, dd, J = 1.2, 5.0 Hz, H-14), 7.89 (1H, d, J = 8.6 Hz, H-5), 7.93 (2H, d, J = 7.3, H-19); 
13C-NMR (125 MHz, CDCl3) δ ppm; 22.5 (C-4’) 25.1 (C-5’), 29.4 (C-6’), 38.9 (C-17),  67.5 
(C-3’), 85.7 (C-1’), 109.9 (C-8), 120.0 (C-6), 121.7 (C-5), 121.8 (C-4), 127.4 (C-15), 127.6 
(C-19), 128.2 (C-21), 128.8 (C-20), 132.1 (C-14), 132.9 (C-16), 133.1 (C-18), 136.9 (C-12), 
139.6 (C-9), 140.9 (C-7), 144.6 (C-3);  MS (ES+) m/z 454.3 [M+H]+. 
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N-(3-Bromo-1H-indazol-6-yl)-N-methylbenzenesulfonamide (250) 
 
Prepared according to general procedure A using 3-bromo-N-methyl-1H-indazol-6-
amine (45 mg, 0.19 mmol) in pyridine (1.5 mL) and benzenesulphonyl chloride (28 µL, 
0.22 mmol) to give the product as an off white solid (35 mg, 48%). 
Rf 0.51 (Et2O); m.p. 158-159 
oC; UV λmax (EtOH/nm) 294.2, 212.8; IR νmax/cm
-1 3325, 
3065, 2929, 1622; 1H-NMR (500 MHz, CDCl3) δ ppm; 3.25 (1H, s, H-16) 6.85 (1H, d, J = 
8.7 Hz, H-6), 7.42 (1H, s, H-8), 7.46 (2H, dd, J = 7.7, 7.7 Hz, H-14), 7.51 (1H, d, J = 8.7 Hz, 
H-5), 7.56 (2H, d, J =7.7 Hz, H-13), 7.59 (1H, t, J = 7.7 Hz, H-15) 10.83 (1H, s-br, H-1); 
13C-NMR (125 MHz, CDCl3) δ ppm; 38.5 (C-16), 109.2 (C-8), 120.2 (C-6), 120.6 (C-5), 
122.0 (C-4), 122.9 (C-9), 127.8 (C-13), 129.0 (C-14), 133.1 (C-15), 136.3 (C-12), 141.0 (C-
3), 141.5 (C-7);  MS (ES+) m/z 368.2 [M+H]+; HRMS calcd for C14H12BrN3O2S 
365.9906/367.9885 [M+H]+ found 365.9901/367.9875. 
N-Methyl-N-(3-methyl-1H-indazol-6-yl)benzenesulfonamide (251) 
 
Prepared according to general procedure D using N-methyl-N-(3-methyl-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazol-6-yl)benzenesulfonamide (38 mg, 0.10 mmol) in MeOH.HCl 
(1.25 M, 3 mL) giving the title compound via semi-preparatory HPLC (H20 (0.1% 
HCOOH) : MeCN (13:7)) as a white solid (7 mg, 24 %). 
Rf 0.56 (Et2O); m.p. <60 
oC; UV λmax (EtOH/nm) 293.8, 213.6; IR νmax/cm
-1 3357, 3175, 
3062, 2924, 1623; 1H-NMR (500 MHz, CDCl3) δ ppm; 2.57 (3H, s, H-17), 3.25 (3H, s, H-
16),  6.79 (1H, dd, J = 1.7, 8.6 Hz, H-6), 7.26 (1H, 8, s, H-8),  7.45 (2H, dd, J = 7.5, 8.1 Hz, 
H-14), 7.54-7.59 (4H, m, H-15, H-13, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 12.0 (17), 
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38.6 (C-16), 108.6 (C-8), 119.0 (C-6), 120.5 (C-5), 121.9 (C-4), 127.9 (C-13), 128.8 (C-14), 
132.9 (C-15), 136.5 (C-12), 140.4 (C-7) 143.5 (C-3);  MS (ES+) m/z 302.2 [M+H]+; HRMS 
calcd for C15H16N3O2S 302.0958 [M+H]
+ found 302.0955. 
N-(3-Cyclopropyl-1H-indazol-6-yl)-N-methylbenzenesulfonamide (252) 
 
Prepared according to general procedure D using N-(3-cyclopropyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)-N-methylbenzenesulfonamide (25 mg, 0.06 mmol) in 
MeOH.HCl (1.25 M, 6 mL) giving the title compound as a white solid (13 mg, 67%) 
Rf 0.59 (Et2O); m.p. 63-65 
oC; UV λmax (EtOH/nm) 298.2, 265.6, 215.2; IR νmax/cm
-1 3352, 
3172, 2925, 1622; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.04-1.07 (4H, m, H-18), 2.19 (1H, 
m, H-17), 3.24 (3H, s, H-16), 6.79 (1H, d, J = 8.6 Hz, H-6), 7.23 (1H, s, H-8), 7.45 (2H, dd, 
J = 7.6, 7.8 Hz, H-14), 7.56-7.60 (3H, m, H-15, H-13), 7.63 (1H, d, J = 8.6 Hz, H-5); 13C-
NMR (125 MHz, CDCl3) δ ppm; 7.3 (18), 8.1 (C-17), 38.6 (C-16), 108.6 (C-8), 119.0 (C-6), 
120.5 (C-5), 127.9 (C-13), 128.8 (C-14), 132.9 (C-15), 136.5 (C-12), 140.4 (C-7);  MS (ES+) 
m/z 328.3 [M+H]+. 
N-(3-Bromo-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (245) 
 
Prepared according to general procedure D using N-(3-bromo-1-(tetrahydro-2H-pyran-
2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (25 mg, 0.06 mmol) in 
MeOH.HCl (1.25 M, 4 mL) giving the title compound as a pale orange solid (19 mg, 92%) 
Rf 0.48 (Et2O); m.p. 158-160 
oC; UV λmax (EtOH/nm) 294.0, 214.6; IR νmax/cm
-1 3286, 
3099, 2923, 1622; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 3.32 (3H, s, H-17), 6.91 (1H, d, J = 
8.7 Hz, H-6), 7.09 (1H, dd, J = 4.5, 3.8 Hz, H-15), 7.34 (1H, d, J = 3.8 Hz, H-16), 7.43 (1H, 
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d, J = 1.6 Hz, H-8), 7.54 (1H, d, J = 8.7 Hz, H-5), 7.87 (1H, d, J = 4.9 Hz, H-14), 10.49 (1H, 
s-br, H-1); 13C-NMR (125 MHz, CDCl3) δ ppm; 38.6 (C-17),  109.2 (C-8), 120.2 (C-6), 
120.7 (C-5), 123.1 (C-4), 127.5 (C-15), 132.4 (C-14), 133.0 (C-16), 136.5 (C-12), 140.1 (C-
9), 141.3 (C-7);  MS (ES+) m/z 372.1 [M(79Br)+H]+. 
N-(3-Ethyl-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (246) 
 
Prepared according to general procedure D using N-methyl-N-(3-methyl-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-sulfonamide (55 mg, 0.14 mmol) in 
MeOH.HCl (1.25 M, 5 mL) giving the title compound as a white solid (13 mg,31 %) 
Rf 0.58 (Et2O); m.p. 172-174
oC; UV λmax (EtOH/nm) 214.8; IR νmax/cm
-1 3270, 3104, 2935, 
1351, 1159; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 2.57 (3H, s, H-18), 3.31 (3H, s, H-17), 
6.84 (1H, dd, J = 8.6, 1.4 Hz, H-6), 7.07 (1H, dd, J = 4.8, 3.9 Hz, H-15), 7.29 (1H, s, H-8), 
7.33 (1H, dd, J = 1.0, 3.9 Hz, H-16), 7.57-7.59 (2H, m, H-14, H-5); 13C-NMR (125 MHz, 
CDCl3) δ ppm; 12.0 (C-18), 38.7 (C-17), 108.7 (C-8), 118.9 (C-6), 120.6 (C-5), 121.2 (C-4), 
127.4 (C-15), 132.2 (C-14), 132.8 (C-16), 136.7 (C-12), 140.0 (C-9), 141.1 (C-7), 148.7 (C-
3); MS (ES+) m/z 308.2 [M+H]+; HRMS calcd for C13H14N3O2S2 308.0522 [M+H]
+ found 
308.0521. 
N-(3-Ethyl-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (247) 
 
Prepared according to general procedure D using N-methyl-N-(3-ethyl-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-sulfonamide (65 mg, 0.16 mmol) in 
MeOH.HCl (1.25 M, 5 mL) giving the title compound as a light pink solid (32 mg, 63%) 
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Rf 0.62 (Et2O); m.p. 54-56 
oC; UV λmax (EtOH/nm) 217.0; IR νmax/cm
-1 3367, 3172, 3107, 
2969, 2933, 1623; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 1.41 (3H, t, J = 7.6 Hz, H-19), 2.99 
(2H, q, J = 7.6 Hz, H-18), 3.31 (3H, s, H-17), 6.85 (1H, dd, J = 8.6, 1.7 Hz, H-6), 7.07 (1H, 
dd, J = 4.9, 3.8 Hz, H-15), 7.29 (1H, d, J = 1.7 Hz, H-8), 7.34 (1H, dd, J = 1.2, 3.8 Hz, H-16), 
7.58 (1H, dd, J = 1.2, 4.9 Hz, H-14), 7.66 (1H, d, J = 8.6 Hz, H-5); 13C-NMR (125 MHz, 
CDCl3) δ ppm; 13.3 (C-19), 20.4 (C-18), 38.8 (C-17), 108.7 (C-8), 118.9 (C-6), 120.6 (C-5), 
121.2 (C-4), 127.4 (C-15), 132.2 (C-14), 132.9 (C-16), 136.7 (C-12), 140.0 (C-9), 141.1 (C-
7), 148.7 (C-3); MS (ES+) m/z 322.2 [M+H]+; HRMS calcd for C14H16N3O2S2 322.0678 
[M+H]+ found 322.0673. 
N-(3-Cyclopropyl-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (248) 
 
Prepared according to general procedure D using N-(3-cyclopropyl-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (66 mg, 0.16 mmol) in 
MeOH.HCl (1.25 M, 8 mL) giving the title compound as a pale orange solid (13 mg, 
24%). 
Rf 0.55 (Et2O); m.p. <60 
oC; UV λmax (EtOH/nm) 298.2, 217.4; IR νmax/cm
-1 3365, 3172, 
3092, 3004, 2929, 1622; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 1.03-1.07 (4H, m, H-19), 
2.18-2.22 (1H, m, H-18), 3.31 (3H, s, H-17), 6.85 (1H, dd, J = 8.6, 1.7 Hz, H-6), 7.07 (1H, 
dd, J = 4.9, 3.8 Hz, H-15), 7.27 (1H, d, J = 1.7 Hz, H-8), 7.34 (1H, dd, J = 1.2, 3.8 Hz, H-16), 
7.58 (1H, dd, J = 1.2, 4.9 Hz, H-14), 7.66 (1H, d, J = 8.6 Hz, H-5); 13C-NMR (125 MHz, 
CDCl3) δ ppm; 7.3 (C-19), 8.1 (C-18), 38.7 (C-17), 108.7 (C-8), 118.9 (C-6), 120.6 (C-5), 
121.6 (C-4), 127.4 (C-15), 132.2 (C-14), 132.9 (C-16), 136.7 (C-12), 140.0 (C-9), 141.2 (C-
7), 148.8 (C-3);  MS (ES+) m/z 334.2 [M+H]+. 
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N-Methyl-N-(3-phenyl-1H-indazol-6-yl)thiophene-2-sulfonamide (249) 
 
Prepared according to general procedure D using N-methyl-N-(3-phenyl-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazol-6-yl)thiophene-2-sulfonamide (68 mg, 0.15 mmol) in 
MeOH.HCl (1.25 M, 5 mL) giving the title compound as a pale orange solid (50 mg, 90%) 
Rf 0.71 (Et2O); m.p. 67-69 
oC; UV λmax (EtOH/nm) 305.2, 244.8, 216.0; IR νmax/cm
-1 3354, 
3167, 3108, 2931, 1623; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 3.32 (3H, s, H-17), 6.94 (1H, 
dd, J = 8.7, 1.7 Hz, H-6), 7.07 (1H, dd, J = 5.0, 3.7 Hz, H-15), 7.34 (1H, d, J = 1.7 Hz, H-8), 
7.36 (1H, dd, J = 1.2, 3.7 Hz, H-16), 7.43 (1H, tt, J = 7.4, 1.1 Hz, H-21), 7.51, (2H, dd, J = 
7.4, 5.8 Hz, H-20), 7.58 (1H, dd, J = 1.2, 5.0 Hz, H-14), 7.92-7.94 (3H, m, H-5, H-19); 13C-
NMR (125 MHz, CDCl3) δ ppm; 38.7 (C-17), 108.9 (C-8), 120.2 (C-6), 120.2 (C-4), 121.6 
(C-5), 127.4 (C-15), 127.5 (C-19), 128.4 (C-21), 129.0 (C-20), 132.3 (C-14), 132.9 (C-16), 
133.0 (C-18), 136.7 (C-12), 140.0 (C-9), 141.2 (C-7), 145.8 (C-3);  MS (ES+) m/z 370.3 
[M+H]+; HRMS calcd for C18H16N3O2S2 370.0678 [M+H]
+ found 370.0671. 
3-Cyclopropyl-1H-indazol-6-amine (254)  
 
Prepared according to general procedure F using 3-bromo-6-nitro-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole (250 mg, 0.75 mmol), cycloprpoyl boronic acid (200 mg, 2.25 
mmol), Pd(dppf)Cl2.DCM (12 mg, 0.02 mmol) and Cs2CO3 (375 mg, 1.15 mmol) in 1,4-
dioxane (9 mL) to give the crude intermediate 3-cyclopropyl-6-nitro-1H-indazole (91 
mg, 58%). Iolatted material was immediately progressed into general procedure E 
using 3-cyclopropyl-6-nitro-1H-indazole (90 mg, 0.44 mmol) in EtOAc (20 mL, 0.015M). 
The product was isolated as a white solid, (71.3 mg, 93%). 
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Rf 0.44 (Et2O); m.p. 175-176 
oC; UV λmax (EtOH/nm) 294.4, 224.6; IR νmax/cm
-1 3374, 
3181, 3080, 2941, 2894, 1625; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.87-0.93 (4H, m, 
H-17), 2.08-2.12 (1H, m, H-16), 5.52 (2H, s-br, H-10), 6.42-6.44 (1H, m, H-8, H-6), 7.35 
(1H, d,  J = 9.2 Hz, H-5) 11.76 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 7.1 
(C-17), 8.0 (C-16), 90.6 (C-8), 111.3 (C-6), 114.3 (C-4), 119.8 (C-5), 143.2 (C-9), 145.9 (C-
7), 147.4 (C-3); MS (ES+) m/z 174.2 [M+H]+; HRMS calcd for C10H12N3 174.1026 [M+H]
+ 
found 174.1023. 
N-(3-Cyclopropyl-1H-indazol-6-yl)benzenesulfonamide (255) 
 
Prepared according to general procedure A using 3-cyclopropyl-1H-indazol-6-amine 
(22 mg, 0.13 mmol) in pyridine (1 mL) and benzenesulphonyl chloride (18 µL, 0.14 
mmol) to give the product as an off white solid (16.5 mg, 41%). 
Rf 0.53 (Et2O); m.p. 73-75 
oC; UV λmax (EtOH/nm) 294.0, 216.4; IR νmax/cm
-1 3248, 3067, 
2923, 1629; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.00-1.02 (4H, m, H-17), 2.14 (1H, m, H-
16), 6.76 (1H, d, J = 8.6 Hz, H-6), 7.28 (1H, s, H-8), 7.37 (1H, s-br, H-10), 7.41 (2H, dd, J = 
7.4, 7.4 Hz, H-14), 7.51 (1H, t, J = 7.4 Hz, H-15), 7.57 (1H, d, J = 8.6 Hz, H-5), 7.67 (2H, d, 
J =7.5 Hz, H-13); 13C-NMR (125 MHz, CDCl3) δ ppm; 7.3 (17), 8.1 (C-16), 102.1 (C-8), 
115.6 (C-6), 121.2 (C-5), 127.2 (C-13), 129.1 (C-14), 133.1 (C-15), 135.5 (C-9), 139.0 (C-
12), 141.6 (C-7), 148.6 (C-3);  MS (ES+) m/z 314.3 [M+H]+; HRMS calcd for C16H15N3O2S 
314.0958 [M+H]+ found 314.0953. 
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N-(3-Cyclopropyl-1H-indazol-6-yl)thiophene-2-sulfonamide (256) 
 
Prepared according to general procedure A using 3-cyclopropyl-1H-indazol-6-amine 
(22 mg, 0.13 mmol) in pyridine (1 mL) and 2-thiophenesulphonyl chloride(25 mg, 0.14 
mmol) to give the product as an off white solid (18.5 mg, 46%). 
Rf 0.48 (Et2O); m.p. 178-180 
oC; UV λmax (EtOH/nm) 293.8, 221.6; IR νmax/cm
-1 3384, 
3103, 2922, 2860, 1626; 1H-NMR (500 MHz, DMSO-d6 ) δ ppm; 0.90, (2H, m, H-18A), 
0.95 (2H, m, H-18B), 2.19 (1H, m, H-17), 6.87 (1H, dd, J = 8.6, 1.6 Hz, H-6), 7.10 (1H, dd, 
J = 4.9, 3.8 Hz, H-15), 7.22 (1H, d, J = 1.6 Hz, H-8), 7.51 (1H, dd, J = 1.2, 3.8 Hz, H-16), 
7.64 (1H, d, J = 8.6 Hz, H-5), 7.87 (1H, dd, J = 1.2, 4.8 Hz, H-14), 10.49 (1H, s-br, H-10), 
12.42 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 7.4 (C-18), 7.8 (C-17), 100.5 
(C-8), 114.1 (C-6), 118.8 (C-4), 120.5 (C-5), 127.6 (C-15), 132.3 (C-16), 133.3 (C-14), 
135.7 (C-7), 139.8 (C-12), 141.2 (C-9), 146.4 (C-3);  MS (ES+) m/z 320.2 [M+H]+; HRMS 
calcd for C14H13N3O2S2 320.0522 [M+H]
+ found 320.0518. 
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6-(N-Methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-
carboxylic acid (261) 
 
 
Prepared according to general procedure N using: N-(3-bromo-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (100 mg, 0.22 mmol), 
Pd(OAc)2 (5 mg, 0.02 mmol), XantPhos (4,5-Bis(diphenylphosphino)-9,9-
dimethylxanthene, 25 mg, 0.04 mmol) lithium formate monohydrate (61 mg, 0.88 
mmol), Et3N (122 µL, 0.88 mmol) and Ac2O (83 µL, 0.88 mmol) in DMF (2 mL) top give 
the product as a white solid (88 mg, 95%). 
1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.56-1.51 (2H, m, H-5’, H-5’), 1.71-1.79 (1H, m, H-
4’), 1.96-2.00 (2H, m, H-6’, H-4’), 2.28-2.34 (1H, m, H-6’),  3.28 (3H, s, H-17), 3.71-3.76 
(1H, m, H-3’), 4.86-4.88 (1H, m, H-3’), 5.93 (1H, dd, J = 2.5, 9.4 Hz, H-1’), 7.10 (1H, dd, J 
= 8.6, 1.6 Hz, H-6), 7.26 (1H, dd, J = 4.8, 3.7 Hz, H-15), 7.52 (1H, dd, J = 3.7, 1.4Hz,  H-
16), 7.60 (1H, d, J = 1.6 Hz, H-8), 8.03-8.05 (2H, m, H-14, H-5); 13C-NMR (125 MHz, 
DMSO-d6) δ ppm; 22.2 (C-4’) 25.1 (C-5’), 29.2 (C-6’), 39.0 (C-17),  67.1 (C-3’), 85.1 (C-1’), 
109.9 (C-8), 122.3 (C-5), 122.9 (C-6), 126.8 (C-4), 128.5 (C-15), 133.9 (C-16), 134.7 (C-
14), 135.1 (C-12), 140.3 (C-7), 168.2 (C-18); MS (ES+) m/z 422.4 [M+H]+. 
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Methyl 6-(N-methylthiophene-2-sulfonamido)-1H-indazole-3-carboxylate (257) 
 
6-(N-Methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-
carboxylic acid (45 mg, 0.11 mmol) was dissolved in MeCN (3 mL) and concentrated 
HCL (0.5 mL) was added and the solution was stirred for 3 hours then reduced to a 
residue under vacuum. The title compound was obtained after MPCL (20-95% EtOAc in 
petrol) as an off white solid (25 mg, 69 %). 
Rf 0.27 (10% MeOH in DCM); m.p. 231-233 
oC; UV λmax (EtOH/nm) 294.2, 208.8; IR 
νmax/cm
-1 3246, 1712, 1338, 1142; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 3.27 (3H, s, H-
17), 7.05 (1H, dd, J = 8.8, 1.9 Hz, H-6), 7.24 (1H, dd, J = 4.8, 3.7 Hz, H-15), 7.37 (1H, d, J 
= 1.9 Hz, H-8), 7.49 (1H, dd, J = 1.4, 3.7 Hz, H-16), 8.00-8.02 (2H, m, H-5, H-14), 13.07 
(1H, s-br, H-19), 13.83 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 38.8 (C-17), 
109.2 (C-8), 122.0 (C-5), 128.5 (C-15), 133.8 (C-16), 134.7 (C-14), 135.9 (C-12), 139.8 (C-
7); MS (ES+) m/z 338.3 [M+H]+. 
Methyl 6-(N-methylthiophene-2-sulfonamido)-1H-indazole-3-carboxylate (258) 
 
Prepared according to general procedure D using 6-(N-Methylthiophene-2-
sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (60 mg, 0.14 
mmol) in MeOH.HCl (1.25 M, 5 mL) and MeOH (5 mL) giving the title compound as a 
white solid (48 mg, 97 %). 
Rf 0.36 (10% MeOH in DCM); m.p. 139-141 
oC; UV λmax (EtOH/nm) 294.8, 234.0, 208.4; 
IR νmax/cm
-1 3257, 3093, 2951, 1720, 1349, 1130; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 
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3.17 (3H, s, H-17), 3.93 (3H, s, H-20), 6.62 (1H, dd, J = 8.7, 1.7 Hz, H-6), 7.24 (1H, dd, J = 
5.0, 3.8 Hz, H-15), 7.40 (1H, d, J = 1.7 Hz, H-8), 7.50 (1H, dd, J = 1.3, 3.8 Hz, H-16), 8.00-
8.02 (2H, m, H-5, H-14), 14.00 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 
38.8 (C-17), 52.2 (C-20), 109.4 (C-8), 121.5 (C-4), 121.7 (C-5), 122.2 (C-6), 128.5 (C-15), 
133.8 (C-16), 134.7 (C-14), 135.9 (C-12), 140.0 (C-7), 141.1 (C-9), 151.0 (C-3) 162.9 (C-
18); MS (ES+) m/z 352.3 [M+H]+. 
N-(3-(Hydroxymethyl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (259) 
 
Prepared according to general procedure G using Methyl 6-(N-methylthiophene-2-
sulfonamido)-1H-indazole-3-carboxylate (34 mg, 0.1 mmol) and LiAlH4 (1M in THF, 0.2 
mL, 0.20 mmol). The product was isolated as a grey solid (15 mg, 47%). 
Rf 0.33 (10% MeOH in DCM); m.p. 166-168 
oC; UV λmax (EtOH/nm) 291.8, 214.0; IR 
νmax/cm
-1 3234, 2926, 1350, 1161, 1014; 1H-NMR (500 MHz, CD3OD) δ ppm; 3.30 (3H, s, 
H-17), 4.58 (1H, s, H-19), 4.94 (2H, s, H-18), 6.90 (1H, dd, J = 8.7, 1.7 Hz, H-6), 7.15 (1H, 
dd, J = 4.9, 3.9 Hz, H-15), 7.27 (1H, d, J = 1.7 Hz, H-8), 7.37 (1H, dd, J = 1.1, 3.9 Hz, H-16), 
7.79-7.81 (2H, m, H-5, H-14); 13C-NMR (125 MHz, CD3OD) δ ppm; 37.8 (C-17), 65.7 (C-
18), 108.3 (C-8), 119.3 (C-6), 120.6 (C-5), 127.2 (C-15), 132.7 (C-16), 132.8 (C-14), MS 
(ES+) m/z 324.2 [M+H]+; HRMS calcd for C13H14N3O3S2 324.0471 [M+H]
+ found 324.0473. 
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Methyl 6-(N-methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-
indazole-3-carboxylate (262) 
 
Prepared according to general procedure N using: N-(3-bromo-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (50 mg, 0.11 mmol), 
Pd(OAc)2 (3 mg, 0.01 mmol), XantPhos (4,5-Bis(diphenylphosphino)-9,9-
dimethylxanthene, 13 mg, 0.02 mmol), methyl formate (27 µL, 0.44 mmol), Et3N (61 µL, 
0.44 mmol) and Ac2O (42 µL, 0.44 mmol) in DMF (2 mL) top give the product as a white 
solid (31 mg, 65%). 
m.p. 65-67 oC; UV λmax (EtOH/nm) 298.6, 245.6, 211.6; IR νmax/cm
-1 3090, 2926, 2854, 
1674, 1348, 1167; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.68-1.81 (3H, m, H-4’, H-4’, H5’), 
2.07-2.18 (2H, m, H-6’, H-5’), 2.54-2.58 (1H, m, H-6’),  2.78 (3H, s, H-20), 3.31 (3H, s, H-
17), 3.74-3.78 (1H, m, H-3’), 3.98-4.02 (1H, m, H-3’), 5.76 (1H, dd, J = 2.8, 9.0 Hz, H-1’), 
6.88 (1H, dd, J = 8.7, 1.8 Hz, H-6), 7.07 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.32 (1H, dd, J = 
1.3, 3.8 Hz, H-16), 7.59 (1H, dd, J = 1.3, 5.0 Hz, H-14), 7.60 (1H, d, J = 1.8 Hz, H-8), 8.23 
(1H, d, J = 8.7 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.1 (C-4’) 24.9 (C-5’), 26.7 
(C-20), 29.1 (C-6’), 38.7 (C-17),  67.4 (C-3’), 86.1 (C-1’), 110.5 (C-8), 121.7 (C-6), 122.2 
(C-4), 123.3 (C-5), 127.4 (C-15), 132.3 (C-14), 132.9 (C-16), 136.7 (C-12), 140.1 (C-7), 
140.7 (C-9), 142.6 (C-3), 195.0 (C-18); MS (ES+) m/z 437.2 [M+H]+; HRMS calcd for 
C19H22N3O5S2 436.0995 [M+H]
+ found 436.0991. 
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N-(3-(2-hydroxypropan-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (378) 
 
Methyl 6-(N-methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-
indazole-3-carboxylate (127 mg, 0.29 mmol) was taken in THF (1.5 mL) under N2 at 0 
oC. 
Methylmagnesium bromide (3M in Et2O, 341 µL, 1.02 mmol) was added dropwise and 
the solution was stirred for 3 hours. The solution was filtered through celite and 
reduced to a residue under vacuum. The title compound was purified by MPLC (0-80% 
EtOAc in petrol) to give a white solid (110 mg, 87%). 
N-(3-(2-hydroxypropan-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (37 mg, 0.09 mmol) was dissolved in THF (1 mL) and 
H2SO4 (aq) (0.4 M, 1 mL) was added. The solution was stirred for 48 h at RT before a 
further addition of H2SO4 (conc., 22 μL). After another 48 h the solution was diluted 
with H2O (5 mL) and extracted into EtOAc (2 x 10 mL), combined organic fractions were 
dried over Na2SO4 and reduced in vacuo and purified by reversephase flash 
chromatography (0-80 % MeCN (0.1% HCOOH) in H2O (0.1% HCOOH) to give the the 
title compound as a white solid (12 mg, 39%). 
Rf 0.46 (Et2O); m.p. 76-78 
oC; UV λmax (EtOH/nm) 292.8, 214.4; IR νmax/cm
-1 3345, 2975, 
1340, 1162; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.74 (6H, s, H-20), 3.30 (3H, s, H-17), 
6.85 (1H, dd, J = 8.7, 1.6 Hz, H-6), 7.08 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.34 (1H, d, J = 1.6 
Hz, H-8), 7.37 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.59 (1H, dd, J = 5.0, 1.3 Hz, H-14), 7.85 
(1H, d, J = 8.7 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 30.5 (C-20), 38.7 (C-17), 71.3 
(C-18), 108.9 (C-8), 119.1 (C-6), 122.4 (C-5), 127.4 (C-15), 132.3 (C-14), 132.9 (C-16), 
136.8 (C-12), 140.0 (C-7), 141.7 (C-9), 152.8 (C-3); MS (ES+) m/z 350.2   [M-H]-; HRMS 
calcd for C15H18N3O3S2 352.0784 [M+H]
+ found 352.0786. 
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N-(3-(2-hydroxypropan-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide 
(260) 
 
N-(3-(2-hydroxypropan-2-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (37 mg, 0.09 mmol) was dissolved in THF (1 mL) and 
H2SO4 (aq) (0.4 M, 1 mL) was added. The solution was stirred for 48 h at RT before a 
further addition of H2SO4 (conc., 22 μL). After another 48 h the solution was diluted 
with H2O (5 mL) and extracted into EtOAc (2 x 10 mL), combined organic fractions were 
dried over Na2SO4 and reduced in vacuo and purified by reversephase flash 
chromatography (0-80 % MeCN (0.1% HCOOH) in H2O (0.1% HCOOH) to give the the 
title compound as a white solid (12 mg, 39%). 
Rf 0.46 (Et2O); m.p. 76-78 
oC; UV λmax (EtOH/nm) 292.8, 214.4; IR νmax/cm
-1 3345, 2975, 
1340, 1162; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.74 (6H, s, H-20), 3.30 (3H, s, H-17), 
6.85 (1H, dd, J = 8.7, 1.6 Hz, H-6), 7.08 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.34 (1H, d, J = 1.6 
Hz, H-8), 7.37 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.59 (1H, dd, J = 5.0, 1.3 Hz, H-14), 7.85 
(1H, d, J = 8.7 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 30.5 (C-20), 38.7 (C-17), 71.3 
(C-18), 108.9 (C-8), 119.1 (C-6), 122.4 (C-5), 127.4 (C-15), 132.3 (C-14), 132.9 (C-16), 
136.8 (C-12), 140.0 (C-7), 141.7 (C-9), 152.8 (C-3); MS (ES+) m/z 350.2   [M-H]-; HRMS 
calcd for C15H18N3O3S2 352.0784 [M+H]
+ found 352.0786. 
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6-(N-Methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-
carboxamide (266) 
 
Prepared according to general procedure O using: 6-(N-Methylthiophene-2-
sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (65 mg, 0.15 
mmol), CDI (50 mg, 0.31 mmol) and ammonia (1M in 1,4-dioxane, 772 µL, 0.39 mmol) 
in THF (3 mL) giving the title compound as a white solid (18 mg, 27%). 
UV λmax (EtOH/nm) 297.0, 259.5, 237.1, 210.8; IR νmax/cm
-1 3469, 3335, 3177, 2930, 
2855; 1H-NMR (500 MHz, CDCl3) δ ppm; ) 1.61-1.79 (3H, m,H-5’,  H-5’, H-4’), 2.06-2.09 
(1H, m, H-6’), 2.13-2.16 (1H, m, H-4’), 2.49-2.55 (1H, m, H-6’), 3.32 (3H, s, H-17), 3.74-
3.78 (1H, m, H-3’), 4.01-4.04 (1H, m, H-3’), 5.58 (1H, s-br, H-19), 5.55 (1H, dd, J = 2.8, 
9.4 Hz, H-1’), 6.82 (1H, dd, J = 8.7, 1.7 Hz, H-6), 6.92 (1H, s-br, H-19), 7.07 (1H, dd, J = 
5.0, 3.8 Hz, H-15), 7.32 (1H, dd, J = 3.8, 1.4, H-16), 7.59 (1H, dd, J = 5.0, 1.4 Hz, H-14), 
7.61 (1H, d, J = 1.7 Hz, H-8), 8.23 (1H, d, J = 8.7 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ 
ppm;  22.3 (C-4’) 24.9 (C-5’), 29.2 (C-6’), 38.7 (C-17),  67.6(C-3’), 85.7 (C-1’), 110.8 (C-8), 
120.8 (C-6), 122.5 (C-4), 123.3 (C-5), 127.4 (C-15), 132.3 (C-14), 132.9 (C-16), 135.0 (C-
12), 140.1 (C-7), 140.8 (C-9), 164.1 (C-18); MS (ES+) m/z 321.4  [M+H]+;  
6-(N-Methylthiophene-2-sulfonamido)-1H-indazole-3-carboxamide (263) 
 
Prepared according to general procedure D using 6-(N-methylthiophene-2-
sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (18 mg, 0.04 
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mmol) in MeOH.HCl (1.25 M, 3 mL) giving the title compound as a white solid (6 mg, 
42%). 
UV λmax (EtOH/nm) 295.0, 232.0, 209.0; IR νmax/cm
-1 3391, 2922, 2852, 1735, 1581, 
1158; 1H-NMR (500 MHz, CD3OD) δ ppm; 3.32 (3H, s, H-17), 6.99 (1H, dd, J = 8.7, 1.7 Hz, 
H-6), 7.16 (1H, dd, J = 4.9, 3.8 Hz, H-15), 7.38-7.39 (2H, m, H-8, H-16), 7.81 (1H, dd, J = 
4.9, 1.2 Hz, H-14), 8.12 (1H, d, J = 8.7 Hz, H-5); 13C-NMR (125 MHz, CD3OD) δ ppm; 37.7 
(C-17), 108.8 (C-8), 121.0 (C-6), 112.8 (C-5), 127.2 (C-15), 132.7 (C-14), 132.9 (C-16), 
136.1 (C-12), 140.1 (C-7), 140.8 (C-9), 156.8 (C-18); MS (ES+) m/z 337.4  [M+H]+. 
N-methyl-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-3-carboxamide (264) 
 
Prepared according to general procedure O using: 6-(N-Methylthiophene-2-
sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (50 mg, 0.12 
mmol), CDI (39 mg, 0.24 mmol) and methylamine (2M in THF, 148 µL, 0.30 mmol) in 
THF (2 mL) giving N-Methyl-6-(N-methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-
pyran-2-yl)-1H-indazole-3-carboxamide as a white solid (48 mg, 93 %). Isolated 
material was used immediately in the next step without full characterisation according 
to general procedure D using: N-methyl-6-(N-methylthiophene-2-sulfonamido)-1-
(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (18 mg, 0.04 mmol) in 
MeOH.HCl (1.25 M, 5 mL) giving the title compound as a white solid (20 mg, 47%). 
m.p. 266-268 oC; UV λmax (EtOH/nm) 295.6, 232.6, 209.6; IR νmax/cm
-1 3426, 3107, 2939, 
1646, 1554, 1338, 1143; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 2.82 (3H, d, J = 4.7 Hz, H-
20), 3.27 (3H, s, H-17), 6.99 (1H, dd, J = 8.7, 1.7 Hz, H-6), 7.23 (1H, dd, J = 5.0, 3.7 Hz, H-
15), 7.34 (1H, d, J = 1.7 Hz, H-8), 7.49 (1H, dd, J = 1.1, 3.7 Hz, H-16), 8.01 (1H, dd, J = 5.0, 
1.1 Hz, H-14), 8.09 (1H, d, J = 8.7 Hz, H-5) 8.38 (1H, q, J = 4.7 Hz, H-19), 13.59 (1H, s-br, 
H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 26.0 (C-20), 38.8 (C-17), 109.0 (C-8), 120.9 
(C-4), 121.2 (C-6), 122.3 (C-5), 128.5 (C-15), 133.7 (C-16), 134.6 (C-14), 136.0 (C-12), 
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139.0 (C-3), 139.8 (C-7), 141.2 (C-9), 162.9 (C-18); MS (ES+) m/z 351.3   [M-H]-; HRMS 
calcd for C14H15N4O3S2 351.0580 [M+H]
+ found 351.0581. 
N,N-dimethyl-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-3-carboxamide 
(265) 
 
 
Prepared according to general procedure O using: 6-(N-Methylthiophene-2-
sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (50 mg, 0.12 
mmol), CDI (39 mg, 0.24 mmol) and dimethylamine (2M in THF, 148 µL, 0.30 mmol) in 
THF (2 mL) giving N,N-Dimethyl-6-(N-methylthiophene-2-sulfonamido)-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazole-3-carboxamide as a white solid (36 mg, 67%). Isolated 
material was used immediately in the next step without full characteisation according 
to general procedure D using: N,N-dimethyl-6-(N-methylthiophene-2-sulfonamido)-1-
(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (18 mg, 0.04 mmol) in 
MeOH.HCl (1.25 M, 5 mL) giving the title compound as a white solid (15 mg, 34%). 
m.p. 230-232 oC; UV λmax (EtOH/nm) 294.4, 210.4; IR νmax/cm
-1 3092, 2925, 2855, 1598, 
1346, 1143; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 3.07 (3H, s, H-17), 3.26 (3H, s, H-20A), 
3.36 (3H, s, H-20B), 6.94 (1H, dd, J = 8.7, 1.8 Hz, H-6), 7.24 (1H, dd, J = 5.0, 3.9 Hz, H-15), 
7.32 (1H, d, J = 1.8 Hz, H-8), 7.49 (1H, dd, J = 1.3, 3.9 Hz, H-16), 7.90 (1H, d, J = 8.7 Hz, 
H-5), 8.01 (1H, dd, J = 5.0, 1.3 Hz, H-14), 13.61 (1H, s-br, H-1); 13C-NMR (125 MHz, 
DMSO-d6) δ ppm; 36.0 (C-17), 38.8 (C-20A), 38.9 (C-20B), 108.8 (C-8), 117.7 (C-4), 
121.0 (C-6), 122.3 (C-5), 128.5 (C-15), 133.8 (C-16), 134.6 (C-14), 136.0 (C-12), 139.6 (C-
3), 139.8 (C-7), 140.5 (C-9), 163.4 (C-18); MS (ES+) m/z  365.2  [M-H]-; HRMS calcd for 
C15H17N4O3S2 365.0737 [M+H]
+ found 365.0733 
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N-(3-((4-methoxybenzyl)amino)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (274) 
 
Cs2CO3 (392 mg, 1.21 mmol), Pd2(dba)3 (39 mg, 0.04 mmol) and BrettPhos (2-
(dicyclohexylphosphino)3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1’-biphenyl, 58 mg, 0.11 mmol) 
were deposited in a  20 mL dry microwave vial under N2 and dissolved in 1,4-dioxane (6 mL). 4-
Methoxyphenyl)methanamine (112 µL, 0.86 mmol) was added and the solution was degassed 
with N2 for ca. 10 minutes before heating at 100 
oC for another 10 minutes. The solution was 
allowed to cool and N-(3-Bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-
yl)thiophene-2-sulfonamide ( 197 mg, 0.43 mmol) was added. The solution was heated to 
100 oC  for 18 , allowed to cool then filtered through Celite®. The filtrate was reduced to a 
residue under vacuum and purified by MPLC (0-80% EtOAc in petrol) to give an off white solid 
(103 mg, 47%) 
Rf 0.47 (Et2O); m.p. 48-50 
oC; UV λmax (EtOH/nm) 332.2, 236.2, 216.4; IR νmax/cm
-1 3373, 
3094, 2926, 2853; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.56-1.61 (1H, m, H-5’), 1.69-1.74 
(2H, m, H-4’, H-5’), 1.97-1.99(1H, m, H-6’), 2.11-2.12 (1H, m, H-4’), 2.49-2.51 (1H, m, H-
6’), 3.29 (3H, s, H-17), 3.65-3.70 (1H, m, H-3’), 3.81 (3H, s, H-25), 4.02-4.05 (1H, m, H-
3’), 4.53 (2H, s, H-19), 5.43 (1H, dd, J = 2.2, 9.7 Hz, H-1’),  6.66 (1H, dd, J = 8.7, 1.7 Hz, 
H-6), 6.89 (2H, d, J = 8.5 Hz, H-22), 7.07 (1H, dd, J = 4.9, 3.8 Hz, H-15), 7.23 (1H, d, J = 
1.7 Hz, H-8), 7.32 (1H, dd, J = 1.2, 3.8 Hz, H-16), 7.34-7.37 (3H, m, H-5, H-21), 7.58 (1H, 
dd, J = 1.2, 4.9 Hz, H-14); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.9 (C-4’) 25.2 (C-5’), 29.4 
(C-6’), 38.8 (C-17), 47.8 (C-19), 55.3 (C-25), 67.7 (C-3’), 85.0 (C-1’), 109.1 (C-8), 114.0 (C-
22), 115.0 (C-4), 117.6 (C-6), 119.6 (C-5), 127.3 (C-15), 129.5 (C-21), 131.8 (C-20), 132.0 
(C-14), 132.9 (C-16), 136.7 (C-12), 140.3 (C-7), 141.3 (C-9), 149.4 (C-3), 159.0 (C-23); MS 
(ES+) m/z 513.3 [M+H]+. 
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N-(3-((4-Methoxybenzyl)amino)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide 
(275) 
 
N-(3-((4-methoxybenzyl)amino)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (50 mg, 0.11 mmol) was dissolved in MeOH (8 mL) 
and concentrated AcOH (2 mL) and heated at reflux for 2 hrs. the solution was reduced 
to a residue in vacuo and partitioned between H2O (10 mL) and EtOAc (3 x 8 mL). 
Combined organic fractions were washed with saturated NaHCO3 (aq, 10 mL) and brine 
(10 mL) then dried over Na2SO4. This solution was purified by MPLC (0-80% EtOAc in 
petroleum ether) giving the title compound as a white solid (42 mg, 43%) 
Rf 0.60 (Et2O); m.p. 61-63 
oC; UV λmax (EtOH/nm) 327.6, 242.2; IR νmax/cm
-1 3385, 3094, 
2926, 1613; 1H-NMR (500 MHz, CDCl3 ) δ ppm; 3.29 (3H, s, H-17), 3.81 (3H, s, H-25), 
4.53 (2H, s, H-19), 6.75 (1H, dd, J = 8.6, 1.7 Hz, H-6), 6.89 (2H, d, J = 8.4 Hz, H-22), 7.06 
(1H, dd, J = 4.9, 3.8 Hz, H-15), 7.13 (1H, d, J = 1.7 Hz, H-8), 7.32 (1H, dd, J = 1.2, 3.8 Hz, 
H-16), 7.36 (2H, d, J = 8.4 Hz, H-21), 7.41 (1H, d, J = 8.6 Hz, H-5), 7.57 (1H, dd, J = 1.2, 
4.9 Hz, H-14); 13C-NMR (125 MHz, CDCl3) δ ppm; 38.7 (C-17), 47.7 (C-19),  55.3 (C-25), 
108.4 (C-8), 113.5 (C-4), 114.1 (C-22), 117.7 (C-6), 119.5 (C-5), 127.4 (C-15), 129.2 (C-
21), 131.5 (C-20), 132.2 (C-14), 132.8 (C-16), 136.7 (C-12), 140.7 (C-7), 142.3 (C-9), 
150.5 (C-3), 159.0 (C-23); MS (ES+) m/z 429.3 [M+H]+; HRMS calcd for C20H21N4O3S2 
429.1050 [M+H]+ found 429.1046. 
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N-Methylbenzenesulfonamide (276)  
 
Prepared according to general procedure J with following reagents and quantities: 
Benzene sulphonyl chloride (255 µL, 2.00 mmol) and methylamine (2 M in THF, 2.1 mL, 
4.20 mmol) in DCM (6 mL) to give a clear liquid (322 mg, 94%). 
Rf 0.56 (Et2O); UV λmax (EtOH/nm) 264.4, 226.0; IR νmax/cm
-1 3287; 1H-NMR (500 MHz, 
CDCl3) δ ppm; 2.60 (3H, d, J = 5.5 Hz, H-7), 5.09 (1H, d, J = 5.5 Hz, H-6), 7.49 (2H, dd, J = 
7.4, 7.4 Hz, H-3), 7.56 (1H, t, J = 7.4 Hz, H-4), 7.85 (2H, d, J = 7.4 Hz, H-2); 13C-NMR (125 
MHz, CDCl3) δ ppm; 29.3 (C-7), 127.2 (C-2), 129.2 (C-3), 132.7 (C-4), 138.7 (C-1);  MS 
(ES+) m/z 172.2 [M+H]+; Aligns with literature data.201 
4-Amino-2-fluorobenzonitrile (277) 
 
2-Fluoro-4-nitrobenzonitrile (5.0 g, 30 mmol) was dissolved in a methanol-acetic acid 
solution (4:1, 75 mL) under N2 and zinc powder (9.8 g, 151 mmol) was added over 10 
minutes. This mixture was heated to 50 oC for 4 h then filtered through Celite® and 
washed with MeOH (30 mL). The filtrate was reduced under low pressure and purified 
by MPLC (0-80% EtOAc in petroleum ether) giving the desired material as a brown solid 
(2.46 g, 61 %). 
Rf 0.44 (Et2O); m.p.  108-110 
oC (lit: 103-105 oC); UV λmax (EtOH/nm) 272.4, 217.0; IR 
νmax/cm
-1 3446, 3347, 2216; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 6.42-6.46 (2H, m, H-
3, H-5), 6.54 (2H, s-br, H-9), 7.41 (1H, dd, JH = 6.1, JF = 8.4 Hz, H-6);
 13C-NMR (125 MHz, 
DMSO-d6) δ ppm;  99.5 (d, JFC = 22.5 Hz, C-3), 110.7 (C-5), 116.4 (C-1), 134.5 (d, JFC = 2.8 
Hz, C-7), 143.3 (C-6), 156.1 (d, JFC = 12.3 Hz, C-4), 163.8-165.7 (d, JFC = 250.5 Hz, C-2); 
19F NMR (470 MHz, DMSO-d6) δ -109.3; MS (ES
+) m/z 137.1 [M+H]+; Aligns with 
literature data.203 
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N-(4-Cyano-3-fluorophenyl)-N-methylthiophene-2-sulfonamide (279)  
 
Prepared according to general procedure A with following reagents and quantities: 2-
Fluoro-4-nitrobenzonitrile (1.53 g, 11.2 mmol), pyridine (20 mL), THF (40 mL) and 2-
thiophenesulfonyl chloride (2.24 g, 12.3 mmol) to give N-(4-cyano-3-
fluorophenyl)thiophene-2-sulfonamide as off white solid (1.7g, 54%) and used directly 
in the next step according to general procedure B with following reagents and 
quantities: N-(4-cyano-3-fluorophenyl)thiophene-2-sulfonamide (1.08 g, 3.86 mmol), 
DMF (35 mL),  methyliodide (200 μL, 8.48 mmol) and K2CO3(586 mg, 4.24 mmol) to 
give an off white solid (1.1 g, 99%). 
m.p. 98-100 oC; UV λmax (EtOH/nm) 253.4; IR νmax/cm
-1 3117, 3056, 2901, 2237, 1354, 
1151; 1H-NMR (500 MHz, CDCl3) δ ppm; 7.10-7.14 (3H, m, H-3, H-5, H-13), 7.41 (1H, dd,  
J = 1.3, 3.8 Hz, H-14), 7.56-7.59 (1H, dd, JH = 7.8, JF = 1.0 Hz, H-6), 7.63 (1H, dd, J = 1.3, 
4.9 Hz, H-12); 13C-NMR (125 MHz, DMSO-d6) δ ppm;  37.5 (C-15), 99.5 (d, JFC = 15.7 Hz, 
C-1), 113.3 (d, JFC = 15.7 Hz, C-3), 113.4 (C-7), 121.3 (d, JFC = 3.5 Hz, C-5), 127.7 (C-13), 
133.2 (C-12), 133.3 (C-14), 133.5 (C-6), 143.3 (C-10), 147.2 (d, JFC = 9.9 Hz, C-4), 162.0-
164.1 (d, JFC = 260.1 Hz, C-2); 
19F NMR (470 MHz, DMSO-d6) δ -104.0; MS (ES
+) m/z 
297.2 [M+H]+. 
N-(3-Amino-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (269) 
 
N-(4-Cyano-3-fluorophenyl)-N-methylthiophene-2-sulfonamide (100 mg, 0.34 mmol) 
was taken in THF (2 mL) under N2 at room temperature and hydrazine (33 µM, 0.68 
mmol) was added and the solution stirred overnight. After this time H2O (5 mL) was 
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added and the solution extracted with EtOAc (3 x 5 mL). Organic fractions were 
combined and washed with brine (10mL) and dried over Na2SO4 before subjection to 
purification by MPLC (0-10% MeOH in DCM) giving the title compound as a white solid 
(62 mg, 59 %). 
Rf 0.31 (10% MeOH in DCM); m.p. 222-224 
oC; UV λmax (EtOH/nm) 316.8, 236.0; IR 
νmax/cm
-1 3378, 3309, 3052, 1340, 1160; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 3.22 (3H, 
s, H-17), 5.38 (2H, s, H-18), 6.62 (1H, dd, J = 8.5, 1.8 Hz, H-6), 6.95 (1H, d, J = 1.8 Hz, H-
8), 7.23 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.47 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.61 (1H, d, J 
= 8.5 Hz, H-5), 7.57 (1H, dd, J = 1.3, 5.0 Hz, H-14), 11.43 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm; 38.9 (C-17), 107.9 (C-8), 113.5 (C-4), 116.6 (C-6), 121.0 (C-5), 
128.4 (C-15), 133.5 (C-16), 134.4 (C-14), 136.3 (C-12), 139.6 (C-7), 141.6 (C-3), 149.6 (C-
9); MS (ES+) m/z 309.2 [M+H]+. 
N-(3-Bromo-4-cyanophenyl)thiophene-2-sulfonamide (280)  
 
Prepared according to general procedure A with following reagents and quantities: 4-
amino-2-bromobenzonitrile (1 g, 5.08 mmol), pyridine (10 mL) and 2-thiophenesulfonyl 
chloride (968 mg, 5.33 mmol) to give an off white solid (1.5 g, 88%). 
m.p.  182-184 oC; UV λmax (EtOH/nm) 271.8, 210.2; IR νmax/cm
-1 3477, 3309, 3210, 2222, 
1589, 1162; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 7.18 (1H, dd, J = 3.8, 4.9 Hz, H-13), 
7.32 (1H, dd, J = 8.6, 2.0 Hz, H-5), 7.51 (1H, d, J = 2.0 Hz, H-3), 7.74 (1H, dd, J = 3.8, 1.4 
Hz, H-12), 7.85 (1H, d, J = 8.6 Hz, H-6), 8.00 (1H, dd, J = 4.9, 1.4 Hz, H-14), 11.43 (1H, s-
br, H-8); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 109.1 (C-1), 117.9 (C-5), 122.0 (C-3), 
125.8 (C-2), 128.5 (C-13), 134.0 (C-12), 135.1 (C-14), 136.4 (C-6), 139.5 (C-10), 143.6 (C-
4), 144.9 (C-7); MS (ES+) m/z 343.2 [M(79Br)+H]+; 
N-(3-Bromo-4-cyanophenyl)-N-methylthiophene-2-sulfonamide (281)  
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Prepared according to general procedure B with the following reagents and quantities: 
N-(4-cyano-3-bromophenyl)thiophene-2-sulfonamide (1.5 g, 4.4 mmol), DMF (30 mL),  
methyliodide (234 μL, 5.28 mmol) and K2CO3(911 mg, 6.60 mmol) to give an off white 
solid (1.25 g, 80%). 
m.p. 82-84 oC; UV λmax (EtOH/nm) 270.6, 256.4, 206.8; IR νmax/cm
-1 3105, 2227, 1594, 
1358; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 3.25 (3H, s, H-15), 7.12 (1H, dd, J = 3.8, 5.0 
Hz, H-13), 7.30 (1H, dd, J = 8.5, 2.0 Hz, H-5), 7.41 (1H, dd, J = 3.8, 1.3 Hz, H-12), 7.51 
(1H, d, J = 2.0 Hz, H-3), 7.61 (1H, d, J = 8.6 Hz, H-6), 7.64 (1H, dd, J = 1.3, 5.0 Hz, H-14); 
13C-NMR (125 MHz, CDCl3) δ ppm; 37.5 (C-15), 113.9 (C-1), 116.7 (C-7), 124.6 (C-5), 
125.5 (C-4), 127.7 (C-13), 129.7 (C-3), 133.1 (C-10), 133.4 (C-14), 134.4 (C-12), 135.9 (C-
5), 145.9 (C-2); MS (ES+) m/z 355.4 [M(79Br)+H]+. 
tert-Butyl 3-amino-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-1-carboxylate 
(282) 
 
N-(4-Cyano-3-bromoophenyl)-N-methylthiophene-2-sulfonamide (50 mg, 0.14 mmol), 
and t-butylcarbazate (23 mg, 0.17 mmol), copper(I) bromide (4 mg, 0.03) and 
potassium carbonate (39 mg, 0.28 mmol) were taken in DMSO (2 mL) under N2 at 
room temperature was added and the solution stirred overnight at 80 oC. After this 
time aqueous NH4Cl (saturated, 5 mL) was added and the solution extracted with 
EtOAc (3 x 5 mL). Organic fractions were combined and washed with brine (10mL) and 
dried over Na2SO4 before subjection to purification by MPLC (0-80% EtOAc in 
petroleum ether) giving the title compound as a white solid (19 mg, 34%). 
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1H-NMR (500 MHz, DMSO-d6) δ ppm; 1.54 (9H, s, H-4’), 3.24 (3H, s, H-17), 6.38 (2H, s, 
H-18), 7.06 (1H, dd, J = 8.4, 1.7 Hz, H-6), 7.24 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.49 (1H, 
dd, J = 1.4, 3.8 Hz, H-16), 7.64  (1H, s, H-8), 7.80 (1H, d, J = 8.4 Hz, H-5), 8.02 (1H, dd, J = 
1.3, 5.0 Hz, H-14); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 28.3 (C-4’), 38.7 (C-17), 83.2 
(C-3’), 112.6 (C-8), 118.6 (C-4), 121.4 (C-5), 121.8 (C-6), 128.5 (C-15), 134.0 (C-16), 
134.7 (C-14), 135.6 (C-12), 140.3 (C-9), 142.1 (C-7), 152.6 (C-3); MS (ES+) m/z 409.2 
[M+H]+; HRMS calcd for C17H21N4O4S2 409.0999 [M+H]
+ found 409.0996. 
tert-Butyl 3-(dimethylamino)-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-1-
carboxylate (284) 
 
Prepared according to general procedure P with the following reagents and quantities: 
tert-butyl 3-amino-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-1-carboxylate 
(30 mg, 0.07 mmol), NaH (5 mg, 0.19), MeI (9 µL, 0.15 mmol), in DMF (4 mL) giving the 
title compound as an off white solid (12 mg, 37 %). 
1H-NMR (500 MHz, CDCl3) δ ppm; 1.42 (9H, s, H-4’), 3.31 (3H, s, H-17), 3.38 (3H, s, H-
19), 3.96 (3H, s, H-19), 6.70 (1H, dd, J = 8.7, 1.8 Hz, H-6), 7.07 (1H, dd, J = 4.9, 3.8 Hz, H-
15), 7.26 (1H, m, H-8), 7.33  (1H, dd, J = 3.8, 1.2 Hz, H-16), 7.52 (1H, d, J = 8.7 Hz, H-5), 
7.58 (1H, dd, J = 1.2, 4.9 Hz, H-14); 13C-NMR (125 MHz, CDCl3) δ ppm; 28.2 (C-4’), 35.5 
(C-19), 36.9 (C-19), 38.7 (C-17), 81.0 (C-3’), 108.6 (C-8), 117.2 (C-4), 117.9 (C-6), 122.8 
(C-5), 127.4 (C-15), 132.1 (C-16), 132.8 (C-14), 136.8 (C-12), 139.6 (C-9), 140.7 (C-7), 
143.9 (C-3), 154.3 (C-1’); MS (ES+) m/z 437.5 [M+H]+; 
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N -Methyl-N-(3-(methylamino)-1H-indazol-6-yl)thiophene-2-sulfonamide (270) 
 
Prepared according to general procedure P with the following reagents and quantities: 
tert-butyl 3-amino-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-1-carboxylate 
(65 mg, 0.16 mmol), NaH (5 mg, 0.19), MeI (7 µL, 0.16 mmol), in DMF (4 mL) giving 
tert-butyl 3-(methylamino)-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-1-
carboxylate as an off white solid (16 mg, 23 %). Isolated material was used immdeatly 
in the nextstep without full characterisation according to general procedure Q with the 
following reagents and quantities: tert-butyl 3-(methylamino)-6-(N-methylthiophene-
2-sulfonamido)-1H-indazole-1-carboxylate (16 mg, 0.04 mmol), in DCM (5 mL) and TFA 
(1 mL) giving the title compound as a yellow solid (7 mg, 57 %). 
m.p. 179-181 oC; UV λmax (EtOH/nm) 332.8, 241.0; IR νmax/cm
-1 3318, 3207, 2925, 1342, 
1148; 1H-NMR (500 MHz, CDCl3) δ ppm; 3.30 (3H, s, H-17), 3.78 (3H, s, H-19), 4.02 (1H, 
s-br, H-18), 6.64 (1H, dd, J = 8.6, 1.7 Hz, H-6), 7.07-7.09 (2H, m, H-15, H-8), 7.34 (1H, dd, 
J = 1.3, 3.8 Hz, H-16), 7.41 (1H, d, J = 8.6 Hz, H-5), 7.59 (1H, dd, J = 1.3, 5.0 Hz, H-14); 
13C-NMR (125 MHz, CDCl3) δ ppm; 34.9 (C-19), 38.7 (C-17), 108.0 (C-8), 113.6 (C-4), 
116.7 (C-6), 119.9 (C-5), 127.3 (C-15), 132.1 (C-14), 132.9 (C-16), 136.8 (C-12), 140.1 (C-
7), 141.3 (C-3), 146.8 (C-9); MS (ES+) m/z 323.2 [M+H]+. 
N-(3-(Dimethylamino)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (271) 
 
Prepared according to general procedure Q with the following reagents and quantities: 
tert-butyl 3-(methylamino)-6-(N-methylthiophene-2-sulfonamido)-1H-indazole-1-
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carboxylate (16 mg, 0.04 mmol), in DCM (5 mL) and TFA (1 mL) giving the title 
compound as an orange solid (8 mg, 86 %). 
m.p. 155-157 oC; UV λmax (EtOH/nm) 340.2, 245.8; IR νmax/cm
-1 3396, 2921, 2852, 1342, 
1145; 1H-NMR (500 MHz, CDCl3) δ ppm; 3.07 (3H, s, H-19), 3.30 (3H, s, H-17), 3.80 (3H, 
s, H-19), 6.61 (1H, d, J = 8.6 Hz, H-6), 7.03 (1H, s, H-8), 7.07 (1H, dd, J = 5.0, 3.8 Hz, H-
15), 7.33 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.38 (1H, d, J = 8.6 Hz, H-5), 7.58 (1H, dd, J = 1.3, 
5.0 Hz, H-14); 13C-NMR (125 MHz, CDCl3) δ ppm; 38.8 (C-17), 107.8 (C-8), 113.3 (C-4), 
116.2 (C-6), 119.7 (C-5), 127.3 (C-15), 132.1 (C-14), 132.8 (C-16), 136.8 (C-12), 140.5 (C-
7), 150.1 (C-9); MS (ES+) m/z 337.2 [M+H]+. 
2-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)thio)thiazole (289) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 2-mercaptothiazole (35 
mg, 0.30 mmol) in DMF (3 mL). The product was isolated a pale yellow solid (55 mg, 
97%). 
Rf 0.44 (10% MeOH in DCM); m.p. 75-77 
oC; UV λmax (EtOH/nm) 297.2, 260.2, 217.8; IR 
νmax/cm
-1 3353, 3175, 3109, 3000, 2918; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.64 (2H, 
m, H-18), 1.01 (2H, m, H-18), 2.23 (1H, m, H-17), 5.00 (2H, s, H-10), 6.29 (1H, s, H-6), 
7.22 (1H, s, H-8), 8.18 (1H, s, H-3), 8.23-8.25 (2H, m, H-14, H-15), 13.09 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.5 (C-18), 13.2 (C-17), 61.0 (C-10), 110.4 (C-8), 
117.5 (C-6), 123.3 (C-4), 126.0 (C-7), 129.4 (C-15), 132.6 (C-3), 137.4 (C-5), 140.1 (C-9), 
145.6 (C-15), 164.6 (C-12);  MS (ES+) m/z 320.2 [M+H]+; HRMS calcd for C14H14N3S2 
288.0624 [M+H]+ found 288.0624. 
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4-Cyclopropyl-6-((pyridin-2-ylthio)methyl)-1H-indazole (290) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and pyridine-2-thiol (33 mg, 
0.30 mmol) in DMF (3 mL). The product was isolated a white solid (50 mg, 89%). 
Rf 0.55 (10% MeOH in DCM); m.p. 49-51 
oC; UV λmax (EtOH/nm) 294.0, 251.8, 215.4; IR 
νmax/cm
-1 3166, 3103, 2997, 2928, 1121; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.88 (2H, m, 
H-19), 1.06 (2H, m, H-19), 2.22 (1H, m, H-17), 4.54 (2H, s, H-10), 6.82 (1H, s, H-6), 7.03 
(1H, dd, J = 4.3, 6.5 Hz, H-15) 7.18 (1H, d, J = 8.1 Hz, H-17), 7.39 (1H, s, H-8), 7.50 (1H, 
dt, J = 8.1, 1.8 Hz, H-16), 8.15 (1H, s, H-3), 8.49 (1H, d, J = 4.3 Hz, H-14); 13C-NMR (125 
MHz, CDCl3) δ ppm; 8.4 (C-19), 13.5 (C-18), 35.1 (C-10), 107.1 (C-8), 118.0 (C-6), 119.9 
(C-15) 122.5 (C-4, C-17), 133.2 (C-3), 136.6 (C-16), 137.4 (C-7), 137.9 (C-5), 140.3 (C-9), 
149.0 (C-14), 158.4 (C-12);  MS (ES+) m/z 282.2 [M+H]+; HRMS calcd for C16H16N3S 
282.1059 [M+H]+ found 282.1055. 
4-Cyclopropyl-6-((pyrimidin-2-ylthio)methyl)-1H-indazole (291) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 2-mercaptopyrimidine 
(33 mg, 0.30 mmol) in DMF (3 mL). The product was isolated a white solid (56 mg, 
99%). 
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Rf 0.52 (10% MeOH in DCM); m.p. 137-139 
oC; UV λmax (EtOH/nm) 291.0, 254.2, 216.4; 
IR νmax/cm
-1 3178, 3104, 2926, 1374; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.83 (2H, m, H-
17), 1.00 (2H, m, H-17), 2.16 (1H, m, H-16), 4.43 (2H, s, H-10), 6.78 (1H, s, H-6), 6.91 
(1H, t, J = 4.9 Hz, H-15), 7.32 (1H, s, H-8), 8.08 (1H, s, H-3), 8.47 (2H, d, J = 4.9 Hz, H-14); 
13C-NMR (125 MHz, CDCl3) δ ppm; 8.4 (C-17), 13.5 (C-16), 35.7 (C-10), 107.0 (C-8), 
116.7 (C-15), 118.0 (C-6), 122.7 (C-4), 133.6 (C-3), 136.8 (C-9), 137.8 (C-7), 140.3 (C-5), 
157.3 (C-14), 172.1 (C-12);  MS (ES+) m/z 283.2 [M+H]+; HRMS calcd for C15H15N4S 
283.1012 [M+H]+ found 283.1010. 
2-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)thio)-1,3,4-thiadiazole (292) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 2-mercapto-1,3,4-
thiadiazole (35 mg, 0.30 mmol) in DMF (3 mL). The product was isolated an off white 
solid (57 mg, 99%). 
Rf 0.36 (10% MeOH in DCM); m.p. 157-159 
oC; UV λmax (EtOH/nm) 264.4, 218.0; IR 
νmax/cm
-1 3185, 3084, 1368, 1064; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.83 (2H, m, H-
18), 1.05 (2H, m, H-18), 2.29 (1H, m, H-17), 4.66 (2H, s, H-10), 6.77 (1H, s, H-6), 7.39 
(1H, s, H-8), 8.16 (1H, s, H-3), 9.51 (1H, s, H-14), 13.04 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm; 9.4 (C-18), 13.6 (C-17), 38.7 (C-10), 107.9 (C-8), 116.6 (C-6), 
122.7 (C-4), 132.6 (C-3), 134.9 (C-7), 137.7 (C-5), 140.1 (C-9), 154.7 (C-14), 165.5 (C-12);  
MS (ES+) m/z 289.2 [M+H]+; HRMS calcd for C13H13N4S2 289.0576 [M+H]
+ found 
289.0574. 
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4-Cyclopropyl-6-(((1-methyl-1H-imidazol-2-yl)thio)methyl)-1H-indazole (293) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 2-mercapto-1-
methylimidazole (34 mg, 0.30 mmol) in DMF (3 mL). The product was isolated a white 
solid (55 mg, 97%). 
Rf 0.50 (10% MeOH in DCM); m.p. 53-55
oC; UV λmax (EtOH/nm) 294.6, 259.6, 218.2; IR 
νmax/cm
-1 3102, 3010, 2930, 2871, 1279; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.83 (2H, m, 
H-18), 1.05 (2H, m, H-18), 2.20 (1H, m, H-17), 3.21 (3H, s, H-19), 4.22 (2H, s, H-10), 6.54 
(1H, s, H-6), 6.84 (1H, s, H-14), 7.04 (1H, s, H-8), 7.14 (1H, s, H-15), 8.13 (1H, s, H-3), 
10.53 (1H, s-br, H-1); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.5 (C-18), 13.4 (C-17), 33.2 (C-
19), 40.5 (C-10), 106.8 (C-8), 117.3 (C-6), 122.5 (C-14), 122.7 (C-4), 129.7 (C-15), 133.5 
(C-3), 136.9 (C-7), 137.9 (C-5), 140.2 (C-9), 140.5 (C-12);  MS (ES+) m/z 285.2 [M+H]+; 
HRMS calcd for C15H17N4S 285.1168 [M+H]
+ found 285.1165. 
4-Cyclopropyl-6-((pyridin-4-ylthio)methyl)-1H-indazole (294) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 4-mercapto-1-
methylimidazole (33 mg, 0.30 mmol) in DMF (3 mL). The product was isolated a white 
solid (46 mg, 83%). 
Rf 0.53 (10% MeOH in DCM); m.p. 148-150 
oC; UV λmax (EtOH/nm) 265.4, 216.0; IR 
νmax/cm
-1 3000, 2852, 2810, 1572, 936; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.91 (2H, m, 
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H-17), 1.09 (2H, m, H-17), 2.25 (1H, m, H-16), 4.29 (2H, s, H-10), 6.79 (1H, s, H-6), 7.13 
(1H, d, J = 6.3 Hz, H-13), 7.32 (1H, s, H-8), 8.16 (1H, s, H-3), 8.38 (2H, d, J = 6.3 Hz, H-14), 
10.30 (1H, s, H-1); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.6 (C-17), 13.6 (C-16), 36.2 (C-10), 
106.7 (C-8), 117.3 (C-6), 120.9 (C-14), 123.0 (C-4), 133.7 (C-3), 134.7 (C-7), 138.4 (C-5), 
140.3 (C-9), 149.2 (C-13);  MS (ES+) m/z 314.3 [M+H]+; HRMS calcd for C16H16N3S 
282.1059 [M+H]+ found 282.1055. 
4-Cyclopropyl-6-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-1H-indazole (295) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 2-methyl-1H-tetrazole-5-
thiol (34 mg, 0.30 mmol) in DMF (3 mL). The product was isolated a white solid (57 mg, 
99%). 
Rf 0.38 (10% MeOH in DCM); m.p. 51-53 
oC; UV λmax (EtOH/nm) 296.8, 261.8, 229.2; IR 
νmax/cm
-1 3183, 2999, 1170, 937; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.89 (2H, m, H-18), 
1.09 (2H, m, H-18), 2.23 (1H, m, H-17), 3.80 (3H, s, H-19), 4.61 (2H, s, H-10), 6.76 (1H, s, 
H-6), 7.35 (1H, s, H-8), 8.18 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.7 (C-18), 
13.6 (C-17), 33.5 (C-19), 38.4 (C-10), 107.8 (C-8), 117.5 (C-6), 134.9 (C-3),  138.7 (C-5), 
153.7 (C-12);  MS (ES+) m/z 287.2 [M+H]+; HRMS calcd for C13H15N6S 287.1073 [M+H]
+ 
found 287.1071. 
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6-(((1H-1,2,4-Triazol-3-yl)thio)methyl)-4-cyclopropyl-1H-indazole (296) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 3-mercapto-1,2,4-triazole 
(31 mg, 0.30 mmol) in DMF (3 mL). The product was isolated a white solid (50 mg, 
93%). 
Rf 0.46 (10% MeOH in DCM); m.p.79-81 
oC; UV λmax (EtOH/nm) 295.0, 261.4, 219.0; IR 
νmax/cm
-1 3099, 2913, 2853, 938; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.81 (2H, m, H-
18), 1.03 (2H, m, H-18), 2.25 (1H, m, H-17), 4.42 (2H, s, H-10), 6.67 (1H, s, H-6), 7.27 
(1H, s, H-8), 8.13 (1H, s, H-3), 8.49 (1H, s, H-15), 12.96 (1H, s, H-1), 14.07 (1H, s-br, H-
14); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.3 (C-18), 13.6 (C-17), 36.6 (C-10), 107.3 (C-
8), 116.5 (C-6), 122.4 (C-4), 124.7 (C-7), 132.4 (C-3), 137.3 (C-5), 140.3 (C-9), 145.7 (C-
15), 163.2 (C-12);  MS (ES+) m/z 272.2 [M+H]+; HRMS calcd for C13H14N5S 272.0964 
[M+H]+ found 272.0963. 
6-(((1H-Imidazol-2-yl)thio)methyl)-4-cyclopropyl-1H-indazole (297) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (50 mg, 0.20 mmol), Cs2CO3 (71 mg, 0.22 mmol) and 2-sulphony-1H-imidazole 
(30 mg, 0.30 mmol) in DMF (3 mL). The product was isolated a white solid (54 mg, 
99%). 
Rf 0.38 (10% MeOH in DCM); m.p. 102-104 
oC; UV λmax (EtOH/nm) 294.8, 259.4, 218.8; 
IR νmax/cm
-1 3091, 3007, 2911; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.77 (2H, m, H-18), 
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1.02 (2H, m, H-18), 2.24 (1H, m, H-17), 4.29 (2H, s, H-10), 6.49 (1H, s, H-6), 7.07 (1H, s, 
H-8), 7.15 (2H, s, H-14), 8.12 (1H, s, H-3), 12.27 (1H, s-br, H-13), 12.09 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.3 (C-18), 13.5 (C-17), 61.3 (C-10), 107.2 (C-8), 
116.3 (C-6), 122.5 (C-4), 126.2 (C-5), 132.4 (C-3), 136.9 (C-7), 140.3 (C-9), 143.3 (C-12);  
MS (ES+) m/z 271.2 [M+H]+; HRMS calcd for C14H15N4S 271.1012 [M+H]
+ found 
271.1009. 
2-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)thiazole (298) 
 
Prepared according to general procedure K using 2-(((4-cyclopropyl-1H-indazol-6-
yl)methyl)thio)thiazole (53 mg, 0.18 mmol) and Oxone® (340 mg, 1.20 mmol) in MeOH 
(10 mL) and H2O (5 mL). The product was isolated as an off white solid (38 mg, 65%). 
Rf 0.38 (10% MeOH in DCM); m.p. 75-77 
oC; UV λmax (EtOH/nm) 297.2, 260.2, 217.8; IR 
νmax/cm
-1 3353, 3175, 3109, 3000, 2918; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.64 (2H, 
m, H-18), 1.01 (2H, m, H-18), 2.23 (1H, m, H-17), 5.00 (2H, s, H-10), 6.29 (1H, s, H-6), 
7.22 (1H, s, H-8), 8.18 (1H, s, H-3), 8.23-8.25 (2H, m, H-14, H-15), 13.09 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.5 (C-18), 13.2 (C-17), 61.0 (C-10), 110.4 (C-8), 
117.5 (C-6), 123.3 (C-4), 126.0 (C-7), 129.4 (C-15), 132.6 (C-3), 137.4 (C-5), 140.1 (C-9), 
145.6 (C-15), 164.6 (C-12);  MS (ES+) m/z 320.2 [M+H]+; HRMS calcd for C14H14N3O2S2 
320.0522 [M+H]+ found 320.0522. 
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4-Cyclopropyl-6-((pyridin-2-ylsulfonyl)methyl)-1H-indazole (299) 
 
Prepared according to general procedure K using 4-cyclopropyl-6-((pyridin-2-
ylthio)methyl)-1H-indazole (40 mg, 0.14 mmol) and Oxone® (262 mg, 0.85 mmol) in 
MeOH (5 mL) and H2O (5 mL). The product was isolated as an off white solid (19 mg, 
42%). 
Rf 0.50 (10% MeOH in DCM); m.p. 88-90 
oC; UV λmax (EtOH/nm) 297.6, 260.4, 216.6; IR 
νmax/cm
-1 3329, 3181, 3092, 3002, 1307, 1164, 1106; 1H-NMR (500 MHz, DMSO-d6) δ 
ppm; 0.59 (2H, m, H-19), 0.99 (2H, m, H-19), 2.21 (1H, m, H-17), 4.88 (2H, s, H-10), 6.27 
(1H, s, H-6), 7.19 (1H, s, H-8), 7.77-7.80 (2H, m, H-15, H-17), 8.05 (1H, ddd, J = 7.6, 7.6, 
1.3 Hz, H-16), 8.16 (1H, s, H-3), 8.89 (1H, d, J = 4.0 Hz, H-14), 13.04 (1H, s, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm; 9.4 (C-19), 13.2 (C-18), 58.1 (C-10), 110.3 (C-8), 
117.7 (C-6), 123.2 (C-4, C-15), 126.5 (C-7), 128.5 (C-17), 132.6 (C-3), 137.1 (C-5), 139.3 
(C-16), 140.1 (C-9), 150.8 (C-14), 156.5 (C-12);  MS (ES+) m/z 314.3 [M+H]+; HRMS calcd 
for C16H16N3O2S 314.0958 [M+H]
+ found 314.0959. 
4-Cyclopropyl-6-((pyrimidin-2-ylsulfonyl)methyl)-1H-indazole (300) 
 
Prepared according to general procedure K using 4-cyclopropyl-6-((pyrimidin-2-
ylthio)methyl)-1H-indazole (50 mg, 0.18 mmol) and Oxone® (327 mg, 1.06 mmol) in 
MeOH (10 mL) and H2O (5 mL). The product was isolated as an off white solid (32 mg, 
58%). 
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Rf 0.48 (10% MeOH in DCM); m.p. 179-181 
oC; UV λmax (EtOH/nm) 297.0, 261.8, 217.6; 
IR νmax/cm
-1 3240, 3079, 1318, 1121; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.69 (2H, m, 
H-17), 1.03 (2H, m, H-17), 2.25 (1H, m, H-16), 5.04 (2H, s, H-10), 6.51 (1H, s, H-6), 7.30 
(1H, s, H-8), 7.88 (1H, t, J = 4.9 Hz, H-15), 8.18 (1H, s, H-3), 9.12 (2H, d, J = 4.9 Hz, H-14), 
13.07 (1H, s, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.4 (C-17), 13.4 (C-16), 57.4 
(C-10), 110.6 (C-8), 118.2 (C-6), 123.1 (C-4), 125.2 (C-15), 125.8 (C-7), 132.6 (C-3), 137.3 
(C-5), 140.1 (C-9), 159.6 (C-15), 165.3 (C-12);  MS (ES+) m/z 315.3 [M+H]+; HRMS calcd 
for C15H15N4O2S 315.0910 [M+H]
+ found 315.0909. 
2-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)-1,3,4-thiadiazole (301) 
 
Prepared according to general procedure K using 2-(((4-cyclopropyl-1H-indazol-6-
yl)methyl)thio)-1,3,4-thiadiazole (50 mg, 0.17 mmol) and Oxone® (320 mg, 1.04 mmol) 
in MeOH (10 mL) and H2O (5 mL). The product was isolated as an off white solid (31 mg, 
56%). 
Rf 0.36 (10% MeOH in DCM); m.p. 173-175 
oC; UV λmax (EtOH/nm) 298.4, 261.0, 218.0; 
IR νmax/cm
-1 3242, 3086, 2914, 1618; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.66 (2H, m, 
H-18), 1.03 (2H, m, H-18), 2.25 (1H, m, H-17), 5.21 (2H, s, H-10), 6.41 (1H, s, H-6), 7.27 
(1H, s, H-8), 8.21 (1H, s, H-3), 9.93 (1H, s, H-14), 13.13 (1H, s-br, H-1); 13C-NMR (125 
MHz, DMSO-d6) δ ppm; 9.5 (C-18), 13.2 (C-17), 61.7 (C-10), 110.7 (C-8), 117.8 (C-6), 
123.4 (C-4), 125.3 (C-5), 132.7 (C-3), 137.7 (C-7), 140.1 (C-9), 160.6 (C-14), 168.3 (C-12);  
MS (ES+) m/z 321.2 [M+H]+; HRMS calcd for C13H13N4O2S2 321.0474 [M+H]
+ found 
321.0475. 
 
 
 
363 
 
4-Cyclopropyl-6-(((1-methyl-1H-imidazol-2-yl)sulfonyl)methyl)-1H-indazole (302) 
 
Prepared according to general procedure K using 4-cyclopropyl-6-(((1-methyl-1H-
imidazol-2-yl)thio)methyl)-1H-indazole (59 mg, 0.20 mmol) and Oxone® (340 mg, 1.20 
mmol) in MeOH (5 mL) and H2O (5 mL). The product was isolated as an off white solid 
(50 mg, 77%). 
Rf 0.44 (10% MeOH in DCM); m.p. 86-88
oC; UV λmax (EtOH/nm) 306.6, 297.6, 241.4, 
216.8; IR νmax/cm
-1 3337, 3114, 3003, 2920; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.66 
(2H, m, H-18), 1.02 (2H, m, H-18), 2.26 (1H, m, H-17), 3.29 (3H, s, H-19), 4.82 (2H, s, H-
10), 6.18 (1H, s, H-6), 7.18 (1H, s, H-8), 7.20 (1H, s, H-15), 7.42 (1H, s, H-14), 8.22 (1H, s, 
H-3), 13.11 (1H, s-br, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.5 (C-18), 13.2 (C-17), 
34.7 (C-19), 61.9 (C-10), 110.4 (C-8), 117.4 (C-6), 123.3 (C-4), 126.2 (C-7), 127.5 (C-14), 
129.3 (C-15), 132.6 (C-3), 137.4 (C-5), 140.0 (C-9), 140.7 (C-12);  MS (ES+) m/z 317.3 
[M+H]+; HRMS calcd for C15H17N4O2S 317.1067 [M+H]
+ found 317.1064. 
4-Cyclopropyl-6-((pyridin-4-ylsulfonyl)methyl)-1H-indazole (303) 
 
Prepared according to general procedure K using 4-cyclopropyl-6-((pyridin-4-
ylthio)methyl)-1H-indazole (52 mg, 0.19 mmol) and Oxone® (114 mg, 0.38 mmol) in 
MeOH (10 mL) and H2O (5 mL). The product was isolated as an off white solid (30 mg, 
52%). 
Rf 0.47 (10% MeOH in DCM); m.p. 159-161 
oC; UV λmax (EtOH/nm) 296.6, 261.8, 217.6; 
IR νmax/cm
-1 3569, 3088,3023, 2974, 1311, 1163; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 
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0.58 (2H, m, H-17), 1.00 (2H, m, H-17), 2.23 (1H, m, H-16), 4.90 (2H, s, H-10), 6.31 (1H, 
s, H-6), 7.19 (1H, s, H-8), 7.66 (2H, d, J = 4.5 Hz, H-13), 8.18 (1H, s, H-3), 8.85 (2H, d, J = 
4.5 Hz, H-14), 13.07 (1H, s, H-1); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.3 (C-17), 13.2, 
(C-16), 60.8 (C-10), 110.3 (C-8), 117.8 (C-6), 121.9 (C-13), 123.2 (C-4), 126.3 (C-7), 132.6 
(C-3), 137.2 (C-5), 140.0 (C-9), 146.6 (C-12), 151.4 (C-14);  MS (ES+) m/z 314.3 [M+H]+; 
HRMS calcd for C16H16N3O2S 314.0958 [M+H]
+ found 314.0958. 
4-Cyclopropyl-6-(((1-methyl-1H-tetrazol-5-yl)sulfonyl)methyl)-1H-indazole (304) 
 
Prepared according to general procedure K using 4-cyclopropyl-6-(((1-methyl-1H-
tetrazol-5-yl)sulfonyl)methyl)-1H-indazole (50 mg, 0.18 mmol) and Oxone® (321 mg, 
1.04 mmol) in MeOH (10 mL) and H2O (5 mL). The product was isolated as an off white 
solid (31 mg, 56%). 
Rf 0.33 (10% MeOH in DCM); m.p. 86-88 
oC; UV λmax (EtOH/nm) 298.6, 260.4, 217.8; IR 
νmax/cm
-1 3386, 3181, 2919, 1618; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.81 (2H, m, H-18), 
1.11 (2H, m, H-18), 2.22 (1H, m, H-17), 3.79 (3H, s, H-19), 4.88 (2H, s, H-10), 6.50 (1H, s, 
H-6), 7.23 (1H, s, H-8), 8.22 (1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 9.1 (C-18), 
13.3 (C-17), 35.8 (C-19), 62.9 (C-10), 110.1 (C-8), 118.5 (C-6), 123.7 (C-4), 139.5 (C-5), 
152.3 (C-12);  MS (ES+) m/z 319.3 [M+H]+; HRMS calcd for C13H15N6O2S 319.0972 
[M+H]+ found 319.0971. 
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6-(((1H-1,2,4-Triazol-3-yl)sulfonyl)methyl)-4-cyclopropyl-1H-indazole (305) 
 
Prepared according to general procedure K using 6-(((1H-1,2,4-triazol-3-
yl)thio)methyl)-4-cyclopropyl-1H-indazole (58 mg, 0.21 mmol) and Oxone® (340 mg, 
1.20 mmol) in MeOH (10 mL) and H2O (5 mL). The product was isolated as a white solid 
(23 mg, 36%). 
Rf 0.40 (10% MeOH in DCM); m.p. 250-252 
oC; UV λmax (EtOH/nm) 297.0, 260.6, 219.2; 
IR νmax/cm
-1 3250, 3136, 3001, 1310; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.68 (2H, m, 
H-18), 1.03 (2H, m, H-18), 2.25 (1H, m, H-17), 4.86 (2H, s, H-10), 6.38 (1H, s, H-6), 7.22 
(1H, s, H-8), 8.18 (1H, s, H-3), 8.92 (1H, s, H-15), 13.08 (1H, s, H-1), 15.03 (1H, s-br, H-
14); 13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.4 (C-18), 13.3 (C-17), 60.5 (C-10), 110.4 (C-
8), 117.9 (C-6), 123.2 (C-4), 126.0 (C-7), 132.5 (C-3), 137.1 (C-5), 140.1 (C-9); MS (ES+) 
m/z 304.2 [M+H]+; HRMS calcd for C13H14N5O2S 304.0863 [M+H]
+ found 304.0862. 
6-(((1H-Imidazol-2-yl)sulfonyl)methyl)-4-cyclopropyl-1H-indazole (306) 
 
Prepared according to general procedure K using 6-(((1H-imidazol-2-yl)thio)methyl)-4-
cyclopropyl-1H-indazole (50 mg, 0.19 mmol) and Oxone® (340 mg, 1.20 mmol) in 
MeOH (5 mL) and H2O (5 mL). The product was isolated as an off white solid (45 mg, 
80%). 
Rf 0.41 (10% MeOH in DCM); m.p. 216-218 
oC; UV λmax (EtOH/nm) 297.2, 216.0; IR 
νmax/cm
-1 3371, 3080, 2983, 2884, 2768, 1587; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 
0.64 (2H, m, H-18), 0.99 (2H, m, H-18), 2.22 (1H, m, H-17), 4.80 (2H, s, H-10), 6.16 (1H, 
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s, H-6), 7.14 (1H, s, H-8), 7.32 (2H, s, H-14), 8.18 (1H, s, H-3), 13.08 (1H, s-br, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm; 9.5 (C-18), 13.2 (C-17), 61.3 (C-10), 110.2 (C-8), 
117.3 (C-6), 123.2 (C-4), 126.5 (C-5), 132.5 (C-3), 137.3 (C-7), 140.1 (C-9), 142.1 (C-12);  
MS (ES+) m/z 303.3 [M+H]+; HRMS calcd for C14H15N4O2S 303.0910 [M+H]
+ found 
303.0908. 
3-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)thio)benzoic acid (312) 
 
Prepared according to general procedure I using 6-(bromomethyl)-4-cyclopropyl-1H-
indazole (100 mg, 0.40 mmol), Cs2CO3 (324 mg, 1.00 mmol) and 3-mercaptobenzoic 
acid (74 mg, 0.48 mmol) in DMF (4 mL). The product was isolated a white solid (118 mg, 
92%). 
1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.79-0.83 (2H, m, H-21), 0.99-1.02 (2H, m, H-21), 
2.17-2.25 (1H, m, H-20), 4.62 (2H, s, H-10), 6.54 (1H, d, J = 9.9 Hz, H- 15), 6.67 (1H, s, H-
6), 7.25 (1H, s, H-8), 7.71 (1H, dd,  J = 7.8, 7.8  Hz, H-16), 7.88 (1H, d, J = 7.8 Hz, H-17), 
8.14 (1H, s, H-13), 8.17 (1H, s, H-3), 13.06 (1H, s-br, H-1), 13.50 (1H, s-br, H-19); 13C-
NMR (125 MHz, DMSO-d6) δ ppm; 7.5 (C-21), 12.6 (C-20), 64.1 (C-10), 104.7 (C-8), 
114.8 (C-6), 122.4 (C-4), 127.1 (C-5), 128.5 (C-13), 130.5 (C-16), 132.0 (C-3), 134.9 (C-
17), 135.2 (C-15), 137.0 (C-7), 137.8 (C-12), 171.4 C-18);  MS (ES+) m/z 325.3 [M+H]+; 
HRMS calcd for C18H17N2O2S 325.1005 [M+H]
+ found 325.1009. 
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3-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)benzoic acid (310) 
 
Prepared according to general procedure K 3-(((4-cyclopropyl-1H-indazol-6-
yl)methyl)thio)benzoic acid (100 mg, 0.31 mmol) and Oxone® (568 mg, 1.85 mmol) in 
MeOH (20 mL) and H2O (10 mL). The product was isolated as a white solid (33 mg, 
30%). 
Rf 0.12 (10% MeOH in DCM); m.p. 246-248 
oC; UV λmax (EtOH/nm) 297.4, 261.2, 217.6; 
IR νmax/cm
-1 3318, 2922, 1684, 1297, 1152; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.55 
(2H, m, H-21), 0.96 (2H, m, H-21), 2.21 (1H, m, H-20), 4.81 (2H, s, H-10), 6.25 (1H, s, H-
6), 7.19 (1H, s, H-8), 7.71 (1H, dd,  J = 7.8, 7.8  Hz, H-16), 7.88 (1H, d, J = 7.8 Hz, H-17), 
8.14 (1H, s, H-13), 8.17 (1H, s, H-3), 13.06 (1H, s-br, H-1), 13.50 (1H, s-br, H-19); 13C-
NMR (125 MHz, DMSO-d6) δ ppm; 9.1 (C-21), 13.1 (C-20), 61.5 (C-10), 110.3 (C-8), 
117.9 (C-6), 123.1 (C-4), 126.9 (C-7), 129.4 (C-13), 130.1 (C-16), 132.4 (C-3), 132.6 (C-
17), 134.6 (C-15), 137.0 (C-5), 139.3 (C-12), 166.3 (C-18);  MS (ES+) m/z 357.2 [M+H]+; 
HRMS calcd for C18H17N2O4S 357.0904 [M+H]
+ found 357.0904. 
 (3-(((4-cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)phenyl)methanol (311) 
 
3-(((4-Cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)benzoic acid (207 mg, 0.58 mmol) 
was taken in THF (15 mL) at 0 oC under N2 and borane.THF complex (1M, 1.45 mL, 1.45 
mmol) was added by syringe over 5 minutes. The reaction mix was stirred for 18 h 
after which time the solution was quenched with H2O (5 mL) and extracted with EtOAc 
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(3 x 10 mL). The title compound was isolated after MPLC (0-70% EtOAc in petroleum 
ether) as a white solid (65 mg, 33%). 
Rf 0.22 (10% MeOH in DCM); m.p. 146-148 
oC; UV λmax (EtOH/nm) 297.2, 261.6, 216.4; 
IR νmax/cm
-1 3299, 3000, 1293, 1139; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.59 (2H, m, 
H-21), 0.98 (2H, m, H-21), 2.22 (1H, m, H-20), 4.55 (2H, s, H-18), 4.72 (2H, s, H-10), 5.44 
(1H, s-br, H-10), 6.28 (1H, s, H-6), 7.20 (1H, s, H-8), 7.51-7.55 (2H, m, H-16, H-17), 7.64 
(1H, d, J = 6.7 Hz, H-15), 7.70 (1H, s, H-13), 8.17 (1H, s, H-3), 13.06 (1H, s, H-1); 13C-
NMR (125 MHz, DMSO-d6) δ ppm; 9.1 (C-21), 13.1 (C-20), 61.5 (C-10), 110.3 (C-8), 
117.9 (C-6), 123.1 (C-4), 126.9 (C-7), 129.4 (C-13), 130.1 (C-16), 132.4 (C-3), 132.6 (C-
17), 134.6 (C-15), 137.0 (C-5), 139.3 (C-12), 166.3 (C-18);  MS (ES+) m/z 343.3 [M+H]+; 
HRMS calcd for C18H19N2O3S 343.1111 [M+H]
+ found 343.1114. 
Methyl 2-(3-(((4-cyclopropyl-1H-indazol-6-yl)methyl)thio)-1H-1,2,4-triazol-1-
yl)acetate (314) 
 
6-(((1H-1,2,4-Triazol-3-yl)thio)methyl)-4-cyclopropyl-1H-indazole (200 mg, 0.74 mmol) 
and Cs2CO3 ( 289 mg, 0.89 mmol) was dissolved in anhydrous DMF (10 mL) and methyl 
bromoacetate (81 μL, 0.89 mmol) was added. The reaction was stirred for 48 hrs at rt 
under N2 before removal of DMF in vacuo. The residue was resuspended in EtOAc and 
water, organic fractions were extracted and combined before purification by MPLC (0-
80% EtOAC in petroleum  ether) giving the title compound as an off white solid (23 mg, 
10%) 
Rf 0.49 (10% MeOH in DCM); m.p. 105-107 
oC; UV λmax (EtOH/nm) 297.0, 261.0, 218.2; 
IR νmax/cm
-1 3181, 2999, 2950, 1746, 1219, 1174; 1H-NMR (500 MHz, CDCl3) δ ppm; 
0.87 (2H, m, H-21), 1.08 (2H, m, H-21), 2.21 (1H, m, H-20), 3.70 (3H, s, H-19), 4.46 (2H, 
s, H-10), 4.74 (2H, s, H-16), 6.68 (1H, s, H-6), 7.20 (1H, s, H-8), 7.96 (1H, s, H-15), 8.15 
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(1H, s, H-3); 13C-NMR (125 MHz, CDCl3) δ ppm; 8.6 (C-21), 13.5 (C-20), 39.2 (C-10), 49.4 
(C-16), 52.9 (C-19), 107.1 (C-8), 117.3 (C-6), 123.0 (C-4), 133.5 (C-7), 135.5 (C-3), 138.4 
(C-5), 140.1 (C-9), 151.9 (C-15), 152.5 (C-12), 166.7 (C-17);  MS (ES+) m/z 344.3 [M+H]+; 
HRMS calcd for C16H18N5O2S 344.1176 [M+H]
+ found 344.1177. 
Methyl 2-(3-(((4-cyclopropyl-1H-indazol-6-yl)methyl)sulfonyl)-1H-1,2,4-triazol-1-
yl)acetate (308) 
 
Prepared according to general procedure K using methyl 2-(3-(((4-cyclopropyl-1H-
indazol-6-yl)methyl)thio)-1H-1,2,4-triazol-1-yl)acetate (23 mg, 0.07 mmol) and Oxone® 
(124 mg, 0.20 mmol) in MeOH (2 mL) and H2O (0.5 mL). The product was isolated as a 
white solid (8 mg, 30%). 
Rf 0.43 (10% MeOH in DCM); m.p. 181-183 
oC; UV λmax (EtOH/nm) 298.6, 261.0, 215.8; 
IR νmax/cm
-1 3222, 1745, 1326, 1143; 1H-NMR (500 MHz, CDCl3) δ ppm; 0.81 (2H, m, H-
21), 1.08 (2H, m, H-21), 2.22 (1H, m, H-20), 3.72 (3H, s, H-19), 4.76 (2H, s, H-10), 5.00 
(2H, s, H-16), 6.55 (1H, s, H-6), 7.25 (1H, s, H-8), 8.08 (1H, s, H-15), 8.20 (1H, s, H-3); 
13C-NMR (125 MHz, CDCl3) δ ppm; 8.8 (C-21), 13.3 (C-20), 51.7 (C-16), 53.1 (C-19), 62.0 
(C-10), 110.0 (C-8), 118.9 (C-6), 124.3 (C-4), 138.8 (C-5), 140.1 (C-9), 150.4 (C-12), 151.0 
(C-15), 166.6 (C-17);  MS (ES+) m/z 376.2 [M+H]+; HRMS calcd for C16H18N5O4S 376.1074 
[M+H]+ found 376.1075. 
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4-Cyclopropyl-6-(((1-methyl-1H-1,2,4-triazol-3-yl)thio)methyl)-1H-indazole (313) 
 
6-(((1H-1,2,4-Triazol-3-yl)thio)methyl)-4-cyclopropyl-1H-indazole (70 mg, 0.26 mmol) 
and Cs2CO3 ( 92 mg, 0.28 mmol) was dissolved in anhydrous DMF (3 mL) and methyl 
iodide (13 μL, 0.28 mmol) was added. The reaction was stirred for 48 hrs at rt under N2 
before removal of DMF in vacuo. The residue was resuspended in EtOAc and water, 
organic fractions were extracted and combined before purification by MPLC (0-80% 
EtOAC in petroleum  ether) giving the title compound as an off white solid (13 mg, 18%) 
Rf 0.52 (10% MeOH in DCM); m.p. 158-160 
oC; UV λmax (EtOH/nm) 295.0, 261.8, 218.6; 
IR νmax/cm
-1 3251, 3101, 2999, 2950, 1356, 1283; 1H-NMR (500 MHz, CDCl3) δ ppm; 
0.88 (2H, m, H-18), 1.06 (2H, m, H-18), 2.22 (1H, m, H-17), 3.86 (3H, s, H-16), 4.41 (2H, 
s, H-10), 6.80 (1H, s, H-6), 7.33 (1H, s, H-8), 7.98 (1H, s, H-15), 8.14 (1H, s, H-3); 13C-
NMR (125 MHz, CDCl3) δ ppm; 8.4 (C-18), 13.5 (C-17), 36.3 (C-16), 37.0 (C-10), 107.0 (C-
8), 117.9 (C-6), 122.7 (C-4), 133.6 (C-3), 136.8 (C-7), 137.8 (C-5), 140.3 (C-9), 144.5 (C-
15), 160.6 (C-12);  MS (ES+) m/z 286.3 [M+H]+; HRMS calcd for C14H16N5S 286.1121 
[M+H]+ found 286.1124. 
4-Cyclopropyl-6-(((1-methyl-1H-1,2,4-triazol-3-yl)sulfonyl)methyl)-1H-indazole (307) 
 
Prepared according to general procedure K using 4-cyclopropyl-6-(((1-methyl-1H-1,2,4-
triazol-3-yl)thio)methyl)-1H-indazole (10 mg, 0.03 mmol) and Oxone® (64 mg, 0.11 
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mmol) in MeOH (4 mL) and H2O (1 mL). The product was isolated as a white solid (11 
mg, 63%). 
Rf 0.48 (10% MeOH in DCM); m.p. 158-160 
oC; UV λmax (EtOH/nm) 297.4, 261.0, 218.8; 
IR νmax/cm
-1 3375, 3113, 1325, 1137; 1H-NMR (500 MHz, DMSO-d6) δ ppm; 0.71 (2H, m, 
H-18), 1.05 (2H, m, H-18), 2.27 (1H, m, H-17), 3.97 (3H, s, H-16), 4.85 (2H, s, H-10), 6.43 
(1H, s, H-6), 7.25 (1H, s, H-8), 8.19 (1H, s, H-3), 8.84 (1H, s, H-15) 13.08 (1H, s-br, H-1); 
13C-NMR (125 MHz, DMSO-d6) δ ppm; 9.3 (C-18), 13.5 (C-17), 37.3 (C-16), 60.5 (C-10), 
110.5 (C-8), 118.0 (C-6), 123.2 (C-4), 125.8 (C-7), 132.5 (C-3), 137.2 (C-5), 140.2 (C-9), 
147.4 (C-15), 160.6 (C-12);  MS (ES+) m/z 318.3 [M+H]+; HRMS calcd for C14H16N5O2S 
318.1019 [M+H]+ found 318.1023. 
N-(3-(Hydroxymethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (324) 
 
Prepared according to general procedure G with the following reagents and quantities: 
methyl 6-(N-methylthiophene-2-sulfonamido)-1-(tetrahydro-2H-pyran-2-yl)-1H-
indazole-3-carboxylate (87 mg, 0.23 mmol) and LiAlH4 (1M in THF, 0.51 mL, 0.51 mmol) 
in THF (3 mL). The product was isolated as a grey solid (73 mg, 90%). 
m.p. 65-67 oC; UV λmax (EtOH/nm) 2293.2, 216.8; IR νmax/cm
-1 3371, 3092, 2931, 2855, 
1347, 1146;1H-NMR (500 MHz, CDCl3 ) δ ppm; 1.63-1.66 (1H, m, H-5’), 1.71-1.75 (2H, m, 
H-4’, H-5’), 2.02-2.04 (1H, m, H-6’), 2.12-2.14 (1H, m, H-4’), 2.49-2.52 (1H, m, H-6’), 
3.32 (3H, s, H-17), 3.69-3.75 (1H, m, H-3’), 4.02-4.05 (1H, m, H-3’), 5.02 (2H, s, H-18), 
5.61 (1H, dd, J = 2.5, 9.8 Hz, H-1’), 6.81 (1H, dd, J = 8.6, 1.7 Hz, H-6), 7.08 (1H, dd, J = 
4.9, 3.9 Hz, H-15), 7.35 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.45 (1H, d, J = 1.7 Hz, H-8), 7.59 
(1H, dd, J = 1.3, 4.8 Hz, H-14), 7.70 (1H, d, J =8.6 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ 
ppm; 22.7 (C-4’) 25.0 (C-5’), 29.5 (C-6’), 38.8 (C-17), 58.5 (C-18), 67.8 (C-3’), 85.3 (C-1’), 
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109.8 (C-8), 119.5 (C-6), 121.0 (C-5), 121.9 (C-4), 127.4 (C-15), 132.1 (C-14), 132.9 (C-
16), 136.9 (C-12), 140.0 (C-9), 145.1 (C-3); MS (ES+) m/z 408.5 [M+H]+. 
N-(3-Formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-
sulfonamide (323) 
 
N-(3-(Hydroxymethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (73 mg, 0.18 mmol) was dissolved in DCM (12 mL) 
under N2. Dess–Martin periodinane (0.3 M in DCM, 661 μL, 0.20 mmol) was added 
dropwise over five minutes at RT and stirred for 3h. Sodium thiosulfate (sat. aq, 15 mL) 
was added and the organic fraction separated and purified by MPLC (0-70% EtOAc in 
petroleum ether) to give the title compound as an off white solid (70 mg, 96%). 
1H-NMR (500 MHz, CDCl3) δ ppm; 1.69-1.82 (3H, m, THP), 2.11-2.19 (2H, m, THP), 2.51-
2.57 (1H, m, THP), 3.32 (3H, s, H-17), 3.75-3.80 (1H, m, THP), 3.98-4.02 (1H, m, THP), 
5.68 (1H, dd, J = 2.6, 8.8 Hz, H-1’), 6.93 (1H, dd, J = 8.7, 1.8 Hz, H-6), 7.09 (1H, dd, J = 
5.0, 3.8 Hz, H-15), 7.34 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.60 (1H, dd, J = 1.3, 5.0 Hz, H-14), 
7.64 (1H, d, J = 1.7 Hz, H-8), 8.18 (1H, d, J = 8.7 Hz, H-5), 10.23 (1H, s, H-18);13C-NMR 
(125 MHz, CDCl3) δ ppm; 22.0 (C-THP), 24.9 (C-THP), 29.1 (C-THP), 38.7 (C-17), 67.4 (C-
THP), 86.2 (C-THP),  110.7 (C-8), 121.4 (C-4), 122.1 (C-6), 122.5 (C-5), 127.4 (C-15), 
132.3 (C-14), 133.0 (C-16), 136.6 (C-12), 140.5 (C-7), 140.8 (C-9), 143.2 (C-3), 187.1 (C-
18); MS (ES+) m/z 322.2 [M+H]+. 
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N-(3-(difluoromethyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-
methylthiophene-2-sulfonamide (325) 
 
N-(3-Formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-
sulfonamide (70 mg, 0.17 mmol) was dissolved in toluene (1 mL) under N2 at rt  
dexoxfluor (2.7 M in toluene, 642 μL, 1.73 mmol) was added and the solution heated 
to 60 oC and stirred for 18h. The solution was quenched with NaHCO3 (sat. aq, 5 mL) 
and extracted with DCM (3 x 5 mL), organic fractions were combined and purified by 
MPLC (0-60 % EtOAc in petroleum ether) to give the title compound as a white solid 
(28 mg, 37%). 
Rf 0.42 (Et2O); m.p. 65-67 
oC; UV λmax (EtOH/nm) 211.6, 256.0; IR νmax/cm
-1 3097, 2939, 
2856, 1352, 1013; 1H-NMR (500 MHz, CDCl3) δ ppm; 1.67-1.78 (3H, m, THP), 2.04-2.07 
(1H, m, THP), 2.12-2.15 (1H, m, THP), 2.44-2.51 (1H, m, THP), 3.32 (3H, s, H-17), 3.70-
3.75 (1H, m, THP), 3.98-4.01 (1H, m, THP), 5.68 (1H, dd, J = 2.6, 9.2 Hz, H-1’), 6.88 (1H, 
dd, J = 8.7, 1.7 Hz, H-6), 6.94 (1H, t, JHF = 54.4 Hz, H-18), 7.09 (1H, dd, J = 5.0, 3.8 Hz, H-
15), 7.35 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.54 (1H, d, J = 1.7 Hz, H-8), 7.60 (1H, dd, J = 1.3, 
5.0 Hz, H-14), 7.81 (1H, d, J = 8.7 Hz, H-5); 13C-NMR (125 MHz, CDCl3) δ ppm; 22.2 (C-
THP), 24.9 (C-THP), 29.2 (C-THP),  38.7 (C-17), 67.5 (C-THP), 85.6 (C-THP), 110.3 (C-8), 
112.3 (t, JCF = 232.8, C-18), 120.0 (C-4), 120.7 (C-6), 121.2 (C-5), 127.4 (C-15), 132.3 (C-
16), 133.0 (C-14), 136.7 (C-12), 139.0 (t, JCF = 30.9, C-3), 140.4 (C-7), 140.5 (C-9); MS 
(ES+) m/z 344.3 [M+H]+; HRMS calcd for C18H20N3O3F2S2 428.0909 [M+H]
+ found 
428.0905. 
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N-(3-(Difluoromethyl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (322) 
 
 
Prepared according to general procedure D using  N-(3-(difluoromethyl)-1-(tetrahydro-
2H-pyran-2-yl)-1H-indazol-6-yl)-N-methylthiophene-2-sulfonamide (27 mg, 0.01 mmol) 
in MeOH.HCl (1.25 M, 5 mL) giving the title compound as a white solid (21 mg, 95%). 
Rf 0.34 (Et2O); m.p. 194-196
oC; UV λmax (EtOH/nm) 254.8, 211.8; IR νmax/cm
-1 3341, 
1343, 1160; 1H-NMR (500 MHz, CD3OD) δ ppm; 3.32 (3H, s, H-17), 7.02 (1H, dd, J = 8.7, 
1.8 Hz, H-6), 7.04 (1H, t, JHF = 54.3 Hz, H-18), 7.17 (1H, dd, J = 5.0, 3.8 Hz, H-15), 7.38 
(1H, d, J = 1.8 Hz, H-8), 7.40 (1H, dd, J = 1.3, 3.8 Hz, H-16), 7.79 (1H, d, J = 8.7 Hz, H-5), 
7.81 (1H, dd, J = 1.3, 5.0 Hz, H-14); 13C-NMR (125 MHz, CD3OD) δ ppm; 37.7 (C-17), 
108.7 (C-8), 112.6 (t, JCF = 234.4, C-18), 118.2 (C-4), 120.0 (C-5), 120.7 (C-6), 127.3 (C-
15), 132.8 (C-16), 132.9 (C-14), 136.1 (C-12), 139.3 (t, JCF = 30.8, C-3), 140.5 (C-7), 141.2 
(C-9); 19F NMR (470 MHz, CDCl3) δ -113.1; MS (ES
+) m/z 344.3 [M+H]+; HRMS calcd for 
C13H12N3O2F2S2 344.0334 [M+H]
+ found 344.0333. 
Methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (328) 
 
2-bromo, 6-fluorobenzoic acid (5 g, 23 mmol) was taken in THF (30 mL) and  SOCl2 
(4.95 mL, 69 mmol) was added followed by and DMF (0.2 mL, 2.3 mmol). The solution 
was stirred at room temperature for 3 hours before volatiles were removed by rotary 
evapourator the resulting crude material was used directly in the next step. AlCl3 (3.8 g, 
29 mmol) was suspended in DCM (30 mL) and Methyl 1H-pyrrole-2-carboxylate (3.83 g, 
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11.5 mmol) and  crude  2-bromo,6-fluorobenzoyl chloride (5.46 g, 23 mmol) were 
added. The solution was stirred at room temperature for 18 hours before addition of 
HCl (1M in H2O, 20 mL) and stirring for a further 2 hours. The producted was extracted 
with DCM (3 x 30 mL) and combined organic fractions wee washed with NaCO3 
(saturated aqueous solution, 50 mL) and brine (40mL). The organic solution was dried 
over Na2SO4 and concentrated in vacuo for purification by MPLC (10-70% EtOAc in 
petrol) giving the title compound as a brown solid (2.4 g, 65%). 
Rf 0.21 (8:2 Petrol/EtOAc); m.p. 142-144 
oC; C λmax (EtOH/nm) 286.5, 231.5; IR νmax/cm
-1  
3230, 3002, 2953, 1730, 1637, 1599, 1564, 1508; 1H NMR (500 MHz, DMSO-d6) δ ppm; 
3.80 (3H, s, H-8), 6.99 (1H, s-br, H-3), 7.40 (1H, dd, J = 8.3, 8.9 Hz, H-4’), 7.48-7.53 (2H, 
m, H-3’, H-5), 7.59 (1H, d, J = 8.3 Hz, H-5’), 12.88 (1H, s, H-1); 13C NMR (125 MHz, 
DMSO-d6) δ ppm 51.7 (C-8), 114.7 (C-3), 115.3 (d, JCF = 22.1 Hz, C-5’), 118.9 (d, JCF = 5.2 
Hz, C-2’), 124.5 (C-2/4), 125.0 (C-2/4), 128.8 (d, JCF = 2.9 Hz, C-3’), 129.7 (d, JCF = 22.8 Hz, 
C-1’), 130.1 (C-5), 132.3 (d, JCF = 9.0 Hz, C-4’), 158.5 (d, JCF = 245.9 Hz, C-6’), 160.2 (C-6), 
184.6 (C-9); 19F NMR (471 MHz, DMSO-d6) δ -113.8 (ArF); MS (ES
+) m/z 326.3 
[M(79Br)+H]+, 328.3 [M(81Br)+H]+; HRMS (ESI) calcd for C13H10BrFNO3 [M(79Br)+H]
+ 
325.9823, found 325.9823. 
4-(2-Bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (329) 
 
Methyl 4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylate (1.4 g, 4.3 mmol), was 
dissolved in THF (20 mL) and LiOH.H2O (3.6 g, 80 mmol) in H2O (40 mL) was added. The 
solution was stirred at 65 oC for 18 hours then acidified to pH3/4 using HCL (1M in H2O). 
The product was extracted using EtOAc (3 x 30 mL) and washed with brine (40 mL). 
Organic solution was dried over Na2SO4 and reduced in vacuo to give the title 
compound as a white solid (1.2 g, 90%).  
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Rf 0.15 (9:1 DCM/MeOH); m.p. 210-211 
oC; λmax (EtOH/nm) 281.0; IR νmax/cm
-1  3342, 
1690, 1648, 1561; 1H NMR (500 MHz, DMSO-d6) δ ppm 6.94 (1H, s-br, H-3), 7.39- 7.43 
(2H, m, H-5, H-5’), 7.50 (1H, ddd, J = 6.3, 8.3, 8.4 Hz, H-4’), 7.59 (1H, d, J = 8.3 Hz, H-3’), 
12.68 (1H, s, H-1), 12.90 (1H, s, H-7); 13C NMR (125 MHz, DMSO-d6) δ ppm 114.2 (C-3), 
115.3 (d, JCF = 21.7 Hz, C-5’), 118.9 (d, JCF = 5.2 Hz, C-2), 124.9 (C-2/4), 125.8 (C-2/4), 
128.8 (d, JCF = 3.1 Hz, C-3’), 129.7 (C-5), 129.9 (d, JCF = 22.7 Hz, C-1’), 132.2 (d, JCF = 8.7 
Hz, C-4’), 158.4 (d, JCF = 249.9 Hz, C-6’), 161.3 (C-6), 184.6 (C-8); 
19F NMR (471 MHz, 
DMSO-d6) δ -113.84; MS (ES
-) m/z 310.1 [M(79Br)-H]-, 312.1 [M(81Br)-H]-; HRMS (ESI) 
calcd for C12H6BrFNO3 309.9521 M(
79Br)-H]- found 309.9518. 
4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-4-yl)-1H-pyrrole-2-carboxamide (327) 
 
Prepared according to general procedure R with the following reagents and quantities: 
4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (540 mg, 1.73 mmol), PCl3 
(151 μL, 1.73 mmol) and 4-aminopyridine (407 mg, 4.33 mmol) in MeCN (11 mL) to 
give the title compound as a white solid (497 mg, 74%). 
Rf 0.32 (19:1 DCM/MeOH); m.p. 312-314 
oC; λmax (EtOH/nm) 291.5, 270.5; IR IR 
νmax/cm
-1 3344, 3112, 2958, 1627, 1591, 1557, 1506; 1H NMR (500 MHz, DMSO-d6) δ 
ppm 7.42-7.46 (1H, m, H-5’), 7.49-7.54 (3H, m, H-3, H-4’, H-5), 7.61-7.62 (1H, m, H-3’), 
7.73 (2H, d, J = 6.4 Hz, H-9), 8.46 (2H, d, J = 6.4 Hz, C-10), 10.35 (1H, s, H-6), 12.74 (1H, 
s, H-1); 13C NMR (125 MHz, DMSO-d6) δ ppm 112.1 (C-3), 113.7 (C-9), 115.4 (d, JCF = 
21.6 Hz, C-5’), 119.0 (d, JCF = 5.1 Hz, C-2’), 125.0 (C-2/4), 128.0 (C-2/4), 128.9 (d, JCF = 
2.9 Hz, C-3’), 129.8 (C-1’), 132.2 (d, JCF = 8.9 Hz, C-4’), 145.6 (C-10), 150.3 (C-8), 158.5 (d, 
JCF = 247.8 Hz, C-1’), 159.0 (C-6), 184.9 (C-9); HRMS calcd for C17H11BrFN3O2 388.0091 
[M(79Br)+H]+ found 388.0088.  
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4-(2-Bromo-6-fluorobenzoyl)-N-(pyridin-3-yl)-1H-pyrrole-2-carboxamide (17) 
 
Prepared according to general procedure R with the following reagents and quantities: 
4-(2-bromo-6-fluorobenzoyl)-1H-pyrrole-2-carboxylic acid (500 mg, 1.60 mmol), PCl3 
(140 μL, 1.60 mmol) and 3-aminopyridine (377 mg, 4.00 mmol) in MeCN (10 mL) to 
give the title compound as a white solid (547 mg, 88%). 
Rf 0.31 (19:1 DCM/MeOH); m.p. 138-140 
oC; λmax (EtOH/nm) 288.0; IR νmax/cm
-1 3127, 
2960, 1635, 1599, 1534; 1H NMR (500 MHz, DMSO-d6) δ ppm 7.39 (1H, dd, J = 4.7, 8.4 
Hz, H-12), 7.42-7.48 (3H, m, H-3, H-5’, H-5), 7.52 (1H, ddd, J = 6.2, 8.3, 8.4 Hz, H-4’), 
7.61-7.63 (1H, m, H-3’), 8.14 (1H, ddd, J = 1.5, 2.5, 8.4 Hz, H-13), 8.30 (1H, dd, J = 1.5, 
4.7 Hz, H-11), 8.89 (1H, d, J = 2.5 Hz, H-9), 10.24 (1H, s, H-7), 12.70 (1H, s, H-1); 13C 
NMR (125 MHz, DMSO-d6) δ ppm 111.7 (C-3), 115.4 (d, JCF = 21.7 Hz, C-5’), 119.0 (d, JCF 
= 5.2 Hz, C-2’), 123.6 (C-12), 124.9 (C-2/4), 127.0 (C-2/4), 128.8 (d, JCF = 2.5 Hz, C-3’), 
129.4 (C-1’), 130.0 (C-9), 132.1 (d, JCF = 8.7 Hz, C-4’), 135.5 (C-13), 141.6 (C-12), 144.4 
(C-8), 158.5 (d, JCF = 245.6 Hz, C-6’), 158.7 (C-6), 184.9 (C-9); HRMS calcd for 
C17H11BrFN3O2  388.0091 [M(
79Br)+H]+ found 388.0090. 
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Abbreviations 
ABC ATP binding cassette transporters 
ADMET 
Adsorption, distribution, metabolism, excretion and 
toxicity 
ADP Adenosine diphosphate 
ALK Anaplastic lymphoma tyrosine kinase receptor  
aq aqueous 
ATP Adenosine triphosphate 
AUC  Area under curve 
BAD Bcl-2-associated death promoter 
bFGF fibroblast growth factor  
Boc tert-butyloxycarbonyl 
CDI 1,1'-Carbonyldiimidazole  
CDK cyclin dependant kinase 
CRT-DL Cancer Research Technology Discovery Labs  
DAST diethylaminosulfur trifluoride 
DCM Dichloromethane 
DFG aspartate, phenylalanine, glycine 
DHP dihydropyran  
DMB dimethoxy benzyl  
DNA Deoxyribonucleic acid 
EDG Electron donating group 
EGF epidermal growth factor  
EGTA ethylene glycol tetraacetic acid  
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ERK5 Extracellular signal regulated kinase 5 
Et2O diethyl ether 
EtOAc Ethyl acetate 
EWG Electron withdrawing group 
FDA Food and Drugs Administration 
GAB1 Grb2-associated binder  
GE Group efficiency 
GPCR G-protein coupled receptor 
HBA Hydrogen bond acceptor 
HBD Hydrogen bond donor 
hERG Human ether-a-go-go related gene product  
HPLC High performance liquid chromatography 
HRMS High resolution mass spectrometry 
HTS High throughput screen 
ID Identification 
IMAP immobilised metal affinity polarisation 
IP intraperitoneal  
IR infrared 
IV intravenous  
LAD Lck-associated adaptor 
LCMS liquid chromatography-mass spectrometry 
LE Ligand efficiency 
LEI Ligand efficiency index 
LIF Leukaemia inhibitory factor  
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LipE lipophilic ligand efficiency 
LLE lipophilic ligand efficiency 
MAPK Mitogen activated protein kinase 
MAPKK MAPK kinase  
MAPKKK MAPK kinase kinase  
MDR multidrug resistance  
MDR1 multidrug resistance 1  
MLM Mouse liver microsome 
MPLC Medium pressure liquid chromatography 
MW Molecular weight 
NBD nucleotide binding domain 
NFG nerve growth factor  
NFSI N-Fluorobenzenesulfonimide  
NLK Nemo-like kinase  
NMP N-methyl-2-pyrrolidone  
NMR Nuclear magnetic resonance spectroscopy 
PDB Protein database 
PDGF platelet derived growth factor  
PEG polyethylene glycol 
P-gp P-glycoprotein  
PLP piecewise linear potential  
PMB Para-methoxy benzyl 
PML promyelocytic leukaemia protein  
PO oral administration 
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PPB Plasma protein binding  
p-TSA para-toluenesulfonic  
QED quantitative estimate of drug likeness  
Rb retinoblastoma protein 
RTV Relative tumour volumes 
SAR structure activity relationship 
SDS sodium dodecyl sulphate 
SEM Trimethylsilyl ethyoxymethyl 
TAD transactivation domain 
TFE Trifluoroethanol 
THP Tetrahydropyran 
TLC Thin layer chromatography 
TMD transmembrane domain  
TNBC Triple negative breast cancer 
tPSA topological polar surface area 
Tris tris(hydroxymethyl)aminomethane  
Ts Tosyl 
UK United Kingdom 
UV Ultraviolet 
Vdss volume of distribution at steady state 
VEGF vascular endothelial growth factor 
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